Skip to main content

Icon Legend
Presentation Icons
Ticketed Event
Ticketed Event
In Person Only
In Person Only
Location: Hilton San Diego Bayfront
Location: Hilton San Diego Bayfront

Posters

Posters

  • Sunday, October 1, 2023
  • 4:45 PM – 6:00 PM PT
    2000 - Population-Based Differences in Cancer Incidence between Immigrants and Non-Immigrants in Canada from 1992-2015
    Location: Hall B2

    Presenter: Robert Olson, MD, MS – BC Cancer and UBC

  • 4:45 PM – 6:00 PM PT
    2001 - Could Poor Outcomes for Patients with Limited Lung Function Treated with SAbR Necessitate PULSAR?
    Location: Hall B2

    Presenter: Maureen Aliru, MD, PhD – University of Texas Southwestern Medical Center

  • 4:45 PM – 6:00 PM PT
    2002 - Clinical Efficacy and Safety of Once-Weekly Fractionation in Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Lesions
    Location: Hall B2

    Presenter: Alexander Allen, MD – University of Maryland Medical Center

  • 4:45 PM – 6:00 PM PT
    2003 - Impact of Lymphopenia on Treatment Outcomes in Unresectable Non Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Francesco Amorelli, MD – Hospital Del Mar - Parc de Salut Mar

  • 4:45 PM – 6:00 PM PT
    2004 - Utilization of Services and Clinical Outcomes among American Indian/Alaska Native (AIAN) Women with Breast Cancer at an Academic Medical Center (AMC)
    Location: Hall B2

    Presenter: August Anderson, MD – University of Washington

  • 4:45 PM – 6:00 PM PT
    2005 - Multi-Parametric Chest Magnetic Resonance Imaging for Assessment of Local Recurrence of Non-Small Cell Lung Cancer after Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: Sarit Appel, MD – Chaim Sheba Medical Center

  • 4:45 PM – 6:00 PM PT
    2006 - Toxicity of Patients with Ultra-Central Thoracic Tumors Treated with Stereotactic Body Radiotherapy (SBRT) with Dose of 50Gy in 5 Fractions
    Location: Hall B2

    Presenter: Rie Asso, MD – Sirio Libanes Hospital

  • 4:45 PM – 6:00 PM PT
    2007 - Association of Artificial Intelligence-Screened Interstitial Lung Disease with Radiation Pneumonitis and Mortality in Locally Advanced Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Hannah Bacon, MD, PhD – University of Toronto

  • 4:45 PM – 6:00 PM PT
    2008 - Efficacy of Postoperative Radiotherapy for Patients with New N2 Descriptors of Subclassification in Completely Resected Non-Small Cell Lung Cancer: A Real-World Study
    Location: Hall B2

    Presenter: Yongxing Bao, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS & PUMC

  • 4:45 PM – 6:00 PM PT
    2009 - Potentiating Local and Abscopal Antitumor Efficacy through Radiation with FAP-CD40 DARPin and Anti-PD1 Therapy
    Location: Hall B2

    Presenter: Thomas Riad, BS – University of Texas MD Anderson Cancer Center

  • 4:45 PM – 6:00 PM PT
    2010 - Radiotherapy Capabilities, Population, Average Income, and Health Insurance Status as Predictors of Cancer Mortality at the County Level in the United States
    Location: Hall B2

    Presenter: Ryan Kraus, MD – Barrow Neurological Institute

  • 4:45 PM – 6:00 PM PT
    2011 - Assessing Depression and Anxiety Levels in English and Spanish-Speaking Patients throughout a Course of Radiation Therapy
    Location: Hall B2

    Presenter: Jenny Zhao, BS – Boston University School of Medicine (BUSM)

  • 4:45 PM – 6:00 PM PT
    2012 - Characterizing the Impact of Race and Redlining on Receipt of Guideline-Compliant Locoregional Therapy among Older Women with Breast Cancer
    Location: Hall B2

    Presenter: Sara Beltran Ponce, MD – Medical College of Wisconsin

  • 4:45 PM – 6:00 PM PT
    2013 - Frequent Friers: Outcomes in Patients Who Receive Multiple Courses of Lung SBRT
    Location: Hall B2

    Presenter: Julie Bloom, MD – Mount Sinai School of Medicine

  • 4:45 PM – 6:00 PM PT
    2014 - PET-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy
    Location: Hall B2

    Presenter: Vincent Bourbonne, MD, PhD – CHU Brest

  • 4:45 PM – 6:00 PM PT
    2015 - A Technology-Informed Approach to Clinical Trial Equity
    Location: Hall B2

    Presenter: Eleanor Brown, BA – Stanford University

  • 4:45 PM – 6:00 PM PT
    2016 - Cardiac and Great Vessel Toxicity with Single Fraction Stereotactic Body Radiotherapy in Early Stage Lung Cancer
    Location: Hall B2

    Presenter: David Buchberger, MD, MSc – Cleveland Clinic Foundation

  • 4:45 PM – 6:00 PM PT
    2017 - Hyperfractionated Reirradiation for Locally Recurrent Thoracic Tumors
    Location: Hall B2

    Presenter: Santino Butler, MD – Stanford University School of Medicine

  • 4:45 PM – 6:00 PM PT
    2018 - A Simulation-Based Approach for Strategic Evaluation of Resource Allocation for Improving Spatial Access to Radiation Oncology
    Location: Hall B2

    Presenter: Vincent Cassidy, MD, MBA – University of Florida

  • 4:45 PM – 6:00 PM PT
    2019 - Determining the Ideal Time for Implementing Adaptive Radiation Therapy in the Treatment of Non-Small Cell Lung Cancer through the Analysis of Cone-Beam Computed Tomography Images
    Location: Hall B2

    Presenter: Tzu-Fang Chang, Rad.T. – Fu Jen Catholic University Hospital

  • 4:45 PM – 6:00 PM PT
    2020 - AI-Derived CT Body Composition in Advanced Non-Small Cell Lung Cancer: A Multicohort Study
    Location: Hall B2

    Presenter: Tafadzwa Chaunzwa, MD – Harvard Medical School

  • 4:45 PM – 6:00 PM PT
    2021 - The Baseline Serum Lipid Levels and Outcomes of NSCLC Patients Receiving Immunotherapy Combined or Non-Combined with Radiotherapy: A Single Center Retrospective Study
    Location: Hall B2

    Presenter: Dawei Chen, MD, MB

  • 4:45 PM – 6:00 PM PT
    2022 - Whole Liver Radiotherapy for Multiple Liver Metastases in Thoracic Malignancies
    Location: Hall B2

    Presenter: Ting-Fong Liu, MD – National Taiwan University Hospital

  • 4:45 PM – 6:00 PM PT
    2023 - Prostate Cancer in New York City: Impact of Neighborhood Level Social Determinants of Care
    Location: Hall B2

    Presenter: Justin Chestang, BS, BA – Columbia University

  • 4:45 PM – 6:00 PM PT
    2026 - Association of Provider Zip Code Sociodemographic Characteristics with Radiation Therapy Modality Use in the Medicare Population
    Location: Hall B2

    Presenter: Patrick Courtney, MD, MAS – UCLA David Geffen School of Medicine/UCLA Medical Center

  • 4:45 PM – 6:00 PM PT
    2027 - Evaluating Geographic Access to Radiotherapy Services in Canada
    Location: Hall B2

    Presenter: Oluwaseun Davies, MD – Alberta Health Services

  • 4:45 PM – 6:00 PM PT
    2028 - Disparities in Stage at Presentation among Hispanic and Latinx Patients with Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Edward Dee, MD – Memorial Sloan Kettering Cancer Center

  • 4:45 PM – 6:00 PM PT
    2029 - Circulating Growth Differentiation Factor 15 as a Biomarker in Patients with Unresected Locally Advanced Non-Small Cell Lung Cancer Treated with Chemo-Radiotherapy with or without Metformin
    Location: Hall B2

    Presenter: Fiorella Di Pastena, PhD

  • 4:45 PM – 6:00 PM PT
    2030 - Accessibility and Impact of Telehealth in Rural Populations with a History of Cancer
    Location: Hall B2

    Presenter: Francisca Douglass, BS – Ohio State University College of Medicine

  • 4:45 PM – 6:00 PM PT
    2031 - Impact of the COVID-19 Pandemic on Financial Burden in Those with a Recent History of Cancer
    Location: Hall B2

    Presenter: Francisca Douglass, BS – Ohio State University College of Medicine

  • 4:45 PM – 6:00 PM PT
    2032 - Stage IIIA Non-Small Cell Lung Cancer Treatment and Outcomes: A Single Institution Retrospective Analysis
    Location: Hall B2

    Presenter: Richard Duan, MS – Northwestern Feinberg School of Medicine

  • 4:45 PM – 6:00 PM PT
    2033 - Impact of the Affordable Care Act on Pediatric Proton Radiation Therapy Access
    Location: Hall B2

    Presenter: Teresa Easwaran, MD, MS – University of Minnesota

  • 4:45 PM – 6:00 PM PT
    2034 - Symptomatic Pneumonitis Rates Among Patients with Stage III Non-Small Cell Lung Cancer Receiving Adjuvant Durvalumab
    Location: Hall B2

    Presenter: Donna Edwards, MD, PhD – University of Michigan

  • 4:45 PM – 6:00 PM PT
    2035 - Invited African-American Radiation Oncology Grand Rounds Speakers: DEI or Die?
    Location: Hall B2

    Presenter: Ifeanyi Ekpunobi, BS – University Hospitals

  • 4:45 PM – 6:00 PM PT
    2036 - Prognostic Value of Hypoxia Gene Expression Signature in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: Nicholas Eustace, MD, PhD, BS – City of Hope National Medical Center

  • 4:45 PM – 6:00 PM PT
    2037 - Recovery Characteristics of Lymphocyte Subsets after Thoracic Radiotherapy: A Single Center Clinical Study
    Location: Hall B2

    Presenter: Fan Xingwen, MD, PhD – Fudan University Shanghai Cancer Center

  • 4:45 PM – 6:00 PM PT
    2038 - Patterns of Failure, Volume of Disease Progression, and Subsequent Ablative Management in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Treated with Definitive Chemoradiation and Consolidatio
    Location: Hall B2

    Presenter: Cole Friedes, MD – University of Pennsylvania

  • 4:45 PM – 6:00 PM PT
    2039 - Equity of Access to Proton Beam Therapy in England: A National NHS analysis
    Location: Hall B2

    Presenter: Simona Gaito, MD – The Christie NHS Foundation Trust

  • 4:45 PM – 6:00 PM PT
    2040 - Outcomes of Hypofractionated Radiotherapy with Induction or Sequential Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Single Institution Experience
    Location: Hall B2

    Presenter: Ian Gerard, MD, PhD – McGill University Health Centre

  • 4:45 PM – 6:00 PM PT
    2041 - Central Lung Tumors Eligible for Stereotactic Ablative Radiotherapy (SABR) Trials: Analysis of a Cohort Treated Using MR-Guided SABR
    Location: Hall B2

    Presenter: Nicolas Giraud, MD – Amsterdam UMC

  • 4:45 PM – 6:00 PM PT
    2042 - Demographic Representation in Clinical Trials Sponsored by the United States Department of Veterans Affairs
    Location: Hall B2

    Presenter: Gabriela Gomez, BS, MPH – Johns Hopkins Medicine

  • 4:45 PM – 6:00 PM PT
    2043 - Five-Fraction Accelerated Partial Breast Irradiation [APBI] may Reduce Health Care Disparity in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer by Overcoming Treatment Barriers of Dist
    Location: Hall B2

    Presenter: Alex Goss

  • 4:45 PM – 6:00 PM PT
    2044 - A Comparative Population-Based Study of Tracheal and Lung Adenoid Cystic Carcinoma
    Location: Hall B2

    Presenter: Yu Gu, PhD

  • 4:45 PM – 6:00 PM PT
    2046 - Role and Modality of Combining Radiotherapy with Immunotherapy in Stage III-IV Unresectable Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Y.X. Guo, MD

  • 4:45 PM – 6:00 PM PT
    2047 - Health System Practices and Perspectives of Social Risk Screening in Oncology
    Location: Hall B2

    Presenter: Kripa Guram, MD, BS – University of California, San Diego

  • 4:45 PM – 6:00 PM PT
    2049 - Proton and Carbon Ion Radiotherapy for Operable Early Stage Lung Cancer: 3-Year Results of a Prospective Nationwide Registry
    Location: Hall B2

    Presenter: Hideyuki Harada, MD, PhD – Shizuoka Cancer Center

  • 4:45 PM – 6:00 PM PT
    2051 - Dosimetric Predictors for Acute Esophagitis during Radiation Therapy for Lung Cancer: An Update of a Large Statewide Observational Study
    Location: Hall B2

    Presenter: Daniel Herr, MD, PhD – University of Michigan

  • 4:45 PM – 6:00 PM PT
    2055 - Predictive Modeling of Radiation Pneumonitis Induced By Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Using Radiomics and Clinical Features
    Location: Hall B2

    Presenter: Nobuki Imano, MD, PhD – Hiroshima University

  • 4:45 PM – 6:00 PM PT
    2056 - Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiotherapy (IMRT) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) in the Era of Immune Checkpoint Inhibitor (ICI) Consolidation: A Ret
    Location: Hall B2

    Presenter: Michelle Iocolano, MD, MA – University of Pennsylvania

  • 4:45 PM – 6:00 PM PT
    2057 - Change in Quality of Life after Stereotactic Body Radiation Therapy (SBRT) on a Prospective Trial of Peripheral Stage I or II Non-Small Cell Lung Cancer Predicts Survival
    Location: Hall B2

    Presenter: Austin Iovoli, MD – Roswell Park Comprehensive Cancer Center

  • 4:45 PM – 6:00 PM PT
    2058 - Sinoatrial Node Irradiation is Associated with Worse Survival in Patients Undergoing Definitive Stereotactic Body Radiation Therapy (SBRT) for Central Lung Cancers
    Location: Hall B2

    Presenter: Austin Iovoli, MD – Roswell Park Comprehensive Cancer Center

  • 4:45 PM – 6:00 PM PT
    2059 - Differential Impact of Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer Based on Systemic Therapy Type and Sex
    Location: Hall B2

    Presenter: Vikram Jairam, MD – Sutter Cancer Centers, Radiation Oncology

  • 4:45 PM – 6:00 PM PT
    2060 - Disparities in Time to Prostate Cancer Treatment Initiation before and after the Affordable Care Act
    Location: Hall B2

    Presenter: James Janopaul-Naylor, MD – Memorial Sloan Kettering Cancer Center

  • 4:45 PM – 6:00 PM PT
    2061 - Prognostic Value of Naples Prognostic Score on Survival in Unresectable Small Cell Lung Cancer Patients Undergoing Chemoradiotherapy
    Location: Hall B2

    Presenter: Shengjun Ji, MD – Nanjing Medical University Affiliated Suzhou Hospital

  • 4:45 PM – 6:00 PM PT
    2062 - Contralateral Esophagus Sparing is Associated with Lack of Severe Esophagitis in Patients with Limited Stage SCLC Treated with QD or BID Chemoradiotherapy Regimens
    Location: Hall B2

    Presenter: Florence Keane, MD – Massachusetts General Hospital

  • 4:45 PM – 6:00 PM PT
    2063 - Gender and the Receipt of the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award
    Location: Hall B2

    Presenter: Karishma Khullar, MD – University of Pennsylvania

  • 4:45 PM – 6:00 PM PT
    2064 - Real-World Study of Overall Survival in Patients with Stage III Non-Small Cell Lung Cancer Treated with Chemoradiotherapy with or without Durvalumab and an Exploratory Analysis of Effective Radiation
    Location: Hall B2

    Presenter: Noriko Kishi, MD, PhD – Kyoto University Hospital

  • 4:45 PM – 6:00 PM PT
    2065 - Risk Factors for Symptomatic Radiation Pneumonitis after Stereotactic Body Radiotherapy (SBRT) for Early-Stage Lung Cancer
    Location: Hall B2

    Presenter: Nozomi Kita, MD, PhD – Nagoya City University Graduate School of Medical Sciences

  • 4:45 PM – 6:00 PM PT
    2066 - Major Cardiovascular Events after Chemoradiotherapy with or without Durvalumab in Patients with Stage III Non-Small Cell Lung Cancer: Supplementary Analysis
    Location: Hall B2

    Presenter: Masaki Kokubo, MD, PhD – Kobe City Medical Center General Hospital

  • 4:45 PM – 6:00 PM PT
    2068 - The Society for Women in Radiation Oncology: Where are We Five Years Later?
    Location: Hall B2

    Presenter: Rebecca Krc, DO – University of Maryland Radiation Oncology

  • 4:45 PM – 6:00 PM PT
    2069 - Predictive Value of Dynamic Tumor Volume Changes in Stage III Non-Small Cell Lung Cancer Treated with Chemoradiation and Consolidative Immunotherapy
    Location: Hall B2

    Presenter: Ritesh Kumar, MD, MBBS – Rutgers Cancer Institute of New Jersey

  • 4:45 PM – 6:00 PM PT
    2070 - Exploration of AI-Assisted On-Board Perfusion Imaging Technique on Patients Undergoing Thoraxradiotherapy
    Location: Hall B2

    Presenter: Yu Lap Lam, MS – Hong Kong Polytechnic University

  • 4:45 PM – 6:00 PM PT
    2071 - A Large National Study on Racial Disparities among Asian American, Native Hawaiian, and Other Pacific Islander Cancer Patients Who Refuse Radiation Therapy and Surgery
    Location: Hall B2

    Presenter: Brianna Lau, BA – Stanford University School of Medicine

  • 4:45 PM – 6:00 PM PT
    2073 - Thoracic Radiation Dose Fractionation Schedules for Limited-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis of Randomized Trials
    Location: Hall B2

    Presenter: Chia Ching Lee, MD – National University Cancer Institute Singapore

  • 4:45 PM – 6:00 PM PT
    2074 - Identifying and Addressing Nutritional Inequities and Psychosocial Needs of Cancer Patients Residing in Zip-Code Designated Food Priority Areas (FPAs)
    Location: Hall B2

    Presenter: Lara LePore, BS – University of Maryland School of Medicine

  • 4:45 PM – 6:00 PM PT
    2075 - Outcome Supervised Deep Learning Model on Pathological Whole Slide Images for Survival Prediction of Immunotherapy in Non-Small Cell Lung Cancer Patients: A Multicenter Study
    Location: Hall B2

    Presenter: Butuo Li, MD, MB, PhD – Shandong Cancer Hospital Affiliated to Shandong First Medical University

  • 4:45 PM – 6:00 PM PT
    2076 - Safety and Efficacy of Stereotactic Body Radiotherapy for Ultra-Central Thoracic Tumors
    Location: Hall B2

    Presenter: George Li, MD – University of Toronto

  • 4:45 PM – 6:00 PM PT
    2078 - Verification and Mechanism Exploration of CDK4 Alterations on Influencing Radiotherapy Sensitivity in Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Li Li, MD, PhD, RT – Shandong Cancer Hospital and Institute

  • 4:45 PM – 6:00 PM PT
    2079 - Dosimetric Analysis of CBCT-Based Weekly Online Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Ruiqi Li, PhD – UT Southwestern Medical Center

  • 4:45 PM – 6:00 PM PT
    2080 - Development and Validation of a Nomogram for Patients with Lung Large Cell Neuroendocrine Carcinoma
    Location: Hall B2

    Presenter: Yan Li, MD – West China Hospital of Sichuan University

  • 4:45 PM – 6:00 PM PT
    2081 - Outcomes of Consolidative Thoracic Radiation within First-Line Chemoimmunotherapy in Extensive-Stage Small-Cell Lung Cancer: Results from a Single Cancer Center
    Location: Hall B2

    Presenter: Yuying Li, MD – Shandong Cancer Hospital and Institute

  • 4:45 PM – 6:00 PM PT
    2082 - A Pilot Trial of Consolidation Bevacizumab after Hypo-Fractionated Concurrent Chemoradiotherapy in Patients with Unresectable Locally Advanced Non-Squamous Non-Small-Cell Lung Cancer
    Location: Hall B2

    Presenter: Hui Liu – Sun Yat-Sen University Cancer Center

  • 4:45 PM – 6:00 PM PT
    2084 - Longitudinal Radiomics-Based Prediction of Local Recurrence after Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Manlu Liu – University of Wisconsin School of Medicine and Public Health

  • 4:45 PM – 6:00 PM PT
    2085 - Assessment of Electronic Health Literacy among Patients in an Urban, Academic Radiation Therapy Department
    Location: Hall B2

    Presenter: Jonathan Lubin, MD – Montefiore Medical Center/Albert Einstein College of Medicine

  • 4:45 PM – 6:00 PM PT
    2086 - Prognostic Significance of Serum Lipids in Patients with Non-Small Cell Lung Cancer Treated with Radiotherapy: A Multicenter Prospective Study
    Location: Hall B2

    Presenter: Jiahua Lv, MD, PhD – Sichuan Cancer Hospital and Institute

  • 4:45 PM – 6:00 PM PT
    2088 - Attitudes and Barriers to Planned Family Building among Professionals and Trainees in Radiation Oncology
    Location: Hall B2

    Presenter: Emily MacDuffie, MD – University of Pennsylvania

  • 4:45 PM – 6:00 PM PT
    2089 - A Survey Study of Practice Patterns in Management of Very Early Small Cell Lung Cancer in Canada
    Location: Hall B2

    Presenter: Bayan Malakouti-Nejad, MD, MS – The Ottawa Hospital & the University of Ottawa

  • 4:45 PM – 6:00 PM PT
    2090 - Daily Adaptive vs. Non-Adaptive External Beam Radiation Therapy with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC): A Prospective Randomized Trial of an Individualiz
    Location: Hall B2

    Presenter: Andrew McDonald, MD, MS – University of Alabama Birmingham School of Medicine

  • 4:45 PM – 6:00 PM PT
    2091 - Radiation-Induced Brachial Plexopathy (RIBP) after Stereotactic Body Radiotherapy (SBRT): Pooled Analyses of Risks
    Location: Hall B2

    Presenter: Michael Milano, MD, PhD, FASTRO – University of Rochester

  • 4:45 PM – 6:00 PM PT
    2092 - Assessing Patterns of Practice in Early-Stage Lung Cancer Radiation Therapy: Findings from a Large Statewide Consortium Study on Hypofractionation
    Location: Hall B2

    Presenter: Sean Miller, MD – University of Michigan

  • 4:45 PM – 6:00 PM PT
    2093 - Predictive Factors for Response to Adaptive Therapy in Thoracic Stereotactic Ablative Radiotherapy
    Location: Hall B2

    Presenter: Steven Montalvo, MD – UT Southwestern Medical Center

  • 4:45 PM – 6:00 PM PT
    2094 - A U.S. Cancer Centers Interactive Cancer Education Program for Spanish-Speaking Latinos during COVID-19 Pandemic
    Location: Hall B2

    Presenter: Javier Mora, MD – Aurora Health Care

  • 4:45 PM – 6:00 PM PT
    2095 - The Effect of Body Mass Index on Tumor Treating Fields (TTFields) Intensity Distribution in the Lungs
    Location: Hall B2

    Presenter: Nadav Shapira

  • 4:45 PM – 6:00 PM PT
    2097 - Increasing Accrual of Racial and Ethnic Minorities in Breast Cancer Clinical Trials by Partnering with Community Hospitals
    Location: Hall B2

    Presenter: Joy Ogunmuyiwa, MD – New York Presbyterian

  • 4:45 PM – 6:00 PM PT
    2098 - Long-Term Results of a Phase II Study of Accelerated Hyperfractionated Thoracic Radiotherapy with Dose Escalation to 54 Gy for Limited-Stage Small-Cell Lung Cancer
    Location: Hall B2

    Presenter: Ayaka Ono, MD – Hiroshima City Hiroshima Citizens Hospital

  • 4:45 PM – 6:00 PM PT
    2099 - Reducing Racial Disparities in Breast Cancer Treatment
    Location: Hall B2

    Presenter: Jacob Oyeniyi, MD – Corewell Health William Beaumont University Hospital

  • 4:45 PM – 6:00 PM PT
    2100 - Malignant Pleural Mesothelioma and Radiotherapy: Lung Toxicity Results of an Interim Analysis in Prospective Pilot Trial
    Location: Hall B2

    Presenter: Elisabetta Parisi, MD – Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS

  • 4:45 PM – 6:00 PM PT
    2101 - Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
    Location: Hall B2

    Presenter: Gabrielle Peters, MD – Yale New Haven Health - Shoreline Medical Center

  • 4:45 PM – 6:00 PM PT
    2101 - Interim Analysis of DD3: A Phase IB/II Trial of Dose-Deescalated 3-Fraction SBRT for Centrally Located Lung Cancer
    Location: Hall B1

    Presenter: Henry Park, MD, MPH – Yale University School of Medicine

  • 4:45 PM – 6:00 PM PT
    2102 - Barriers to Care for Pediatric Rural Medulloblastoma Patients Receiving Craniospinal Proton Radiotherapy without In-State Facilities
    Location: Hall B2

    Presenter: Melisa Pasli, BS – Brody School of Medicine

  • 4:45 PM – 6:00 PM PT
    2103 - Rural Pediatric Radiation Oncology in the Era of COVID-19: A Single Institution Analysis
    Location: Hall B2

    Presenter: Megan Goins, MS, BS – Brody School of Medicine

  • 4:45 PM – 6:00 PM PT
    2104 - Disparities in Acute Radiation-Related Pain and Dermatitis between Black and White Patients with Early-Stage Breast Cancer Receiving Adjuvant Radiation Following Breast Conserving Surgery
    Location: Hall B2

    Presenter: Rohan Patel, MD – UH Seidman Cancer Center Case Western Reserve University

  • 4:45 PM – 6:00 PM PT
    2106 - Characterizing First Events in LA-NSCLC Patients Treated with Chemoradiotherapy
    Location: Hall B2

    Presenter: Michael Pennock, MD, MBiot – Montefiore Medical Center/Albert Einstein College of Medicine

  • 4:45 PM – 6:00 PM PT
    2107 - The Effect of Stereotactic Body Radiotherapy (SBRT) Dose-Fraction (fx) Schema on Non-Small Cell Lung Cancer (NSCLC)
    Location: Hall B2

    Presenter: Aneesh Pirlamarla, MD – Fox Chase Cancer Center

  • 4:45 PM – 6:00 PM PT
    2108 - Cardiopulmonary Toxicity from Intensity Modulated Proton Therapy for Thymic Malignancies
    Location: Hall B2

    Presenter: Manaahil Rao, BS – University of Maryland School of Medicine, Baltimore

  • 4:45 PM – 6:00 PM PT
    2109 - Analysis of Racial Disparity among U.S. Patients with Gynecologic Cancers and COVID-19 Infection
    Location: Hall B2

    Presenter: Atefeh Rezaei, MD – Case Comprehensive Cancer Center, Case Western Reserve University

  • 4:45 PM – 6:00 PM PT
    2111 - Long-Term Outcomes of Multidisciplinary Radiation Oncology Equity and Inclusion Committee Programming at an Academic Health System
    Location: Hall B2

    Presenter: Carlos Rodriguez-Russo, MD – Icahn School of Medicine at Mount Sinai

  • 4:45 PM – 6:00 PM PT
    2112 - Dosimetric Risk Estimation of Chest Wall Pain Following 5-Fraction Lung Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Keaton Rummel, MD – University of Tennessee Medical Center

  • 4:45 PM – 6:00 PM PT
    2113 - Long-Term Survival in Patients with Brain-Only Metastatic Lung Cancer Undergoing Upfront Intracranial Stereotactic Radiosurgery and Definitive Treatment to the Thoracic Primary Site
    Location: Hall B2

    Presenter: Kamran Salari, MD, BS – Beaumont Health

  • 4:45 PM – 6:00 PM PT
    2114 - Ultra-Central Tumors Treated with Stereotactic Body Radiotherapy: Clinical Outcome and Prognostic Factors
    Location: Hall B2

    Presenter: Mauro Loi, MD – Azienda Ospedaliera Universitaria Careggi

  • 4:45 PM – 6:00 PM PT
    2114 - Ultra-Central Tumors Treated with Stereotactic Body Radiotherapy: Clinical Outcome and Prognostic Factors
    Location: Hall B2

    Presenter: Viola Salvestrini, MD

  • 4:45 PM – 6:00 PM PT
    2115 - Outcomes of Cytoreductive Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic or Oligoprogressive Dominant Lung Metastases from Colorectal Primary
    Location: Hall B2

    Presenter: Maria Sandoval, MD, MS – Moffitt Cancer Center

  • 4:45 PM – 6:00 PM PT
    2117 - Disparities in Inpatient Care Including Receipt of Radiotherapy and Mortality in Unhoused Adults with Cancer in the United States
    Location: Hall B2

    Presenter: Patricia Santos, MD, MS – Memorial Sloan Kettering Cancer Center

  • 4:45 PM – 6:00 PM PT
    2119 - Comorbidities and Their Impact on Treatment Tolerance and Outcome in Elderly NSCLC Patients Treated with Concurrent Chemoradiation Using Proton or Photon Followed By Immunotherapy
    Location: Hall B2

    Presenter: Yuki Sasaki, MD, PhD – MD Anderson Cancer Center

  • 4:45 PM – 6:00 PM PT
    2120 - Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
    Location: Hall B2

    Presenter: Alexander Sasse, BS – Yale School of Medicine

  • 4:45 PM – 6:00 PM PT
    2121 - High Risk Prognostic Factors Predictive of Outcome Following Stereotactic Body Radiation Therapy (SBRT) for Early Stage Lung Cancer
    Location: Hall B2

    Presenter: Jacob Schick, MD

  • 4:45 PM – 6:00 PM PT
    2122 - Sexual Orientation and Gender Identity (SOGI) Data Collection: Opportunities to Advance Best Clinical Practices for LGBTQ+ Patients in Radiation Oncology
    Location: Hall B2

    Presenter: Benjamin Schrank, MD, PhD – MD Anderson Cancer Center

  • 4:45 PM – 6:00 PM PT
    2123 - Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients with Pleural Metastases from Thymic Malignancies
    Location: Hall B2

    Presenter: Annemarie Shepherd, MD – Memorial Sloan Kettering Cancer Center

  • 4:45 PM – 6:00 PM PT
    2125 - Molecular Status Predicts for Local Control in Patients with Non-Small Cell Lung Cancer Spinal Metastases Following Spine Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Dana Shor, MBBS – Sunnybrook Odette Cancer Centre

  • 4:45 PM – 6:00 PM PT
    2126 - SABRSeq: A Randomized Phase Ib Trial of SABR Sequencing with Pembrolizumab in Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Location: Hall B2

    Presenter: Ryan McMahon, MD, MBBS – Peter MacCallum Cancer Centre

  • 4:45 PM – 6:00 PM PT
    2127 - Combined Model Based on CT Radiomics and Clinical Parameters Predicts Risk of Cachexia in Extensive-Stage Small Cell Lung Cancer Patients Treated with First-Line Immunotherapy
    Location: Hall B2

    Presenter: Ruiting Song, MS

  • 4:45 PM – 6:00 PM PT
    2128 - Patient Advocate Presence Helps Poster Presenters Understand Clinical Significance of their Research and Increases Empathy
    Location: Hall B2

    Presenter: Christina Soule – Thomas Jefferson University

  • 4:45 PM – 6:00 PM PT
    2129 - Patterns of Cancer Treatment among People with HIV in the Mountain West
    Location: Hall B2

    Presenter: Maya Stephens, MS, BS – University of Utah

  • 4:45 PM – 6:00 PM PT
    2130 - Prospective Characterization of Circulating Tumor Cell Kinetics in Patients with Localized Lung Cancer Treated with Radiotherapy or Chemoradiotherapy with Definitive Intent
    Location: Hall B2

    Presenter: Shivani Sud, MD – The University of North Carolina at Chapel Hill

  • 4:45 PM – 6:00 PM PT
    2131 - Survival Outcomes of Extensive Stage Small Cell Lung Cancer Patients Treated with Consolidative Thoracic Radiotherapy at a Tertiary Cancer Center
    Location: Hall B2

    Presenter: Rohan Salunkhe, MD, MBBS – Princess Margaret Cancer Center, University Health Network

  • 4:45 PM – 6:00 PM PT
    2132 - Association of Proton Pump Inhibitor Use and Severe Pneumonitis in Stage III Non-Small-Cell Lung Cancer Treated with Primary Chemoradiation and Adjuvant Durvalumab
    Location: Hall B2

    Presenter: Grace Sun, MD, BS – Michigan Medicine

  • 4:45 PM – 6:00 PM PT
    2134 - Analysis of the Measured FDG Uptake from the First-in-Human Clinical Trial of Biology-Guided Radiotherapy
    Location: Hall B2

    Presenter: Murat Surucu, PhD – Stanford University School of Medicine

  • 4:45 PM – 6:00 PM PT
    2135 - The Incidence of Severe Radiation-Induced Lymphopenia during Chemoradiotherapy for Stage ? Non-Small Cell Lung Cancer: A Comparative Study of Proton Versus Photon-Based Radiotherapy
    Location: Hall B2

    Presenter: Yuya Tabuchi, MD – Yokohama Municipal Citizen's Hospital

  • 4:45 PM – 6:00 PM PT
    2136 - Dosimetric Comparison of Nodal Clinical Target Volume for Locally Advanced Non-Small Cell Lung Cancer: Options for Geometric Expansion vs. Lymph Node Stations
    Location: Hall B2

    Presenter: Shigeo Takahashi, MD, PhD – Kagawa University Hospital

  • 4:45 PM – 6:00 PM PT
    2137 - Difference in Radiosensitivity Depending on the Presence and Absence of EGFR Mutations: Clinical and In Vitro analyses
    Location: Hall B2

    Presenter: Hidekazu Tanaka, MD, PhD – Yamaguchi University Graduate School of Medicine

  • 4:45 PM – 6:00 PM PT
    2138 - Deep-Inspiration Breath-Hold Stereotactic Body Radiation Therapy by Combining Spirometer-Guided Breath-Hold and a Real-Time Tumor Tracking System: A Novel Approach
    Location: Hall B2

    Presenter: Hidekazu Tanaka, MD, PhD – Yamaguchi University Graduate School of Medicine

  • 4:45 PM – 6:00 PM PT
    2139 - Racial Disparities in Brachytherapy Treatment among Women with Cervical and Endometrial Cancers: A United States Cohort Study between 2004-2017
    Location: Hall B2

    Presenter: Kekoa Taparra, MD, PhD – Stanford Health Care

  • 4:45 PM – 6:00 PM PT
    2140 - Effects of Respiratory and Cardiac Motion on Dose to the Left Anterior Descending Artery in Patients Undergoing Radiation Therapy for Locally Advanced Lung Cancer
    Location: Hall B2

    Presenter: Ross Taylor, MD – Virginia Commonwealth University/MCV Massey Cancer Center

  • 4:45 PM – 6:00 PM PT
    2141 - Using CT Radiomics and Machine Learning to Distinguish Radiotherapy vs. Immune Checkpoint Inhibitor-Induced Pneumonitis in Non-Small Cell Lung Cancer Patients
    Location: Hall B2

    Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

  • 4:45 PM – 6:00 PM PT
    2142 - Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Non-small Cell Lung Cancer
    Location: Hall B2

    Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

  • 4:45 PM – 6:00 PM PT
    2143 - Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

  • 4:45 PM – 6:00 PM PT
    2144 - Treatment of Thymoma and Thymic Carcinoma with Proton Beam Therapy: Outcomes from the Proton Collaborative Group Prospective Registry
    Location: Hall B2

    Presenter: Sibo Tian, MD – Winship Cancer Institute of Emory University

  • 4:45 PM – 6:00 PM PT
    2145 - Long Term Outcomes of Conventional Palliative Radiotherapy in Bone Metastases of Lung Cancer - A Prospective Study
    Location: Hall B2

    Presenter: AMIYA AGRAWAL, MD, MBBS – Tata Memorial Hospital

  • 4:45 PM – 6:00 PM PT
    2146 - Facility-Level Analysis of Twice Daily Radiation Utilization for Limited Stage Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Ian Tsekouras, BBA – UABHSOM

  • 4:45 PM – 6:00 PM PT
    2147 - Investigating the Influence of Cardiac Substructure Dose on Survival of Lung Cancer Patients
    Location: Hall B2

    Presenter: Luuk van der Pol, Msc – University Medical Centre Utrecht

  • 4:45 PM – 6:00 PM PT
    2148 - AI Serial Image Prediction of Progression-Free Survival (PFS) for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) Patients Treated with Chemoradiation (CRT) and Durvalumab Consolidation
    Location: Hall B2

    Presenter: Harini Veeraraghavan, PhD – Memorial Sloan Kettering Cancer Center

  • 4:45 PM – 6:00 PM PT
    2149 - Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
    Location: Hall B2

    Presenter: Nipun Verma, MD, PhD – Yale New Haven Health

  • 4:45 PM – 6:00 PM PT
    2150 - Single-Fraction Lung SBRT Outcomes for Tumors = 3cm
    Location: Hall B2

    Presenter: Gregory Videtic, MD, FASTRO, CM, FRCPC, FACR – Cleveland Clinic Taussig Cancer Center

  • 4:45 PM – 6:00 PM PT
    2151 - Simulation CT Features and Radiation Cardiotoxicity in Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Gerard Walls, MD, PhD – Patrick G Johnston Centre for Cancer Research

  • 4:45 PM – 6:00 PM PT
    2153 - Plasma Exosomal miRNAs as Response Biomarkers of Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
    Location: Hall B2

    Presenter: Boyan Wang, MD – Fudan University Shanghai Cancer Center

  • 4:45 PM – 6:00 PM PT
    2154 - Effect of Segmental Abutting Esophagus-Sparing Technique to Reduce Severe Esophagitis in Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Hypofractionated Thoracic Radiation and C
    Location: Hall B2

    Presenter: Jianyang Wang, MD

  • 4:45 PM – 6:00 PM PT
    2155 - Anatomy-Guided Deep Learning Model for Accurate and Robust Gross Tumor Volume Segmentation in Lung Cancer Radiation Therapy
    Location: Hall B2

    Presenter: Qifeng Wang, MD, PhD – Sichuan Cancer Hospital and Institute

  • 4:45 PM – 6:00 PM PT
    2156 - Incidence and Risk Factors for Brain Metastases in Patients with Lung Cancer: A Systematic Review and Meta-Analysis
    Location: Hall B2

    Presenter: Shilin Wang, MS – Chongqing University Cancer Hospital

  • 4:45 PM – 6:00 PM PT
    2158 - Could Residual Disease Irradiation be Better than Involved Field Irradiation for Limited-Stage Small Cell Lung Cancer? A Failure Pattern Analysis
    Location: Hall B2

    Presenter: Xinran Wang, MD, MS – Shandong First Medical University and Shandong Academy of Medical Science

  • 4:45 PM – 6:00 PM PT
    2159 - Improved Prediction of Chemoradiation and Immune Checkpoint Blockade Efficacy with Dynamic bTMB Combined with ctDNA in Unresectable Locally Advanced NSCLC
    Location: Hall B2

    Presenter: Yu Wang, MD – Chinese Academy of Medical Sciences and Peking Union Medical College

  • 4:45 PM – 6:00 PM PT
    2160 - Dose Constraints and Planning Considerations for Thoracic Radiation Therapy: Delphi Consensus from a National Survey of Experts
    Location: Hall B2

    Presenter: Julius Weng, MD, BS – MD Anderson Cancer Center

  • 4:45 PM – 6:00 PM PT
    2162 - Pentoxifylline and Vitamin E in Preventing Pneumonitis Using Stereotactic Ablative Radiotherapy in Previously Irradiated Patients
    Location: Hall B2

    Presenter: Andrew Willett, BS, MS4 – University of Louisville School of Medicine

  • 4:45 PM – 6:00 PM PT
    2163 - Vertebral Dose Sparing during Lung and Esophageal Radiation Therapy
    Location: Hall B2

    Presenter: Robert Wilson, MD – UT Health San Antonio MD Anderson Cancer Center

  • 4:45 PM – 6:00 PM PT
    2164 - Socio-Economic Status in Risk of Acute Adverse Events Following Radiotherapy
    Location: Hall B2

    Presenter: Philip Wong, MD – Princess Margaret Cancer Centre

  • 4:45 PM – 6:00 PM PT
    2165 - Induction Immunochemotherapy Followed by Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Leilei Wu

  • 4:45 PM – 6:00 PM PT
    2166 - Predicting local control with dosimetric parameters in patients receiving individualized stereotactic ablative radiotherapy for lung tumors
    Location: Hall B2

    Presenter: Yufan (Fred) Wu, MD, BS – Stanford University

  • 4:45 PM – 6:00 PM PT
    2167 - Risk-Adapted SABR for Ultra-Central Lung Tumors Attaining High BED10 to Targets in a Steep Dose-Response Window of 72-105 Gy under Tumor Tracking: A Planning Study
    Location: Hall B2

    Presenter: Hong Xiang, PhD – Penn Medicine Lancaster General Health

  • 4:45 PM – 6:00 PM PT
    2168 - Pattern of Failure and Re-Irradiation for Stereotactic Radiotherapy Treated Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)
    Location: Hall B2

    Presenter: Dayu Xu, MD

  • 4:45 PM – 6:00 PM PT
    2169 - The Causes of Death and Conditional Survival for Long-Term Survivors of Thymoma
    Location: Hall B2

    Presenter: Kunpeng Xu, MD – Chinese Academy of Medical Sciences and Peking Union Medical College

  • 4:45 PM – 6:00 PM PT
    2170 - Prediction of Lymphopenia and Survival with Baseline Absolute Lymphocyte Count and Irradiated Dose to Immune Cells in Patients with Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Gowoon Yang, MD – Yonsei Cancer Center YUMC

  • 4:45 PM – 6:00 PM PT
    2171 - A Randomized Controlled Phase ? Study of Nab-Paclitaxel vs. Paclitaxel plus Cisplatin in Concomitant Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: wengang Yang, RT – Guizhou Cancer Hospital

  • 4:45 PM – 6:00 PM PT
    2173 - Salvage Thoracic Radiotherapy for Locoregional Recurrence Improves Overall Survival of Patients with Completely Resected PIIIA-N2 NSCLC
    Location: Hall B2

    Presenter: Meng Yuan, MD – None

  • 4:45 PM – 6:00 PM PT
    2175 - Survival Analysis of Patients with Locally Advanced Non-Small Cell Lung Cancer Who Received Neoadjuvant Immunotherapy
    Location: Hall B2

    Presenter: Yaping Xu, PhD – Shanghai Pulmonary Hospital

  • 4:45 PM – 6:00 PM PT
    2176 - Cancer-Related Mortality Rates are Lower in U.S. States with Higher GDP per Capita
    Location: Hall B2

    Presenter: Peter Zaki, MD – University of Washington

  • 4:45 PM – 6:00 PM PT
    2177 - Clinical Outcomes with Thoracic Radiotherapy for Extensive-Stage Small-Cell Lung Cancer in the Era of Immunotherapy: A Retrospective Analysis.
    Location: Hall B2

    Presenter: Chaonan Zhang, MD – National Cancer Center/National Clinical Research Center for Cance

  • 4:45 PM – 6:00 PM PT
    2178 - Oligo-Residual Disease in PD-1/PD-L1 Inhibitors Treated Metastatic Non-Small Cell Lung Cancer: Incidence, Pattern of Failure and Clinical Value of Local Consolidative Therapy
    Location: Hall B2

    Presenter: Jinmeng Zhang, MD

  • 4:45 PM – 6:00 PM PT
    2180 - The Value of Postoperative Radiotherapy in Thymoma with Myasthenia Gravis
    Location: Hall B2

    Presenter: Rongrong Zhou, MD, DO, PhD, BSN – Xiangya Hospital Central South University

  • 4:45 PM – 6:00 PM PT
    2181 - A Nomogram Based on Radiomics and Genomics Factors for Predicting Radiation Pneumonia in Patients with Limited-Stage Small Cell Lung Cancer after Definitive Chemoradiotherapy
    Location: Hall B2

    Presenter: He Zhu, MD

  • 4:45 PM – 6:00 PM PT
    2182 - Contralateral Esophagus Sparing Prevents Symptomatic Esophagitis in Ultra-Central NSCLC Receiving Hypofractionated Radiotherapy
    Location: Hall B2

    Presenter: Lin Zhu, MD, PhD – Harvard Radiation Oncology Program

  • Monday, October 2, 2023
  • 10:45 AM – 12:00 PM PT
    Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostics to harmonize the resistant high TGF-Beta stromal microenvironment with PDL-1 based immunothe

    Presenter: G Lohith, MD – HCG

  • 10:45 AM – 12:00 PM PT
    Quality of Palliative Radiation Therapy Assessed Using Quality Indicators: A Multicenter Survey

    Presenter: Tetsuo Saito, MD, PhD – Arao Municipal Hospital

  • 10:45 AM – 12:00 PM PT
    2183 - Stereotactic Body Radiotherapy (SBRT) for Adrenal Metastases: Practice Patterns at Community-Based Radiotherapy Centers
    Location: Hall B2

    Presenter: Anesa Ahamad, MD, MB, BS, FRCR – GenesisCare

  • 10:45 AM – 12:00 PM PT
    2184 - The Feasibility of Dose-Escalated Radiation Therapy for Glioblastoma Using Biological Image Guided Adaptive Radiotherapy (BIGART)
    Location: Hall B2

    Presenter: Doaa Almeldin, MD, PhD

  • 10:45 AM – 12:00 PM PT
    2185 - Effect of Cobalt-60 Calibration Dose-Rate on Arteriovenous Malformation Obliteration after Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Victoria Anthes, HBSc – Princess Margaret Cancer Center, University Health Network

  • 10:45 AM – 12:00 PM PT
    2186 - Hyperbaric Oxygen Therapy plus Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
    Location: Hall B2

    Presenter: DONATELLA ARPA, MD – IRCCS IRST

  • 10:45 AM – 12:00 PM PT
    2187 - Pre-Treatment MRI Radiomics Can Predict Distant Brain Metastases Following Stereotactic Radiosurgery/Radiotherapy
    Location: Hall B2

    Presenter: Joseph Bae, MS, BS – Stony Brook University

  • 10:45 AM – 12:00 PM PT
    2188 - Symptomatic Posttreatment Edema after Stereotactic Radiotherapy for Intracranial Meningiomas: Patterns and Predictive Factors
    Location: Hall B2

    Presenter: Jean-Paul Bahary, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)

  • 10:45 AM – 12:00 PM PT
    2189 - Tumor Treating Fields (TTFields) for Newly Diagnosed Glioblastoma in the Real World: A Systematic Review and Survival Meta-Analysis
    Location: Hall B2

    Presenter: Matthew Ballo, MD – West Cancer Center & Research Institute

  • 10:45 AM – 12:00 PM PT
    2190 - Leveraging Quantitative Imaging and Machine Learning to Differentiate Radionecrosis from Disease Recurrence in Patients with Brain Metastases
    Location: Hall B2

    Presenter: Mustafa Basree, DO, MS – University of Wisconsin Hospitals and Clinics

  • 10:45 AM – 12:00 PM PT
    2191 - Impact of Concurrent Targeted Therapy and Immunotherapy on the Incidence of Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastases
    Location: Hall B2

    Presenter: Adam Beighley, MD – Kaiser Permanente Los Angeles Medical Center

  • 10:45 AM – 12:00 PM PT
    2192 - Spectroscopic MRI Detects Occult Glioblastoma Invasion during Chemoradiation
    Location: Hall B2

    Presenter: Jonathan Bell, MD, PhD – University of Miami

  • 10:45 AM – 12:00 PM PT
    2193 - Patient-Specific Segmentation-Based Treatment Planning vs. NovoTAL for TTFields Therapy in Glioblastoma
    Location: Hall B2

    Presenter: Brian Berger, MD – Novocure - Williamsburg

  • 10:45 AM – 12:00 PM PT
    2194 - Post-Operative Stereotactic Radiotherapy for Resected Brain Metastases: Results of the Multicenter Analysis (AURORA) of the German Working Group "Stereotactic Radiotherapy"
    Location: Hall B2

    Presenter: Denise Bernhardt, MD – Technical University of Munich (TUM), Radiation Oncology

  • 10:45 AM – 12:00 PM PT
    2195 - Outcomes of Brain Metastases with Suspicious Imaging Undergoing Resection to Evaluate for Radionecrosis vs. Tumor Progression
    Location: Hall B2

    Presenter: Rohini Bhatia, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 10:45 AM – 12:00 PM PT
    2196 - Risk Factors Associated with Development of Peritumoral Edema Following Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma
    Location: Hall B2

    Presenter: Yazeed Kesbeh, MD – Southern California Permanente Medical Group

  • 10:45 AM – 12:00 PM PT
    2196 - Risk Factors Associated with Development of Peritumoral Edema Following Stereotactic Radiosurgery and Radiotherapy for Intracranial Meningioma
    Location: Hall B1

    Presenter: Onita Bhattasali, MD, MPH – Kaiser Permanente Los Angeles Medical Center

  • 10:45 AM – 12:00 PM PT
    2197 - Phase II Randomized Trial of Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases
    Location: Hall B2

    Presenter: Cole Billena, MD – Cleveland Clinic Foundation

  • 10:45 AM – 12:00 PM PT
    2198 - Clinical Outcomes of Patients with Brain Metastases from Colorectal Cancer Treated with Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Anirudh Bommireddy, MD – Anirudh Bommireddy

  • 10:45 AM – 12:00 PM PT
    2199 - Clinical Outcomes for Patients with Brain Metastases from Upper Gastrointestinal Cancer Treated with Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Anirudh Bommireddy, MD – Anirudh Bommireddy

  • 10:45 AM – 12:00 PM PT
    2200 - Conditional Survival Estimates for Malignant Glioma Patients by RPA Class: Secondary Analysis of RTOG 9006
    Location: Hall B2

    Presenter: Matthew Brown, MD – University of Maryland Radiation Oncology

  • 10:45 AM – 12:00 PM PT
    2201 - Stereotactic Body Radiotherapy for Posterior Element Only Spinal Metastases: Outcomes and Validation of Recommended Clinical Target Volume Delineation Practice
    Location: Hall B2

    Presenter: Laura Burgess, MD, MS – Odette Cancer Centre

  • 10:45 AM – 12:00 PM PT
    2203 - Functional Outcomes and Toxicities Associated with SBRT to Bone Metastases Involving the Joint Space
    Location: Hall B2

    Presenter: Hayden Byrd, MD – Vanderbilt University Medical Center

  • 10:45 AM – 12:00 PM PT
    2204 - Institutional Validation Study Inferring 2% MGMT Methylation Positive Impact on Survival in Newly Diagnosed Glioblastoma (GBM) Patients
    Location: Hall B2

    Presenter: Louis Cappelli, DO – Thomas Jefferson University

  • 10:45 AM – 12:00 PM PT
    2205 - Body Mass Index (BMI) at Time of Diagnosis as a Prognostic Indicator in Patients with Newly Diagnosed Glioblastoma (GBM)
    Location: Hall B2

    Presenter: Louis Cappelli, DO – Thomas Jefferson University

  • 10:45 AM – 12:00 PM PT
    2206 - Retrospective Review of the Factors Limiting Optune Initiation in GBM patients
    Location: Hall B2

    Presenter: Luis Carranza Pena, BS – UTHSCSA

  • 10:45 AM – 12:00 PM PT
    2208 - Estimation of Conditional Neurocognitive Function Failure (NCFF) Incidence in Patients Receiving Whole Brain Radiation Therapy (WBRT) for Brain Metastases (BM): Secondary Analysis of NRG CC001
    Location: Hall B2

    Presenter: Hua-Ren Cherng, MD – University of Maryland Medical Center

  • 10:45 AM – 12:00 PM PT
    2209 - Frameless Fractionated Linear Accelerator-Based Stereotactic Radiotherapy for Brain Metastases: Results of a Single-Arm Phase II Multi-Institutional Clinical Trial
    Location: Hall B2

    Presenter: Stephen Chun, MD – MD Anderson Cancer Center

  • 10:45 AM – 12:00 PM PT
    2210 - Cannabis Use Patterns among Patients with Early-Stage Breast Cancer in a Large Multicenter Cohort from a State with Legalized Adult Non-Medical Cannabis
    Location: Hall B2

    Presenter: Matthew Cousins, MD, PhD – Self Regional Healthcare

  • 10:45 AM – 12:00 PM PT
    2211 - A Survival Score for Patients Treated with Whole-Brain Radiotherapy plus Simultaneous Integrated Boost for Brain Metastases
    Location: Hall B2

    Presenter: Florian Cremers, PhD – University of Luebeck

  • 10:45 AM – 12:00 PM PT
    2212 - Rates of Radiosurgical Decompression for High Grade Epidural Spinal Disease due to Solid Tumor Metastases
    Location: Hall B2

    Presenter: Anjali D'Amiano, BS – Johns Hopkins University

  • 10:45 AM – 12:00 PM PT
    2213 - A Potential Cause for Unexplained Radiation Toxicity in Proton Therapy
    Location: Hall B2

    Presenter: Juliane Daartz, PhD – Massachusetts General Hospital

  • 10:45 AM – 12:00 PM PT
    2214 - Stratifying Response to Stereotactic Radiosurgery for Spinal Metastases by Primary Site Genomic Mutations
    Location: Hall B2

    Presenter: Ethan Damron, BS – McGovern Medical School

  • 10:45 AM – 12:00 PM PT
    2215 - Patient-Free Simulation: Analysis of Hospitalized Patients Treated without CT Simulation
    Location: Hall B2

    Presenter: Erik Davies, MD – Cleveland Clinic Taussig Cancer Center

  • 10:45 AM – 12:00 PM PT
    2216 - Inpatient Simulation Resource Utilization for Inpatient Radiation Oncology Consults
    Location: Hall B2

    Presenter: Edward Dee, MD – Memorial Sloan Kettering Cancer Center

  • 10:45 AM – 12:00 PM PT
    2217 - Helical Tomotherapy Planning Technique Improves Dosimetry for Hippocampal-Avoidant Whole Brain Radiotherapy Compared with VMAT
    Location: Hall B2

    Presenter: David DiBartolo, CMD – NYU Langone Health - Long Island

  • 10:45 AM – 12:00 PM PT
    2218 - Vertebral Compression Fracture Post Spine Stereotactic Body Radiotherapy: The Role of Vertebral Endplate
    Location: Hall B2

    Presenter: Khaled Dibs, MD – The James Cancer Hospital & Solove Research Institute

  • 10:45 AM – 12:00 PM PT
    2219 - Inter-fractional Assessment during MR-guided Online Adaptive Radiotherapy for Glioblastoma
    Location: Hall B2

    Presenter: Shouliang Ding, MS – Sun Yat-Sen University Cancer Center

  • 10:45 AM – 12:00 PM PT
    2220 - Influence of Eyes Movement on Lens Dose during MR-Guided Radiotherapy for Brain Tumor
    Location: Hall B2

    Presenter: Shouliang Ding, MS – Sun Yat-Sen University Cancer Center

  • 10:45 AM – 12:00 PM PT
    2221 - Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series
    Location: Hall B2

    Presenter: Ammoren Dohm, MD – H. Lee Moffitt Cancer Center and Research Institute

  • 10:45 AM – 12:00 PM PT
    2222 - Identification of Excellent Prognosis IDH Wildtype Glioblastomas Using Genomic and Metabolic Profiling
    Location: Hall B2

    Presenter: Donna Edwards, MD, PhD – University of Michigan

  • 10:45 AM – 12:00 PM PT
    2223 - The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases
    Location: Hall B2

    Presenter: Jordan Eichholz, MS, BS – Memorial Sloan Kettering Cancer Center

  • 10:45 AM – 12:00 PM PT
    2226 - Stereotactic Radiosurgery as an Effective and Safe Treatment Modality in Central Nervous System Lymphoma, a Single Institution Experience
    Location: Hall B2

    Presenter: Fatemeh Fekrmandi, MD, MS – Roswell Park Comprehensive Cancer Center

  • 10:45 AM – 12:00 PM PT
    2227 - Validation of the Prognostic Index for Spine Metastasis (PRISM) Score for Stratifying Survival in Patients Treated with Spinal Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Marcus Florez, PhD – Baylor College of Medicine

  • 10:45 AM – 12:00 PM PT
    2228 - A Phase II Trial of Intraoperative Radiotherapy after Surgical Resection of Brain Metastases: Feasibility and Efficacy NCT04847284
    Location: Hall B1

    Presenter: Palmira Foro, MD, PhD – Hospital Del Mar - Parc de Salut Mar

  • 10:45 AM – 12:00 PM PT
    2229 - Use of Lattice Therapy for Dose-Escalation in Palliative Treatment of Bulky Head and Neck Tumors
    Location: Hall B2

    Presenter: Andrew Frankart, MD – University of Cincinnati

  • 10:45 AM – 12:00 PM PT
    2230 - Stereotactic Radiosurgery (SRS) for Large Brain Metastases: Dosimetric and Clinical Predictors of Local Progression and Radionecrosis
    Location: Hall B2

    Presenter: Kelsey Frechette, MD – Mayo Clinic College of Medicine and Science Rochester

  • 10:45 AM – 12:00 PM PT
    2231 - Stereotactic Body Radiation Therapy for Large Volume Solid Tumor Spinal Metastases Involving Three or More Contiguous Vertebral Levels
    Location: Hall B2

    Presenter: Ulysses Gardner, MD, MBA – Johns Hopkins Hospital

  • 10:45 AM – 12:00 PM PT
    2232 - Extrapulmonary Small Cell Carcinoma: A Single Institution Review of Brain Metastases, Treatment Paradigms and Patient Outcomes
    Location: Hall B2

    Presenter: Sarah Glynn, DO – Wake Forest Baptist Health

  • 10:45 AM – 12:00 PM PT
    2233 - Clinical Outcomes and Dosimetric Predictive Factors in Patients Undergoing Reirradiation for Recurrent Meningiomas
    Location: Hall B2

    Presenter: Daniela Greto, MD

  • 10:45 AM – 12:00 PM PT
    2234 - Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases
    Location: Hall B2

    Presenter: Jacob Hall, MD – UNC Health

  • 10:45 AM – 12:00 PM PT
    2235 - Communicating the External Beam Radiotherapy Experience (CEBRE) Discussion Guides: Real World Implementation and Evaluation
    Location: Hall B2

    Presenter: Alicia Haydon

  • 10:45 AM – 12:00 PM PT
    2237 - Stereotactic Radiosurgery (SRS) for Brain Metastasis in the Era of Evolving Systemic Treatment (Immunotherapy or Targeted Therapy) in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Location: Hall B2

    Presenter: Ying Hou, MD – University of Kansas Cancer Center

  • 10:45 AM – 12:00 PM PT
    2238 - Modeling Gamma Knife Radiosurgical Toxicity for Multiple Brain Metastases
    Location: Hall B2

    Presenter: Eric Hsu, MD, PhD – JPS Health

  • 10:45 AM – 12:00 PM PT
    2239 - Pretreatment Clinical Parameters Associated with Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-Institutional Brain Metastases Cohort
    Location: Hall B2

    Presenter: Christina Huang, MD, MS – Duke University School of Medicine

  • 10:45 AM – 12:00 PM PT
    2240 - CNS Control after First-Line Osimertinib in Patients with Metastatic EGFR-Mutant NSCLC
    Location: Hall B2

    Presenter: Caressa Hui, MD, BS – Stanford

  • 10:45 AM – 12:00 PM PT
    2242 - Quality of Palliative Radiation Therapy Assessed Using Quality Indicators: A Multicenter Survey
    Location: Hall B2

    Presenter: Nobuki Imano, MD, PhD – Hiroshima University

  • 10:45 AM – 12:00 PM PT
    2243 - A Pilot Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for Oligometastatic Hormone Sensitive Prostate Cancer
    Location: Hall B2

    Presenter: Brandon Imber, MD, MS – Memorial Sloan Kettering Cancer Center

  • 10:45 AM – 12:00 PM PT
    2244 - MR-Guided Stereotactic Ablative Body Radiotherapy for Pancreatic Oligometastases from Renal Cell Carcinoma
    Location: Hall B2

    Presenter: Martijn Intven, MD, PhD – University Medical Center Utrecht

  • 10:45 AM – 12:00 PM PT
    2245 - Evaluation of Brain Atrophy after One Year of Whole Brain Irradiation Using Voxel Based Morphometry
    Location: Hall B2

    Presenter: Takeshi Ito, MD – Nagaoka RedCross Hospital

  • 10:45 AM – 12:00 PM PT
    2246 - A Pilot Study of Simulation-Free Hippocampal-Avoidance Whole Brain Radiotherapy Using Diagnostic MR-Based and Online Adaptive Planning
    Location: Hall B2

    Presenter: Kylie Kang, MD, MSCI – University of Washington School of Medicine

  • 10:45 AM – 12:00 PM PT
    2247 - Exploiting Enhanced Lipid Metabolism in Glioblastoma through Diet Modification
    Location: Hall B2

    Presenter: Shiva Kant, PhD – William Beaumont Hospital

  • 10:45 AM – 12:00 PM PT
    2248 - Predictors of Long-Term Survival in Patients Treated for Oligometastases
    Location: Hall B2

    Presenter: Johnny Kao, MD – Good Samaritan University Hospital

  • 10:45 AM – 12:00 PM PT
    2249 - Palliative Whole Brain Radiotherapy: International State of Practice 2022
    Location: Hall B2

    Presenter: Emily Keit, MD, BS – Moffitt Cancer Center

  • 10:45 AM – 12:00 PM PT
    2250 - A Combined Phase 0/2 "Trigger" Trial Evaluating Pamiparib or Olaparib with Concurrent Radiotherapy in Patients with Newly-Diagnosed or Recurrent Glioblastoma
    Location: Hall B2

    Presenter: William Kennedy, MD – Barrow Neurological Institute

  • 10:45 AM – 12:00 PM PT
    2251 - Hippocampal Avoidance Whole Brain Radiotherapy with Reduced Whole Brain Dose Enables Sparing of Hippocampi without Increased Risk of Distant Brain Failure in Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Melin Khandekar, MD, PhD – Massachusetts General Hospital

  • 10:45 AM – 12:00 PM PT
    2252 - Frameless Fractionated Stereotactic Radiosurgery for Brain Metastases: An Institutional Series of 145 Cases
    Location: Hall B2

    Presenter: Sarah Kilic, MD, MS – Arizona Oncology

  • 10:45 AM – 12:00 PM PT
    2254 - MGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy
    Location: Hall B2

    Presenter: Connor Kinslow, MD – Columbia University Irving Medical Center

  • 10:45 AM – 12:00 PM PT
    2255 - Role of Fractionation in Local Control of Spinal Metastases Treated with Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Daniella Klebaner, MD, BS, MPH – Stanford University Cancer Center

  • 10:45 AM – 12:00 PM PT
    2256 - Escalating SBRT Dose to Hypoxic Centers of Large Pulmonary Tumors via Simultaneous Integrated Boost Confers Effective Local Control with Minimal Toxicity
    Location: Hall B2

    Presenter: James Knight, MD – University of Kentucky

  • 10:45 AM – 12:00 PM PT
    2257 - Progression-Free Survival in Patients with WHO-2 Meningioma Undergoing Active Surveillance Based on DOTATATE PET Evidence of Gross Total Resection: Prospective Observational Study
    Location: Hall B2

    Presenter: Jonathan Knisely, MD, FASTRO – Weill Cornell Medical College

  • 10:45 AM – 12:00 PM PT
    2258 - Classification of Patients with Painful Tumors to Predict the Response to Palliative Radiotherapy
    Location: Hall B2

    Presenter: Yutaro Koide, MD, PhD – Aichi Cancer Center Hospital

  • 10:45 AM – 12:00 PM PT
    2259 - Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery (SSRS): Phase 1 Proof-of-Concept Interim Analysis
    Location: Hall B2

    Presenter: Alonso La Rosa, MD – Miami Cancer Institute

  • 10:45 AM – 12:00 PM PT
    2259 - Characterization of Large Brain Metastases with 18F-Fluciclovine PET/CT Treated with Staged Stereotactic Radiosurgery (SSRS): Phase 1 Proof-of-Concept Interim Analysis
    Location: Hall B1

    Presenter: Rupesh Kotecha, MD – Miami Cancer Institute

  • 10:45 AM – 12:00 PM PT
    2260 - Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-Institutional Registry
    Location: Hall B2

    Presenter: David Brachman, MD – GammaTile

  • 10:45 AM – 12:00 PM PT
    2260 - Surgically Targeted Radiation Therapy (STaRT) for Brain Metastases: Initial Experience from a Prospective Multi-Institutional Registry
    Location: Hall B1

    Presenter: Rupesh Kotecha, MD – Miami Cancer Institute

  • 10:45 AM – 12:00 PM PT
    2261 - Assessment of Minimum Dose As a Strong Predictor of Local Failure after Spine SBRT
    Location: Hall B2

    Presenter: Roman Kowalchuk, MD, BS – Mayo Clinic College of Medicine and Science Rochester

  • 10:45 AM – 12:00 PM PT
    2262 - Hypoxia-Inducible Transgelin-2 Confers Treatment Resistance through Activation of PI3K/Akt/GSK3ß Pathway in Glioblastoma
    Location: Hall B2

    Presenter: Ashok Kumar, PhD – The Ohio State University-Comprehensive Cancer Center

  • 10:45 AM – 12:00 PM PT
    2263 - A Comparison of Local Failure and Necrosis Following Different Radiosurgery Strategies for Large Brain Metastases
    Location: Hall B2

    Presenter: Tugce Kutuk, MD – Baptist Health South Florida

  • 10:45 AM – 12:00 PM PT
    2264 - Outcomes of Stereotactic Body Radiation Therapy (SBRT) for Femur Oligometastases
    Location: Hall B2

    Presenter: Caitlyn Kwan, BS – Dana-Farber/Brigham and Women's Cancer Center

  • 10:45 AM – 12:00 PM PT
    2265 - A Genomic Score to Predict Local Control among Patients with Brain Metastases Managed with Radiation
    Location: Hall B2

    Presenter: Nayan Lamba, MD – Harvard Radiation Oncology Program

  • 10:45 AM – 12:00 PM PT
    2266 - Fractionated Radiosurgery Improves Survival in Large Volume Relapsed Glioblastoma Multiforme
    Location: Hall B2

    Presenter: Luis Larrea, MD, PhD – Hospital Vithas Valencia Consuelo

  • 10:45 AM – 12:00 PM PT
    2267 - Long-Term Outcomes of Non-Vestibular Cranial Nerve Schwannomas Treated with Fractionated Stereotactic Radiotherapy and Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Talya Laufer, MD – Sidney Kimmel Cancer Center at Thomas Jefferson University

  • 10:45 AM – 12:00 PM PT
    2268 - Prospective and Comprehensive Characterization of an Inpatient Radiation Oncology Consult Service: Examining Interdisciplinary Coordination of Palliative Radiation Access and Receipt
    Location: Hall B2

    Presenter: Anna LaVigne, MD – Johns Hopkins University School of Medicine

  • 10:45 AM – 12:00 PM PT
    2269 - RBE Model Based Proton Planning of Stereotactic Body Radiotherapy for Spine Metastasis: A Dosimetric Analysis
    Location: Hall B2

    Presenter: Michael LeCompte, MD, MS – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 10:45 AM – 12:00 PM PT
    2270 - Adjuvant Radiotherapy in Atypical Meningioma: Are the Risks Worth the Benefit?
    Location: Hall B2

    Presenter: Grace Lee, MD – Harvard Radiation Oncology Program

  • 10:45 AM – 12:00 PM PT
    2271 - Choosing Wisely between Radiotherapy Dose-Fractionation Schedules: The Molecular Graded Prognostic Assessment (molGPA) for Elderly Glioblastoma (eGBM-molGPA)
    Location: Hall B2

    Presenter: Hye In Lee, MD – Seoul National University Hospital

  • 10:45 AM – 12:00 PM PT
    2272 - A Prospective Study Assessing the Efficacy and Toxicity of Stereotactic Body Radiation Therapy for Oligometastatic Bone Metastases
    Location: Hall B2

    Presenter: Joyce Lee, BS – Case Western Reserve School of Medicine

  • 10:45 AM – 12:00 PM PT
    2273 - Clinical Outcomes with Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer: Results from a Prospective Registry Trial
    Location: Hall B2

    Presenter: Katie Lee, MD, PhD – Harvard Radiation Oncology Program

  • 10:45 AM – 12:00 PM PT
    2274 - Spatially Resolved Whole Transcriptome Analysis of Histologically-Characterized Tissue Microarray of Patient-Matched Primary and Recurrent Glioblastomas to Identify Underlying Mechanisms of Treatment
    Location: Hall B2

    Presenter: Christopher Willey, MD, PhD – University of Alabama Birmingham School of Medicine

  • 10:45 AM – 12:00 PM PT
    2275 - Immune Checkpoint Inhibition and Single Fraction Stereotactic Radiosurgery in Non-Small Cell Lung Cancer Brain Metastases: An International Multicenter Study of 395 Patients
    Location: Hall B2

    Presenter: Eric Lehrer, MD, MS – Mayo Clinic

  • 10:45 AM – 12:00 PM PT
    2276 - Clinical Outcomes Following an Initial Stereotactic Radiosurgery Course for Brain Metastases from Melanoma
    Location: Hall B2

    Presenter: Jim Leng, MD – Duke University

  • 10:45 AM – 12:00 PM PT
    2277 - Safety and Efficacy of Spatially Fractionated Radiation Therapy Using Lattice Radiation for Metastatic and/or Bulky Disease
    Location: Hall B2

    Presenter: Anchuan Li, MD – Fujian Medical University Union Hospital

  • 10:45 AM – 12:00 PM PT
    2278 - Examining the Efficacy and Safety Profile of Palliative Radiotherapy Using 30 Gy in 5 Fractions
    Location: Hall B2

    Presenter: Zhang Hao (Jim) Li, MD – BC Cancer Agency

  • 10:45 AM – 12:00 PM PT
    2279 - Intensity-Modulated Radiotherapy (IMRT) for the Treatment of Cushings Disease
    Location: Hall B2

    Presenter: Xin Lian, MD, PhD – Chinese Academy of Medical Sciences and Peking Union Medical College

  • 10:45 AM – 12:00 PM PT
    2280 - Optimizing Radiation Therapy for Brain Metastasis Patients: A Comparative Study of Knowledge-Based Treatment Planning with HyperArc
    Location: Hall B2

    Presenter: Yu-Wei Lin, MD, PhD, MS – Kaohsiung Veterans General Hospital

  • 10:45 AM – 12:00 PM PT
    2281 - Safety Profile of Combination Treatment with Radiotherapy and Immune Checkpoint Blockades: A Multi-Institute Real World Experience
    Location: Hall B2

    Presenter: Cheng Sheng Liu, MD – Taipei Medical University Hospital

  • 10:45 AM – 12:00 PM PT
    2282 - Adjuvant Chemoradiotherapy within One Year of Resection for Molecularly Defined Astrocytoma
    Location: Hall B2

    Presenter: S. John Liu, MD, PhD – UCSF

  • 10:45 AM – 12:00 PM PT
    2283 - Comparison of Hippocampal Volume Change after Whole-Brain Radiotherapy with and without Hippocampal Avoidance: A Post-Hoc Analysis of a Phase II Randomized Trial
    Location: Hall B2

    Presenter: Ting-Fong Liu, MD – National Taiwan University Hospital

  • 10:45 AM – 12:00 PM PT
    2284 - Clinical Outcomes Following Postoperative Cavity Stereotactic Radiosurgery for Brain Metastases
    Location: Hall B2

    Presenter: Kenneth Lodin, MD – Kaiser Permanente - Pasadena

  • 10:45 AM – 12:00 PM PT
    2285 - Local Control after Re-Irradiation of Spinal Metastases with Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: John Lucido, PhD – Mayo Clinic Health System

  • 10:45 AM – 12:00 PM PT
    2288 - Neurologic Events and Outcomes in Patients Receiving Proton and Photon Reirradiation for High Grade Non-Codeleted Gliomas
    Location: Hall B2

    Presenter: Taylor MacDonald, DO – University of Cincinnati Medical Center/College of Medicine

  • 10:45 AM – 12:00 PM PT
    2289 - Early Bone Mineral Density Changes and Endocrinal Dysfunction in Childhood Brain Tumor Patients: A Prospective Study
    Location: Hall B2

    Presenter: Renu Madan, MD – Post Graduate Institute of Medical Education and Research

  • 10:45 AM – 12:00 PM PT
    2290 - Efficacy of Protontherapy in Atypical Meningiomas
    Location: Hall B2

    Presenter: Hamid Mammar, PhD, MD – Institut Curie

  • 10:45 AM – 12:00 PM PT
    2292 - Outcomes of a Single Isocenter Brain Multi-Metastases Linear Accelerator Delivered Stereotactic Radiosurgery (SRS)
    Location: Hall B2

    Presenter: Jacob Mapp, BS – The University of Arizona - Radiation Oncology

  • 10:45 AM – 12:00 PM PT
    2293 - Phase II Trial of Definitive Therapy for Osseous Oligometastases in Breast Cancer
    Location: Hall B2

    Presenter: Kathryn Marqueen, MD – University of Texas MD Anderson Cancer Center

  • 10:45 AM – 12:00 PM PT
    2294 - Reirradiation vs. Systemic Therapy vs. Combination Therapy for Recurrent High-Grade Glioma: A Meta-Analysis of Survival and Toxicity
    Location: Hall B2

    Presenter: Ravi Marwah, MBBS – Townsville University Hospital

  • 10:45 AM – 12:00 PM PT
    2295 - Development of an RPA for Prediction of Radiation Necrosis Following Single Fraction Gamma Knife Radiosurgery for Brain Metastases
    Location: Hall B2

    Presenter: Zachary Mayo, MD – Cleveland Clinic Foundation

  • 10:45 AM – 12:00 PM PT
    2296 - WBRT is Associated with Higher Rates of Hematologic Toxicity than Stereotactic Radiosurgery in Brain Metastasis Patients
    Location: Hall B2

    Presenter: Aliah McCalla, MD, BS – Central Michigan University College of Medicine

  • 10:45 AM – 12:00 PM PT
    2297 - Pneumonitis after Palliative Thoracic Radiotherapy +/- Immunotherapy: A Retrospective Propensity-Matched Cohort Study
    Location: Hall B2

    Presenter: David Miller, MD, MS – Perelman School of Medicine at the University of Pennsylvania

  • 10:45 AM – 12:00 PM PT
    2297 - Pneumonitis after Palliative Thoracic Radiotherapy +/- Immunotherapy: A Retrospective Propensity-Matched Cohort Study
    Location: Hall B2

    Presenter: Sylvia Rhodes, BA – University of Pennsylvania Perelman School of Medicine

  • 10:45 AM – 12:00 PM PT
    2298 - Pulsed Reduced Dose Rate Re-Irradiation for Recurrent Grade 4 Gliomas: A Retrospective Analysis of Safety and Efficacy
    Location: Hall B2

    Presenter: Brett Morris, MD, PhD – University of Wisconsin

  • 10:45 AM – 12:00 PM PT
    2299 - What Do We Know about Grade 3 Intracranial Ependymoma in Adults?
    Location: Hall B2

    Presenter: Rafal Tarnawski, MD, PhD – Maria Sklodowska-Curie National Research Institute of Oncology

  • 10:45 AM – 12:00 PM PT
    2300 - Early Outcomes from Proton Craniospinal Irradiation (pCSI) for Leptomeningeal Disease from Solid Tumors
    Location: Hall B2

    Presenter: Susan McGovern, MD, PhD – MD Anderson Cancer Center

  • 10:45 AM – 12:00 PM PT
    2300 - Early Outcomes from Proton Craniospinal Irradiation (pCSI) for Leptomeningeal Disease from Solid Tumors
    Location: Hall B2

    Presenter: Lewis Nasr, MD, MS

  • 10:45 AM – 12:00 PM PT
    2301 - Dosimetric Impact of Seed Segmentation in GammaTile Surgically Targeted Radiation Therapy for Gliomas and Brain Metastases Cases
    Location: Hall B2

    Presenter: Sook Kien Ng, PhD – Indiana University School of Medicine

  • 10:45 AM – 12:00 PM PT
    2302 - Dosimetric Impact of Radiolucent Carbon Fiber Hardware for Post-Operative Spine Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: Macklin Nguyen, MD – University of Washington

  • 10:45 AM – 12:00 PM PT
    2303 - RAPid SimPLE (RAPPLE) Targeted Radiation Treatment vs. Whole Brain Radiotherapy: A Retrospective Study of Matched Patients with Brain Metastases and Poor Prognosis
    Location: Hall B2

    Presenter: Alan Nichol, MD, FRCPC – BC Cancer - Vancouver Centre

  • 10:45 AM – 12:00 PM PT
    2304 - Fracture Risk Following Lumbosacral Spine SBRT in Patients Having Received Previous Whole Pelvis Radiation Therapy
    Location: Hall B2

    Presenter: Elizabeth Obi, MD, BA – Cleveland Clinic Foundation

  • 10:45 AM – 12:00 PM PT
    2305 - Predictors of Tumor Dynamics during a 6-Week Course of Chemoradiotherapy for Glioblastoma
    Location: Hall B2

    Presenter: Wee Loon Ong, MBBS – Alfred Health Radiation Oncology

  • 10:45 AM – 12:00 PM PT
    2306 - Outcomes Specific to Spinal Metastases with Paraspinal Disease Extension Following Spine Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Wee Loon Ong, MBBS – Alfred Health Radiation Oncology

  • 10:45 AM – 12:00 PM PT
    2307 - Quantitative Analysis of BrainAge using Neuroimaging Data to Estimate Radiation-Induced Brain Aging and Associations with Cognitive Changes in Brain Metastases Patients
    Location: Hall B2

    Presenter: Megan Orr, MD – UC San Diego Health

  • 10:45 AM – 12:00 PM PT
    2308 - Stereotactic Body Radiotherapy (SBRT) for Sacral Metastases: Deviation from Recommended Target Volume Delineation Predicts Higher Risk of Local Failure
    Location: Hall B2

    Presenter: Daniel Palhares, MD, MSc – Sunnybrook Odette Cancer Centre

  • 10:45 AM – 12:00 PM PT
    2309 - Population Analysis of SABR/SRS for the Treatment of Metastatic Cancer in a Jurisdiction of 15 Million People
    Location: Hall B2

    Presenter: Jason Pantarotto, MD, FRCPC – Ontario Health - Cancer Care Ontario

  • 10:45 AM – 12:00 PM PT
    2310 - Oncologic Outcomes and Safety After Spinal Re-Irradiation with Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: Palak Patel, MD, BS – Johns Hopkins Medicine

  • 10:45 AM – 12:00 PM PT
    2311 - Interobserver Variation in Tumor Delineation of Liver Metastases using Magnetic Resonance Imaging
    Location: Hall B2

    Presenter: Julia Peltenburg, MD – Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AVL)

  • 10:45 AM – 12:00 PM PT
    2312 - Advancing beyond the Hippocampus to Preserve Cognition for Patients with Brain Metastases: Dosimetric Results from a Phase 2 Trial of Memory-Avoidance Whole Brain Radiotherapy
    Location: Hall B2

    Presenter: Haley Perlow, MD – Ohio State University James Cancer Hospital

  • 10:45 AM – 12:00 PM PT
    2313 - Stereotactic Radiosurgery (SRS) vs. Hypofractionated Stereotactic Radiotherapy (SRT) in Brain Metastases: Kinetic Responses
    Location: Hall B2

    Presenter: Siwadol Pleanarom, MS – Siriraj Hospital Mahidol University

  • 10:45 AM – 12:00 PM PT
    2314 - Multi-Institutional Outcomes Following Stereotactic Radiosurgery for Gastrointestinal Brain Metastases
    Location: Hall B2

    Presenter: Jamiluddin Qazi, MD – Duke University Medical Center

  • 10:45 AM – 12:00 PM PT
    2315 - Impact of Prior Radiation Therapy on Bone Mineral Density Change Over Time: Secondary Analysis of the Control Arm of a Phase III Randomized Trial
    Location: Hall B2

    Presenter: Soumyajit Roy, MBBS – Rush University Medical Center

  • 10:45 AM – 12:00 PM PT
    2317 - Multi-Institutional Study of Stereotactic Radiosurgery for Recurrent WHO Grade 2/3 Meningiomas: An Interim Analysis
    Location: Hall B2

    Presenter: Geoffrey Sedor, MD, MS, BS – NewYork-Presbyterian Hospital Columbia

  • 10:45 AM – 12:00 PM PT
    2318 - Dosimetric Analysis of Local Failure Outcomes and Vertebral Compression Fracture Risk in Single-Fraction Spine Stereotactic Radiosurgery for Metastatic Sarcoma
    Location: Hall B2

    Presenter: Mihir Shanker, MD – Queensland Health

  • 10:45 AM – 12:00 PM PT
    2319 - Clinical Variables Impact Time to Inpatient Radiation Oncology Consultation for Spine Metastases: A Single Institution Study
    Location: Hall B2

    Presenter: Saad Sheikh, MD – Case Western University Hospital

  • 10:45 AM – 12:00 PM PT
    2320 - Fractionated Stereotactic Radiotherapy vs. Stereotactic Radiosurgery for Vestibular Schwannoma: Local Control, Hearing Preservation, and Toxicities
    Location: Hall B2

    Presenter: Sanjna Shelukar, BS – Thomas Jefferson University

  • 10:45 AM – 12:00 PM PT
    2321 - Staged Stereotactic Radiosurgery as a Novel Adaptive Approach to Salvage Previously Irradiated Brain Metastases
    Location: Hall B2

    Presenter: Dana Shor, MBBS – Sunnybrook Odette Cancer Centre

  • 10:45 AM – 12:00 PM PT
    2324 - Adrenal Stereotactic Body Radiation Therapy: Do Dosimetric Factors Predict for Grade 2+ Lymphopenia?
    Location: Hall B2

    Presenter: Pranit Singh, BS – USF Health Morsani College of Medicine

  • 10:45 AM – 12:00 PM PT
    2325 - Factors Associated with Short Interval from Treatment to Death in Patients Treated with Stereotactic Body Radiotherapy for Lung Metastases: Experience at a Large Academic Facility
    Location: Hall B2

    Presenter: Ethan Steele, MD, MS – University of North Carolina at Chapel Hill

  • 10:45 AM – 12:00 PM PT
    2326 - Incidence and Prognostic Factors of Painful Vertebral Compression Fracture Caused by Spine Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Kentaro Taguchi, MD – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

  • 10:45 AM – 12:00 PM PT
    2327 - Assessment of Local and Regional Control in Atypical (WHO Grade 2) Meningiomas Receiving Fractioned Stereotactic Radiotherapy
    Location: Hall B2

    Presenter: Madyson Taylor, MS – Heersink School of Medicine

  • 10:45 AM – 12:00 PM PT
    2328 - Stereotactic Body Radiotherapy (SBRT) for Breast Cancer Spinal Metastases is Associated with Low Rates of Long-Term Local Failure (LF) and Vertebral Compression Fracture (VCF) Independent of Molecular
    Location: Hall B2

    Presenter: Bryce Thomsen, MD – University of Toronto

  • 10:45 AM – 12:00 PM PT
    2329 - Patient-Reported Cognitive Outcomes and Survival after Stereotactic Radiosurgery for 15 or More Brain Metastases
    Location: Hall B2

    Presenter: Rituraj Upadhyay, MD, MBBS, DNB – Ohio State University

  • 10:45 AM – 12:00 PM PT
    2330 - Conformality Indices and Brain Dose Objective for Multi-Lesion Brain Single Isocenter Linac-Based Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Sarah Ashmeg, PhD – UPMC

  • 10:45 AM – 12:00 PM PT
    2331 - Hypofractionated Stereotactic Radiotherapy vs. Single Fraction Stereotactic Radiosurgery to the Resection Cavity of Brain Metastases after Surgical Resection (SATURNUS trial): A Prospective, Randomize
    Location: Hall B2

    Presenter: Maria Waltenberger, MD – TU Muenchen

  • 10:45 AM – 12:00 PM PT
    2332 - Radiation Necrosis following SRS or FSRT with Higher BED for Brain Metastases >20 mm
    Location: Hall B2

    Presenter: Elisa Marie Werner, MD – UKSH Campus Luebeck

  • 10:45 AM – 12:00 PM PT
    2333 - Outcomes of Tolerability, Acute Toxicity and Quality of Life from MR-Guided Radiation Therapy (1.5T MR-Linac) for Liver Metastases in the MOMENTUM Study
    Location: Hall B2

    Presenter: Rosalyne Westley – The Royal Marsden Hospital

  • 10:45 AM – 12:00 PM PT
    2334 - Clinical Outcomes and Patterns of Failure in Patients with High-Risk Atypical Meningioma Treated with Single Fraction vs. Hypofractionated Gamma Knife Radiosurgery
    Location: Hall B2

    Presenter: Yen-Ruh Wuu, MD – Northwell Health

  • 10:45 AM – 12:00 PM PT
    2335 - Prioritizing Radiation and Targeted Systemic Therapy in Patients with Resected Brain Metastases from Lung Cancer Primaries with Targetable Mutations: A Report from a Multi-Site Single Institution
    Location: Hall B2

    Presenter: Yen-Ruh Wuu, MD – Northwell Health

  • 10:45 AM – 12:00 PM PT
    2336 - A Prospective Clinical Trial of Radiotherapy Combined with PD-1 Inhibitors and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Advanced Refractory Solid Tumors
    Location: Hall B2

    Presenter: Pengfei Xing, MD

  • 10:45 AM – 12:00 PM PT
    2337 - An Innovative Regimen Basing on HFRT/SBRT and RC48-ADC Coactivation for Salvage Therapy in Patients with HER2-Expressing Advanced Solid Tumors
    Location: Hall B2

    Presenter: Meiling Xu, MD, PhD, RT – The Second Affiliated Hospital of Soochow University

  • 10:45 AM – 12:00 PM PT
    2338 - The Safety and Efficacy of SCART for Bulky Metastatic or Recurrent Cancer, a Phase I Study
    Location: Hall B2

    Presenter: Weisi Yan, MD, PhD – Golden Comprehensive Medicine

  • 10:45 AM – 12:00 PM PT
    2339 - Predicting Neurocognitive Decline in Multiple Brain Metastases Patients Undergoing Distributed Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Zi Yang, PhD – Stanford University

  • 10:45 AM – 12:00 PM PT
    2340 - Overall Survival Prediction in Stereotactic Radiosurgery Patients with Glioblastoma Via a Deep-Learning Approach
    Location: Hall B2

    Presenter: Zi Yang, PhD – Stanford University

  • 10:45 AM – 12:00 PM PT
    2341 - Stereotactic Radiosurgery for Small Intact Brain Metastasis: A Comparative Evaluation of 3 Different Single Fraction Prescription Doses
    Location: Hall B2

    Presenter: Sreenija Yarlagadda, MD – Miami Cancer Institute

  • 10:45 AM – 12:00 PM PT
    2342 - MD Anderson Phase III Randomized Preoperative Stereotactic Radiosurgery (SRS) vs. Postoperative SRS for Brain Metastases Trial
    Location: Hall B2

    Presenter: Debra Yeboa, MD – MD Anderson Cancer Center

  • 10:45 AM – 12:00 PM PT
    2343 - Dose Escalated Radiotherapy is Associated with Improved Outcomes for High Grade Meningioma
    Location: Hall B2

    Presenter: K. Liang Zeng, MD – Sunnybrook Odette Cancer Centre

  • 10:45 AM – 12:00 PM PT
    2344 - Efficacy and Safety of Multifraction Stereotactic Radiation Therapy with Volumetric Modulated Arc Therapy Technique for Multiple Brain Metastases
    Location: Hall B2

    Presenter: Mai Zhang, MS

  • 10:45 AM – 12:00 PM PT
    2345 - GlioPredictor: A Deep Learning Model for Identification of High-Risk Low Grade Glioma toward Adjuvant Treatment Planning
    Location: Hall B2

    Presenter: Shuhua Zheng, DO, PhD – Northwestern Feinberg School of Medicine

  • 3:00 PM – 4:00 PM PT
    2346 - Predictors of Locoregional Recurrence and Distant Failure after Neoadjuvant Chemotherapy Among Patients Treated with Mastectomy Versus Breast-Conserving Surgery
    Location: Hall B2

    Presenter: Hazim Ababneh, MD – Massachusetts General Hospital

  • 3:00 PM – 4:00 PM PT
    2347 - CANTO: Skin Toxicities Evaluation of a Multicenter Large Prospective Cohort of Irradiated Patients for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Sofiane Allali, MD

  • 3:00 PM – 4:00 PM PT
    2348 - Timing of physical therapy to optimize shoulder range of motion among patients receiving breast radiotherapy
    Location: Hall B2

    Presenter: Carolyn Baek, DPT, CLT – Massachusetts General Hospital

  • 3:00 PM – 4:00 PM PT
    2349 - Interim Analysis of a Non-Randomized Prospective Trial Comparing Hypofractionated Post-Mastectomy Radiotherapy (HF-PMRT) to Conventional Post-Mastectomy Radiotherapy (CF-PMRT) for Breast Cancer (BC) P
    Location: Hall B2

    Presenter: Marc Vincent Barcelona, MD – Princess Margaret Cancer Centre

  • 3:00 PM – 4:00 PM PT
    2350 - Decreasing Skin Toxicity in Whole Breast Irradiation with Helical Tomotherapy IMRT
    Location: Hall B2

    Presenter: Awens Alphonse, MS – Baptist Health

  • 3:00 PM – 4:00 PM PT
    2350 - Decreasing Skin Toxicity in Whole Breast Irradiation with Helical Tomotherapy IMRT
    Location: Hall B2

    Presenter: Rashmi Benda, MD – University of Maryland School of Medicine, Baltimore

  • 3:00 PM – 4:00 PM PT
    2352 - Marginless 5-Fraction Robotic Radiosurgery for Unfavorable Nonfunctioning Pituitary Macroadenoma: 5-year Outcomes from a Single Institution Protocol
    Location: Hall B2

    Presenter: Akrita Bhatnagar, MD, PhD

  • 3:00 PM – 4:00 PM PT
    2353 - A Biosignature Integrating Immune and Metabolic Signaling Axes to Assess Limited Radiation Therapy Response in Early Stage Breast Cancer from a Low-Risk Cohort
    Location: Hall B2

    Presenter: Troy Bremer, PhD – PreludeDx

  • 3:00 PM – 4:00 PM PT
    2354 - Does Dual Anti-HER2 Therapy Increase Early Cardiac Toxicity in Comparison with Trastuzumab Alone in Breast Cancer Patients Receiving Adjuvant Radiotherapy? A Multicenter Retrospective Study
    Location: Hall B2

    Presenter: Lu Cao, MD, PhD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2355 - Dosimetry Comparison of Incidental Irradiation to the Low Axilla in Whole Breast Irradiation Using IMRT and IMPT Therapy
    Location: Hall B2

    Presenter: Lu Cao, MD, PhD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2356 - Hyperfractionated and Accelerated Reirradiation for Angiosarcoma Following Breast-Conserving Therapy: Long-Term Clinical Outcomes
    Location: Hall B2

    Presenter: Anthony Casper, DO – University of Florida Shands Cancer Center

  • 3:00 PM – 4:00 PM PT
    2357 - Comparison of Early Outcomes of Stereotactic Accelerated Partial Breast Irradiation vs. Volumetric Modulated Arc Therapy-Based FAST-FORWARD Whole Breast Irradiation for Breast Cancer
    Location: Hall B2

    Presenter: Jeesuk Chang, MD – Yonsei University College of Medicine

  • 3:00 PM – 4:00 PM PT
    2358 - Interpretable Deep Learning Identified the Significance of 1 Gy Volume on Lymphopenia After Radiotherapy in Breast Cancer
    Location: Hall B2

    Presenter: Fang Chen, MD, MS – The University of Hong Kong-Shenzhen Hospital

  • 3:00 PM – 4:00 PM PT
    2359 - Quality Assurance of Protocol Compliance in a Multicenter Randomized Trial Investigating the Role of Hypofractionated Comprehensive Reginal Nodal Irradiation in Node-Positive Breast Cancer (HARVEST)
    Location: Hall B2

    Presenter: Jiayi Chen, MD, PhD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2360 - Early Cardiotoxicity in Patients Receiving Hypofractionated Radiotherapy after Breast Conserving Surgery: Analysis of a Prospective Study
    Location: Hall B2

    Presenter: Si-Ye Chen, MD

  • 3:00 PM – 4:00 PM PT
    2361 - Analysis of Skin Dose and Position Stability for a New Personalized Device for Breast Radiotherapy
    Location: Hall B2

    Presenter: Tung-Ho Chen, MS – Taipei Medical University Hospital

  • 3:00 PM – 4:00 PM PT
    2362 - Intensity-Modulated Proton Therapy (IMPT) Offered Advantageous Dosimetry Compared to Volumetric Arc Therapy (VMAT) or Helical Tomotherapy (HT) in Patients with Synchronous Bilateral Breast Cancer
    Location: Hall B2

    Presenter: Gail Chua, MD – National Cancer Centre Singapore

  • 3:00 PM – 4:00 PM PT
    2363 - Managing RT Schedules of Early-Stage Breast Cancer Patients with a Genetic-Dosimetric Validated Model for Late Fibrosis
    Location: Hall B2

    Presenter: Tiziana Rancati, MS – Fondazione IRCCS - Istituto Nazionale dei Tumori

  • 3:00 PM – 4:00 PM PT
    2364 - Dosimetry Predictors of Late Skin Reactions after Whole Breast Radiotherapy on a Large Mono-Institutional Cohort of Patients
    Location: Hall B2

    Presenter: Tiziana Rancati, MS – Fondazione IRCCS - Istituto Nazionale dei Tumori

  • 3:00 PM – 4:00 PM PT
    2365 - Long Term Evaluation of Cardiac Events and Outcomes Following Breast Cancer Irradiation
    Location: Hall B2

    Presenter: Colleen Conger, BS – University of Texas Health Science Center San Antonio

  • 3:00 PM – 4:00 PM PT
    2366 - 3D Surface Imaging in Reducing Setup Error for Prone Whole Breast Radiotherapy
    Location: Hall B2

    Presenter: Tyler Cordero, BS – UCLA

  • 3:00 PM – 4:00 PM PT
    2367 - Late Toxicity and Patient Satisfaction in Hypofractionated Post-Mastectomy Radiotherapy after Immediate-Autologous Reconstruction
    Location: Hall B2

    Presenter: Alba Galatea Curbelo Artiles, MD

  • 3:00 PM – 4:00 PM PT
    2368 - Does Endocrine Therapy for DCIS Patients Treated with Breast-Conserving Surgery Followed by Postoperative Radiation Therapy is Needed? A Brazilian Retrospective Cohort Study
    Location: Hall B2

    Presenter: Cecília de Sousa, MD – Johns Hopkins School of Public Health

  • 3:00 PM – 4:00 PM PT
    2369 - Analysis of Institutional DIBH Coaching Program for Surface Guided-DIBH Patients
    Location: Hall B2

    Presenter: Sufen Deng, BS

  • 3:00 PM – 4:00 PM PT
    2370 - Locoregional Control Benefit of a Tumor Bed Boost for Ductal Carcinoma In Situ (DCIS)
    Location: Hall B2

    Presenter: Alexandra Dreyfuss, MD – Memorial Sloan Kettering Cancer Center

  • 3:00 PM – 4:00 PM PT
    2371 - Outcomes with Five Fraction Image-Guided Partial Breast Irradiation to Reduced Target Volumes
    Location: Hall B2

    Presenter: Ahmed Halima, MD – Cleveland Clinic Taussig Cancer Center

  • 3:00 PM – 4:00 PM PT
    2371 - Outcomes with Five Fraction Image-Guided Partial Breast Irradiation to Reduced Target Volumes
    Location: Hall B1

    Presenter: Lauren Fane, BS – Case Western Reserve School of Medicine

  • 3:00 PM – 4:00 PM PT
    2372 - Association of Left Anterior Descending Coronary Artery Calcium Progression and Radiation Dose with Major Adverse Cardiac Events in Breast Cancer
    Location: Hall B2

    Presenter: Jordan Gasho, BS – Cedars-Sinai Medical Center

  • 3:00 PM – 4:00 PM PT
    2373 - One Year Follow-up And Toxicity Review In a Series of 6 Patients Receiving Stereotactic Arrhythmia Radioablation For Ventricular Tachycardia
    Location: Hall B2

    Presenter: Ian Gerard, MD, PhD – McGill University Health Centre

  • 3:00 PM – 4:00 PM PT
    2374 - The Effect of Clinical (Anatomical) and Prognostic Stage Groups on Survival in Patients Diagnosed with Breast Cancer ? MULTI-Center Study Results ? TROD Breast Cancer Study Group
    Location: Hall B2

    Presenter: Ä°lknur Gorken, MD

  • 3:00 PM – 4:00 PM PT
    2375 - Post Mastectomy Radiation Therapy Impact on Clinical Outcomes of Male Breast Cancer: A Meta-Analysis of Comparative Studies
    Location: Hall B2

    Presenter: Philip Haddad, MD, MPH, MHA – LSU Health Sciences Center Shreveport

  • 3:00 PM – 4:00 PM PT
    2376 - Frameless Linear Accelerator (LINAC) Based Radiosurgery (SRS) vs. Framed Gamma Knife SRS for Idiopathic Trigeminal Neuralgia (TN)
    Location: Hall B2

    Presenter: Nilanjan Haldar, MD, BS – Thomas Jefferson University

  • 3:00 PM – 4:00 PM PT
    2377 - Five Fraction Accelerated Partial Breast Irradiation vs. Intraoperative Radiation Therapy for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Ahmed Halima, MD – Cleveland Clinic Taussig Cancer Center

  • 3:00 PM – 4:00 PM PT
    2378 - A Phase II, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of a Caffeine-Based Antifibrosis Cream in Patients with Breast Cancer Undergoing Radiation Therapy
    Location: Hall B2

    Presenter: Camille Hardy Abeloos, MD – NYU Grossman School of Medicine

  • 3:00 PM – 4:00 PM PT
    2379 - Incidence, Radiologic and Dosimetric Parameters Associated with Radiation Induced Breast Lymphedema
    Location: Hall B2

    Presenter: Laila Hasnain, BS – Loyola University Stritch School of Medicine

  • 3:00 PM – 4:00 PM PT
    2380 - The Impact of Tumor Location on Cardiac Toxicity in Patients Receiving Partial Breast Irradiation
    Location: Hall B2

    Presenter: Allison Hazy, MD – Beaumont Health

  • 3:00 PM – 4:00 PM PT
    2381 - Combined Analysis of a Phase III Randomized Trial and Phase II Prospective Trial with Blind Control Matching of Patients Receiving Whole-Lung, Low-Dose Radiation for COVID-19: Full Results and Immunol
    Location: Hall B2

    Presenter: Clayton Hess, MD, MPH – Grass Valley Radiation Oncology

  • 3:00 PM – 4:00 PM PT
    2382 - Prospective Clinical Trial of Premastectomy Radiotherapy Followed By Immediate Breast Reconstruction for Operable Breast Cancer
    Location: Hall B2

    Presenter: Karen Hoffman, MD, FASTRO – MD Anderson Cancer Center

  • 3:00 PM – 4:00 PM PT
    2383 - Effect of Dose to the Heart and Cardiac Substructures on Cardiac Toxicity after Breast Cancer Radiation
    Location: Hall B2

    Presenter: Jacob Hogan, BS – Washington University in St. Louis School of Medicine

  • 3:00 PM – 4:00 PM PT
    2384 - Stereotactic Radiosurgery for Trigeminal Neuralgia: A Comparison of Proximal and Distal Isocenter Outcomes
    Location: Hall B2

    Presenter: Benjamin Hopkins, MD – Emory University

  • 3:00 PM – 4:00 PM PT
    2385 - Early Clinical Experience of Utilizing Online Adaptive Radiotherapy for Accelerated Partial Breast Irradiation with Stereotactic Body Radiation Therapy for Early Stage Breast Cancer Patients
    Location: Hall B2

    Presenter: Whitney Hotsinpiller, MD – University of Alabama at Birmingham

  • 3:00 PM – 4:00 PM PT
    2386 - Patient-Specific Deep Learning Model for Clinical Target Volume Delineation on Daily CBCT of Breast Cancer Patients based on Intentional Deep Overfit Learning (IDOL) Framework
    Location: Hall B2

    Presenter: Joonil Hwang – KAIST

  • 3:00 PM – 4:00 PM PT
    2387 - Target Volumes Comparison between Postoperative Simulation MRI and Preoperative Diagnostic MRI for Prone Breast Radiotherapy after Breast-Conserving Surgery
    Location: Hall B2

    Presenter: Ying Jin, BS

  • 3:00 PM – 4:00 PM PT
    2388 - A Retrospective Dosimetric Study in Breast Cancer Patients Who Received Conformal Radiation Therapy for Achievability of Recommended Dose Constraints of  RTOG, DBCG, EORTC for Lung and Heart
    Location: Hall B2

    Presenter: Rajendra Benny K, MD – Christian Medical College and Hospital

  • 3:00 PM – 4:00 PM PT
    2389 - Clinical Trials of Carbon Ion Radiotherapy for Early Stage Breast Cancer
    Location: Hall B2

    Presenter: Kumiko Karasawa, MD, PhD – Tokyo Women's Medical University

  • 3:00 PM – 4:00 PM PT
    2390 - A Comprehensive Deep Learning Framework for Automatic Target Volumes Segmentation in Post-Operative Stereotactic Partial Breast Irradiation (S-PBI)
    Location: Hall B2

    Presenter: Mahdieh Kazemimoghadam, PhD – UT Southwestern Medical Center

  • 3:00 PM – 4:00 PM PT
    2391 - Five-Fraction Stereotactic Radiation for Head-and-Neck Paragangliomas
    Location: Hall B2

    Presenter: Dana Keilty, MD, MS, MDCM, MSc, BHSc – Princess Margaret Cancer Centre, University Health Network, University of Toronto

  • 3:00 PM – 4:00 PM PT
    2392 - Observed and Predicted Toxicity in Daily Cone-Beam CT-Based Online Adaptive Stereotactic Partial Breast Irradiation with Decreased PTV Margins
    Location: Hall B2

    Presenter: Dana Keilty, MD, MS, MDCM, MSc, BHSc – Princess Margaret Cancer Centre, University Health Network, University of Toronto

  • 3:00 PM – 4:00 PM PT
    2393 - Predicted Cardiac Toxicity in Daily Cone-Beam CT-Based Online Adaptive Stereotactic Partial Breast Irradiation with Decreased PTV Margins
    Location: Hall B2

    Presenter: Dana Keilty, MD, MS, MDCM, MSc, BHSc – Princess Margaret Cancer Centre, University Health Network, University of Toronto

  • 3:00 PM – 4:00 PM PT
    2394 - Correlation between Thyroid Radiation Dose and Thyroid Function after Adjuvant Hypofractionated Locoregional Radiotherapy in Breast Cancer Patients
    Location: Hall B2

    Presenter: Waleed Arafat, MD, PhD – University of Alexandria

  • 3:00 PM – 4:00 PM PT
    2395 - The Number of Positive Lymph Nodes as Prognostic Factor in ypN1 Breast Cancer with Neoadjuvant Chemotherapy
    Location: Hall B2

    Presenter: Aram Kim, MD

  • 3:00 PM – 4:00 PM PT
    2396 - Racial Difference in Outcomes in Breast Cancer Patients with Residual Nodal Disease after Neoadjuvant Chemotherapy
    Location: Hall B2

    Presenter: Nathan Kim, MD, PhD

  • 3:00 PM – 4:00 PM PT
    2397 - Reappraisal of an Adequate Negative Margin Following Breast Conservation Therapy in Young Patients with Invasive Breast Cancer
    Location: Hall B2

    Presenter: Sang-Won Kim, MD – Konyang University College of Medicine

  • 3:00 PM – 4:00 PM PT
    2398 - Contact of the Tumor with the Internal Mammary Perforator Vessels as Risk Factor for Internal Mammary Lymph Node Involvement Based on Dynamic Contrast Enhancing MRI Imaging in Breast Cancer Patients
    Location: Hall B2

    Presenter: Sophie Klusen, MD – TU München

  • 3:00 PM – 4:00 PM PT
    2399 - Optimized Target Delineation Procedure for the Radiosurgery Treatment of Ventricular Tachycardia: Observer-Independent Accuracy
    Location: Hall B2

    Presenter: LUKAS KNYBEL, PhD – University Hospital Ostrava

  • 3:00 PM – 4:00 PM PT
    2400 - Oncotype Recurrence Score (RS) at the Extremes of Tumor Size: Which Drives Clinical Outcomes?
    Location: Hall B2

    Presenter: Olufela Koleoso, MS, BS – Philadelphia College of Osteopathic Medicine

  • 3:00 PM – 4:00 PM PT
    2401 - Neoadjuvant Radiation Therapy in the Treatment of Breast Cancer
    Location: Hall B2

    Presenter: Hana Kristofovicova, MD – Instituto Nacional del Cancer

  • 3:00 PM – 4:00 PM PT
    2402 - Dose DIBH Really Reduce the Subclinical Cardiac Acute Injury? Analysis of Clinical Real World from Our Institute
    Location: Hall B2

    Presenter: Zhang Kun, BS – Chinese Academy of Medical Sciences and Peking Union Medical College

  • 3:00 PM – 4:00 PM PT
    2403 - Autologous Stem Cell Transplantation with Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis
    Location: Hall B2

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 3:00 PM – 4:00 PM PT
    2404 - The Early and Late Effects of High-Dose Irradiation on Cardiac Injury in a Rat Model
    Location: Hall B2

    Presenter: Hye In Lee, MD – Seoul National University Hospital

  • 3:00 PM – 4:00 PM PT
    2405 - Proton Re-Irradiation with Concurrent Hyperthermia in Patients with Recurrent Breast Cancer
    Location: Hall B2

    Presenter: Joseph Lee, MD, PhD – Beaumont Health

  • 3:00 PM – 4:00 PM PT
    2406 - The Effect of Age on Health-Related Quality of Life in Patients Treated for Early Stage, Estrogen Receptor Positive Breast Cancer
    Location: Hall B2

    Presenter: Keva Li, BS – Icahn School of Medicine at Mount Sinai

  • 3:00 PM – 4:00 PM PT
    2407 - Nodal Response to Neo-Adjuvant Systemic Therapy Predicts Prognosis of cN3c Breast Cancer Patients Receiving Multidisciplinary Therapy
    Location: Hall B2

    Presenter: Shuyan Li, PhD

  • 3:00 PM – 4:00 PM PT
    2408 - Stereotactic Cardiac Ablative Radiotherapy (SCAR) for Refractory Ventricular Tachycardia: Western Australia Experience
    Location: Hall B2

    Presenter: Tee Lim, MD, MBBS, FRANZCR – Genesis Cancer Care

  • 3:00 PM – 4:00 PM PT
    2409 - Radiosurgical Thalamotomy for Essential Tremor: A Prospective Study with Blinded Assessment By a Movement Disorder Neurologist
    Location: Hall B2

    Presenter: Chris Loiselle, MD – Tumor Institute Radiation Oncology Group

  • 3:00 PM – 4:00 PM PT
    2410 - Impact of Post-Mastectomy Radiotherapy on Cosmesis and Quality of Life after Deep Inferior Epigastric Perforator Flap Breast Reconstruction: A Single Institution Experience
    Location: Hall B2

    Presenter: Mathilde Mahé

  • 3:00 PM – 4:00 PM PT
    2411 - Complication Avoidance of Reconstruction Implant Radiation Therapy (CARIT): A Retrospective Case-Cohort Analysis
    Location: Hall B2

    Presenter: Kimya Manouchehri, BS – Schulich School of Medicine and Dentistry, Western University

  • 3:00 PM – 4:00 PM PT
    2412 - The New Quantum Image by Dynamic Nuclear Polarized MRI for the Assessment of Cardiac Radioablation to the Cavotricuspid Isthmus
    Location: Hall B2

    Presenter: Masayuki Matsuo, MD, PhD – Gifu University

  • 3:00 PM – 4:00 PM PT
    2413 - Impact of Breast Volume on Achieving a Conservative Heart and Target Coverage Metric for Patients Receiving Whole Breast Radiotherapy in a Statewide Consortium
    Location: Hall B2

    Presenter: Alexander Moncion, PhD – Michigan Medicine

  • 3:00 PM – 4:00 PM PT
    2414 - Practice Patterns and Disparities of Fractionation Schemes for Post-Mastectomy Comprehensive Nodal Irradiation
    Location: Hall B2

    Presenter: Julia Muallem, BS – New York Proton Center

  • 3:00 PM – 4:00 PM PT
    2415 - Near-Surface Dose Avoidance in Patients with Implant-Based Reconstruction Receiving Post-Mastectomy Proton Irradiation
    Location: Hall B2

    Presenter: Derek Mumaw, MD – Beaumont Health

  • 3:00 PM – 4:00 PM PT
    2416 - Uncovering the Armpit of Axillary SBRT
    Location: Hall B2

    Presenter: Adam Mutsaers, MD – London Health Sciences Centre

  • 3:00 PM – 4:00 PM PT
    2417 - Omission of Chest Wall/Scar Boost and Skin Bolus Does Not Increase Risk of Local Recurrence for Breast Cancer Patients
    Location: Hall B2

    Presenter: George Naoum, MD, MS – Massachusetts General Hospital

  • 3:00 PM – 4:00 PM PT
    2418 - Long Term Patient Reported Quality of Life Outcomes and Patient Satisfaction of 1-Week Hypofractionated Whole Breast Radiation Therapy Using IMRT for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Ashley Arms, MD, MS – Baylor Scott and White

  • 3:00 PM – 4:00 PM PT
    2418 - Long Term Patient Reported Quality of Life Outcomes and Patient Satisfaction of 1-Week Hypofractionated Whole Breast Radiation Therapy Using IMRT for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Jason Naziri, MD – Baylor Scott & White Health

  • 3:00 PM – 4:00 PM PT
    2419 - Posterior Neck Coverage in Patients Receiving Regional Nodal Irradiation for Breast Cancer
    Location: Hall B2

    Presenter: Jacob Oyeniyi, MD – Corewell Health William Beaumont University Hospital

  • 3:00 PM – 4:00 PM PT
    2420 - A Novel Strategy to Enhance Radiotherapy Efficacy: Results from the Prospective Phase I Clinical Trial of MR-Guided Focused Ultrasound-Stimulated Microbubbles (MRgFUS+MB) Treatment for Breast Cancer
    Location: Hall B2

    Presenter: Daniel Palhares, MD, MSc – Sunnybrook Odette Cancer Centre

  • 3:00 PM – 4:00 PM PT
    2421 - Patterns and longitudinal changes in the practice of breast cancer radiotherapy in Korea: Korean Radiation Oncology Group 22-01
    Location: Hall B2

    Presenter: Hae Jin Park, MD, PhD – Hanyang University

  • 3:00 PM – 4:00 PM PT
    2422 - Impact of the New ESTRO-ACROP Target Volume Delineation Guideline on Breast-Related Complications after Implant-Based Reconstruction and Postmastectomy Radiotherapy
    Location: Hall B2

    Presenter: Jung Bin Park, MD

  • 3:00 PM – 4:00 PM PT
    2423 - Disparities in Breast-Conserving Therapy vs. Mastectomy among Asian American and Pacific Islander Women
    Location: Hall B2

    Presenter: Tej Patel, BS – University of Pennsylvania

  • 3:00 PM – 4:00 PM PT
    2424 - Dosimetric Analysis Using Automated Tools of Trigeminal Neuralgia Treatment with Stereotactic Radiosurgery
    Location: Hall B2

    Presenter: Christina Phuong, MD – UCSF Dept Radiation Oncology

  • 3:00 PM – 4:00 PM PT
    2425 - Utility of Stereotactic Body Radiation Therapy (SBRT) in Establishing Local Control for Invasive Breast Cancer Patients not Undergoing Definitive Surgery
    Location: Hall B2

    Presenter: Simran Polce, MD, BS – Northwell Health

  • 3:00 PM – 4:00 PM PT
    2426 - Characterization of Objective Skin Color Changes during and after Breast and Chest Wall Radiotherapy and Correlation with Radiation-Induced Skin Toxicity in Breast Cancer Patients, Including Patients
    Location: Hall B2

    Presenter: Juhi Purswani, MD – New York University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2427 - A Radiation Therapy Contouring Atlas for Delineation of the Level I-II Axilla in the Prone Position
    Location: Hall B2

    Presenter: Juhi Purswani, MD – New York University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2428 - Phase I-II Study of Prone Hypofractionated Accelerated Breast and Nodal Intensity Modulated Radiation Therapy
    Location: Hall B2

    Presenter: Juhi Purswani, MD – New York University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2429 - Establishing a Risk Stratification Model to Identify Clinically High-Risk N0 Breast Cancer Who Could Benefit from Regional Nodal Irradiation: A Single Institute Analysis
    Location: Hall B2

    Presenter: Wei-Xiang Qi, MD, RT – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 3:00 PM – 4:00 PM PT
    2430 - A Nomogram to Predict Pathological Axillary Status in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Location: Hall B2

    Presenter: Zihan Qiu

  • 3:00 PM – 4:00 PM PT
    2431 - The Impact of Cardiac Sparing Techniques on Major Cardiac Events for Patients Undergoing Breast Radiotherapy
    Location: Hall B2

    Presenter: Sarah Quirk, PhD – Dana-Farber/Brigham and Women's Cancer Center

  • 3:00 PM – 4:00 PM PT
    2432 - Multi-Institutional Phase II Trial Using Dose Escalated Five Fraction Stereotactic Partial Breast Irradiation (S-PBI) with GammaPodTM for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Asal Rahimi, MD, MS – University of Texas Southwestern Medical Center

  • 3:00 PM – 4:00 PM PT
    2433 - The Role of Tumor Bed Boost in Breast Cancer Patients with HER2-Positive Disease Treated with Breast Conservation Therapy
    Location: Hall B2

    Presenter: Eric Roach, BS – University of Utah

  • 3:00 PM – 4:00 PM PT
    2434 - Radiotherapy Dose as a Predictor of Outcomes Following Cardiac Radioablation for High-risk Refractory VT
    Location: Hall B2

    Presenter: Clifford Robinson, MD – Washington University School of Medicine in St. Louis

  • 3:00 PM – 4:00 PM PT
    2435 - Accelerated Partial Breast Irradiation (APBI) For HER2+ Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Diana Roth O'Brien, MD – Memorial Sloan Kettering Cancer Center

  • 3:00 PM – 4:00 PM PT
    2436 - Prospective Cohort Study to Evaluate Toxicity and Cosmesis between Interstitial APBI and Ultra-Hypo-Fractionated Whole Breast Irradiation in Patients with Early Breast Cancer
    Location: Hall B2

    Presenter: Daya Nand Sharma, MD, PhD – AIIMS New Delhi

  • 3:00 PM – 4:00 PM PT
    2436 - Prospective Cohort Study to Evaluate Toxicity and Cosmesis between Interstitial APBI and Ultra-Hypo-Fractionated Whole Breast Irradiation in Patients with Early Breast Cancer
    Location: Hall B2

    Presenter: Soham Sanyal, MD, MBBS – AIIMS New Delhi

  • 3:00 PM – 4:00 PM PT
    2437 - Delayed Nipple-Areola Complex Radiotherapy after Nipple Sparing Mastectomy and Immediate Reconstruction for Invasive Breast Cancer or DCIS: Long-Term Results of a Phase I Study
    Location: Hall B2

    Presenter: Crystal Seldon Taswell, MD, BS – University of Miami School of Medicine

  • 3:00 PM – 4:00 PM PT
    2438 - Clinical Outcomes and Setup Reproducibility in Patients Receiving Synchronous Bilateral Breast Radiation in the Prone Position
    Location: Hall B2

    Presenter: Aishwarya Shah, MD – NYU Langone Health

  • 3:00 PM – 4:00 PM PT
    2439 - Impact on Radiation Therapy Recommendation and Treatment Modality for Patients With Ductal Carcinoma In Situ Using the 7Gene Biosignature: Analysis of the PREDICT Study
    Location: Hall B2

    Presenter: Chirag Shah, MD – Cleveland Clinic

  • 3:00 PM – 4:00 PM PT
    2440 - Surface Dose and Skin Toxicity Analysis in Breast Cancer Radiotherapy after Conserving Surgery with Five Treatment Modalities
    Location: Hall B2

    Presenter: Shucan Shan, MS

  • 3:00 PM – 4:00 PM PT
    2441 - Skin Microbiome Composition is Associated with Radiation Dermatitis in Breast Cancer Patients Undergoing Radiation after Reconstructive Surgery: A Prospective, Longitudinal Study
    Location: Hall B2

    Presenter: Wei Shi, MD, PhD – Fudan University Shanghai Cancer Center

  • 3:00 PM – 4:00 PM PT
    2442 - Heart Dose Uncertainty Caused by Heartbeat during Adjuvant Breast Radiotherapy
    Location: Hall B2

    Presenter: Litsun Shieh

  • 3:00 PM – 4:00 PM PT
    2443 - Mutations of the BRCA1/2 Genes in Patients with Breast Cancer do Not Alter Treatment Outcomes Following Radiation Therapy (RT)
    Location: Hall B2

    Presenter: Zachary Kiss, DO – Fox Chase Cancer Center

  • 3:00 PM – 4:00 PM PT
    2443 - Mutations of the BRCA1/2 Genes in Patients with Breast Cancer do Not Alter Treatment Outcomes Following Radiation Therapy (RT)
    Location: Hall B1

    Presenter: Rebecca Shulman, MD – Fox Chase Cancer Center

  • 3:00 PM – 4:00 PM PT
    2444 - Comparison of Supraclavicular Surgery plus Radiotherapy vs. Radiotherapy Alone in Breast Cancer Patients with Synchronous Ipsilateral Supraclavicular Lymph Node Metastasis: A Multicenter Retrospective
    Location: Hall B2

    Presenter: Yuchun Song, MD – Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

  • 3:00 PM – 4:00 PM PT
    2445 - Toxicity and Efficacy of Hypofractionated Regional Nodal Irradiation
    Location: Hall B2

    Presenter: Daphna Spiegel, MD, MS – Beth Israel Deaconess Medical Center

  • 3:00 PM – 4:00 PM PT
    2446 - Intra-Operative Radiotherapy (IORT) in Breast Conserving Therapy in Early-Stage Breast Cancer and DCIS
    Location: Hall B2

    Presenter: Andrew Suen, MD – Virginia Mason Medical Center

  • 3:00 PM – 4:00 PM PT
    2447 - A Population-Based Assessment of Long-Term Sexual Well-Being and Patient Satisfaction after Breast Reconstruction and Post-Mastectomy Radiation
    Location: Hall B2

    Presenter: Jamie Takayesu, MD – University of Michigan

  • 3:00 PM – 4:00 PM PT
    2448 - Standardizing Breast Adjuvant Radiation Therapy Practices in a Diverse Health System through Development of a Delphi Consensus Supported Clinical Algorithm
    Location: Hall B2

    Presenter: Leila Tchelebi, MD – Northern Westchester Hospital

  • 3:00 PM – 4:00 PM PT
    2449 - Omission of Adjuvant Radiotherapy in Low-Risk Elderly Males With Breast Cancer
    Location: Hall B2

    Presenter: Kim Vo, MS, BS – Western University of Health Sciences, College of Osteopathic Medicine of the Pacific

  • 3:00 PM – 4:00 PM PT
    2450 - Recurrence Risk Score Model for Evaluating the Impact of Postmastectomy Radiotherapy in Breast Cancer Patients with Pathologic Nodal Negative after Neoadjuvant Chemotherapy and Mastectomy
    Location: Hall B2

    Presenter: Dan-Qiong Wang, MD – National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Acade

  • 3:00 PM – 4:00 PM PT
    2451 - Dose-Volume Predictors for Radiation Esophagitis in Breast Cancer Patients Undergoing Hypofractionated Regional Nodal Radiotherapy
    Location: Hall B2

    Presenter: Dan-Qiong Wang, MD – National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Acade

  • 3:00 PM – 4:00 PM PT
    2452 - Methodological and Reporting Quality of Non-Inferiority or Equivalence Designs: A Systematic Review of Trial Characteristics, Design Consideration and Interpretation in Breast Cancer Radiotherapy Tria
    Location: Hall B2

    Presenter: Shijia Wang, MD

  • 3:00 PM – 4:00 PM PT
    2453 - Total Lymphoid Irradiation in the Treatment of Heart Transplant Rejection: Single Institution Long-Term Results
    Location: Hall B2

    Presenter: Zachary White, MD, MS – Stanford Health Care

  • 3:00 PM – 4:00 PM PT
    2454 - Health-Related Quality of Life Analysis in Patients with Non-Functioning Pituitary Macroadenomas Treated with Transsphenoidal Surgery with or without Radiation Therapy
    Location: Hall B2

    Presenter: Amy Wisdom, MD, PhD – Harvard Radiation Oncology Program

  • 3:00 PM – 4:00 PM PT
    2455 - Dosimetric Evaluation of a Novel Non-Metallic Dual Port Expander for Proton Therapy
    Location: Hall B2

    Presenter: Andrew Wroe, PhD – Miami Cancer Institute

  • 3:00 PM – 4:00 PM PT
    2456 - Adjuvant Breast Radiation Therapy for Early-Stage Breast Cancer or Ductal Carcinoma In-Situ in the Breast: A Systematic Review and Network Meta-Analysis of Randomized Trials
    Location: Hall B2

    Presenter: Caryn Wujanto, MBBS – National University Cancer Institute Singapore

  • 3:00 PM – 4:00 PM PT
    2457 - Texture Analysis Using Machine Learning-Based 3-T Magnetic Resonance Imaging for Predicting Pathological Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
    Location: Hall B2

    Presenter: Feihong Xie – Shandong Cancer Hospital and Institute

  • 3:00 PM – 4:00 PM PT
    2458 - Convolution Neural Network-Based Automatic Scoring of Coronary Artery Calcification and Its Value to Identify the Risk of Radiation-Induced Cardiac Toxicity on Radiotherapy Planning CT Scans in Breast
    Location: Hall B2

    Presenter: Jing Yang, MB

  • 3:00 PM – 4:00 PM PT
    2459 - Non-Animal Stabilized Hyaluronic Acid (NASHA) Gel Marker vs. Surgical Clips for Tumor Bed Delineation in Breast Cancer Using MR-Simulation
    Location: Hall B2

    Presenter: Janice Yeh, MBBS, FRANZCR – Peter MacCallum Cancer Centre

  • 3:00 PM – 4:00 PM PT
    2460 - Are All Prognostic Stage IB Breast Cancers Equivalent?
    Location: Hall B2

    Presenter: Stephanie Yoon, MD – City of Hope National Medical Center

  • 3:00 PM – 4:00 PM PT
    2461 - Postmastectomy Radiation in HER-2 Positive Breast Cancer after Neoadjuvant Therapy: Secondary Analysis of Two Randomized Trials
    Location: Hall B2

    Presenter: Youssef Zeidan, MD, PhD – Florida International University and Lynn Cancer Institute

  • 3:00 PM – 4:00 PM PT
    2462 - Lymphocyte Count Kinetics and the Effect of Different Radiotherapy Techniques on Radiation-Induced Lymphopenia in Patients with Breast Cancer Receiving Hypofractionated Postmastectomy Radiotherapy
    Location: Hall B2

    Presenter: Xuran Zhao, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy

  • 3:00 PM – 4:00 PM PT
    2463 - A Retrospective Analysis of Immediate Postoperative Electron Radiotherapy for Keloids
    Location: Hall B2

    Presenter: Wei Zhou, MD, DVM – Xijing Hospital Air Force Medical University

  • 3:00 PM – 4:00 PM PT
    2464 - Does Epigallocatechin Gallate as a Radiation Protective Agent Reduce the Anti-Tumor Effect of Radiotherapy in Postoperative Breast Cancer Radiotherapy?
    Location: Hall B2

    Presenter: Wanqi Zhu, MD, PhD

  • 5:00 PM – 6:00 PM PT
    2048 - Clinical Outcomes with Triple Tandem Brachytherapy for Medically Inoperable Endometrial Cancer in a Predominantly Black Patient Population
    Location: Hall B2

    Presenter: Michael Gutman, MD – University of Chicago

  • 5:00 PM – 6:00 PM PT
    2465 - Patient Reported Outcomes Following Palliative Whole Brain Radiation Therapy in Patients with Brain Metastasis
    Location: Hall B2

    Presenter: Boalnle Adegboyega, MBBS, FMCR – Lagos University Teaching Hospital

  • 5:00 PM – 6:00 PM PT
    2466 - Role of ATP Binding Cassette Subfamily A Member 1 (ABCA1) in Chemoradiotherapy-induced Renal Injury
    Location: Hall B2

    Presenter: Anis Ahmad, PhD – University of Miami

  • 5:00 PM – 6:00 PM PT
    2467 - Improving Patient Compliance with Vaginal Dilator Therapy by Implementation of Sexual Health Consult in Gynecologic Malignancies after Radiation Therapy
    Location: Hall B2

    Presenter: Heather Augustyniak, DNP – Baptist MD Anderson

  • 5:00 PM – 6:00 PM PT
    2468 - Characterization of Radiographic and Molecular Changes in Mouse Brain after FLASH Irradiation
    Location: Hall B2

    Presenter: Khaled Aziz, MD, PhD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:00 PM – 6:00 PM PT
    2469 - Ginsenoside Rg5 Enhances Radiosensitivity of Lung Adenocarcinoma via Reducing HSP90 CDC37 Interaction and Promoting Client Protein Degradation
    Location: Hall B2

    Presenter: Han-song Bai, MD, PhD – Sichuan Provincial People's Hospital

  • 5:00 PM – 6:00 PM PT
    2470 - Engaging Ambulatory Cancer Patients to Develop and Validate a Comprehensive New Patient-Reported Outcomes Measure
    Location: Hall B2

    Presenter: Lisa Barbera, MD – Tom Baker Cancer Centre

  • 5:00 PM – 6:00 PM PT
    2471 - Dosimetric Parameters Correlate with Taste Alterations in Head and Neck Radiotherapy
    Location: Hall B2

    Presenter: Danielle Cerbon, MD – University of Miami

  • 5:00 PM – 6:00 PM PT
    2472 - IL-1ß+ Tumor Associated Macrophages Induced by Type I Interferon Initiates Radiotherapy-Mediated Abscopal Effect
    Location: Hall B2

    Presenter: Dawei Chen, MD, MB

  • 5:00 PM – 6:00 PM PT
    2473 - Carm1 Inhibition Potentiates Irradiation-Induced Antitumor Immunity via Tumor Intrinsic STING Pathway Activation
    Location: Hall B2

    Presenter: Dawei Chen, MD, MB

  • 5:00 PM – 6:00 PM PT
    2474 - Remodeling Tumor Immune Microenvironment by Targeting XPO1 Combined with Radiotherapy Enhances Systemic Anti-tumor Effects in Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Dawei Chen, MD, MB

  • 5:00 PM – 6:00 PM PT
    2475 - Spatial Proteome Analysis Identifies Lymphocyte CD44 as a Biomarker Associated with SBRT Resistance in Early-Stage Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Dawei Chen, MD, MB

  • 5:00 PM – 6:00 PM PT
    2476 - Brachytherapy-on-Chip: A Microfluidic Setup for In Vitro Interrogation of Hypoxic Spheroids
    Location: Hall B2

    Presenter: Rodin Chermat, M.Sc, M.Eng – Polytechnique Montreal/CRCHUM

  • 5:00 PM – 6:00 PM PT
    2477 - Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition Induces DNA Damage and Radiosensitization in Glioblastoma Cell Lines
    Location: Hall B2

    Presenter: Serah Choi, MD, PhD (she/her/hers) – UPMC Department of Radiation Oncology

  • 5:00 PM – 6:00 PM PT
    2478 - Differential Oxidative Stress Responses in Type II Airway Epithelial Cells Impact Premature Senescence and Lung Fibrosis Susceptibility
    Location: Hall B2

    Presenter: Eun Chung, PhD – National Institute of Health

  • 5:00 PM – 6:00 PM PT
    2479 - The Effects of Glypican-3 Deficiency on Radiosensitivity in Liver Cancer Cells
    Location: Hall B2

    Presenter: Joon-Yong Chung, PhD – National Cancer Institute

  • 5:00 PM – 6:00 PM PT
    2480 - Disabling Tumor Cell-Intrinsic PD-L1 Reprograms Radiation-Induced Locoregional Antitumor Immunity
    Location: Hall B2

    Presenter: Curtis Clark, MD, PhD – UAB Hazelrig Salter Radiation Oncology Center

  • 5:00 PM – 6:00 PM PT
    2481 - Prospective Longitudinal Assessment of Quality of Life after Stereotactic Ablative Radiotherapy for Oligometastases: Analysis of the Population-Based SABR-5 Phase II Trial
    Location: Hall B2

    Presenter: Ella Mae Cruz-Lim, MD – West Metro Cancer Center

  • 5:00 PM – 6:00 PM PT
    2482 - ePRO Use in Men Receiving Radiotherapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Heather Curry, MD – Varian Medical Systems, A Siemens Healthineers Company

  • 5:00 PM – 6:00 PM PT
    2483 - Reshaping Macrophage Polarization Potential Enhances Antitumor Immune Response to Radiation Therapy
    Location: Hall B2

    Presenter: Tahir Dar, PhD – Cedars-Sinai Medical Center

  • 5:00 PM – 6:00 PM PT
    2484 - Proof-of-Concept and Characterization of Photosynthetic Bacteria as Radiation Enhancers
    Location: Hall B2

    Presenter: Neeladrisingha Das, PhD – Stanford University

  • 5:00 PM – 6:00 PM PT
    2485 - Radiosensitization of Glioblastoma Using Targeted Inhibition of N-Myristoylation
    Location: Hall B2

    Presenter: Deepak Dinakaran, MD, PhD – National Institute of Health

  • 5:00 PM – 6:00 PM PT
    2486 - Radiobiological Characterization of Pancreatic Cancer Patient-Derived Organoids
    Location: Hall B2

    Presenter: Sophie Dobiasch, MD – Technical University Munich

  • 5:00 PM – 6:00 PM PT
    2487 - Esophageal Cancer-Derived Organoids to Predict Patients Treatment Response
    Location: Hall B2

    Presenter: Liang Du, PhD – Chongqing University Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2488 - MTA3 Enhances Radiosensitivity of Patients with Esophageal Cancer by Inhibiting Glutamine Synthetase-Mediated Glutaminolysis
    Location: Hall B2

    Presenter: Liang Du, PhD – Chongqing University Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2489 - Non-Canonical p16-SP1 Signaling in Head and Neck Cancer Potentially Affects Cell Plasticity
    Location: Hall B2

    Presenter: Mohamed Elfayoumi, BS – University of Pittsburgh, UPMC Hillman Cancer Center

  • 5:00 PM – 6:00 PM PT
    2490 - Sexual Function and Dosimetric Relationships to Erectile Structures among Patients Treated Definitively with Pd-103 LDR Prostate Brachytherapy
    Location: Hall B2

    Presenter: Keara English, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:00 PM – 6:00 PM PT
    2491 - Dual Immune Checkpoint Therapy Combined with Radiotherapy Treats Castration-Resistant Prostate Cancer
    Location: Hall B2

    Presenter: Matthew Eximond, BS – N/A

  • 5:00 PM – 6:00 PM PT
    2492 - Influence of Bacterial Metabolites on the Systemic Antitumor Immune Response after Radiation Therapy in Combination with Immune Checkpoint Inhibitors
    Location: Hall B2

    Presenter: Julius Fischer, MD – TU München

  • 5:00 PM – 6:00 PM PT
    2493 - Predictors of Low Anterior Resection Syndrome after Long-Course Chemoradiation for Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Ty Forbes, BS – McGovern Medical School

  • 5:00 PM – 6:00 PM PT
    2494 - Comparing Acute Oral Mucosa Toxicity Associated with Minibeam and Conventional Radiotherapy
    Location: Hall B2

    Presenter: Darwin Garcia, BA – Mayo Clinic College of Medicine and Science Rochester

  • 5:00 PM – 6:00 PM PT
    2495 - Enhanced Peroxide Fluxes and Radiosensitization in Colorectal Tumors but Not Normal Enterocytes from the Combination of Superoxide Disumutase Mimetics and Pharmacological Ascorbate
    Location: Hall B2

    Presenter: Benjamin George, BA – University of Iowa

  • 5:00 PM – 6:00 PM PT
    2496 - Assessing the Sexual Health of Female Survivors of Pelvic Malignancies after Radiotherapy
    Location: Hall B2

    Presenter: Kimberly Gergelis, MD – Wilmot Cancer Center

  • 5:00 PM – 6:00 PM PT
    2497 - HPV Infection Causes Dependence on Alternative DNA Damage Response Pathways Providing Cancer Specific Targets for Radiosensitization
    Location: Hall B2

    Presenter: Michael Goldstein, MD, PhD – Johns Hopkins School of Medicine

  • 5:00 PM – 6:00 PM PT
    2498 - The Effects of Adjuvant Chemoradiotherapy (CRT) on Myeloid-Derived Suppressor Cell (MDSC) Subsets in Glioblastoma (GBM)
    Location: Hall B2

    Presenter: Matt Berkseth, PhD – University of Minnesota

  • 5:00 PM – 6:00 PM PT
    2498 - The Effects of Adjuvant Chemoradiotherapy (CRT) on Myeloid-Derived Suppressor Cell (MDSC) Subsets in Glioblastoma (GBM)
    Location: Hall B1

    Presenter: Lindsey Greenlund, BS – University of Minnesota Medical School

  • 5:00 PM – 6:00 PM PT
    2499 - Sensitivity of the PROMIS-10 for Capturing Radiation-Related Quality of Life Changes
    Location: Hall B2

    Presenter: Heather Gunn, PhD – Mayo Clinic

  • 5:00 PM – 6:00 PM PT
    2500 - Tumor-Myeloid Cell Crosstalk Pathways Associated with Abscopal Responses in Breast Cancer
    Location: Hall B2

    Presenter: Gaorav Gupta, MD, PhD – University of North Carolina

  • 5:00 PM – 6:00 PM PT
    2501 - Targeted Pubic Neoantigen Immunotherapy Using Encapsulated Nanoparticles, Directed by Radiation
    Location: Hall B2

    Presenter: Satoshi Harada, MD, PhD – Iwate Medical University School of Medicine

  • 5:00 PM – 6:00 PM PT
    2502 - Prospective Evaluation of Patient-Reported Outcomes of Invisible Ink Tattoos for the Delivery of External Beam Radiation Therapy: The PREFER Trial
    Location: Hall B2

    Presenter: Camille Hardy Abeloos, MD – NYU Grossman School of Medicine

  • 5:00 PM – 6:00 PM PT
    2503 - Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy
    Location: Hall B2

    Presenter: Jeremy Harris, MD, MPhil – Stanford Radiation Oncology

  • 5:00 PM – 6:00 PM PT
    2504 - Patterns of Independence in Adolescent/ Young Adult (AYA) Survivors of Childhood Cancer Having Received Radiotherapy (RT)
    Location: Hall B2

    Presenter: Christine Hill-Kayser, MD – University of Pennsylvania

  • 5:00 PM – 6:00 PM PT
    2505 - Hyperbaric Oxygen Therapy Attenuates the Whole Brain Radiotherapy-Induced Progressive Cognitive Dysfunction via Promoting Hippocampal Neurogenesis in Rats
    Location: Hall B2

    Presenter: Sheng-Yow Ho, MD, MS – Chi Mei Medical Center

  • 5:00 PM – 6:00 PM PT
    2506 - WEE1 Inhibition Promotes Radiotherapy-Induced Myeloid Suppressor Cells through cGAS/STING-STAT3-IRF3 Pathway
    Location: Hall B2

    Presenter: Jing Hu, MD – Xijing Hospital

  • 5:00 PM – 6:00 PM PT
    2507 - Carbon Ion Radiotherapy Exerts Anti-Tumor Activity by Inducing cGAS-STING Activation and Immune Response in Prostate Cancer-Bearing Mice
    Location: Hall B2

    Presenter: Wei Hu – Shanghai Proton and Heavy Ion Center

  • 5:00 PM – 6:00 PM PT
    2509 - Single-Cell Analysis Reveals the Alteration of Immune Checkpoint Molecules Induced by Radiochemotherapy in Cervical Cancer Microenvironment
    Location: Hall B2

    Presenter: Qingyu Huang, MD

  • 5:00 PM – 6:00 PM PT
    2510 - Voice Handicap Following Curative Therapy for Locally Advanced Head and Neck Cancer
    Location: Hall B2

    Presenter: Adam Hubler, MD – University of Alabama at Birmingham

  • 5:00 PM – 6:00 PM PT
    2511 - Impact of Employment and Insurance Status on Hope Among Patients Treated within Radiation Oncology
    Location: Hall B2

    Presenter: Caressa Hui, MD, BS – Stanford

  • 5:00 PM – 6:00 PM PT
    2512 - Early Assessment of Radiation Treatment at Clinical Field Strength by D2O Administration and Deuterium MRI
    Location: Hall B2

    Presenter: Fuminori Hyodo, PhD – Gifu University

  • 5:00 PM – 6:00 PM PT
    2513 - Bothersome Gynecomastia Following Neoadjuvant GnRH Agonists and Stereotactic Body Radiotherapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Simran Jatar, MPH – Georgetown University School of Medicine

  • 5:00 PM – 6:00 PM PT
    2514 - A Bidirectional Mendelian Randomization Analysis of Circulating Inflammatory Cytokines with Colon and Rectum Cancers
    Location: Hall B2

    Presenter: Shengjun Ji, MD – Nanjing Medical University Affiliated Suzhou Hospital

  • 5:00 PM – 6:00 PM PT
    2515 - Shoulder Muscle Dosimetry and Post-Treatment Rehabilitation Utilization for Early-Stage Breast Cancer Patients
    Location: Hall B2

    Presenter: Shannon Jiang, MD – Washington University/B-JH/SLCH Consortium

  • 5:00 PM – 6:00 PM PT
    2516 - Trends in Racial and Ethnicity Disparities in the Health-Related Quality of Life in Older Adults with Breast Cancer: A SEER-MHOS National Database Study
    Location: Hall B2

    Presenter: Nicki Karimi-Mostowfi, BS

  • 5:00 PM – 6:00 PM PT
    2517 - Refining Surveillance Guidelines after SBRT for Early-Stage Lung Cancer
    Location: Hall B2

    Presenter: Samuel Keltner, MD, BS – University of Cincinnati - Barrett Cancer Center

  • 5:00 PM – 6:00 PM PT
    2518 - The Landscape of Genetic Alterations Associated with Metachronous Metastasis in Patients with Pancreatic Ductal Adenocarcinoma and Its Prognostic Significance
    Location: Hall B2

    Presenter: Jongmyung Kim, MD, PhD – Rutgers Cancer Institute of New Jersey

  • 5:00 PM – 6:00 PM PT
    2519 - Combination Immunotherapy with Partial or Whole Tumor Radiotherapy in Preclinical Melanoma Tumor Model
    Location: Hall B2

    Presenter: Sean Koerner, MD, MS – UPMC Hillman Cancer Center, Department of Radiation Oncology

  • 5:00 PM – 6:00 PM PT
    2520 - Pre- and Post-Treatment Patient-Reported Financial Toxicity in Head and Neck Cancer: Identifying Influential Factors and Clinical Significance
    Location: Hall B2

    Presenter: Eric Ku, MD – UC Irvine

  • 5:00 PM – 6:00 PM PT
    2521 - The Ferroptosis Induced by Palmitic Acid via CD36 Activating ER Stress to Break Calcium-Iron Balance in Colon Cancer Cells
    Location: Hall B2

    Presenter: Hao Kuang, MD

  • 5:00 PM – 6:00 PM PT
    2522 - Comprehensive Use of a Multifunction Software Tool to Facilitate Education and Communication of Treatment-Related Distress in Patients with Cancer Receiving Radiation Therapy
    Location: Hall B2

    Presenter: Ian Kudel, PhD – Varian Medical Systems

  • 5:00 PM – 6:00 PM PT
    2523 - Targeting VEGF/Neuropilin-2 as a Novel Approach to Induce Radiosensitivity in Triple Negative Breast Cancer
    Location: Hall B2

    Presenter: Ayush Kumar, BS – UMass Chan Medical School / QARC

  • 5:00 PM – 6:00 PM PT
    2524 - Long-Term Quality of Life Following Head and Neck Radiation: A Study Using the Vanderbilt Head and Neck Symptom Survey
    Location: Hall B2

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 5:00 PM – 6:00 PM PT
    2525 - Experimental Investigation of Lung Toxicity after Radiation Therapy Combined with Immune Checkpoint Inhibitors
    Location: Hall B2

    Presenter: Laura Lansink Rotgerink – Klinikum rechts der Isar TUM

  • 5:00 PM – 6:00 PM PT
    2526 - Src Kinase Activates Signal Transducer and Activator of Transcription 3 to Enhance Radioresistance in Triple Negative Breast Cancer Cells
    Location: Hall B2

    Presenter: Yueh Chun Lee, MD, PhD – Chung Shan Medical University Hospital

  • 5:00 PM – 6:00 PM PT
    2527 - Dynamic Effects of Thoracic Irradiation on Immune Status of Organs in and out of Radiation Field in Mice
    Location: Hall B2

    Presenter: Yaqi Li, MD

  • 5:00 PM – 6:00 PM PT
    2528 - Study of DNA Damage-Induced MSI1 Serine-347 Phosphorylation in Regulation of Radiosensitivity in Glioblastoma Multiforme
    Location: Hall B2

    Presenter: Liang-Ting Lin, PhD – Hong Kong Polytechnic University

  • 5:00 PM – 6:00 PM PT
    2529 - Robust Radiosensitization by Combined Treatment of Cancer Cells with Talazoparib and Pol? Inhibitors
    Location: Hall B2

    Presenter: Xixi Lin, MS – University Hospital Essen

  • 5:00 PM – 6:00 PM PT
    2530 - Hepatoma Derived Growth Factor (HDGF) Targeting as a Therapeutic Approach for Radio-Naive and Radioresistant Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Yu-Wei Lin, MD, PhD, MS – Kaohsiung Veterans General Hospital

  • 5:00 PM – 6:00 PM PT
    2531 - Single-Cell Dissection of Concurrent Chemoradiotherapy-Induced Immunosenescence in Cervical Cancer
    Location: Hall B2

    Presenter: Chao Liu, MD, PhD – Shandong Cancer Hospital and Institute, First Medical University

  • 5:00 PM – 6:00 PM PT
    2532 - Dissecting Systemic T Cell Responses after Stereotactic Ablative Radiotherapy in NSCLC by Single-Cell RNA and T Cell Receptor Sequencing
    Location: Hall B2

    Presenter: Chao Liu, MD, PhD – Shandong Cancer Hospital and Institute, First Medical University

  • 5:00 PM – 6:00 PM PT
    2533 - Understanding Treatment Anxiety and Utility of Mixed Media Educational Tools in Radiation Oncology Consultation: A Qualitative Study
    Location: Hall B2

    Presenter: Elisa Liu, MD, BS – NYU School of Medicine

  • 5:00 PM – 6:00 PM PT
    2534 - Evaluation of Antitumor Immunity by a Combination Treatment of Radiation, Anti-PD1, and Anti-Angiogenic Therapy in Esophageal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Yudi Liu – No

  • 5:00 PM – 6:00 PM PT
    2535 - Identification of Hepatocellular Carcinoma-specific Targets for Imaging and Therapy
    Location: Hall B2

    Presenter: Valeria Londono, BS – Georgetown University School of Medicine

  • 5:00 PM – 6:00 PM PT
    2536 - m6A Reader YTHDC1 Inhibits Ferroptosis and Radiosensitivity by Promoting SREBF1 mRNA Nuclear Export in Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Zhi-Qing Long, PhD – Sun Yat-Sen University Cancer Center

  • 5:00 PM – 6:00 PM PT
    2537 - AKR1C3 Induces Resistance to Radiotherapy in Prostate Cancer Cells by Inhibiting Ubiquitinated Degradation of Nrf2 through Interacting with KEAP1
    Location: Hall B2

    Presenter: Feng Lyu, MD, PhD – Peking University First Hospital

  • 5:00 PM – 6:00 PM PT
    2538 - The Role and Mechanism of Ferroptosis Mediated by METTL3-m6A Modification in Regulating Radioresistance of Esophageal Cancer
    Location: Hall B2

    Presenter: Rui Ma, MS – Xijing Hospital, Air Force Medical University

  • 5:00 PM – 6:00 PM PT
    2539 - Longitudinal Profiling of Tumor RNA Expression Signatures Reveal Key Biological Features Associated with Response to Neoadjuvant Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer
    Location: Hall B2

    Presenter: Ariel Marciscano, MD – Massachusetts General Hospital

  • 5:00 PM – 6:00 PM PT
    2540 - Safety and Feasibility of the Addition of a Radiosensitizing Methionine-Restricted Diet to Radiation Therapy
    Location: Hall B2

    Presenter: Malcolm Mattes, MD – Rutgers Cancer Institute of New Jersey

  • 5:00 PM – 6:00 PM PT
    2541 - Mechanisms of Intrinsic Radioresistance in Breast Cancer Identify Potential Therapeutic Vulnerabilities
    Location: Hall B2

    Presenter: Breanna McBean, BA – University of Michigan

  • 5:00 PM – 6:00 PM PT
    2542 - Fear of Cancer Recurrence (FCR) in Human Papillomavirus-Associated Oropharyngeal Cancer (HPVOPC) Patients 12 months (12m) after (Chemo)Radiation (RT/CRT)
    Location: Hall B2

    Presenter: Lachlan Joseph McDowell, MB, BS, MBBS, FRANZCR – Princess Alexandra Hospital

  • 5:00 PM – 6:00 PM PT
    2543 - Evaluation of 68Ga-Fibroblast Activation Protein Inhibitor vs. 18F-FDG as a Novel Radiotracer for Biologically-Guided Radiotherapy
    Location: Hall B2

    Presenter: Heather McGee, MD, PhD – City of Hope Comprehensive Cancer Center

  • 5:00 PM – 6:00 PM PT
    2544 - Comparison of Tumor Control between FLASH and CONV in an Orthotopic Breast Cancer Model
    Location: Hall B2

    Presenter: Stavros Melemenidis, PhD – Stanford University

  • 5:00 PM – 6:00 PM PT
    2545 - Patient Reported Financial Distress and its Association with Quality of Life and Symptom Burden in Cancer Patients Reporting to a Public Facility in LMIC
    Location: Hall B2

    Presenter: Shagun Misra, MD – Sanjay Gandhi Postgraduate Institute of Medical Sciences

  • 5:00 PM – 6:00 PM PT
    2546 - Tracking Changes in Global Longitudinal Strain in Lung Cancer Patients Receiving Thoracic Radiation
    Location: Hall B2

    Presenter: Steven Montalvo, MD – UT Southwestern Medical Center

  • 5:00 PM – 6:00 PM PT
    2547 - Differential Response to Radiation Fractionation in Head and Neck Cancer Patient-Derived Xenografts
    Location: Hall B2

    Presenter: Musaddiq Awan, MD – Medical College of Wisconsin

  • 5:00 PM – 6:00 PM PT
    2548 - Macrophage Mediated Abscopal Effects of Radiation Therapy
    Location: Hall B2

    Presenter: Yoko Nishiga, MD – Stanford University

  • 5:00 PM – 6:00 PM PT
    2549 - Dose Volume Thresholds Associated with Acute Skin Toxicities in Proton Beam Therapy
    Location: Hall B2

    Presenter: Kenneth Oguejiofor, MD

  • 5:00 PM – 6:00 PM PT
    2550 - Pathway Analysis of Transcriptional Alterations in the Salivary Gland Following Radiation Exposure
    Location: Hall B2

    Presenter: Cristina Paz, MS – University of Wisconsin

  • 5:00 PM – 6:00 PM PT
    2551 - Impact of PRaG Therapy on Peripheral Immune Cells of Subcutaneous Tumor Peritoneal Metastasis Model of Colon Cancer
    Location: Hall B2

    Presenter: Yong Peng – The Second Affiliated Hospital of Soochow University

  • 5:00 PM – 6:00 PM PT
    2552 - Transcriptomic Analysis to Uncover the Mechanism of Radiosensitization of AR-Positive Triple Negative Breast Cancers with AR Inhibition
    Location: Hall B2

    Presenter: Courtney Pisano, DO, MS, MPH – UH Seidman Cancer Center Case Western Reserve University

  • 5:00 PM – 6:00 PM PT
    2553 - Hyperthermic Enhancement of Immunotherapy: Findings of In Vitro Modeling
    Location: Hall B2

    Presenter: Danielle Quaranto, MS

  • 5:00 PM – 6:00 PM PT
    2554 - Comparison of Two Triple Therapy Regimens for Enhancing the Abscopal Effect in Mice
    Location: Hall B2

    Presenter: XI Rao, MD

  • 5:00 PM – 6:00 PM PT
    2555 - A Molecular Approach to Characterize the Effects of Fluence, Fluence Rate and LET on Radiation Damage
    Location: Hall B2

    Presenter: Mohammad Rezaee, PhD, MS – Johns Hopkins University School of Medicine

  • 5:00 PM – 6:00 PM PT
    2556 - Psychiatric or Drug Hospitalizations in Older Cancer Survivors on Long-Term Opioids
    Location: Hall B2

    Presenter: Paul Riviere, MD – UCSD Radiation Medicine and Applied Sciences

  • 5:00 PM – 6:00 PM PT
    2559 - Preclinical Intraoperative FLASH Radiotherapy
    Location: Hall B2

    Presenter: Daniel Sforza, PhD – Johns Hopkins University

  • 5:00 PM – 6:00 PM PT
    2560 - Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Sarthak Shah, BS – GW Medical School

  • 5:00 PM – 6:00 PM PT
    2561 - Pancreatic Cancer Derived 3-D Organoids as Clinical Tool to Predict Response to Radiation and Chemo-Radiation Therapy
    Location: Hall B2

    Presenter: Hem Shukla, PhD – University of Maryland School of Medicine

  • 5:00 PM – 6:00 PM PT
    2562 - Financial Toxicity and Patient Experience Outcomes on a Multi-Institutional Phase I Single Fraction Stereotactic Partial Breast Irradiation Protocol for Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Ambrosia Simmons, MD, PhD – UT Southwestern Medical Center

  • 5:00 PM – 6:00 PM PT
    2563 - Financial Toxicity and Out-of-Pocket Costs for Patients with Head and Neck Cancer: An Australian Perspective
    Location: Hall B2

    Presenter: Justin Smith, MBBS – Queensland Health Radiation Oncology Princess Alexandra Hospital

  • 5:00 PM – 6:00 PM PT
    2564 - Stroke Risk in Survivors of Head and Neck Cancer: A Descriptive Epidemiologic Cohort Study
    Location: Hall B2

    Presenter: Shing Fung Lee, MBBS – National University Hospital

  • 5:00 PM – 6:00 PM PT
    2565 - Loss of ADAR1 Enhances Radiosensitivity of Esophagus Cancer by Causing Cell Apoptosis via NF-kB Signaling Pathway
    Location: Hall B2

    Presenter: Liangchao Sun

  • 5:00 PM – 6:00 PM PT
    2566 - The Effect of MDSC-Derived Exosomes Played in Esophageal Squamous Carcinoma Cells after Ionising Radiation
    Location: Hall B2

    Presenter: Sun Rui, MD

  • 5:00 PM – 6:00 PM PT
    2567 - Transcriptomic Heterogeneity of Metastatic Disease Timing within Metastatic Castration-Sensitive Prostate Cancer
    Location: Hall B2

    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:00 PM – 6:00 PM PT
    2568 - Analyzing the Predictive Effects of PD-L1 Expression, Early Changes of bTMB and Circulated CD8+T Cells during Treatment for Responses of RT Combined with ICI in NSCLC
    Location: Hall B2

    Presenter: Feifei Teng, MD, PhD – Shandong Anti-Cancer Association

  • 5:00 PM – 6:00 PM PT
    2569 - Radiation Therapy Generates Release of Microvesicle Particles in Keratinocytes
    Location: Hall B2

    Presenter: Ericson John Torralba – Wright State University Boonshoft School of Medicine

  • 5:00 PM – 6:00 PM PT
    2570 - Adverse Events Relating to Radiation Therapy in Patients with Collagen Vascular Disorders
    Location: Hall B2

    Presenter: Emily Tran, BS – University of Oklahoma Health Sciences Center

  • 5:00 PM – 6:00 PM PT
    2571 - Comparative Analysis of Tumor Microbiome, Molecular Profile and Immune Cell Abundance by HPV Status in Head and Neck Cancers and Their Impact on Survival
    Location: Hall B2

    Presenter: Rituraj Upadhyay, MD, MBBS, DNB – Ohio State University

  • 5:00 PM – 6:00 PM PT
    2572 - Improving Cancer Care by Incorporating the Patients Voice in Symptom Management (IMPROVE): A Multicenter-Prospective Pilot Study
    Location: Hall B2

    Presenter: Khinh Ranh Voong, MD, MPH – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:00 PM – 6:00 PM PT
    2574 - High Salt Diet Exacerbates Intestinal Radiotoxicity by Promoting Intestinal Epithelial Barrier Dysfunction after RT
    Location: Hall B2

    Presenter: Caroline Walther – Technische Universitat Munchen

  • 5:00 PM – 6:00 PM PT
    2575 - Single-Cell and Bulk RNA Sequencing Reveal the Potential Immune Suppressive Role of PODXL in Cervical Cancer Treated with Radiochemotherapy
    Location: Hall B2

    Presenter: Fuhao Wang, MD

  • 5:00 PM – 6:00 PM PT
    2576 - Study on the Dynamic Changes of Myocardial Injury Markers in Radiotherapy for Esophageal Carcinoma and Its Correlation with Cardiac Dosimetry
    Location: Hall B2

    Presenter: Jin Zhi Wang, MD – Shandong Anti-Cancer Association

  • 5:00 PM – 6:00 PM PT
    2577 - Ubiquitinated H2A.X-Induced RNF168 Condensation Promotes DNA Double-Strand Break Repair and Tumor Radioresistance
    Location: Hall B2

    Presenter: Yun-Long Wang, PhD – Sixth Affiliated Hospital, Sun Yat-sen University

  • 5:00 PM – 6:00 PM PT
    2578 - Spatiotemporal Optimization of Pelvic Radiation Therapy
    Location: Hall B2

    Presenter: William Watkins, PhD – City of Hope National Medical Center

  • 5:00 PM – 6:00 PM PT
    2579 - The Impact of Supervised, Individualized Exercise on Fatigue and Quality of Life during Adjuvant Radiotherapy for Breast Cancer
    Location: Hall B2

    Presenter: Karen Wonders, PhD

  • 5:00 PM – 6:00 PM PT
    2580 - Metformin Antagonizes Radiotherapy-Induced Anti-Tumor Effects via Inhibition of cGAS-STING Pathway Mediated Immune Responses
    Location: Hall B2

    Presenter: Meng Wu, PhD – Shandong Cancer Hospital and Institute

  • 5:00 PM – 6:00 PM PT
    2581 - RUNX1 is a Potential Target for Combined Radioimmunotherapy of Lung Adenocarcinoma
    Location: Hall B2

    Presenter: Changyan Xiao

  • 5:00 PM – 6:00 PM PT
    2582 - Modified Ketogenic Diet can Promote the Anti-Tumor Activity of Radiotherapy for Lung Cancer through AMPK Signaling Pathway
    Location: Hall B2

    Presenter: Ling Xiao, PhD – Sichuan Cancer Hospital and Institute

  • 5:00 PM – 6:00 PM PT
    2583 - Probiotic Consortia and their Metabolites Protect Intestine Against Radiation Injury by Improving Intestinal Epithelial Homeostasis
    Location: Hall B2

    Presenter: Liwei Xie, PhD – The Second Affiliated Hospital of Soochow University

  • 5:00 PM – 6:00 PM PT
    2584 - Prognostic and Predictive Significance of Tumor Immune Microenvironment in Breast Ductal Carcinoma In Situ
    Location: Hall B2

    Presenter: Fei-Fei Xu, MD

  • 5:00 PM – 6:00 PM PT
    2585 - Impact of PRaG Therapy on Immune Microenvironment of Bilateral Subcutaneous Tumor Model of Colon Cancer
    Location: Hall B2

    Presenter: Meiling Xu – The Second Affiliated Hospital of Soochow University

  • 5:00 PM – 6:00 PM PT
    2586 - Tumor Regression with 5-Aminolevulinic Acid (5-ALA)-Mediated Radiodynamic Therapy (RDT) Using Different Megavoltage Energies
    Location: Hall B2

    Presenter: Dae-Myoung Yang, PhD – Fox Chase Cancer Center

  • 5:00 PM – 6:00 PM PT
    2587 - Investigation of Hydrogen Peroxide for 45MV 5-Aminolevulinic Acid-Mediated Radiodynamic Therapy
    Location: Hall B2

    Presenter: Dae-Myoung Yang, PhD – Fox Chase Cancer Center

  • 5:00 PM – 6:00 PM PT
    2588 - Single-Cell Analyses Reveal SBRT-Induced Ccl8+ Mrc1+Macrophage Associated with NK Cells Exhaustion in Lung Cancer
    Location: Hall B2

    Presenter: Haonan Yang, MD – None

  • 5:00 PM – 6:00 PM PT
    2589 - Investigation of ATR inhibitor VX970 as radiosensitizer in colorectal cancer cells
    Location: Hall B2

    Presenter: Linlin Yang, MD, PhD – City of Hope Comprehensive Cancer Center

  • 5:00 PM – 6:00 PM PT
    2590 - Radiosensitizing Effects of CDK4/6 Inhibitors in Hormone Receptor-Positive and HER2-Negative Breast Cancer are through Downregulating DNA Repair Mechanism and NF-?B-Signaling Pathway
    Location: Hall B2

    Presenter: Wen-Chi Yang, MD – National Taiwan University Hospital

  • 5:00 PM – 6:00 PM PT
    2591 - Equivalent Dose Estimation in FLASH Irradiation with a Deep Learning Approach
    Location: Hall B2

    Presenter: Zi Yang, PhD – Stanford University

  • 5:00 PM – 6:00 PM PT
    2592 - Incidence of Major Depression, Suicidal Ideation, and Mental Health Treatment Amongst Cancer Survivors
    Location: Hall B2

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 5:00 PM – 6:00 PM PT
    2592 - Incidence of Major Depression, Suicidal Ideation, and Mental Health Treatment Amongst Cancer Survivors
    Location: Hall B2

    Presenter: Linda Ye, MD – Touro College of Osteopathic Medicine

  • 5:00 PM – 6:00 PM PT
    2593 - The Effect of Dose Rate on Tumor Microenvironment in External Beam Radiotherapy
    Location: Hall B2

    Presenter: Melek Tugce Yilmaz, MD

  • 5:00 PM – 6:00 PM PT
    2594 - Radiotherapy Combined with PD-L1 Antibody Exerts a Synergistic Anti-tumor Effect in a Mouse Model of Esophageal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Hao Yin, MD, PhD – Hangzhou Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2595 - The Role of Esophagography in the Diagnosis of Orthotopic Esophageal Squamous Cell Carcinoma in a Mouse Mode
    Location: Hall B2

    Presenter: Hao Yin, MD, PhD – Hangzhou Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2596 - Effects of the PARP Inhibitor Niraparib on the Radiosensitivity of Human Lung and Cervical Cancer Cells
    Location: Hall B2

    Presenter: Jingping Yu

  • 5:00 PM – 6:00 PM PT
    2597 - Dynamic Exosome Analysis to Predict Response to the Combination of SABR and Immunotherapy in Oligoprogressive Disease
    Location: Hall B2

    Presenter: Juan Zafra Martin, MD – Hospital Universitario Virgen de la Victoria

  • 5:00 PM – 6:00 PM PT
    2598 - Development and Validation of CT-Based Dose-Volume-Radiomics Nomogram for Radiation Induced Hypothyroidism in Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Jian Zang, PhD

  • 5:00 PM – 6:00 PM PT
    2599 - Determining the Minimal Clinically Important Difference of the FACT-E to Evaluate the Change in the Quality of Life of Patients with Esophageal Cancer Treated with Curative Radiotherapy
    Location: Hall B2

    Presenter: Todd DeWees, PhD – City of Hope Comprehensive Cancer Center

  • 5:00 PM – 6:00 PM PT
    2601 - CDC73 Promotes Breast Cancer through Impairing MAPK1 Ubiquitination and Activating mTOR Signaling Pathway
    Location: Hall B2

    Presenter: Haige Zhang, PhD – The First Affiliated Hospital of Henan University of Science and Technology

  • 5:00 PM – 6:00 PM PT
    2602 - The Effect of Dose-Fractionation Mode on the Immune Response and Therapeutic Effect of Lewis Lung Cancer Mice Model Based on Tumor Microenvironment
    Location: Hall B2

    Presenter: Hangyue Zhang, MS – Sichuan Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2603 - Up-Regulation of TCF21 Expression Reverses the Malignant Phenotype of Cancer-Associated Fibroblasts in Esophageal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Hongfang Zhang, PhD – Hangzhou Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2604 - Hyperthermia Enhances the Radiosensitivity of Pancreatic Cancer Cells by Inhibiting Wnt2B Signaling
    Location: Hall B2

    Presenter: Hongfang Zhang, PhD – Hangzhou Cancer Hospital

  • 5:00 PM – 6:00 PM PT
    2605 - LINC00921 Diminishes Lung Cancer Radiosensitivity by Bestabilizing NUDT21 and Driving Aberrant MED23 Alternative Polyadenylation
    Location: Hall B2

    Presenter: Nasha Zhang

  • 5:00 PM – 6:00 PM PT
    2606 - Impacts of Combining Pulsed Low Dose Rate Radiotherapy (PLDR) and Anti-PD-1 Antibody on Tumor Growth and Its Mechanism for Lung Cancer in Mice
    Location: Hall B2

    Presenter: Peng Zhang, MD – Sichuan Cancer Hospital and Institute

  • 5:00 PM – 6:00 PM PT
    2607 - Hypofractionated Radiotherapy with Prolonged Inter-Fraction Interval (Hypo-Slow RT) to Facilitate Immune Priming of Tumor
    Location: Hall B2

    Presenter: Shichuan Zhang, MD, PhD – Sichuan Cancer Hospital and Institute

  • 5:00 PM – 6:00 PM PT
    2608 - Targeting Immunosuppressive Myeloid Cells and Exhausted CD8+ T Cells Overcomes Radioresistance in NSCLC
    Location: Hall B2

    Presenter: Yuhan Zhang, PhD – Tianjin Medical University Cancer Institute and Hospital

  • 5:00 PM – 6:00 PM PT
    2609 - Exploring the Efficacy and Molecular Mechanism of Systemic Therapy-Based Split-Course Stereotactic Body Radiation Therapy for Solid Tumors
    Location: Hall B2

    Presenter: Rong Zheng, MD, PhD – Fujian Medical University Union Hospital

  • 5:00 PM – 6:00 PM PT
    2610 - Radiation Induced Lung Injury in Rats after Pre-Oxygenation Radiotherapy
    Location: Hall B2

    Presenter: Ziyang Zhou, MD – Zhejiang University The First Affiliated Hospital College of Medicine

  • 5:00 PM – 6:00 PM PT
    2611 - A Ferroptosis Microneedle Integrated Wireless Implanted Photodynamic Therapy Pellet for Cancer Treatment
    Location: Hall B2

    Presenter: Pingjin Zou, PhD – University of Electronic Science and Technology of China

  • Tuesday, October 3, 2023
  • 12:45 PM – 2:00 PM PT
    2612 - Long-Term Outcomes and Toxicity in Esophageal Cancer Patients after Neoadjuvant or Definitive Concurrent Chemotherapy with Proton Beam Therapy
    Location: Hall B2

    Presenter: Chike Abana, MD, PhD – The University of Texas M.D. Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2613 - Treatment Outcomes and Toxicity Profile of MRI-Guided Gated-Real Time Online Adaptive Stereotactic Body Radiotherapy to Patients with Pancreatic Tumors
    Location: Hall B2

    Presenter: Lamiaa Abdallah, MD, MS – Loyola University Medical Center

  • 12:45 PM – 2:00 PM PT
    2614 - Borderline Resectable Pancreatic Cancer: Impact on Neoadjuvant Response Post Integration of MRI Guided Adaptive Radiation Therapy
    Location: Hall B2

    Presenter: Matthew Adams, BS – Lake Erie College of Osteopathic Medicine

  • 12:45 PM – 2:00 PM PT
    2616 - Clinical Outcomes and Immunotoxicity in People with HIV (PWH) after Definitive Chemoradiation (CRT) for Anal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: August Anderson, MD – University of Washington

  • 12:45 PM – 2:00 PM PT
    2617 - Hypofractionated Preoperative Radiotherapy 30Gy in Five Fractions for Soft Tissue Sarcoma of the Extremity
    Location: Hall B2

    Presenter: Constanza Martinez, MD, PhD – McGill University Health Centre

  • 12:45 PM – 2:00 PM PT
    2617 - Hypofractionated Preoperative Radiotherapy 30Gy in Five Fractions for Soft Tissue Sarcoma of the Extremity
    Location: Hall B2

    Presenter: Rie Asso, MD – Sirio Libanes Hospital

  • 12:45 PM – 2:00 PM PT
    2618 - HPV Infection and Immunohistochemical Analysis of P16, P53, and PD-L1 Expression as Prognostic Biomarkers in Squamous Cell Anal Cancer Patients Receiving Definitive Radiotherapy/Chemoradiotherapy
    Location: Hall B2

    Presenter: Beril Balci Topuz

  • 12:45 PM – 2:00 PM PT
    2619 - Quality of Life Before and After Radiotherapy for Early-Stage Keratinocyte Carcinoma: A Longitudinal Analysis
    Location: Hall B2

    Presenter: Christopher Barker, MD – Memorial Sloan Kettering Cancer Center

  • 12:45 PM – 2:00 PM PT
    2620 - Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes
    Location: Hall B2

    Presenter: Sara Beltran Ponce, MD – Medical College of Wisconsin

  • 12:45 PM – 2:00 PM PT
    2621 - Pancreatic Cancer Outcome: Local Treatment with Radiation Using MRI-Linac
    Location: Hall B2

    Presenter: Merav Ben-David, MD – Assuta Medical Center

  • 12:45 PM – 2:00 PM PT
    2622 - The Predictive Value of Changes in Basal Myocardial F-18 Fluorodeoxyglucose Uptake for Cardiotoxicity in Locally Advanced Esophageal Cancer Patients Receiving Definitive Radiotherapy
    Location: Hall B2

    Presenter: Guoxin Cai, MD – Shandong Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2623 - Gastric Radiotherapy in the UK - Current Practice and Opinion on Future Directions
    Location: Hall B2

    Presenter: Amy Case, MBBCh – South West Wales Cancer Centre

  • 12:45 PM – 2:00 PM PT
    2624 - Inaugural Experience with Real-time Gated Liver Proton SBRT and Treatment Plan Quality Improvement
    Location: Hall B2

    Presenter: Hao Chen, PhD – Johns Hopkins University

  • 12:45 PM – 2:00 PM PT
    2625 - Primary Small Cell Carcinoma of the Esophagus in a Large Multicenter Cohort: Prognostic Factors and Treatment Strategies in the Modern Era
    Location: Hall B2

    Presenter: Silin Chen, MD – National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academ

  • 12:45 PM – 2:00 PM PT
    2626 - Grade 4 Lymphopenia Might Associate with Pericardial Irradiation Dose and Worse Prognosis in Patients with Locally Advanced Esophageal Cancer Receiving Concurrent Chemo-Radiotherapy
    Location: Hall B2

    Presenter: Xianyan Chen, MD – West China Hospital of Sichuan University

  • 12:45 PM – 2:00 PM PT
    2627 - The Effect of Three Different Positioning Approaches for Prone Rectum Radiotherapy on Positioning Accuracy and Treatment Margins
    Location: Hall B2

    Presenter: xuemei chen – Sun Yat-Sen University Cancer Center

  • 12:45 PM – 2:00 PM PT
    2629 - The Role of Postoperative Radiotherapy in T4 Rectal Cancer with Synchronous Distant Metastasis
    Location: Hall B2

    Presenter: Kyu Hye Choi, MD, PhD – Seoul St. Mary's Hospital

  • 12:45 PM – 2:00 PM PT
    2630 - MRI Guided Adaptive Radiotherapy (MRgART) in Primary and Metastatic Liver Lesions
    Location: Hall B2

    Presenter: Tee Lim, MD, MBBS, FRANZCR – Genesis Cancer Care

  • 12:45 PM – 2:00 PM PT
    2630 - MRI Guided Adaptive Radiotherapy (MRgART) in Primary and Metastatic Liver Lesions
    Location: Hall B1

    Presenter: Caris Chong, MBBS – Fiona Stanley Hospital (Genesis Care)

  • 12:45 PM – 2:00 PM PT
    2632 - Ablative 5-Fraction CT vs. MR-Guided Pancreatic SBRT: Evaluation of Interfraction Anatomic Changes on Dosimetric Constraints
    Location: Hall B2

    Presenter: Michael Chuong, MD – Miami Cancer Institute

  • 12:45 PM – 2:00 PM PT
    2633 - Fungating Soft Tissue Sarcoma: A Complex Treatment Dilemma
    Location: Hall B2

    Presenter: Bailey Corson, MD, MS – Naval Medical Center San Diego

  • 12:45 PM – 2:00 PM PT
    2633 - Fungating Soft Tissue Sarcoma: A Complex Treatment Dilemma
    Location: Hall B2

    Presenter: Jonathan Bear, MD – U.S. Navy

  • 12:45 PM – 2:00 PM PT
    2634 - CT-Based Radiomics Combined with Genomics may Predict Survival in Esophageal Cancer Patients Receiving Definitive Chemoradiotherapy
    Location: Hall B2

    Presenter: Jinfeng Cui, MD

  • 12:45 PM – 2:00 PM PT
    2635 - Development and Validation of a Radiomics-Based Model to Predict Overall Survival after Definitive Chemoradiotherapy in Patients With Esophageal Cancer
    Location: Hall B2

    Presenter: Jinfeng Cui, MD

  • 12:45 PM – 2:00 PM PT
    2636 - Patient-Reported Outcomes of Rectal Cancer Patients Treated on a 1.5T MR-Linac within the MOMENTUM Study
    Location: Hall B2

    Presenter: Lois Daamen, MD, PhD – UMC Utrecht

  • 12:45 PM – 2:00 PM PT
    2637 - Efficacy and Safety of High-Dose Vitamin C Combined with Total Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer (HCCSC R02 Study)
    Location: Hall B2

    Presenter: Jing Dai, MD, PhD – Zhongnan Hospital of Wuhan University

  • 12:45 PM – 2:00 PM PT
    2638 - Salvage Abdominoperineal Resection for Locally Recurrent or Persistent Anal Squamous Cell Carcinoma after Definitive Chemoradiation
    Location: Hall B2

    Presenter: Ethan Damron, BS – McGovern Medical School

  • 12:45 PM – 2:00 PM PT
    2639 - Scalp Volumetric Modulated Arc Therapy Using 3D Milled Bolus: Dosimetry, Toxicity and Outcome
    Location: Hall B2

    Presenter: Khaled Dibs, MD – The James Cancer Hospital & Solove Research Institute

  • 12:45 PM – 2:00 PM PT
    2640 - Multicenter Retrospective Study of Stereotactic Body Radiotherapy for Patients with Previously Untreated Initial Small Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Yoshiko Doi, MD, PhD – Hiroshima Prefectual Hospital

  • 12:45 PM – 2:00 PM PT
    2641 - Prospective Evaluation of MRI-Based Endoluminal Brachytherapy with Novel Applicator for Anorectal Cancer
    Location: Hall B2

    Presenter: Alexandra Dreyfuss, MD – Memorial Sloan Kettering Cancer Center

  • 12:45 PM – 2:00 PM PT
    2642 - Racial Disparties in the Utilization of Stereotactic Body Radiation Therapy (SBRT) in Patients with Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Kevin Du, MD, PhD, MS – Yale School of Medicine

  • 12:45 PM – 2:00 PM PT
    2643 - PD-1 Inhibitors and Chemotherapy Combined with or without Radiotherapy for Patients with Oligometastatic Esophageal Cancer
    Location: Hall B2

    Presenter: Yanan Duan

  • 12:45 PM – 2:00 PM PT
    2644 - Post-Progression Survival in Patients with Oligometastatic or Polymetastatic Pancreatic Adenocarcinoma
    Location: Hall B2

    Presenter: Ahmed Elamir, MD, MS – UT Southwestern Medical Center

  • 12:45 PM – 2:00 PM PT
    2645 - Dose Escalation Using Magnetic Resonance Guided High-Dose-Rate Endorectal Brachytherapy to Enhance Clinical Response after Neoadjuvant Radiotherapy in Rectal Adenocarcinoma
    Location: Hall B2

    Presenter: Reena Engineer, MD – Tata Memorial Hospital

  • 12:45 PM – 2:00 PM PT
    2646 - Racial and Ethnic Disparities in Health-Related Quality of Life for Patients with Colorectal Cancer: Analysis of the SEER-MHOS Linked Data Set
    Location: Hall B2

    Presenter: Matthew Farrell, MD, MFA – UCLA Radiation Oncology

  • 12:45 PM – 2:00 PM PT
    2647 - Intratumoral Dose Escalation Using Lattice Radiotherapy for Hepatocellular Carcinoma with Unfavorable Size and Location
    Location: Hall B2

    Presenter: Andrew Frankart, MD – University of Cincinnati

  • 12:45 PM – 2:00 PM PT
    2648 - Advanced Hepatocellular Carcinoma Patients with Poor Access to Systemic Therapy Treated with Definitive Stereotactic Body Radiation Therapy: A Single-Institution Experience in Latin America
    Location: Hall B2

    Presenter: Maximiliano Fuentealba, MD – Clinica IRAM

  • 12:45 PM – 2:00 PM PT
    2649 - Sarcopenia Predicts Poor Tolerance to Chemotherapy during Definitive Treatment of Primary Anal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Ramesh Gadam, MD, MBBS – University of Kansas Medical Center

  • 12:45 PM – 2:00 PM PT
    2650 - Anal Canal Adenocarcinomas: Prognostic Factors and Outcomes at a Single Institution
    Location: Hall B2

    Presenter: Derek Go, MD, MS – Kaiser Permanente Los Angeles Medical Center

  • 12:45 PM – 2:00 PM PT
    2651 - Efficacy of Single-Fraction Postoperative Radiotherapy in Resected, Early-Stage Merkel Cell Carcinoma with High-Risk Features
    Location: Hall B2

    Presenter: Peter Goff, MD, PhD – University of Washington

  • 12:45 PM – 2:00 PM PT
    2652 - Comparison of Estimated Late Toxicities between IMRT and IMPT when Treating Retroperitoneal Sarcoma Preoperatively with Ultra-Hypofractionation
    Location: Hall B2

    Presenter: Emile Gogineni, DO – The Ohio State University Wexner Medical Center

  • 12:45 PM – 2:00 PM PT
    2653 - Spine Stereotactic Radiosurgery for Primary and Metastatic Osteosarcoma
    Location: Hall B2

    Presenter: Adam Grippin, MD, PhD – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2654 - The Association of Chemoradiation Induced Lymphopenia with Racial Disparity and Its Prognostic Impact on Survival for Anal Cancer
    Location: Hall B2

    Presenter: Bin Gui, MD – Northwell Health

  • 12:45 PM – 2:00 PM PT
    2655 - Safety of Radiation Therapy for Treatment of Malignancy in Patients with Inflammatory Bowel Disease
    Location: Hall B2

    Presenter: Jennifer Hall, BS – Stanford University School of Medicine

  • 12:45 PM – 2:00 PM PT
    2656 - Correlation between Lymph Node Regression Grading and Tumor Regression Grading after Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Lei He

  • 12:45 PM – 2:00 PM PT
    2657 - Effect of Anemia on Tumor Response to Preoperative Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Lei He

  • 12:45 PM – 2:00 PM PT
    2658 - Neoadjuvant Chemoradiotherapy Combined with Nimotuzumab and Camrelizumab in Initially Inoperable Patients with Locally Advanced Esophageal Cancer: A Prospective, One-Arm, Phase II Study
    Location: Hall B2

    Presenter: Yuan He

  • 12:45 PM – 2:00 PM PT
    2659 - Dose Escalation in Oesophageal Cancer: Comparing Pre-Accrual and On-Trial Target Volume Delineation in the UK SCOPE2 Trial

    Presenter: Jonathan Helbrow – South West Wales Cancer Centre

  • 12:45 PM – 2:00 PM PT
    2659 - Dose Escalation in Oesophageal Cancer: Comparing Pre-Accrual and On-Trial Target Volume Delineation in the UK SCOPE2 Trial
    Location: Hall B2

    Presenter: Sarah Gwynne, MD, MB, ChB – South West Wales Cancer Centre

  • 12:45 PM – 2:00 PM PT
    2660 - The Role of Coronary Artery Calcium Score to Assess Risk of Cardiovascular Disease in Irradiated Esophageal Cancer Patients
    Location: Hall B2

    Presenter: Alexandra Hotca-Cho, MD – Icahn School of Medicine at Mount Sinai

  • 12:45 PM – 2:00 PM PT
    2661 - Adding Bevacizumab to Neoadjuvant Concurrent Chemoradiation Causes a Paradoxical Increase in Circulating Vascular Endothelial Growth Factor-A and an Inferior Outcome in Locally Advanced Esophageal Squ
    Location: Hall B2

    Presenter: Feng-Ming Hsu, MD, PhD – National Taiwan University Hospital

  • 12:45 PM – 2:00 PM PT
    2662 - Salvage Radiotherapy Improves Survival in Patients with Metastatic Liver Cancer after Immunotherapy Oligoprogression
    Location: Hall B2

    Presenter: Shu Jung Hsu, MD – Zhongshan Hospital Fudan University

  • 12:45 PM – 2:00 PM PT
    2663 - Effect of Histopathological Regression of Tumor and Lymph Node on the Progression of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy
    Location: Hall B2

    Presenter: Bing Hu, MD, MS – Shandong First Medical University and Shandong Academy of Medical Sciences

  • 12:45 PM – 2:00 PM PT
    2664 - Predicting Radiation Esophagitis using 18F-FAPI-04 PET/CT in Patients with LA-ESCC Treated with Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Xinying Hu, MD

  • 12:45 PM – 2:00 PM PT
    2665 - Patterns of Failure for Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer
    Location: Hall B2

    Presenter: Caressa Hui, MD, BS – Stanford

  • 12:45 PM – 2:00 PM PT
    2666 - Combination of Radiotherapy and Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Pilot Study
    Location: Hall B2

    Presenter: Youn Ji Hur, MD

  • 12:45 PM – 2:00 PM PT
    2667 - Towards Global Consensus for MR-Guided Treatment Planning for Pancreatic Tumors on a 1.5 T MR-Linac
    Location: Hall B2

    Presenter: Martijn Intven, MD, PhD – University Medical Center Utrecht

  • 12:45 PM – 2:00 PM PT
    2668 - How the Underlying Etiology of Cirrhosis Impacts Response to SBRT
    Location: Hall B2

    Presenter: Evrosina Isaac, MD – Virginia Commonwealth University Health System

  • 12:45 PM – 2:00 PM PT
    2669 - The Outcomes of Neoadjuvant Chemoradiotherapy Using Moderately Hypofractionated Intensity Modulated Radiotherapy for Borderline Resectable Pancreatic Cancer
    Location: Hall B2

    Presenter: Takahiro Iwai, MD – Kyoto University Graduate School of Medicine

  • 12:45 PM – 2:00 PM PT
    2670 - Molecular Subtypes and Outcomes in a Multi-Institutional Review of Rectal Cancer Patients
    Location: Hall B2

    Presenter: Einsley-Marie Janowski, MD, PhD – University of Virginia

  • 12:45 PM – 2:00 PM PT
    2671 - Evaluation of the Possibility of Dose Realignment Adaptation by Shifting the Isocenter in Proton Beam Therapy for Pancreatic Cancer
    Location: Hall B2

    Presenter: Norio Katoh, MD, PhD – Hokkaido University Faculty of Medicine

  • 12:45 PM – 2:00 PM PT
    2672 - Experience with 177Lu-Dotatate in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors at a Single Urban Cancer Center
    Location: Hall B2

    Presenter: Aria Kieft, MD – Detroit Medical Center

  • 12:45 PM – 2:00 PM PT
    2673 - Liver-Directed Combined Radiotherapy for Downstaging of the Milan Advanced Hepatocellular Carcinoma Converting to Liver Transplantation
    Location: Hall B2

    Presenter: Yong Tae Kim, MD – Yonsei Cancer Center, Yonsei University College of Medicine

  • 12:45 PM – 2:00 PM PT
    2674 - Association between Liver Metastases and Treatment Response in Patients with Metastatic, Microsatellite Stable Colorectal Cancer Treated with Radiation Therapy and Dual Immune Checkpoint Blockade
    Location: Hall B2

    Presenter: Julie Koenig, MD – Harvard Radiation Oncology Program

  • 12:45 PM – 2:00 PM PT
    2675 - A Risk Prediction Model for Severe Radiation Induced Lymphopenia in Patients with Pancreatic Cancer Treated with Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Fuki Koizumi, MD – Hokkaido University Hospital

  • 12:45 PM – 2:00 PM PT
    2676 - Radiotherapy for Patients with Locally Advanced Esophageal Squamous Cell Carcinoma Receiving Neoadjuvant Immunotherapy Combined with Chemotherapy
    Location: Hall B2

    Presenter: Yue Kong

  • 12:45 PM – 2:00 PM PT
    2678 - Predictive Value of Tumor Volume on Local Control in Hepatocellular Carcinoma Treated with Image Guided Hypofractionated Radiation Treatment
    Location: Hall B2

    Presenter: Ritesh Kumar, MD, MBBS – Rutgers Cancer Institute of New Jersey

  • 12:45 PM – 2:00 PM PT
    2679 - Study of a Geometric Score to Identify the Increased Risk of Local Failure after SBRT for Locally Advanced Pancreatic Cancer (LAPC)
    Location: Hall B2

    Presenter: Eliana La Rocca, MD – Azienda Ospedaliera universitaria Integrata di Verona

  • 12:45 PM – 2:00 PM PT
    2680 - Patient Selection is Critical When Evaluating Candidates for 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Locally Advanced Pancreatic Cancer
    Location: Hall B2

    Presenter: David Lakomy, MD – Washington University in St. Louis

  • 12:45 PM – 2:00 PM PT
    2681 - CT-Guided Online Adaptive Stereotactic Body Radiotherapy for Pancreas Ductal Adenocarcinoma: Dosimetric and Initial Clinical Experience
    Location: Hall B2

    Presenter: Albert Lee, MD – Columbia University Irving Medical Center

  • 12:45 PM – 2:00 PM PT
    2682 - A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Katie Lee, MD, PhD – Harvard Radiation Oncology Program

  • 12:45 PM – 2:00 PM PT
    2683 - Pre-Treatment Trends in Child-Pugh Score as an Indicator of Post-Treatment Survival in Patients Receiving Liver SBRT for HCC
    Location: Hall B2

    Presenter: Peter Lee, MD, PhD – Fox Chase Cancer Center

  • 12:45 PM – 2:00 PM PT
    2684 - Efficacy and Safety of Image-Guided Hypofractionated Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
    Location: Hall B2

    Presenter: Sang Min Lee – Seoul National University College of Medicine

  • 12:45 PM – 2:00 PM PT
    2685 - Treatment Outcomes of Stereotactic Body Radiation Therapy for Pulmonary Metastasis from Sarcoma: A Multicenter, Retrospective Study
    Location: Hall B2

    Presenter: Tae Hoon Lee, MD – Samsung Medical Center

  • 12:45 PM – 2:00 PM PT
    2686 - Outcomes and Failure Patterns after Chemoradiotherapy for Locally Advanced Rectal Cancer with Positive Lateral Pelvic Lymph Nodes: A Propensity Score-Matched Analysis
    Location: Hall B2

    Presenter: Shuai Li, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences

  • 12:45 PM – 2:00 PM PT
    2687 - Sintilimab Injection Combination with Concurrent Chemoradiotherapy (cCRT) in Patients with Localized Esophageal Squamous Cell Carcinoma: A Prospective, Multi-Center, Single-Arm Trial in Progress
    Location: Hall B2

    Presenter: Tao Li, MD, PhD – School of Medicine, University of Electronic Science and Technology of China, Chengdu, China

  • 12:45 PM – 2:00 PM PT
    2688 - Exploration of Multiomic Profiles and Biomarkers as Predictors of Neoadjuvant Chemoradiotherapy Responsiveness in Esophageal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Yue Li, MD – Shanghai Jiao Tong University

  • 12:45 PM – 2:00 PM PT
    2689 - Clinical-Radiomics Nomogram for Risk Prediction of Esophageal Fistula in Patients with Esophageal Squamous Cell Carcinoma Treated by IMRT or VMAT
    Location: Hall B2

    Presenter: Zhaohui Li, BS – Xijing Hospital

  • 12:45 PM – 2:00 PM PT
    2690 - The Association of Time Interval between Surgery and Neoadjuvant Chemoradiation Therapy with pCR and Overall Survival for Locally Advanced Rectal Adenocarcinoma
    Location: Hall B2

    Presenter: Chi Lin, MD, PhD, MS – UNMC

  • 12:45 PM – 2:00 PM PT
    2691 - Impact of Local Therapy on Outcomes in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation
    Location: Hall B2

    Presenter: Timothy Lin, MD, MBA – Johns Hopkins University

  • 12:45 PM – 2:00 PM PT
    2692 - Local Time-to-Event Endpoint Under-Reporting and Variability in Pancreatic Cancer Trials Involving Radiotherapy
    Location: Hall B2

    Presenter: Timothy Lin, MD, MBA – Johns Hopkins University

  • 12:45 PM – 2:00 PM PT
    2693 - Visceral Artery Pseudoaneurysm Rates after Pancreatoduodenectomy in Patients Who Received Pre-Operative Radiation for Pancreatic Cancer
    Location: Hall B2

    Presenter: I-Chia Liu, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 12:45 PM – 2:00 PM PT
    2694 - Patterns of Care for Patients with Locally Advanced Rectal Cancer Treated with Total Neoadjuvant Therapy between 2016-2020: An NCDB Analysis
    Location: Hall B2

    Presenter: Jason Liu, MD – City of Hope National Medical Center

  • 12:45 PM – 2:00 PM PT
    2695 - Role of Radiation Therapy in Liver-Only Oligometastatic Disease: A SEER Analysis
    Location: Hall B2

    Presenter: Yirong Liu, MD, PhD – Northwestern Memorial Hospital

  • 12:45 PM – 2:00 PM PT
    2696 - A Machine Learning Method to Predict Pathological Complete Response of Esophageal Cancer after Neoadjuvant Chemoradiotherapy with Clinicohematological Markers and MR Radiomics: A Multi-Center Study
    Location: Hall B2

    Presenter: Yunsong Liu, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC

  • 12:45 PM – 2:00 PM PT
    2697 - Association between Tumor Volume Change on MRI with Surgical Margin Status, Pathological Response, and Local Control Following Pre-Operative Radiation Therapy for Soft Tissue Sarcoma
    Location: Hall B2

    Presenter: Casey Liveringhouse, MD, BA – H. Lee Moffitt Cancer Center and Research Institute

  • 12:45 PM – 2:00 PM PT
    2698 - Treatment Modalities to Manage Hepatocellular Carcinoma Patients with Portal Vein Thrombus: A Systematic Review and Meta-Analysis
    Location: Hall B2

    Presenter: Michael Lock, MD – London Health Sciences Centre

  • 12:45 PM – 2:00 PM PT
    2699 - Radiotherapy for Liver Cancer: An International Multi-Centre Pooled Analysis of 925 Cases
    Location: Hall B2

    Presenter: Michael Lock, MD – London Health Sciences Centre

  • 12:45 PM – 2:00 PM PT
    2700 - Preoperative Radiotherapy of Soft Tissue Sarcoma with Simultaneous Integrated Boost: A Phase II Study
    Location: Hall B2

    Presenter: Mauro Loi, MD – Azienda Ospedaliera Universitaria Careggi

  • 12:45 PM – 2:00 PM PT
    2701 - Evaluation of Metastatic Potential in Esophageal and Gastroesophageal Junction (GEJ) Cancer with Adherence to Elective Nodal Volume Guidelines: A Retrospective Analysis of Elective Nodal Irradiation
    Location: Hall B2

    Presenter: Jared Lyons, MS – University of California, Irvine School of Medicine

  • 12:45 PM – 2:00 PM PT
    2702 - Characterization of DNA Damage Response-Associated Somatic Mutations in Borderline Resectable and Locally Advanced Pancreatic Cancer
    Location: Hall B2

    Presenter: Vrinda Madan, BA – Johns Hopkins University School of Medicine

  • 12:45 PM – 2:00 PM PT
    2703 - Timing of Surgery and Pathologic Complete Response (pCR) after Completing Total Neoadjuvant Therapy for Rectal Adenocarcinoma: A Retrospective Study of the National Cancer Database
    Location: Hall B2

    Presenter: Megan Mai, MPH – Texas Tech University Health Science Center

  • 12:45 PM – 2:00 PM PT
    2704 - Multi-Institutional Experience of Proton Therapy for Osteosarcoma in the Proton Collaborative Group (PCG) Prospective Registry
    Location: Hall B2

    Presenter: Keitrina Mair, MS, BS – Miami Cancer Institute: Baptist Health South Florida

  • 12:45 PM – 2:00 PM PT
    2705 - Proton Beam Therapy for HCC Exceeding up-to-Seven Criteria
    Location: Hall B2

    Presenter: Hirokazu Makishima, MD, PhD – University of Tsukuba

  • 12:45 PM – 2:00 PM PT
    2706 - Post-Hypofractionated Radiotherapy Neutrophil-to-Lymphocyte Ratio in Soft Tissue Sarcomas is a Prognostic Biomarker of Recurrence and Distant Metastases
    Location: Hall B2

    Presenter: Constanza Martinez, MD, PhD – McGill University Health Centre

  • 12:45 PM – 2:00 PM PT
    2708 - Image-Guided Superficial Radiation Therapy Has Superior 2-Year Recurrence Rates to Mohs Micrographic Surgery
    Location: Hall B2

    Presenter: Erin McClure, BS

  • 12:45 PM – 2:00 PM PT
    2709 - Outcomes and after Hyperfractionated, Accelerated Reirradiation for Recurrent Anal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Jordan McDonald, MD – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2710 - Short Course Radiotherapy (SCRT) with Simultaneous Integrated Boost (SIB) in the Treatment of Rectal Cancer: Feasibility and Early toxicities
    Location: Hall B2

    Presenter: Michael Melton, MD – University of Alabama Birmingham Hospital

  • 12:45 PM – 2:00 PM PT
    2711 - Neoadjuvant Stereotactic MR-Guided Ablative Radiation Therapy (SMART) and Surgical Outcomes in Patients with Pancreatic Cancer
    Location: Hall B2

    Presenter: Hari Menon, MD, BS – University of Wisconsin Radiation Oncology

  • 12:45 PM – 2:00 PM PT
    2712 - Adjuvant Radiation Therapy Improves Local Control in the Treatment of Adnexal Carcinoma
    Location: Hall B2

    Presenter: Devarati Mitra, MD, PhD – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2713 - Predictive Value of Day of Treatment SPECT/CT Radiomics in Lobar Y90 Radioembolization of Hepatocellular Carcinoma: A Pilot Study
    Location: Hall B2

    Presenter: Chris Montoya, MD – Sylvester Comprehensive Cancer Center

  • 12:45 PM – 2:00 PM PT
    2714 - Long-Term Clinical Outcome of Carbon Ion Radio Therapy for Hepatocellular Carcinoma in the Caudate Lobe
    Location: Hall B2

    Presenter: Yasumasa Mori, MD, DVM, PhD – QST Hospital, National Institutes for Quantum and Radiological Science and Technology

  • 12:45 PM – 2:00 PM PT
    2715 - Laryngo-Esophageal Dysfunction Free Survival of Chemoradiation for Cervical Esophageal Cancer
    Location: Hall B2

    Presenter: Yuji Murakami, MD, PhD – Hiroshima University

  • 12:45 PM – 2:00 PM PT
    2716 - Long-Term Outcomes in a Phase II Study of Hypofractionated IGRT 60Gy/ 20F in Patients with Isolated Lymph Node Recurrence after Surgery for Esophageal Carcinoma
    Location: Hall B2

    Presenter: Miyako Myojin, MD, PhD – Keiyukai Sapporo

  • 12:45 PM – 2:00 PM PT
    2717 - Outcomes of Moderately Dose Escalated Hypofractionated Chemoradiation for Pancreatic Cancer
    Location: Hall B2

    Presenter: Ansel Nalin, MD, PhD – UT Health Science Center at Houston

  • 12:45 PM – 2:00 PM PT
    2718 - Outcome of Proton Beam Therapy for Primary Hepatocellular Carcinoma with "Unfavorable" Macroscopic Classification
    Location: Hall B2

    Presenter: Hikaru Niitsu, MD – University of Tsukuba

  • 12:45 PM – 2:00 PM PT
    2719 - Impact of the G8 Score on Treatment Strategies and Outcome in Definitive Radiotherapy for the Elderly Esophageal Cancer Patients
    Location: Hall B2

    Presenter: Ikuno Nishibuchi, MD, PhD – Hiroshima University

  • 12:45 PM – 2:00 PM PT
    2720 - A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Canc
    Location: Hall B2

    Presenter: Sean O'Cathail, MD, PhD – University of Glasgow

  • 12:45 PM – 2:00 PM PT
    2721 - Machine Learning Based Prediction of Distant Metastasis in Rectal Cancer Patients with Complete Response following Neoadjuvant Chemoradiotherapy
    Location: Hall B2

    Presenter: Gulsah Ozden, MD – Marmara University

  • 12:45 PM – 2:00 PM PT
    2722 - Role of Stereotactic Body Radiation Therapy in Portal Vein Tumor Thrombosis in Hepatocellular Carcinoma: A Prospective Single Institute Experience
    Location: Hall B2

    Presenter: Suyash Pandey, MD – All India Institute of Medical Sciences

  • 12:45 PM – 2:00 PM PT
    2723 - Biological Response Assessment in Hepatocellular Carcinoma Post Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Haresh Kunhiparambath, MD – All India Institute of Medical Sciences

  • 12:45 PM – 2:00 PM PT
    2724 - Dosimetric Analysis of Major Wound Complications Following Preoperative Ultra-Hypofractionated Radiation Therapy for Soft Tissue Sarcoma
    Location: Hall B2

    Presenter: Sean Parker, MD – Cleveland Clinic Health System

  • 12:45 PM – 2:00 PM PT
    2725 - Liver Stereotactic Body Radiation Therapy (SBRT) to Downstage Patients with Hepatocellular Carcinoma prior to Liver Transplant
    Location: Hall B2

    Presenter: Sean Parker, MD – Cleveland Clinic Health System

  • 12:45 PM – 2:00 PM PT
    2726 - Assessment of the Spatial Bio-Distribution of NBTXR3 for Locally Advanced or Borderline-Resectable Pancreatic Ductal Adenocarcinoma (LAPC or BRPC) Patients Undergoing Radiation Therapy
    Location: Hall B2

    Presenter: Luis Perles, PhD – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2727 - Surgical Outcomes in Patients Treated with 5-Day Preoperative Radiotherapy for Soft Tissue Sarcoma
    Location: Hall B2

    Presenter: Nicholas Peterson, MD – UCI Radiation Oncology

  • 12:45 PM – 2:00 PM PT
    2728 - Early Outcomes of MR-Guided SBRT for Patients with Recurrent Pancreatic Adenocarcinoma
    Location: Hall B2

    Presenter: Spencer Poiset, MD, BS – Thomas Jefferson University

  • 12:45 PM – 2:00 PM PT
    2729 - Single Institutional Experience Using Radiation Therapy in the Treatment of Neuroendocrine Tumor Primary and Metastatic Lesions
    Location: Hall B2

    Presenter: Kaitlin Qualls, MD – Mayo Clinic College of Medicine and Science Rochester

  • 12:45 PM – 2:00 PM PT
    2730 - Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas
    Location: Hall B2

    Presenter: Rohit Raj, MD – The Ohio State University Wexner Medical Center

  • 12:45 PM – 2:00 PM PT
    2731 - Favorable Survival after Definitive Ablative RT in Surgically Resectable Pancreatic Cancer Patients
    Location: Hall B2

    Presenter: Marsha Reyngold, MD, PhD – MSKCC

  • 12:45 PM – 2:00 PM PT
    2732 - Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer -  Evaluating Radiation, Ablation and Surgery (ERASur)
    Location: Hall B2

    Presenter: Paul Romesser, MD – Memorial Sloan Kettering Cancer Center

  • 12:45 PM – 2:00 PM PT
    2733 - Non-Operative Management of Rectal or Anal Canal Adenocarcinoma: National Cancer Database Analysis of the Impact of Disease, Treatment, and Social Determinants of Health on Overall Survival
    Location: Hall B2

    Presenter: Keaton Rummel, MD – University of Tennessee Medical Center

  • 12:45 PM – 2:00 PM PT
    2734 - Patterns of Recurrence for Lymph Node Positive Cutaneous Melanoma in the Era of Immunotherapy
    Location: Hall B2

    Presenter: Kamran Salari, MD, BS – Beaumont Health

  • 12:45 PM – 2:00 PM PT
    2735 - Five-Fraction Proton Therapy for Chordomas and Condrosarcomas of the Skull Base: Preliminary Results of a Prospective Series
    Location: Hall B2

    Presenter: Morena Sallabanda, MD, PhD – Quironsalud

  • 12:45 PM – 2:00 PM PT
    2736 - Longer Interval between Neoadjuvant Chemotherapy and Radiation Therapy Associated with Higher Metastasis Risk for Inoperable Non-Metastatic Pancreatic Adenocarcinoma
    Location: Hall B2

    Presenter: Steven Seyedin, MD – UC Irvine School of Medicine

  • 12:45 PM – 2:00 PM PT
    2737 - Patient-Reported Adverse Effects in 15-Fraction Pancreatic Cancer Radiation Therapy
    Location: Hall B2

    Presenter: Yasamin Sharifzadeh, MD – Mayo Clinic Rochester

  • 12:45 PM – 2:00 PM PT
    2739 - The Prevalence and Management of Synchronous Prostate and Rectal Cancer
    Location: Hall B2

    Presenter: Baho Sidiqi, MD, MPH – Northwell Health Cancer Institute

  • 12:45 PM – 2:00 PM PT
    2740 - Association of Radiation and Neutrophil to Lymphocyte Ratio with Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombus
    Location: Hall B2

    Presenter: Karin Skalina, MD, PhD – Montefiore Medical Center/Albert Einstein College of Medicine

  • 12:45 PM – 2:00 PM PT
    2741 - Definitive Radiotherapy in Patients with Clinical T1N0M0 Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Study
    Location: Hall B2

    Presenter: Jun Yeong Song, BS – Seoul National University Hospital

  • 12:45 PM – 2:00 PM PT
    2742 - Outcomes of Watch and Wait Following Total Neoadjuvant Therapy for Rectal Cancer
    Location: Hall B2

    Presenter: Susan Sun, MD – University of Minnesota

  • 12:45 PM – 2:00 PM PT
    2743 - "Moderately Hypofractionated" Radiotherapy with a Simultaneously Integrated Boost for Synchronous Treatment of Prostate and Anorectal Cancer
    Location: Hall B2

    Presenter: Elsa Sutton, MD – Mayo Clinic

  • 12:45 PM – 2:00 PM PT
    2744 - Enhancement Patterns of Metastatic Intrahepatic Cholangiocarcinoma and Outcomes after Chemotherapy and Radiation
    Location: Hall B2

    Presenter: Fikir Tadesse, BS – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2745 - Real-World Experience of Intensity Modulated Radiation Therapy and Concurrent Chemotherapy for Anal Cancer with Long-Term Follow up and Clinical Outcomes
    Location: Hall B2

    Presenter: Amandeep Taggar, MD, MS, BS – Sunnybrook Odette Cancer Centre

  • 12:45 PM – 2:00 PM PT
    2746 - Synergistic Effect of TVEC and Radiotherapy in the Treatment of Advanced Melanoma
    Location: Hall B2

    Presenter: Andrew Tam, MD – City of Hope National Medical Center

  • 12:45 PM – 2:00 PM PT
    2747 - Dosimetric Evaluation of Cardiac Substructures in Irradiation of Esophagus
    Location: Hall B2

    Presenter: Andrew Tam, MD – City of Hope National Medical Center

  • 12:45 PM – 2:00 PM PT
    2748 - Evaluation of Liver Functionality after Liver Stereotactic Body Radiation Therapy (SBRT) Using Blood Tests and Imaging Examinations
    Location: Hall B2

    Presenter: Osamu Tanaka, MD, PhD – Asahi Univeristy Hospital

  • 12:45 PM – 2:00 PM PT
    2749 - Pancreas Cancer Learning Health Network Established to Share Best Practice Across 14 Centers and Improve Patient Outcomes
    Location: Hall B2

    Presenter: Leila Tchelebi, MD – Northern Westchester Hospital

  • 12:45 PM – 2:00 PM PT
    2750 - Carbon-Ion Radiotherapy for Postoperative Locoregional Recurrence of Pancreatic Cancer
    Location: Hall B2

    Presenter: Kotaro Terashima, MD, PhD – Ion Beam Therapy Center, SAGA-HIMAT Foundation

  • 12:45 PM – 2:00 PM PT
    2751 - Conventionally Fractionated vs. Hypofractionated Radiotherapy for Treatment of Unresectable Pancreatic Cancer: Local Control and Survival Outcomes in a Retrospective Single-Institutional Analysis
    Location: Hall B2

    Presenter: Daniel Tesolin, MS, BS – The Ottawa Hospital and University of Ottawa

  • 12:45 PM – 2:00 PM PT
    2752 - Long-Term Outcome of Rectal Cancer Patients Treated by High-Dose Radiotherapy and Concurrent Chemotherapy
    Location: Hall B2

    Presenter: Xue Tian, MD, MS – Sun Yat-Sen University Cancer Center

  • 12:45 PM – 2:00 PM PT
    2753 - A Comparison of Clinicopathologic Outcomes and Patterns of Lymphatic Spread across Neoadjuvant Chemotherapy, Neoadjuvant Chemoradiotherapy and Neoadjuvant Immunochemotherapy in Locally Advanced Esopha
    Location: Hall B2

    Presenter: Yuanyuan Tian, MD

  • 12:45 PM – 2:00 PM PT
    2754 - Longitudinal Analysis of Circulating Tumor DNA and Detection of Tumor Genomic Alterations Using Liquid Biopsy in Patients with Locally Advanced Esophagogastric Carcinoma
    Location: Hall B2

    Presenter: Hao To, MD – University of Washington

  • 12:45 PM – 2:00 PM PT
    2755 - Compensatory Enlargement of the Liver after Proton Beam Therapy for Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Kento Tomizawa, MD, PhD – National Cancer Center Hospital East

  • 12:45 PM – 2:00 PM PT
    2756 - Comparing 90-Day Post-Operative Mortality after Neoadjuvant Proton-Based vs. Photon-Based Chemoradiotherapy for Esophageal Cancer
    Location: Hall B2

    Presenter: Peter van Rossum, MD, PhD – Amsterdam UMC

  • 12:45 PM – 2:00 PM PT
    2757 - A Novel CT-Based Radiomic Analysis for the Prediction of Overall Survival in Rectal Cancer Patients Treated with Short Course RT Total Neoadjuvant Therapy
    Location: Hall B2

    Presenter: Gabriel Lazcano Alvarez, MD – Hospital Carlos Van Buren

  • 12:45 PM – 2:00 PM PT
    2757 - A Novel CT-Based Radiomic Analysis for the Prediction of Overall Survival in Rectal Cancer Patients Treated with Short Course RT Total Neoadjuvant Therapy
    Location: Hall B2

    Presenter: Gabriel Veillon Contreras, MD – HCVB

  • 12:45 PM – 2:00 PM PT
    2758 - Preoperative Carbon Ion Radiotherapy (CIRT) with Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma (PCa): A Multicenter Prospective Phase II Clinical Study (Pioppo study N
    Location: Hall B2

    Presenter: Viviana Vitolo

  • 12:45 PM – 2:00 PM PT
    2759 - Clinical Outcomes of Carbon-Ion Radiotherapy for Large-Sized (=4cm) Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Hirokazu Makishima, MD, PhD – University of Tsukuba

  • 12:45 PM – 2:00 PM PT
    2759 - Clinical Outcomes of Carbon-Ion Radiotherapy for Large-Sized (=4cm) Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Masaru Wakatsuki, MD, PhD – QST Hospital

  • 12:45 PM – 2:00 PM PT
    2760 - Pathway Mutations are Associated with Clinical Outcomes in Localized Pancreatic Cancer Treated with Neoadjuvant Chemoradiation Followed By Surgery
    Location: Hall B2

    Presenter: Jarey Wang, MD, PhD

  • 12:45 PM – 2:00 PM PT
    2761 - Elective Nodal Irradiation vs. Involved-Field Irradiation for Stage ?-? Cervical Esophageal Squamous Cell Carcinoma Patients Undergoing Definitive Concurrent Chemoradiotherapy: A Retrospective Propens
    Location: Hall B2

    Presenter: Jun Wang, MD, PhD – Fourth Hospital of Hebei Medical University

  • 12:45 PM – 2:00 PM PT
    2762 - Endoscopic Ultrasonography-Derived Maximum Tumor Thickness and Tumor Shrinkage Rate as Independent Prognostic Factors in Locally Advanced Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradi
    Location: Hall B2

    Presenter: Qifeng Wang, MD, PhD – Sichuan Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2763 - An Immune-Related Gene Prognostic Prediction Risk Model for Neoadjuvant Chemoradiotherapy in Rectal Cancer Using Artificial Intelligence
    Location: Hall B2

    Presenter: Xin Wang, MD – West China Hospital of Sichuan University

  • 12:45 PM – 2:00 PM PT
    2764 - Comparison of Pathologic Response and Survival Outcomes between Neoadjuvant Immunochemotherapy (nICT) and Neoadjuvant Chemoradiotherapy (nCRT) in Patients with Locally Advanced Esophageal Squamous Cel
    Location: Hall B2

    Presenter: Yi Wang, MD

  • 12:45 PM – 2:00 PM PT
    2765 - The Role of CT-Based Radiomics Nomogram in Differential Diagnosis of Immune Checkpoint Inhibitor-Related Pneumonitis from Radiation Pneumonitis for Patients with ESCC
    Location: Hall B2

    Presenter: Qiang Wen

  • 12:45 PM – 2:00 PM PT
    2766 - Long-Term Results of Induction Chemotherapy for Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Geng Xiang

  • 12:45 PM – 2:00 PM PT
    2767 - Re-Irradiation for Locally Primary Recurrence in Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT
    Location: Hall B2

    Presenter: Geng Xiang

  • 12:45 PM – 2:00 PM PT
    2768 - The Japanese Nationwide Cohort Data of Particle Beam Therapy for Liver Oligometastasis in Esophagogastric Cancer Patients
    Location: Hall B2

    Presenter: Hisashi Yamaguchi, MD – Fukushima Medical University

  • 12:45 PM – 2:00 PM PT
    2769 - The Japanese Nationwide Cohort Data of Proton Beam Therapy for Liver Oligometastasis in Breast Cancer Patients
    Location: Hall B2

    Presenter: Hisashi Yamaguchi, MD – Fukushima Medical University

  • 12:45 PM – 2:00 PM PT
    2770 - Influence of Contrast Materials on Dose Accuracy ofMR-Linac in Patients with SBRT Liver Cancer
    Location: Hall B2

    Presenter: Feng Yang, PhD, MS

  • 12:45 PM – 2:00 PM PT
    2771 - Prevalence and Predictors of Sexual Dysfunction (SD) after Treatment of Localized Rectal and Anal Cancer (LRAC)
    Location: Hall B2

    Presenter: Hilario Yankey, MD, MBA – Fox Chase Cancer Center

  • 12:45 PM – 2:00 PM PT
    2772 - Evaluating the Utility of Traditional Bowel Dose Constraints when Treating Abdominal and Pelvic Sarcomas with Preoperative Radiation Therapy
    Location: Hall B2

    Presenter: Alison Yoder, MD, MPH – MD Anderson Cancer Center

  • 12:45 PM – 2:00 PM PT
    2773 - Efficacy of Nimotuzumab plus Concurrent Chemo-Radiotherapy for Unresectable Esophageal Cancer: A Real-World Study
    Location: Hall B2

    Presenter: Jingping Yu

  • 12:45 PM – 2:00 PM PT
    2774 - Chemoradiotherapy Combined with Nab-Paclitaxel plus Cisplatin in Patients with Locally Advanced Borderline Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase ?/? Study
    Location: Hall B2

    Presenter: Nuo Yu, BS

  • 12:45 PM – 2:00 PM PT
    2775 - Camrelizumab with Chemoradiotherapy is Tolerable and Effective for Locally Advanced Biliary Tract Cancer: Peliminary Results from A Phase II Study
    Location: Hall B2

    Presenter: Jinbo Yue, MD, PhD – Shandong Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2776 - Impact of FAPI-PET/CT on Target Volume Definition in Radiation Therapy of Locally Advanced Biliary Tract Cancer: Compared with MRI/CT
    Location: Hall B2

    Presenter: Jinbo Yue, MD, PhD – Shandong Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2777 - Dosimetric Predictors of Acute Diarrhea in Locally Advanced Rectal Cancer Patients Treated with Neoadjuvant Chemoradiation with Capecitabine and Irinotecan: A Discovery and Validation Study
    Location: Hall B2

    Presenter: Jing Zhang, MD – Fudan University Shanghai Cancer Center

  • 12:45 PM – 2:00 PM PT
    2778 - Treatment Response Prediction Using a Combination of Hematological Biomarkers and CT Deep Learning Radiomics in Locally Advanced Esophageal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Zhenjiang Li, PhD

  • 12:45 PM – 2:00 PM PT
    2778 - Treatment Response Prediction Using a Combination of Hematological Biomarkers and CT Deep Learning Radiomics in Locally Advanced Esophageal Squamous Cell Carcinoma
    Location: Hall B1

    Presenter: Meng Zhang – Shandong University

  • 12:45 PM – 2:00 PM PT
    2779 - The Applicability of the AJCC TNM Staging 8th Edition to Esophageal Small-Cell Carcinoma: A Multicenter Retrospective Trial from China
    Location: Hall B2

    Presenter: Qi Zhang, MD, MS – Shandong Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2780 - Cost-Effectiveness of Short-Course Radiotherapy Based Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer in China
    Location: Hall B2

    Presenter: Wenjue Zhang, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences

  • 12:45 PM – 2:00 PM PT
    2781 - Perturbation of Gut Microbiota Modulated the Abscopal Effects of Immunoradiotherapy in Rectal Cancer
    Location: Hall B2

    Presenter: Xiang Zhang, MD, PhD – Shandong Cancer Hospital and Institute

  • 12:45 PM – 2:00 PM PT
    2783 - Multiomics Analysis Revealed the Close Connection between Intratumoral Microbiota and Immune Cell Infiltration in Colorectal Cancer
    Location: Hall B2

    Presenter: Mengyu Zhao, MS

  • 12:45 PM – 2:00 PM PT
    2784 - Prediction of Response to Neoadjuvant Chemoradiotherapy Combined with Pembrolizumab in Esophageal Squamous Cell Carcinoma with CT/FDG PET Radiomic Signatures Based on Machine Learning Classification
    Location: Hall B2

    Presenter: Shengguang Zhao, MD, PhD – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 12:45 PM – 2:00 PM PT
    2785 - Sarcopenia as a Predictor of Neoadjuvant Therapy-Related Toxicity in Esophageal Squamous Cell Carcinoma Patients
    Location: Hall B2

    Presenter: Siyue Zheng, MD

  • 12:45 PM – 2:00 PM PT
    2786 - 4D-MRI guided stereotactic body radiation therapy for unresectable colorectal liver metastases
    Location: Hall B2

    Presenter: xuan zheng, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy

  • 12:45 PM – 2:00 PM PT
    2787 - Radical Chemoradiotherapy vs. Radical Surgery plus Adjuvant Chemotherapy or Chemoradiotherapy in Locally Advanced Primary Small Cell Carcinoma of the Esophagus: A Multicenter Retrospective Study in Ch
    Location: Hall B2

    Presenter: Jie Zhu, MD

  • 12:45 PM – 2:00 PM PT
    2788 - 18F-AlF-NOTA-FAPI-04 PET/CT can Predict Treatment Response and Survival in Patients with Inoperable Pancreatic Adenocarcinoma
    Location: Hall B2

    Presenter: Ziyuan Zhu, MD – Weifang Medical University

  • 12:45 PM – 2:00 PM PT
    2789 - Safety and Efficacy of Hypofractionated Radiotherapy Combined with Tyrosine Kinase Inhibitors in Patients with Lung Metastases after Liver Transplantation for Hepatocellular Carcinoma
    Location: Hall B2

    Presenter: Yuan Zhuang, MD, PhD – Zhongshan Hospital, Fudan University

  • 12:45 PM – 2:00 PM PT
    2790 - Comparison of Survival Outcomes between Adults and Pediatrics with Non-Metastatic Head and Neck Rhabdomyosarcoma: A SEER Database Analysis of 550 Patients
    Location: Hall B2

    Presenter: Teng Zou, MD

  • 2:30 PM – 3:45 PM PT
    Trial in Progress: Adaptive RADiation therapy with concurrent Sacituzumab Govitecan (SG) for bladder preservation in patients with MIBC (RAD-SG)

    Presenter: Omar Mian, MD, PhD – Cleveland Clinic Taussig Cancer Center

  • 2:30 PM – 3:45 PM PT
    2791 - Long-Term Urinary Toxicity Follow-Up of Combined External Beam Radiation and Cs-131 LDR Brachytherapy Boost for Prostate Cancer
    Location: Hall B2

    Presenter: Mohamed Abdelhakiem, MD – UPMC Hillman Cancer Center

  • 2:30 PM – 3:45 PM PT
    2792 - A Checklist for Radiation Therapy Planning: Update 2023
    Location: Hall B2

    Presenter: Mohamed Abdi, MD – Shenandoah Medical Center

  • 2:30 PM – 3:45 PM PT
    2793 - Stereotactic Body Radiation Therapy and High-Dose Rate Brachytherapy Boost in Combination with Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Cohort Study
    Location: Hall B2

    Presenter: Jessica Aduwo, BS – The Ohio State University College of Medicine

  • 2:30 PM – 3:45 PM PT
    2794 - Transient Radiographic Pseudoprogression Following Fractionated SBRT for Primary Renal Cell Carcinoma
    Location: Hall B2

    Presenter: Nima Aghdam, MD, MS – Beth Israel Deaconess Medical Center

  • 2:30 PM – 3:45 PM PT
    2795 - Virtual Reality Changes the Concept of Patients Education, Patient Experience Report Study
    Location: Hall B2

    Presenter: Abdulrahman Aldakheel, MBBS – KFSH&RC

  • 2:30 PM – 3:45 PM PT
    2796 - Change in Therapeutic Approach after PET/TC PSMA-18F DCFPyL in Occult Biochemical Recurrence of Prostate Carcinoma with Low PSA Values
    Location: Hall B2

    Presenter: Francesco Amorelli, MD – Hospital Del Mar - Parc de Salut Mar

  • 2:30 PM – 3:45 PM PT
    2797 - Diagnostic Utility of PSMA 18F-DCFPyL PET/TC in Occult Biochemical Recurrence of Prostate Carcinoma with PSA Values <2ng/ml More than Two Years of Experience
    Location: Hall B2

    Presenter: Francesco Amorelli, MD – Hospital Del Mar - Parc de Salut Mar

  • 2:30 PM – 3:45 PM PT
    2798 - A SEER Database Cohort of 547 Patients with Non-Squamous Cell Carcinoma of the Penis: Clinical Characteristics and Outcomes
    Location: Hall B2

    Presenter: Lucas Ashley, MS

  • 2:30 PM – 3:45 PM PT
    2798 - A SEER Database Cohort of 547 Patients with Non-Squamous Cell Carcinoma of the Penis: Clinical Characteristics and Outcomes
    Location: Hall B2

    Presenter: Arjun Bhatt, BA – Vidant Heart and Vascular Care

  • 2:30 PM – 3:45 PM PT
    2799 - Conditional Prostate Cancer-Specific Survival Probabilities in Recurrent Prostate Cancer Patients Receiving Radiation ± Antiandrogen Therapy: Secondary Analysis of a Randomized Clinical Trial
    Location: Hall B2

    Presenter: James Assif, MD – University of Maryland Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2800 - Patterns of recurrence following radiation and ADT for pathologic lymph node positive prostate cancer: A multi-institutional study
    Location: Hall B2

    Presenter: Leslie Ballas, MD – Cedars Sinai

  • 2:30 PM – 3:45 PM PT
    2801 - Clinicopathologic Features of Prostate Cancer with Mesorectal Lymph Node Involvement on PSMA or Fluciclovine PET/CT
    Location: Hall B2

    Presenter: Andrew Barbour, MD, PhD – University of Washington

  • 2:30 PM – 3:45 PM PT
    2802 - ARTIA-Bladder: Daily Online Adaptive Short-Course Radiation Therapy (RT) and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer (MIBC): A Prospective Trial of an Individualized Approach for Re
    Location: Hall B2

    Presenter: Brian Baumann, MD – Springfield Clinic

  • 2:30 PM – 3:45 PM PT
    2803 - Erectile Dysfunction Pharmacotherapy Utilization after 60Gy in 20 Fractions Volumetric Modulated Arc Therapy to the Prostate
    Location: Hall B2

    Presenter: Conrad Bayley, MD, BS – University of Calgary

  • 2:30 PM – 3:45 PM PT
    2804 - Prospective Characterization of Circulating Tumor Cells in Hormone Sensitive Oligometastatic Prostate Cancer Patients on a Metastasis-Directed Therapy Trial
    Location: Hall B2

    Presenter: Soha Bazyar, MD, PhD – University of Maryland

  • 2:30 PM – 3:45 PM PT
    2805 - F18-DCFPyL PSMA-PET/CT vs. mpMRI for Localizing the Gross Target Volume for Radiotherapy in Prostate Cancer
    Location: Hall B2

    Presenter: Colin Belliveau, MD – Centre Hospitalier de l'Universite de Montreal (CHUM)

  • 2:30 PM – 3:45 PM PT
    2806 - DCE-MRI-Based Atlas for Prostate Bed Recurrence after Radical Prostatectomy: Consistency of CTV Delineation with the Available Contouring Guidelines
    Location: Hall B2

    Presenter: Marta Bottero, MD – Regina Elena National Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2807 - Disease and Toxicity Outcomes after Salvage Radiotherapy (SRT) for Biochemically Recurrent Prostate Cancer (PC) for Patients Enrolled in a Phase II, Open Label Trial Investigating Neoadjuvant Chemohor
    Location: Hall B2

    Presenter: Graham Campbell, MD, BS – University of Wisconsin Hospitals and Clinics

  • 2:30 PM – 3:45 PM PT
    2808 - Health-Related Quality of Life after Combined External Beam and Either High Dose Rate (HDR) or Low Dose Rate (LDR) Brachytherapy: Does the Rectal Dose from the LDR Brachytherapy Make a Difference?
    Location: Hall B2

    Presenter: Felipe Castro, MD, DRCPSC – Instituto Nacional de Enfermedades Neoplásicas

  • 2:30 PM – 3:45 PM PT
    2809 - Quantifying Value in an Iterative Disease-Site Specific Peer Review System
    Location: Hall B2

    Presenter: Leslie Chang, MD – Johns Hopkins University

  • 2:30 PM – 3:45 PM PT
    2810 - Does Stereotactic Online Adaptive MRgRT to the Prostate Preclude the Need for Rectal Spacer
    Location: Hall B2

    Presenter: Daniel Chapman, MD – Henry Ford Hospital-Henry Ford Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2811 - Partial Stereotactic Ablative Radiotherapy In Bulky Urinary Tract Malignancy: An Update Clinical Outcomes and Dosimetric Analysis
    Location: Hall B2

    Presenter: Jiayan Chen, MD – Peking University First Hospital

  • 2:30 PM – 3:45 PM PT
    2812 - Patient Education Practices and Preferences of Interprofessional Radiation Oncology Providers
    Location: Hall B2

    Presenter: Jie Jane Chen, MD – University of California, San Francisco

  • 2:30 PM – 3:45 PM PT
    2813 - Complexity Metrics and Planning Dose-Based Pretreatment Patient-Specific Quality Assurance Prediction: Classification, Gamma Passing Rates, and DVH Deviation
    Location: Hall B2

    Presenter: Liyuan Chen, MS – Chongqing University Cancer Hospital

  • 2:30 PM – 3:45 PM PT
    2814 - Utility of PSMA PET Guided Metastasis-Directed Radiotherapy
    Location: Hall B2

    Presenter: William Chen, MD – UCSF

  • 2:30 PM – 3:45 PM PT
    2815 - The Efficacy of Silver Sulfadiazine (SSD) Dressing Combined with Recombinant Human Epidermal Growth Factor in the Treatment of Third-Grade Radiation Dermatitis: A Randomized Controlled Study
    Location: Hall B2

    Presenter: Ming Cheng, BS – First Affiliated Hospital of Air Force Medical University

  • 2:30 PM – 3:45 PM PT
    2816 - Mapping the Anatomical Distribution of MRI-Identified Locoregional Recurrence following Robotic-Assisted Laparoscopic Prostatectomy for Prostate Adenocarcinoma
    Location: Hall B2

    Presenter: Hyeok Choi, MD – Yonsei Cancer Center

  • 2:30 PM – 3:45 PM PT
    2818 - Navigating the Global IV Contrast Shortage: The Experience of a Comprehensive Cancer Center
    Location: Hall B2

    Presenter: Varun Chowdhry, MD, MBA – Roswell Park Comprehensive Cancer Center

  • 2:30 PM – 3:45 PM PT
    2819 - Utilization of Radical Prostatectomy vs. Radiation Therapy for Gleason Grade Group 5 Prostate Cancer before and after USPSTF Grade D Recommendation against Prostate-Specific Antigen Screening in 2012
    Location: Hall B2

    Presenter: Taylor Corriher, MD, MBA – Emory University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2820 - Does a Dominant Intraprostatic Lesion Boost Require Daily Adaptation when Treated with Stereotactic Online Adaptive MR-Guided Therapy?
    Location: Hall B2

    Presenter: Elliott Czarnecki, MD – Henry Ford Hospital

  • 2:30 PM – 3:45 PM PT
    2821 - Customizable Health Literacy Appropriate Patient Education Materials: The Impact on Patient Satisfaction
    Location: Hall B2

    Presenter: Leah D'Souza, MD, MS – Rush University Medical Center

  • 2:30 PM – 3:45 PM PT
    2822 - Determinants of Widespread Metastases and of Metastatic Tropism in Patients with Prostate Cancer: A Genomic Analysis of Primary and Metastatic Tumors
    Location: Hall B2

    Presenter: Alexander Goglia, MD, PhD – Memorial Sloan Kettering Cancer Center

  • 2:30 PM – 3:45 PM PT
    2823 - Biochemical Relapse-Free Survival in Post-Prostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed Only Radiation: Post-Hoc Analysis of a Prospective Randomized Trial
    Location: Hall B2

    Presenter: Vishal Dhere, MD – Emory University

  • 2:30 PM – 3:45 PM PT
    2824 - Rapid Reinstatement of Cancer Care after Hurricane Ian
    Location: Hall B2

    Presenter: Eric Dick, MS, DABR – GenesisCare USA

  • 2:30 PM – 3:45 PM PT
    2825 - Dynamic Changes of Molecular Subtype Classification and Genomic Classifier Scores in High-Risk Prostate Cancer Patients Undergoing Pre-Operative Stereotactic Body Radiation Therapy
    Location: Hall B2

    Presenter: Marshall Diven, MD – NYP/BMH

  • 2:30 PM – 3:45 PM PT
    2826 - Radiation Therapy and Irreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
    Location: Hall B2

    Presenter: Marshall Diven, MD – NYP/BMH

  • 2:30 PM – 3:45 PM PT
    2827 - Randomized Trial of Five or Two MRI-guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT)
    Location: Hall B2

    Presenter: Marshall Diven, MD – NYP/BMH

  • 2:30 PM – 3:45 PM PT
    2828 - Advantages of Implementing Sliding Window Gamma Thresholding to Traditional QA Methods
    Location: Hall B2

    Presenter: Jeremy Donaghue, MS – Akron General Medical Center

  • 2:30 PM – 3:45 PM PT
    2829 - Liver Fat and Its Association with Time to Biochemical Failure (TTBCF) after Definitive Treatment to the Prostate
    Location: Hall B2

    Presenter: Timothy Dougherty, MD – Fox Chase Cancer Center

  • 2:30 PM – 3:45 PM PT
    2830 - Standardization of Stereotactic MR-Guided Adaptive Radiation Therapy Planning for Prostate Cancer
    Location: Hall B2

    Presenter: Joeseph Drabble, RT – GenesisCare

  • 2:30 PM – 3:45 PM PT
    2831 - Association between National Area Deprivation Index Rank on Disease Characteristics in Prostate Cancer
    Location: Hall B2

    Presenter: Elizabeth Duran, MS – UCSD Health

  • 2:30 PM – 3:45 PM PT
    2832 - Androgen Deprivation Therapy Use among Intermediate Risk Prostate Cancer Patients Undergoing Radiation Therapy across a Statewide Radiation Oncology Quality Consortium
    Location: Hall B2

    Presenter: Michael Dykstra, MD – University of Michigan

  • 2:30 PM – 3:45 PM PT
    2833 - Impact of Prostate Cancer Treatment with Low Dose Rate Brachytherapy on Testosterone: A Retrospective Analysis
    Location: Hall B2

    Presenter: Daniel Ebner, MD, MPH – Mayo Clinic

  • 2:30 PM – 3:45 PM PT
    2834 - Increasing Use of Conservative Management of Low-Risk Prostate Cancer in the Veterans Affairs System from 2012 to 2021
    Location: Hall B2

    Presenter: Ameer Elaimy, MD, PhD, BS – University of Michigan

  • 2:30 PM – 3:45 PM PT
    2835 - Impact of Severe Weather on Operations of a Radiation Oncology Department
    Location: Hall B2

    Presenter: Fatemeh Fekrmandi, MD, MS – Roswell Park Comprehensive Cancer Center

  • 2:30 PM – 3:45 PM PT
    2836 - Hypofractionated Radiotherapy for Prostate Cancer (HRT20) Trial: Results
    Location: Hall B2

    Presenter: Nicolas Feltes, RT

  • 2:30 PM – 3:45 PM PT
    2837 - Prehabilitation in Radiation Therapy: A Scoping Review
    Location: Hall B2

    Presenter: Laura Flores, PhD – University of Nebraska Medical Center

  • 2:30 PM – 3:45 PM PT
    2838 - Evaluating the Reliability of Chat-GPT Model Responses for Radiation Oncology Patient Inquiries
    Location: Hall B2

    Presenter: Warren Floyd, MD, PhD, BS – MD Anderson Cancer Center

  • 2:30 PM – 3:45 PM PT
    2839 - Radiotherapy vs. Cystectomy for Treatment of Muscle Invasive Bladder Cancer in Very Elderly Patients
    Location: Hall B2

    Presenter: Melissa Frick, MD – University of Pennsylvania Lancaster General Health

  • 2:30 PM – 3:45 PM PT
    2840 - Daikenchuto Therapy Reduces the Rate of Rectal Bleeding after IMRT for Prostate Cancer
    Location: Hall B2

    Presenter: Masateru Fujiwara, MD, PhD – Japan

  • 2:30 PM – 3:45 PM PT
    2841 - Adaptive Ultra-Hypofractionated Whole-Pelvic Radiotherapy in High-Risk and Very High-Risk Prostate Cancer on 1.5-Tesla MR Linac: The Estimated Delivered Dose and Early Toxicity Results
    Location: Hall B2

    Presenter: Lin-rui Gao, MD – Chinese Academy of Medical Sciences and Peking Union Medical College

  • 2:30 PM – 3:45 PM PT
    2842 - Are Psychiatric Comorbidities in the Radiation Oncology Patient Population Under-Recognized by Providers?
    Location: Hall B2

    Presenter: Nancy Garren, MSN, RN, CRNP, PMHN-BC, GC-C – National Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2843 - Long-Term Patient-Reported Bowel and Urinary Quality of Life in Patients Treated with Intensity-Modulated Radiotherapy and Intensity-Modulated Proton Therapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Kimberly Gergelis, MD – Wilmot Cancer Center

  • 2:30 PM – 3:45 PM PT
    2844 - Splenic Irradiation and Late Volume Changes Following Stereotactic Ablative Radiotherapy (SABR) for Adrenal Tumors
    Location: Hall B2

    Presenter: Nicolas Giraud, MD – Amsterdam UMC

  • 2:30 PM – 3:45 PM PT
    2845 - Volumes Changes in Adrenal Metastases during Delivery of 5-Fraction Stereotactic Magnetic Resonance-Guided Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Nicolas Giraud, MD – Amsterdam UMC

  • 2:30 PM – 3:45 PM PT
    2846 - Evaluation of Peer Review Practice in Radiation Oncology Treatment Planning: Single Institution Experience
    Location: Hall B2

    Presenter: Heba Gomaa, MD, PhD – King Abdullah Medical City

  • 2:30 PM – 3:45 PM PT
    2847 - Clinical Usefulness of PSMA PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer after Primary RT with PSA below the Phoenix Criteria Threshold: Systematic Review and Meta-Analysis
    Location: Hall B2

    Presenter: ELIAS GOMIS SELLES, MD, PhD

  • 2:30 PM – 3:45 PM PT
    2848 - Implementing an Additional Weekly Treatment Visit with an Advance Practice Provider to Reduce Hospitalizations and Improve Quality of Care in Patients Undergoing Radiation Therapy
    Location: Hall B2

    Presenter: Julie Greenwalt, MD – Baptist MD Anderson

  • 2:30 PM – 3:45 PM PT
    2849 - The Effect of Nursing Intervention Based on HFMEA Model on the Prevention of Radiation Dermatitis: A Randomized Controlled Study
    Location: Hall B2

    Presenter: Jing Guo, BS – Xijing Hospital Air Force Medical University

  • 2:30 PM – 3:45 PM PT
    2850 - Focal Brachytherapy for Localized Prostate Cancer: Systematic Review and Meta-Analysis
    Location: Hall B2

    Presenter: Enrique Gutierrez, MD – Princess Margaret Cancer Center

  • 2:30 PM – 3:45 PM PT
    2851 - Patterns of Adaptive Replanning in Proton Therapy for Thoracic Malignancies
    Location: Hall B2

    Presenter: Muhammad Hamza, MD, BS – University of Maryland Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2852 - Concurrent Radiation and Deep Hyperthermia Therapy for the Treatment of Recurrent Prostate Cancer
    Location: Hall B2

    Presenter: Muhammad Hamza, MD, BS – University of Maryland Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2853 - Timely Initiation of Radiation Treatment for Primary Head and Neck Squamous Cell Carcinoma in an Urban Safety Net Hospital during the COVID-19 Pandemic
    Location: Hall B2

    Presenter: Hye Ri Han, MD, MS – University of Southern California/LAC+ USC Medical Center

  • 2:30 PM – 3:45 PM PT
    2854 - Focal Boosted IMRT Treatment of Prostate Cancer to 84 Gy in 28 Fractions: Preliminary Clinical Outcomes and Dosimetry
    Location: Hall B2

    Presenter: Jacob Hands

  • 2:30 PM – 3:45 PM PT
    2855 - Development of a Screening Nomogram for Regional Lymph Node Metastasis Development in Muscle Invasive Bladder Cancer after Multiagent Systemic Therapy
    Location: Hall B2

    Presenter: Garrett Harada, MD – UCI Health

  • 2:30 PM – 3:45 PM PT
    2856 - Empowering the Role of Nurse Triage in Radiation Oncology - A Single Center Analysis
    Location: Hall B2

    Presenter: Colin Harari, MD – University of Wisconsin Carbone Cancer Center

  • 2:30 PM – 3:45 PM PT
    2857 - Evaluation of kV Triggered Fiducial Tracking for Prostate SBRT Intrafraction Motion Management
    Location: Hall B2

    Presenter: Colin Harari, MD – University of Wisconsin Carbone Cancer Center

  • 2:30 PM – 3:45 PM PT
    2858 - Improving Patient Compliance for More Efficient Deep Inspiration Breath Hold Treatment through Innovation and Education
    Location: Hall B2

    Presenter: Wendy Harris, PhD – Memorial Sloan Kettering Cancer Center

  • 2:30 PM – 3:45 PM PT
    2860 - A Needs Assessment Exploring Radiation Oncology Nursing Confidence in Caring for Patients with Acute and Late Radiation Therapy Effects
    Location: Hall B2

    Presenter: John Hillson, OCN, BSN, RN, dnp – Duke University Medical Center

  • 2:30 PM – 3:45 PM PT
    2861 - A Phase I/II Dose-Escalation Study Evaluating the Safety of 21 Gy, 23 Gy, and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy: An Interim Toxicity Report
    Location: Hall B2

    Presenter: Daniel Hong, MD – Washington University in St. Louis

  • 2:30 PM – 3:45 PM PT
    2862 - Development and Validation of MRI Imaging Biomarkers for Prostate Cancer Using Deep Learning
    Location: Hall B2

    Presenter: Sajid Hossain, MS, BS – Yale School of Medicine

  • 2:30 PM – 3:45 PM PT
    2863 - Early Experience with CBCT-Guided Online Adaptive Radiotherapy for Muscle Invasive Bladder Cancer
    Location: Hall B2

    Presenter: Whitney Hotsinpiller, MD – University of Alabama at Birmingham

  • 2:30 PM – 3:45 PM PT
    2864 - Initial Clinical Outcomes of a Phase II Trial of Focal Salvage LDR Brachytherapy for Local Recurrence of Prostate Cancer After External Beam Radiation Therapy
    Location: Hall B2

    Presenter: R. Hsi, MD – University of Washington-Fred Hutchinson Cancer Center

  • 2:30 PM – 3:45 PM PT
    2865 - Changes and Relationship in Nutrition Impact Symptoms, Malnutrition during Esophageal Cancer Treatment
    Location: Hall B2

    Presenter: Guiyu Huang

  • 2:30 PM – 3:45 PM PT
    2866 - Multifocal MRI-Directed Simultaneous Integrated Boost (SIB) in the Treatment of Prostate Cancer with Stereotactic Body Radiation Therapy (SBRT)
    Location: Hall B2

    Presenter: Joshua Hurwitz, BA – New York University Long Island School of Medicine

  • 2:30 PM – 3:45 PM PT
    2867 - Phase II Clinical Trial of Hypofractionated Image-Guided Proton Therapy with 12 Fractions for Prostate Cancer
    Location: Hall B2

    Presenter: Hiromitsu Iwata, MD, PhD – Nagoya Proton Therapy Center

  • 2:30 PM – 3:45 PM PT
    2868 - Dosimetric Implications of Prostate Bed Deformability: An Analysis of the SCIMITAR Clinical Trial
    Location: Hall B2

    Presenter: Tommy Jiang, BA – UCLA

  • 2:30 PM – 3:45 PM PT
    2869 - One Year Radiographic Response Following Prostrate SBRT: An Exploratory Analysis of a Phase III Randomized Trial
    Location: Hall B2

    Presenter: Tommy Jiang, BA – UCLA

  • 2:30 PM – 3:45 PM PT
    2870 - MR-Guided HDR Brachytherapy Boost in Localized Prostate Cancer - Results of a Phase II Trial
    Location: Hall B2

    Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network

  • 2:30 PM – 3:45 PM PT
    2871 - Prostate Cancer Screening Uptake in Transgender Females
    Location: Hall B2

    Presenter: Sandhya Kalavacherla, BS – University of California San Diego

  • 2:30 PM – 3:45 PM PT
    2872 - Prophylactic ?-Blockers for Radiotherapy-Induced LUTS in Men with Prostate Cancer: A Phase III Randomized Trial Analysis
    Location: Hall B2

    Presenter: Tamim Niazi, MD – McGill University

  • 2:30 PM – 3:45 PM PT
    2873 - Prospective Validation of Single Nucleotide Polymorphisms As Predictors of Gastrointestinal, Genitourinary, and Sexual Patient-Reported Outcomes Following Radiotherapy for Prostate Cancer
    Location: Hall B2

    Presenter: Sophia Kamran, MD – Massachusetts General Hospital

  • 2:30 PM – 3:45 PM PT
    2875 - Long-Term Safety and Efficacy of SAbR for Metastatic RCC
    Location: Hall B2

    Presenter: Dana Keilty, MD, MS, MDCM, MSc, BHSc – Princess Margaret Cancer Centre, University Health Network, University of Toronto

  • 2:30 PM – 3:45 PM PT
    2876 - Location of Local Recurrences Post-Prostatectomy Detected by 18F-DCPFyL and Implications for Salvage Radiotherapy Target Volumes
    Location: Hall B2

    Presenter: Fiona Kelly – Genesis Care (Australia)

  • 2:30 PM – 3:45 PM PT
    2877 - Low Incidence of Late Lymphopenia Following Stereotactic Body Radiotherapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Irfan Khan, PhD – Georgetown University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2878 - Multidisciplinary Institutional Guidelines for Workflow Efficiency in Optimizing Patient Start Time
    Location: Hall B2

    Presenter: Cody Kilar, DO, PhD – West Virginia University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2879 - Optimal Planning Target Margin for Prostate Radiotherapy Based on Interfractional and Intrafractional Variability Assessment during 1.5T MR-Guided Radiotherapy
    Location: Hall B2

    Presenter: Jina Kim, MD – Yonsei Cancer Center

  • 2:30 PM – 3:45 PM PT
    2880 - Association of Apical Spacing with Bowel Quality-of-Life: A Secondary Analysis of the Hyaluronic Acid Randomized Trial
    Location: Hall B2

    Presenter: Martin King, MD, PhD – Brigham and Womens Hopsital

  • 2:30 PM – 3:45 PM PT
    2882 - Real-World Toxicity of Conventional Versus Hypofractionated Definitive Prostate Radiotherapy across a Large, Diverse, Academic and Community-Based Enterprise
    Location: Hall B2

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 2:30 PM – 3:45 PM PT
    2883 - Implementation of a Systematic, Digital Oncology Workflow for Patient Distress Screening in a National, Multi-site Radiotherapy Outpatient Setting
    Location: Hall B2

    Presenter: Kieu Lai, RT – GenesisCare

  • 2:30 PM – 3:45 PM PT
    2883 - Implementation of a Systematic, Digital Oncology Workflow for Patient Distress Screening in a National, Multi-site Radiotherapy Outpatient Setting
    Location: Hall B2

    Presenter: Timothy Fox, PhD – GenesisCare

  • 2:30 PM – 3:45 PM PT
    2884 - Squamous Cell Carcinoma of the Bladder: Analysis of Treatments and Outcomes
    Location: Hall B2

    Presenter: Michael Larkins, BS – East Carolina University Brody School of Medicine

  • 2:30 PM – 3:45 PM PT
    2885 - Association between Gut Microbial Change and Acute Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Definitive Radiation Therapy: A Prospective Pilot Analysis
    Location: Hall B2

    Presenter: Dong Soo Lee, MD, PhD

  • 2:30 PM – 3:45 PM PT
    2886 - Immunohistochemistry-Based Biomarkers and Impact on Outcomes Following Salvage Radiotherapy for Prostate Cancer
    Location: Hall B2

    Presenter: Emerson Lee, MD, BS – Johns Hopkins University

  • 2:30 PM – 3:45 PM PT
    2887 - Implementation Science in Radiation Oncology: Case Study for Liver SBRT
    Location: Hall B2

    Presenter: Jacob Lee, BS – Creighton University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2888 - Individual Patient Data Analysis of 17 Randomized Trials vs. Real-World Data for Men with Localized Prostate Cancer Receiving Radiotherapy
    Location: Hall B2

    Presenter: Joan Lee, MD

  • 2:30 PM – 3:45 PM PT
    2889 - Artificial Intelligence-Derived Dominant Intraprostatic Lesion Volume Predicts Indications for Adjuvant Radiation after Radical Prostatectomy
    Location: Hall B2

    Presenter: Katie Lee, MD, PhD – Harvard Radiation Oncology Program

  • 2:30 PM – 3:45 PM PT
    2890 - A Modified Robust Nomogram for Predicting the Probability of Pelvic Lymph Node Invasion in Localized Prostate Cancer
    Location: Hall B2

    Presenter: Huan Li, MD – Shanghai Jiao Tong University

  • 2:30 PM – 3:45 PM PT
    2891 - The Potential Ability of Plan Complexity Metrics on the Dose Calculation and Plans Delivery in Intensity Modulated Radiotherapy
    Location: Hall B2

    Presenter: Shi Li, MS – Chongqing University Cancer Hospital

  • 2:30 PM – 3:45 PM PT
    2892 - Real-World Evaluation of Adjuvant Radiotherapy in Upper Tract Urothelial Carcinoma Patients: A Prospective Cohort Study
    Location: Hall B2

    Presenter: Xiaoying Li, MD – Peking University First Hospital

  • 2:30 PM – 3:45 PM PT
    2893 - Characterizing Hospital Admissions after Proton Beam Therapy Using the National Inpatient Sample Database
    Location: Hall B2

    Presenter: Keldon Lin, BA – Mayo Clinic Alix School of Medicine Scottsdale

  • 2:30 PM – 3:45 PM PT
    2894 - Designing Patient-Centered Health Education Materials for Radiation Dermatitis in Breast Cancer Patients: A Pilot Study and Single-Center Clinical Trial
    Location: Hall B2

    Presenter: Ting-Chun Lin, MD – China Medical University Hospital

  • 2:30 PM – 3:45 PM PT
    2895 - Incidence of Radiotherapy Induced Cardiac Implantable Electronic Devices Malfunction: Australian-Based Observation Study
    Location: Hall B2

    Presenter: Yuan-Hong Lin, MD – Alfred Health

  • 2:30 PM – 3:45 PM PT
    2896 - High-Dose Rate Brachytherapy Alone for Treatment of Unfavorable Intermediate Risk Prostate Cancer: A Propensity-Score Matched Analysis
    Location: Hall B2

    Presenter: Eulanca Liu, MD, PhD – UCLA Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2897 - Safety and Efficacy of Radiotherapy Combined with Chemotherapy for Recurrent Metastatic Renal Pelvic and Ureteral Carcinoma
    Location: Hall B2

    Presenter: Ming-Zhu Liu, MD – Peking University First Hospital

  • 2:30 PM – 3:45 PM PT
    2898 - Radiation Therapy Knowledge and Health Literacy among Culturally Diverse Patients with Prostate Cancer Treated at a Safety-Net Hospital
    Location: Hall B2

    Presenter: Derrick Lock, MD – University of Southern California/LAC+ USC Medical Center

  • 2:30 PM – 3:45 PM PT
    2899 - Real World Multi-Institutional Outcomes of Bladder Carbogen and Nicotinamide (BCON) in Muscle-Invasive Bladder Cancer (MIBC)
    Location: Hall B2

    Presenter: Ananya Choudhury, PhD, MA MRCP FRCR – The Christie NHS Foundation Trust

  • 2:30 PM – 3:45 PM PT
    2900 - Three Months PSA Response after PSMA-Guided Approach for Biochemical Relapse after Prostatectomy (PSICHE Trial)
    Location: Hall B2

    Presenter: Mauro Loi, MD – Azienda Ospedaliera Universitaria Careggi

  • 2:30 PM – 3:45 PM PT
    2901 - Proton Radiation Therapy for Stage IIA/IIB Testicular Seminoma
    Location: Hall B2

    Presenter: Andrew Lui, BS – University of Washington

  • 2:30 PM – 3:45 PM PT
    2902 - Identification and Validation of a Ferroptosis Prognostic Model for Prostate Cancer Patients through Screening the TCGA and scRNA-seq Datasets
    Location: Hall B2

    Presenter: Feng Lyu, MD, PhD – Peking University First Hospital

  • 2:30 PM – 3:45 PM PT
    2903 - Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients
    Location: Hall B2

    Presenter: Ming-Wei Ma, MD

  • 2:30 PM – 3:45 PM PT
    2904 - Effect of Adjuvant Chemotherapy in Highly Malignant Non-Metastatic Prostate Cancer: An Interim Analysis of Non-Randomized Comparative Trials
    Location: Hall B2

    Presenter: Ming-Wei Ma, MD

  • 2:30 PM – 3:45 PM PT
    2905 - Integration of Multiparameter MRI Into Conventional Pretreatment Risk Factors to Predict Adverse Features After Radical Prostatectomy
    Location: Hall B2

    Presenter: Ming-Wei Ma, MD

  • 2:30 PM – 3:45 PM PT
    2906 - Outcomes in Locally Advanced Non-Metastatic Prostate Cancer Presenting with Low PSA at Diagnosis
    Location: Hall B2

    Presenter: Priyamvada Maitre, MD – The Christie NHS Foundation Trust

  • 2:30 PM – 3:45 PM PT
    2907 - Association of Prostate Specific Antigen Kinetics after Testosterone Recovery with Subsequent Recurrence: Secondary Analysis of a Phase III Randomized Controlled Trial
    Location: Hall B2

    Presenter: Shawn Malone, MD – The Ottawa Hospital

  • 2:30 PM – 3:45 PM PT
    2909 - The Anatomy and Evolution of a Quality Proton Therapy Plan Check Process: An Institutional Review
    Location: Hall B2

    Presenter: Andrew Wroe, PhD – Miami Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2910 - A Novel Brachytherapy Needle Design to Reduce Urethra Dose in HDR Prostate Brachytherapy
    Location: Hall B2

    Presenter: Moeen Meftahi, PhD – Emory University

  • 2:30 PM – 3:45 PM PT
    2911 - A Single Institution Experience of a Biweekly Head and Neck Contouring Peer Review
    Location: Hall B2

    Presenter: Romy Megahed, MD – UAMS Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2912 - Risk Factors Predicting Relapse 10 Years Following Extreme Dose-escalated SBRT for Intermediate-risk Prostate Cancer: Is De-Intensification Feasible in Unfavorable Subgroups?
    Location: Hall B2

    Presenter: Robert Meier, MD – Swedish Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2913 - Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old-Updated Results
    Location: Hall B2

    Presenter: Christopher Mendez, MA – Perlmutter Cancer Center at NYU Langone Hospital - Long Island

  • 2:30 PM – 3:45 PM PT
    2914 - Implementing Standardized Patient Education in Radiation Oncology
    Location: Hall B2

    Presenter: Courtney Misher, RT, BS, MPH – Penn Medicine

  • 2:30 PM – 3:45 PM PT
    2915 - Comparison of the Efficacy of Low Dose tadalafil with tamsulosin against Lower Urinary Tract Symptoms and Sexual Dysfunction after Low Dose Rate Prostate Brachytherapy
    Location: Hall B2

    Presenter: Ryuichi Mizuno, MD – Keio University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2916 - Long Term Results of Prostate Cancer Patients Treated with Cs131 LDR Brachytherapy Compared with Recently Published SBRT Data
    Location: Hall B2

    Presenter: Mohammed Mohammed, MD – UPMC Hillman Cancer Center

  • 2:30 PM – 3:45 PM PT
    2917 - Toxicity Analysis of a Modified Prostate Bed CTV Based on PSMA-PET Patterns of Failure
    Location: Hall B2

    Presenter: Chris Montoya, MD – Sylvester Comprehensive Cancer Center

  • 2:30 PM – 3:45 PM PT
    2918 - Radiation-Associated Lymphopenia in Advanced Prostate Cancer Treated with Contemporary Radiation Techniques
    Location: Hall B2

    Presenter: Javier Mora, MD – Aurora Health Care

  • 2:30 PM – 3:45 PM PT
    2919 - Hyaluronic Acid Rectal Spacer Stability during Radiation Therapy for Localized Prostate Cancer: An Intercontinental Study
    Location: Hall B2

    Presenter: Elena Moreno-Olmedo, MD – Genesiscare UK (Oxford)

  • 2:30 PM – 3:45 PM PT
    2920 - Association of Transgender or Gender Non-Binary Identity on Disease Characteristics and Survival Outcomes in Prostate Cancer
    Location: Hall B2

    Presenter: Kylie Morgan, BS – UCSD Health

  • 2:30 PM – 3:45 PM PT
    2921 - Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial
    Location: Hall B2

    Presenter: Abdenour Nabid, MD – CHUS

  • 2:30 PM – 3:45 PM PT
    2922 - Compatibility of Topical Products to Manage Skin Irritation Associated with TTFields
    Location: Hall B2

    Poster Presenter: Narasimha Karanam, PhD

  • 2:30 PM – 3:45 PM PT
    2923 - A Prospective Phase II Dose Escalation Study using IMRT for High Risk N0M0 Prostate Cancer
    Location: Hall B2

    Presenter: Jill Nicholson, MBBS – St. Luke's Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2924 - Improving Complex Brachytherapy Efficiency in the Current Financial Climate
    Location: Hall B2

    Presenter: Karina Nieto, MD – University Hospitals Case Medical Center

  • 2:30 PM – 3:45 PM PT
    2925 - Tolerability of Metastasis-Directed Stereotactic Body Radiotherapy with Short-Course Triple-Agent Androgen Annihilation Therapy in Recurrent Oligometastatic Prostate Cancer: Secondary Analysis of a Ph
    Location: Hall B2

    Presenter: John Nikitas, MD – UCLA Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2926 - Predictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study
    Location: Hall B2

    Presenter: John Nikitas, MD – UCLA Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2927 - Dose-Volume Parameters to the Urinary Tract Sub-Volumes and Predictors of Genitourinary Acute Toxicity in a Phase 2 Clinical Trial Assessing MRI-Guided Prostate Boost for Localized Prostate Cancer - T
    Location: Hall B2

    Presenter: Miguel Noy, BS – Albany Medical College

  • 2:30 PM – 3:45 PM PT
    2928 - An Analysis of Patients Treated with Stereotactic Body Radiotherapy for Metastatic Urinary Tract Tumors to Identify Predictors of Response
    Location: Hall B2

    Presenter: Nayeon Oh

  • 2:30 PM – 3:45 PM PT
    2929 - Treatment Outcomes of Simultaneous Integrated Boost to Intraprostatic Lesions with External Beam Radiotherapy in Localized Prostate Cancer Patients
    Location: Hall B2

    Presenter: Huseyin Cem Onal, MD, PhD – Baskent University Faculty of Medicine

  • 2:30 PM – 3:45 PM PT
    2930 - Dosimetric Predictors of Toxicities and Quality of Life Following Two-Fraction Stereotactic Body Radiotherapy for Prostate Cancer
    Location: Hall B2

    Presenter: Wee Loon Ong, MBBS – Alfred Health Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2931 - Improving Radiation Oncology Staff Engagement with Quality Improvement and Safety through a QI Committee Visiting Staff Initiative
    Location: Hall B2

    Presenter: Itai Pashtan, MD – Brigham and Women's/Dana Farber Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2932 - A Phase I Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer
    Location: Hall B2

    Presenter: Krishnan Patel, MD – National Institutes of Health

  • 2:30 PM – 3:45 PM PT
    2933 - Contouring — How Do We Manage This Pivotal but Time-Consuming Workload?
    Location: Hall B2

    Presenter: Mira Patel, BS – Medical College of Wisconsin

  • 2:30 PM – 3:45 PM PT
    2934 - Factors Associated with Stereotactic Radiation Plan Revision in Prospective Peer Review
    Location: Hall B2

    Presenter: Luke Peng, MD, MS – Brigham and Women's/Dana Farber Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2935 - Long-Term Effectiveness of a Nonsurgical BPH Treatment System in Prostate Radiation Patients with Medication-Refractory Lower Urinary Tract Symptoms
    Location: Hall B2

    Presenter: Anthony Pham, MD – Fred Hutch Cancer Center - Peninsula

  • 2:30 PM – 3:45 PM PT
    2936 - Application of a Radiopaque Viscous Hydrogel Spacer for Prostate Cancer Radiotherapy - A Prospective Multi-Institutional Phase II Study
    Location: Hall B2

    Presenter: Michael Pinkawa, MD, PhD – MediClin Robert Janker Klinik

  • 2:30 PM – 3:45 PM PT
    2937 - Impact of Prophylactic Pelvic Lymph Node Irradiation in De-novo Oligometastatic Prostate Cancer
    Location: Hall B2

    Presenter: Xin Qi, MD, MS – Peking University First Hospital

  • 2:30 PM – 3:45 PM PT
    2938 - Radiation Treatment Preparation Safety Risk Prediction
    Location: Hall B2

    Presenter: Sarah Quirk, PhD – Dana-Farber/Brigham and Women's Cancer Center

  • 2:30 PM – 3:45 PM PT
    2939 - Factors Associated with Grade 3-4 Late Toxicity after Hypofractionated Prostate Salvage Radiation
    Location: Hall B2

    Presenter: Kaili Ranta, MD, PhD, BS – UW Health Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2940 - Validating a Simple Urethra Surrogate Model to Facilitate Dosimetric Analysis to Predict Genitourinary Toxicity
    Location: Hall B2

    Presenter: Ragu Ratnakumaran, MBBS – Royal Marsden NHS Foundation Trust

  • 2:30 PM – 3:45 PM PT
    2941 - ADT Use and Nodal Irradiation in Men Receiving Post-Prostatectomy Salvage Radiotherapy within a Statewide Radiation Oncology Quality Consortium
    Location: Hall B2

    Presenter: Samuel Regan, MD – University of Michigan

  • 2:30 PM – 3:45 PM PT
    2942 - Multidisciplinary Management of Primary Urethral Cancer with Radiotherapy
    Location: Hall B2

    Presenter: Austin Retzloff – USF Health Morsani College of Medicine

  • 2:30 PM – 3:45 PM PT
    2943 - The Importance of Multi-Parametric MRI, PET/CT, and Biopsy for Identifying and Delineating the Extent of Locally Radiorecurrent Prostate Cancer: A Multi-institutional Analysis of the F-SHARP Clinical
    Location: Hall B2

    Presenter: Dylan Ross, BS – Loyola University Chicago Stritch School of Medicine

  • 2:30 PM – 3:45 PM PT
    2944 - Impact of Workflow and Educational Interventions on MR Safety in Radiation Oncology
    Location: Hall B2

    Presenter: Rachel Sabol, MD, PhD – UCSF

  • 2:30 PM – 3:45 PM PT
    2945 - Long-Term Outcomes Associated with Different High-Dose-Rate Brachytherapy Dose Regimens for Favorable and Unfavorable Intermediate Risk Prostate Cancer
    Location: Hall B2

    Presenter: Kamran Salari, MD, BS – Beaumont Health

  • 2:30 PM – 3:45 PM PT
    2946 - Clinical Presentation and Management of Prostate Cancer in the Middle East
    Location: Hall B2

    Presenter: Mutlay Sayan, MD – Brigham and Women's Hospital/Dana Farber Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2947 - Prostate Cancer Awareness in the Middle East
    Location: Hall B2

    Presenter: Mutlay Sayan, MD – Brigham and Women's Hospital/Dana Farber Cancer Institute

  • 2:30 PM – 3:45 PM PT
    2948 - Evaluation of Volumetric Response Assessment from Stereotactic Ablative Radiotherapy (SABR) for Renal Cell Carcinoma (RCC)
    Location: Hall B2

    Presenter: Daniel Schep, MD, MS – Juravinski Cancer Centre

  • 2:30 PM – 3:45 PM PT
    2949 - Association of Radiation Facility Volume with Overall Survival in Patients with Very High Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy
    Location: Hall B2

    Presenter: Nikhil Sebastian, MD – Winship Cancer Institute of Emory University

  • 2:30 PM – 3:45 PM PT
    2950 - Machine Learning and Explainable Artificial Intelligence to Predict Occult Pelvic Nodal Metastases in Prostate Cancer
    Location: Hall B2

    Presenter: Colton Ladbury, MD, BS – City of Hope National Medical Center

  • 2:30 PM – 3:45 PM PT
    2950 - Machine Learning and Explainable Artificial Intelligence to Predict Occult Pelvic Nodal Metastases in Prostate Cancer
    Location: Hall B2

    Presenter: Hemal Semwal, MS, BS

  • 2:30 PM – 3:45 PM PT
    2951 - Online Correction of Intrafraction Motion during Volumetric Modulated Arc Therapy for Prostate Radiotherapy: A Cohort Study Quantifying the Frequency of Shifts and Analysis of Men at Highest Risk
    Location: Hall B2

    Presenter: Lucas Serra, MD, MS – University of Chicago

  • 2:30 PM – 3:45 PM PT
    2952 - Prophylaxis for Treatment-Induced Gynecomastia in Prostate Cancer Patients: A Network Meta-Analysis
    Location: Hall B2

    Presenter: Parvez Shaikh, MD, ScB MSHI – West Virginia University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2953 - CT vs. MRI: Which is More Accurate in Grading Rectal Wall Infiltration after Hydrogel Spacer Placement for Prostate Cancer Patients?
    Location: Hall B2

    Presenter: Parisa Shamsesfandabadi, MD – Allegheny General Hospital

  • 2:30 PM – 3:45 PM PT
    2954 - H2H Standardized Nutritional Support Management Mode Improves Nutritional Status of Patients with Head and Neck Cancer Receiving Radiotherapy: A Randomized Controlled Study
    Location: Hall B2

    Presenter: Juanli Shi – Xijing Hospital Air Force Medical University

  • 2:30 PM – 3:45 PM PT
    2955 - Pilot Study of Peer Review in Low Middle Income Country (LMIC) through Cloud-Based Platform
    Location: Hall B2

    Presenter: Manjinder Sidhu, MD, MBBS – American Oncology Institute

  • 2:30 PM – 3:45 PM PT
    2956 - Comparison of Low Dose Rate and High Dose Rate Brachytherapy Boost Techniques in Prostate Cancer: Evaluation of Toxicity
    Location: Hall B2

    Presenter: Andrew Skipper, MD – University of Tennessee Medical Center

  • 2:30 PM – 3:45 PM PT
    2957 - PSMA PET Guided Salvage Radiotherapy Among Prostate Cancer Patients in the Post-Prostatectomy Setting: A Single Center Post-Hoc Analysis
    Location: Hall B2

    Presenter: Clayton Smith, MD – UCLA Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2958 - Dosimetric Parameters Predictive of Treatment-Related Toxicity in High Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
    Location: Hall B2

    Presenter: Jiheon Song, MD, MS – Virginia Mason Medical Center

  • 2:30 PM – 3:45 PM PT
    2959 - Stereotactic Ablative Radiotherapy for the Treatment of Glandular Metastases from Renal Cell Carcinoma
    Location: Hall B2

    Presenter: Tidie Song, BS – UT Southwestern Medical Center

  • 2:30 PM – 3:45 PM PT
    2960 - A Comparison of Treatment Plan Adaptation Methods on PTV Margin Coverage in MR-Linac Prostate SBRT
    Location: Hall B2

    Presenter: Fady Sourial, DO – Allegheny Health Network

  • 2:30 PM – 3:45 PM PT
    2961 - Oncologic Outcomes of Conventionally Fractionated, Hypofractionated, and Stereotactic Body Spot-Scanned Proton Radiation Therapy for Prostate Cancer: The Mayo Clinic Experience
    Location: Hall B2

    Presenter: Will Sperduto, MD – Mayo Clinic Arizona

  • 2:30 PM – 3:45 PM PT
    2962 - Incident Learning in an Academic Radiation Oncology Practice During the COVID Era
    Location: Hall B2

    Presenter: Matthew Whitmill, MD – UNC Health

  • 2:30 PM – 3:45 PM PT
    2963 - Workflow Considerations for Biology-Guided Radiotherapy (BgRT) Implementation
    Location: Hall B2

    Presenter: Murat Surucu, PhD – Stanford University School of Medicine

  • 2:30 PM – 3:45 PM PT
    2964 - Identification of a Predictive Genomic Biomarker for Prostate Directed Therapy in Synchronous Low-Volume Metastatic Castration Sensitive Prostate Cancer
    Location: Hall B2

    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 2:30 PM – 3:45 PM PT
    2965 - Multi-Institutional Analysis of Metastasis Directed Therapy with or without Androgen Deprivation Therapy in Oligometastatic Castration Sensitive Prostate Cancer
    Location: Hall B2

    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 2:30 PM – 3:45 PM PT
    2966 - The Impact of TP53 Mutations and Use of the TP53-Mutation-Reactivating Agent APR-246 on Metastatic Castrate-Sensitive Prostate Cancer
    Location: Hall B2

    Presenter: Philip Sutera, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 2:30 PM – 3:45 PM PT
    2967 - International Clinical Radiotherapy Audit in CCCN- iPAAC Project
    Location: Hall B2

    Presenter: Aleksandra Sztuder, MD – Lower Silesian Oncology Center

  • 2:30 PM – 3:45 PM PT
    2968 - Effects of Radiation Doses on Clinical Recurrence in Patients with Biochemically Recurrent Prostate Cancer after Prostatectomy
    Location: Hall B2

    Presenter: Seiya Takano, MD – Nagoya City University Graduate School of Medical Sciences

  • 2:30 PM – 3:45 PM PT
    2969 - A Systematic Review and Network Meta-Analysis Assessing the Impact of Adding First Generation Non-Steroidal Anti-Androgens (NSAA) to LHRH Agonists (LHRHa) in Men Receiving Radiotherapy for Localized P
    Location: Hall B2

    Presenter: Jamie Takayesu, MD – University of Michigan

  • 2:30 PM – 3:45 PM PT
    2970 - A Prospective, Multi-Institutional Study of Problematic Plan Detection during Physician Chart Rounds
    Location: Hall B2

    Presenter: Wesley Talcott, MD, MBA – Northwell Health Center for Advanced Medicine

  • 2:30 PM – 3:45 PM PT
    2971 - Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update from the FASTR/FASTR-2 Trials
    Location: Hall B2

    Presenter: Terence Tang, MD – London Health Sciences Centre

  • 2:30 PM – 3:45 PM PT
    2972 - Diagnostic Performance of 18F-rhPSMA-7.3 PET in Men with Newly Diagnosed High-Risk Prostate Cancer and Negative Conventional Imaging
    Location: Hall B2

    Presenter: Phillip Kuo, MD, PhD

  • 2:30 PM – 3:45 PM PT
    2973 - Success of Liquid Tumor Biopsy in Men with Metastatic Prostate Cancer According to Self-Identified Race
    Location: Hall B2

    Presenter: Luca Valle, MD – UCLA Radiation Oncology

  • 2:30 PM – 3:45 PM PT
    2974 - Did COVID-19 Have an Impact on Incident Leaning? Implications for Patient Safety
    Location: Hall B2

    Presenter: Matthew Volpini, MD

  • 2:30 PM – 3:45 PM PT
    2975 - Trial in Progress: Adaptive RADiation Therapy with Concurrent Sacituzumab Govitecan (SG) for Bladder Preservation in Patients with MIBC (RAD-SG)
    Location: Hall B2

    Presenter: Winston Vuong, MD – Cleveland Clinic Foundation

  • 2:30 PM – 3:45 PM PT
    2976 - Gastrointestinal Toxicity Following Proton and Photon Radiation for Prostate Cancer in Patients with Inflammatory Bowel Disease
    Location: Hall B2

    Presenter: Loise Wairiri, MD – University of Washington

  • 2:30 PM – 3:45 PM PT
    2977 - Investigating Incidence of Nausea and Vomiting in Patients Receiving Concurrent Chemoradiotherapy: A Real World Cohort Study
    Location: Hall B2

    Presenter: Lili Wang, BS

  • 2:30 PM – 3:45 PM PT
    2978 - The Need for Patience When Making Operational Changes to Address Quality
    Location: Hall B2

    Presenter: Ashley Weiner, MD, PhD – UNC School of Medicine

  • 2:30 PM – 3:45 PM PT
    2980 - Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
    Location: Hall B2

    Presenter: Amy Wisdom, MD, PhD – Harvard Radiation Oncology Program

  • 2:30 PM – 3:45 PM PT
    2981 - Pilot Study of a Novel Ring Gantry-Based PET/CT Linear Accelerator in Patients with Prostate Cancer Receiving [18F]-DCFPyL for PSMA PET Imaging
    Location: Hall B2

    Presenter: Jeffrey Wong, MD, FASTRO – City of Hope National Medical Center

  • 2:30 PM – 3:45 PM PT
    2982 - A Pilot Study of an Interactive Virtual Tour Tool for Patient Education Prior to Undergoing High-Dose Rate Brachytherapy for Prostate Cancer
    Location: Hall B2

    Presenter: Yufan (Fred) Wu, MD, BS – Stanford University

  • 2:30 PM – 3:45 PM PT
    2983 - Can SGRT be a Substitute for Plan Verification Procedure?
    Location: Hall B2

    Presenter: Geng Xu, BS

  • 2:30 PM – 3:45 PM PT
    2985 - Association between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy
    Location: Hall B2

    Presenter: Martin King, MD, PhD – Brigham and Womens Hopsital

  • 2:30 PM – 3:45 PM PT
    2985 - Association between Artificial Intelligence-Derived Tumor Volume and Oncologic Outcomes for Localized Prostate Cancer Treated with Radiation Therapy
    Location: Hall B2

    Presenter: David Yang, MD – Harvard Radiation Oncology Program

  • 2:30 PM – 3:45 PM PT
    2986 - The Effectiveness of Music Interventions for Improving Anxiety Symptoms in Cancer Patients Undergoing Radiation Therapy
    Location: Hall B2

    Presenter: Huei Fang Yang, BS, RN – Chung Shan Medical University Hospital

  • 2:30 PM – 3:45 PM PT
    2987 - Coping Strategies among Filipino Cancer Patients Undergoing Radiation Therapy in Two Tertiary Care Hospitals in the Philippines: An Analytical Cross-Sectional Study
    Location: Hall B2

    Presenter: Jose Ma. Zaldarriaga, MD, MBA – St. Luke's Medical Center

  • 2:30 PM – 3:45 PM PT
    2988 - Use of Focal Radiotherapy Boost for Prostate Cancer and Perceived Barriers toward its Implementation: A Survey
    Location: Hall B2

    Presenter: Allison Zhong, BA – University of California, San Diego Health System

  • 2:30 PM – 3:45 PM PT
    2989 - Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost
    Location: Hall B2

    Presenter: Allison Zhong, BA – University of California, San Diego Health System

  • 2:30 PM – 3:45 PM PT
    2990 - Ten-Year Outcomes of Hypofractionated (45 Gy in 9 Fractions) Intensity Modulated Radiotherapy for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Sijin Zhong, MD

  • 4:00 PM – 5:00 PM PT
    2991 - Outcomes of Bridging and Salvage Radiotherapy in Relapsed or Refractory Mantle Cell Lymphoma Patients Undergoing CD19-Targeted CAR T-Cell Therapy
    Location: Hall B2

    Presenter: Hazim Ababneh, MD – Massachusetts General Hospital

  • 4:00 PM – 5:00 PM PT
    2992 - Development of Population-Based Pediatric Computational Phantoms for Radiotherapy Applications
    Location: Hall B2

    Presenter: Catarina Veiga, PhD – University College London

  • 4:00 PM – 5:00 PM PT
    2993 - Racial and Ethnic Disparities in Health-Related Quality of Life in Older Adults with Non-Hodgkin Lymphoma
    Location: Hall B2

    Presenter: Wisdom Akingbemi, BS – Drexel University College of Medicine

  • 4:00 PM – 5:00 PM PT
    2994 - Hypofractionated Radiotherapy for Hematological Malignancies during COVID-19 Pandemic and Beyond
    Location: Hall B2

    Presenter: Arbind Dubey, FRCPC – Cancercare Manitoba

  • 4:00 PM – 5:00 PM PT
    2995 - Intelligent Interactive Deformable Image Registration for Online Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Ti Bai, PhD

  • 4:00 PM – 5:00 PM PT
    2995 - Intelligent Interactive Deformable Image Registration for Online Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Weiguo Lu, PhD – UT-Southwestern Medical Center

  • 4:00 PM – 5:00 PM PT
    2996 - Low Dose Splenic Radiotherapy for Myeloproliferative Neoplasms prior to Allogeneic Hematopoietic Stem Cell Transplant
    Location: Hall B2

    Presenter: Claire Baniel, MD – Stanford University

  • 4:00 PM – 5:00 PM PT
    2997 - Clinical Implementation and Evaluation of Automated Contouring for Breast Malignancies
    Location: Hall B2

    Presenter: Andrew Bonner, BS – University of Alabama at Birmingham

  • 4:00 PM – 5:00 PM PT
    2998 - Local Control after Low-Dose Radiation for Two Rare Forms of Indolent Non-Hodgkin Lymphoma
    Location: Hall B2

    Presenter: Jessica Burlile, MD – Mayo Clinic College of Medicine and Science Rochester

  • 4:00 PM – 5:00 PM PT
    2999 - Salvage Radiotherapy as a Bridge for Relapsed Secondary CNS Lymphoma
    Location: Hall B2

    Presenter: Gustav Cederquist, MD, PhD – Memorial Sloan Kettering Cancer Center

  • 4:00 PM – 5:00 PM PT
    3000 - Outcomes and Toxicities in Patients with Diffuse Large B-Cell Lymphoma of the Gastrointestinal Tract
    Location: Hall B2

    Presenter: Elaine Cha, MD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3001 - Demystifying the Role of Radiation Dose Bath in Brain Injury Using Machine Learning
    Location: Hall B2

    Presenter: Annie Chan, MD – Massachusetts General Hospital

  • 4:00 PM – 5:00 PM PT
    3002 - Identifying Common Topics in Patient Portal Messages with Unsupervised Natural Language Processing
    Location: Hall B2

    Presenter: Ji Hyun Chang, MD, PhD – Seoul National University Hospital

  • 4:00 PM – 5:00 PM PT
    3003 - Homeostatic Balance of Gut Microbiota in Head and Neck Squamous Cell Carcinoma Patients during Radiotherapy
    Location: Hall B2

    Presenter: Ying Chen, MD – The First Affiliated Hospital of Zhejiang University Medical College

  • 4:00 PM – 5:00 PM PT
    3004 - Whole Regional Lymph Node Area Delineation with Deep Learning Model for Total Marrow and Lymphoid Irradiation
    Location: Hall B2

    Presenter: Hyeonseok Choi, BS – Seoul National University College of Medicine

  • 4:00 PM – 5:00 PM PT
    3005 - Novel Deep Learning Segmentation Models for Accurate GTV and OAR Segmentation in MR-Guided Adaptive Radiotherapy for Pancreatic Cancer Patients
    Location: Hall B2

    Presenter: Wookjin Choi, PhD – Thomas Jefferson University

  • 4:00 PM – 5:00 PM PT
    3006 - Predicting Treatment Response of Esophageal Cancer Treated by Concurrent Chemoradiotherapy using Pre- and Posttreatment 18F-FDG PET Metabolic Characteristics
    Location: Hall B2

    Presenter: Ying-Hsiang Chou, MD, PhD, MBA – Chung Shan Medical University Hospital

  • 4:00 PM – 5:00 PM PT
    3007 - Feasibility and Acceptability of ChatGPT Generated Radiology Report Summaries for Cancer Patients
    Location: Hall B2

    Presenter: Eric Chung, MD, MS – Cedars-Sinai Medical Center

  • 4:00 PM – 5:00 PM PT
    3009 - Prevalence of Non-Hodgkin Lymphoma Patients at High Risk of Failure after CAR T-Cell Therapy Eligible for Bridging Radiation Therapy
    Location: Hall B2

    Presenter: Adnan Danish, MD – St. Josephs Health/RCCA Hackensack Division

  • 4:00 PM – 5:00 PM PT
    3010 - Interpretable Machine Learning for Predicting Symptomatic Pneumonitis in Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy and Immune Checkpoint Inhibitor
    Location: Hall B2

    Presenter: Lian Duan, MS, BS – University of Pennsylvania

  • 4:00 PM – 5:00 PM PT
    3011 - Craniospinal Irradiation for CNS Leukemia: Rates of Response and Durability of CNS Control
    Location: Hall B2

    Presenter: Maryam Ebadi, MD – University of Washington

  • 4:00 PM – 5:00 PM PT
    3012 - Significance of Radiomics in Predicting Local Control for Patients with Malignant Liver Tumors Treated Using Stereotactic Body Radiotherapy
    Location: Hall B2

    Presenter: Arun Elangovan, MD – Cross Cancer Institute

  • 4:00 PM – 5:00 PM PT
    3013 - An MRI-Based Convolutional Neural Network to Predict Biochemical Recurrence Following Radiotherapy for Intermediate and High-Risk Localized Prostate Cancer
    Location: Hall B2

    Presenter: Scott Morgan, MD, MSc, FRCPC – The Ottawa Hospital, University of Ottawa

  • 4:00 PM – 5:00 PM PT
    3014 - Dosimetric Advantages of VMAT TBI Plans: A Direct Comparison to Conventional TBI Plans
    Location: Hall B2

    Presenter: Samantha Freije, MD – Indiana University School of Medicine

  • 4:00 PM – 5:00 PM PT
    3015 - Radiomic-Based Prediction of Lesion-Specific Systemic Treatment Response in Metastatic Disease
    Location: Hall B2

    Presenter: Caryn Geady, MS, BS – University Health Network

  • 4:00 PM – 5:00 PM PT
    3016 - CT Based Tumor Radiomics with Machine Learning Classifiers for Molecular Subtyping of Diffuse Large B Cell Lymphoma
    Location: Hall B2

    Presenter: Jayant Goda, MD – Tata Memorial Centre

  • 4:00 PM – 5:00 PM PT
    3017 - Development of a Machine Learning Model to Evaluate Changes during Radiotherapy in Cervical Cancer Tumor Cells
    Location: Hall B2

    Presenter: Masaaki Goto, MD – University of Tsukuba

  • 4:00 PM – 5:00 PM PT
    3019 - Multimodality deep learning fusion methods for predicting mandibular osteoradionecrosis incidence
    Location: Hall B2

    Presenter: Laia Humbert-Vidan, PhD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3020 - Development of a Radiomic Signature from Pre-Treatment FDG-PET for Recurrence Prediction in Cervical Cancer
    Location: Hall B2

    Presenter: Matthew Inkman, MS – Washington University

  • 4:00 PM – 5:00 PM PT
    3021 - Developing a Word Lexicon from Electronic Health Records for Natural Language Processing Analysis of Free-Text Reports for Patients with Venous Thromboembolism
    Location: Hall B2

    Presenter: Sarisha Jagasia, BS

  • 4:00 PM – 5:00 PM PT
    3022 - Outcomes of Proton Therapy for Patients with Infradiaphragmatic Lymphoma
    Location: Hall B2

    Presenter: Cecilia Jiang, MD – University of Pennsylvania

  • 4:00 PM – 5:00 PM PT
    3023 - AI Beam Angle Prediction in Proton Therapy for Brain Patients
    Location: Hall B2

    Presenter: Robert Kaderka, PhD – University of Miami Sylvester Comprehensive Cancer Center

  • 4:00 PM – 5:00 PM PT
    3024 - A Nomogram Based on Pretreatment Radiomics and Dosiomics Features for Predicting Overall Survival for Esophageal Squamous Cell Cancer: Multi-Institutional Study
    Location: Hall B2

    Presenter: Daisuke Kawahara, PhD – Hiroshima University

  • 4:00 PM – 5:00 PM PT
    3025 - Treatment of Mantle and Inverted Y Fields in Modern Era: A VMAT Approach
    Location: Hall B2

    Presenter: Gocha Khelashvili, PhD – Northwestern Memorial Hospital

  • 4:00 PM – 5:00 PM PT
    3026 - Impact of Salvage Versus Palliative Dose Bridging Radiation Therapy on Local Control and Overall Survival in Patients with DLBCL Receiving CD19 CAR T Cell Therapy
    Location: Hall B2

    Presenter: Kendall Kiser, MD, MS – Washington University/B-JH/SLCH Consortium

  • 4:00 PM – 5:00 PM PT
    3027 - A Generalized Deep Learning Method for Synthetic CT Generation
    Location: Hall B2

    Presenter: Lingke Kong, DO, MBBS

  • 4:00 PM – 5:00 PM PT
    3028 - Utility of the "All of Us" Database for Radiation Oncology Research
    Location: Hall B2

    Presenter: Jason Krastein, BS – George Washington University School of Medicine

  • 4:00 PM – 5:00 PM PT
    3029 - The Value of Equivalent Dose Calculation for Dosiomics and Radiomics-Based Prediction of Pneumonitis after Thoracic Radiotherapy with Immune Checkpoint Inhibition
    Location: Hall B2

    Poster Presenter: Jan Peeken, MD – Technical University Munich

  • 4:00 PM – 5:00 PM PT
    3030 - Integration of an App-based Cognitive Evaluation Program into Radiosurgery Practice: Outcomes and Patient Survey Analysis from a Prospective Observational Study
    Location: Hall B2

    Presenter: Tugce Kutuk, MD – Baptist Health South Florida

  • 4:00 PM – 5:00 PM PT
    3031 - The Theoretical Role for Radiotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Secondary Analysis of a Prospective Randomized Controlled Trial
    Location: Hall B2

    Presenter: Claire Lanier, MD – Wake Forest School of Medicine

  • 4:00 PM – 5:00 PM PT
    3032 - Early Prediction of Radiation Treatment Response via Longitudinal Analysis of CBCT Radiomic Features for Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Zi Rong Li, BS

  • 4:00 PM – 5:00 PM PT
    3033 - Deep Learning-Based Synthesis of Contrast-Enhanced MRI for Automated Delineation of Primary Gross Tumor Volume in Radiotherapy of Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Li Lin, MD, PhD – Sun Yat-Sen University Cancer Center

  • 4:00 PM – 5:00 PM PT
    3035 - Objective Boundary Generation for Gross Target Volume and Organs at Risk Using 3D Multi-Modal Medical Images
    Location: Hall B2

    Presenter: Xiao Liu, MS

  • 4:00 PM – 5:00 PM PT
    3036 - Automated Detection, Segmentation, and Tracking of Brain Metastases in Repeated Courses of Stereotactic Radiosurgery Using Integrated Artificial Intelligence
    Location: Hall B2

    Presenter: Wen-Chi Yang, MD – National Taiwan University Hospital

  • 4:00 PM – 5:00 PM PT
    3037 - Optimizing the Combination of Cytotoxic Drugs Along with Radiotherapy as Effective Treatment for Extranodal NK/T-Cell Lymphoma
    Location: Hall B2

    Presenter: Fei Luo

  • 4:00 PM – 5:00 PM PT
    3038 - Thirty-Year Experience of Radiotherapy for Primary Intraocular Lymphoma with and without Chemotherapy
    Location: Hall B2

    Presenter: Nikhil Mankuzhy, MD – Memorial Sloan Kettering Cancer Center

  • 4:00 PM – 5:00 PM PT
    3039 - Cardiac Sparing with Volumetric Modulated Arc Therapy Enabled Total Body Irradiation (CS VMAT-TBI)
    Location: Hall B2

    Presenter: Steven Montalvo, MD – UT Southwestern Medical Center

  • 4:00 PM – 5:00 PM PT
    3040 - Combining obinutuzumab with Radiation for Treatment Refractory Diffuse Large B Cell Lymphoma: Retrospective Safety and Efficacy Analysis
    Location: Hall B2

    Presenter: Brett Morris, MD, PhD – University of Wisconsin

  • 4:00 PM – 5:00 PM PT
    3041 - Webapp for Data Recollection and Presentation in a Head and Neck Tumor Board
    Location: Hall B2

    Presenter: Jose Felipe Munoz Lozano, MD – Hospital Universitario

  • 4:00 PM – 5:00 PM PT
    3042 - Outcomes of Patients with Transformed Diffuse Large B-Cell Lymphoma (DLBCL)
    Location: Hall B2

    Presenter: Justyn Nakashima, DO – Moffitt Cancer Center

  • 4:00 PM – 5:00 PM PT
    3043 - Low Dose Involved Site Radiotherapy as Single Modality Treatment for Early Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma
    Location: Hall B2

    Poster Presenter: Peter Hoskin, MD – Mount Vernon Hospital

  • 4:00 PM – 5:00 PM PT
    3044 - Prediction of Radiomics-Based Machine Learning for Specific Dosimetric Verification of Pelvic Intensity Modulated Radiotherapy
    Location: Hall B2

    Presenter: Qianxi Ni, PhD

  • 4:00 PM – 5:00 PM PT
    3045 - Investigating PET Responses to Treatment in Nodular Lymphocyte-Predominant Hodgkin Lymphoma
    Location: Hall B2

    Presenter: Natalie Park, BA – Stanford University School of Medicine

  • 4:00 PM – 5:00 PM PT
    3046 - Deep Learning vs. Handcrafted Radiomics to Predict Chemoradiotherapy Response for Locally Advanced Cervical Cancer
    Location: Hall B2

    Presenter: Shin-Hyung Park, MD, PhD – Korea, Republic of

  • 4:00 PM – 5:00 PM PT
    3047 - A Photograph-Based Visualization and Prediction Framework for Radiation-Induced Dermatitis
    Location: Hall B2

    Presenter: Ye-In Park, MS

  • 4:00 PM – 5:00 PM PT
    3048 - Predicting Complete Response after Chemoradiation in Patients with Localized Rectal Cancer
    Location: Hall B2

    Presenter: Ignacio Azinovic Gamo, PhD – Hospital Universitario Fundacion Jimenez Diaz

  • 4:00 PM – 5:00 PM PT
    3049 - Clinical Evaluation of Deep Learning-Based Auto-Segmentation toward MRI-Only Prostate Radiotherapy
    Location: Hall B2

    Presenter: James Perez-Sanchez, MS – University of Florida

  • 4:00 PM – 5:00 PM PT
    3049 - Clinical Evaluation of Deep Learning-Based Auto-Segmentation toward MRI-Only Prostate Radiotherapy
    Location: Hall B2

    Presenter: Chihray Liu, PhD – University of Florida

  • 4:00 PM – 5:00 PM PT
    3050 - The Microvascular Network Density and Morphology Affect the Radiotherapy Outcome at the Microscale Level: A Computational Analysis
    Location: Hall B2

    Presenter: Tiziana Rancati, MS – Fondazione IRCCS - Istituto Nazionale dei Tumori

  • 4:00 PM – 5:00 PM PT
    3051 - Interdigitation of Radiation Earlier in the Multimodal Treatment of Patients with Lymphoma: The Effect on Opiate Analgesic Requirements
    Location: Hall B2

    Presenter: Greeshma Rajeev-Kumar, MD – University of Chicago Medicine

  • 4:00 PM – 5:00 PM PT
    3052 - Development and Validation of a Deep Learning-Based Auto-Delineation of Target Volume and Organs at Risk in Pancreatic Cancer Radiotherapy
    Location: Hall B2

    Presenter: Gang Ren, MD – Air Force Medical Center

  • 4:00 PM – 5:00 PM PT
    3053 - Man vs. Machine (Learning): Comparing Speed and Cost-Effectiveness of Manual vs. Deep Learning Segmentation-Aided Volume Delineation for Head and Neck Lymph Node Targets
    Location: Hall B2

    Presenter: Paul Roberts, MD, BS – University of Mississippi Medical Center

  • 4:00 PM – 5:00 PM PT
    3053 - Man vs. Machine (Learning): Comparing Speed and Cost-Effectiveness of Manual vs. Deep Learning Segmentation-Aided Volume Delineation for Head and Neck Lymph Node Targets
    Location: Hall B2

    Presenter: William Duggar, PhD – University of MS Medical Center

  • 4:00 PM – 5:00 PM PT
    3054 - Outcomes with Bridging Radiation Therapy Prior to CAR-T Cell Therapy in Pts with Aggressive B Cell Lymphomas
    Location: Hall B2

    Presenter: Michael Rooney, MD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3055 - Machine Learning for the Prediction of Adverse Pathological Outcomes in Patients Treated with Radical Prostatectomy
    Location: Hall B2

    Presenter: Ali Sabbagh, MD – University of California San Francisco

  • 4:00 PM – 5:00 PM PT
    3056 - Machine Learning for the Prediction of Biochemical Recurrence in Patients Treated with Radical Prostatectomy
    Location: Hall B2

    Presenter: Ali Sabbagh, MD – University of California San Francisco

  • 4:00 PM – 5:00 PM PT
    3057 - The Role of Radiation Therapy in the Management of Gray Zone Lymphoma
    Location: Hall B2

    Presenter: Omran Saifi, MD – Mayo Clinic Florida

  • 4:00 PM – 5:00 PM PT
    3058 - Automated Small Tumor Segmentation by a Template-Based Global Hierarchical Attention Method
    Location: Hall B2

    Presenter: Shengtian Sang, PhD – Stanford University

  • 4:00 PM – 5:00 PM PT
    3060 - Developing an Online Interactive Volumetric Surface Viewer for Visualizing Spatial Distribution of Intracranial Lesions
    Location: Hall B2

    Presenter: Ricky Savjani, MD, PhD – UCLA Radiation Oncology

  • 4:00 PM – 5:00 PM PT
    3061 - Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia
    Location: Hall B2

    Presenter: Benjamin Schrank, MD, PhD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3062 - Radiation Oncology Practice Changes during the COVID-19 Pandemic
    Location: Hall B2

    Presenter: Aaron Seo, MD, PhD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3063 - Global Plan Check: A Software to Register and Analyze Dose Distribution Independent from Treatment Planning Systems
    Location: Hall B2

    Presenter: Fatma Sert – Ege University School of Medicine

  • 4:00 PM – 5:00 PM PT
    3064 - Clinical prior Knowledge-Based One-Shot Learning for Automatic Delineation of Clinical Target Volumes in Adaptation Radiotherapy of Cervical Cancer
    Location: Hall B2

    Presenter: Shuai Sun, MD, PhD – Peking Union Medical College Hospital

  • 4:00 PM – 5:00 PM PT
    3065 - A Multicenter Study on Deep Learning for Glioblastoma Auto-Segmentation with Prior Knowledge in Multimodal Imaging
    Location: Hall B2

    Presenter: Suqing Tian, MD – Peking University Third Hospital

  • 4:00 PM – 5:00 PM PT
    3066 - Risk of Cardiac-Specific Mortality in Patients with Lymphoma Treated with Radiotherapy
    Location: Hall B2

    Presenter: Eduardo Urias, MD, MBA – University of Utah

  • 4:00 PM – 5:00 PM PT
    3067 - Evaluation of Observer Variation as Natural Experiment to Detect Sensitive Heart Subregions
    Location: Hall B2

    Presenter: Marcellinus van Herk, PhD – University of Manchester

  • 4:00 PM – 5:00 PM PT
    3068 - Deep Learning-Based Quality Assurance for Auto-Segmentation Masks in Radiotherapy
    Location: Hall B2

    Presenter: Mu-Han Lin, PhD – UT Southwestern Medical Center

  • 4:00 PM – 5:00 PM PT
    3069 - Interpretable Machine Learning Models for Severe Esophagitis Prediction in LA-NSCLC Patients Treated with Chemoradiation Therapy
    Location: Hall B2

    Presenter: Du Wang, MS – Hospital of the University of Pennsylvania

  • 4:00 PM – 5:00 PM PT
    3070 - Prospective Clinical Adoption of Artificial Intelligence for Organ Contouring in Head and Neck Radiation Treatment Planning
    Location: Hall B2

    Presenter: Jen-Yeu Wang, BS – Stanford University School of Medicine

  • 4:00 PM – 5:00 PM PT
    3071 - Develop a Deep Radiomics Model for Predicting the Response to Neoadjuvant Chemoradiotherapy (nCRT) in Patients with Locally Advanced Esophageal Cancer Using Three-Stage Longitudinal CT Images
    Location: Hall B2

    Presenter: Qifeng Wang, MD, PhD – Sichuan Cancer Hospital and Institute

  • 4:00 PM – 5:00 PM PT
    3072 - Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiotherapy for Patients with Stage I-II Nasal-Type Natural Killer/T-Cell Lymphoma
    Location: Hall B2

    Presenter: Shubei Wang, MD

  • 4:00 PM – 5:00 PM PT
    3073 - Radiotherapy Effect on Long-Term Net Survival Benefit for Early-Stage Diffuse Large B-Cell Lymphoma in the Rituximab Era
    Location: Hall B2

    Presenter: Xin Wang, MD

  • 4:00 PM – 5:00 PM PT
    3074 - Ultra Low-Dose Radiation for Extranodal Marginal Zone Lymphoma of the Lung
    Location: Hall B2

    Presenter: Susan Wu, MD – MD Anderson Cancer Center

  • 4:00 PM – 5:00 PM PT
    3075 - Association of Treatment Disparities and Primary Sites with the Survival of Non-Gastric Early-Stage MALT Lymphoma
    Location: Hall B2

    Presenter: Yunpeng Wu, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

  • 4:00 PM – 5:00 PM PT
    3076 - Evaluating the Performance of ChatGPT at Breast Tumor Board
    Location: Hall B2

    Presenter: Yang Xu, MD – Alberta Health Services

  • 4:00 PM – 5:00 PM PT
    3077 - Dosimetric Quality of Artificial Intelligence Based Organ at Risk Segmentation
    Location: Hall B2

    Presenter: Chenyu Yan, PhD – Cleveland Clinic Taussig Cancer Center

  • 4:00 PM – 5:00 PM PT
    3078 - A Cascaded Deep Learning-Based Cardiac Substructures Segmentation Frame and on Non-Gated Non-Enhanced Planning CT Scans in Breast Cancer Patients
    Location: Hall B2

    Presenter: Jing Yang, MB

  • 4:00 PM – 5:00 PM PT
    3079 - Feasibility of Using Pseudo-CT for Dosimetry, Radiomics, and Efficacy Assessment in IMRT/VMAT of Brain Tumors: A Multi-Omics Analysis
    Location: Hall B2

    Presenter: Xin Yang, MS – Chongqing University Cancer Hospital

  • 4:00 PM – 5:00 PM PT
    3080 - CAU-Net: An Improved Attention U-Net for CT Head and Neck Organs at Risk Contouring
    Location: Hall B2

    Presenter: Xin Yang, PhD

  • 4:00 PM – 5:00 PM PT
    3081 - Is a Deep Learning Based Segmentation Model Trained on planning CTs Transferable for Segmentation of Organs at Risk in Replanning CTs?
    Location: Hall B2

    Presenter: Xin Yang, PhD

  • 4:00 PM – 5:00 PM PT
    3082 - Proliferation Saturation Index to Simulate Adaptive Radiation Fractionation in HPV-Associated Oropharyngeal Cancer
    Location: Hall B2

    Presenter: Mohammad Zahid, PhD – Moffitt Cancer Center

  • 4:00 PM – 5:00 PM PT
    3083 - Deep Learning for Automated Contouring of Primary Gross Tumor Volumes by MRI for Radiation Therapy of Brain Metastasis
    Location: Hall B2

    Presenter: Rui-ping Zhang

  • 4:00 PM – 5:00 PM PT
    3084 - Real World Utilization of Cranial or Craniospinal Radiation in Adult Acute Lymphoid Leukemia Patients: Data from the Center for International Blood and Marrow Transplant Research
    Location: Hall B2

    Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center

  • 4:00 PM – 5:00 PM PT
    3085 - Unsupervised Domain Adaptation of Auto-Segmentation on Multi-Source MRIs
    Location: Hall B2

    Presenter: Wei Zhang, ME – Manteia Technologies Co.,Ltd.

  • 4:00 PM – 5:00 PM PT
    3086 - Development and Assessment of a Multi-Purpose Knowledge-Based Planning Model (RapidPlan) for Prostate Radiation
    Location: Hall B2

    Presenter: Xin Zhang, PhD – Boston University Medical Center

  • 4:00 PM – 5:00 PM PT
    3088 - Deep Learning-Based Multi-Modality Segmentation of Primary Gross Tumor Volume in CT and MRI for Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Yixiao Zhang – Johns Hopkins University

  • 4:00 PM – 5:00 PM PT
    3089 - Change in Blood Counts after Palliative Radiotherapy for Multiple Myeloma
    Location: Hall B2

    Presenter: Conan Zhao, PhD – Mayo Clinic Alix School of Medicine

  • 4:00 PM – 5:00 PM PT
    3090 - The Role of Radiotherapy in Patients with Refractory Hodgkin Lymphoma after Brentuximab Vedotin and -/or Immune Checkpoint Inhibitors
    Location: Hall B2

    Presenter: RuiZhi Zhao, MD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences

  • 4:00 PM – 5:00 PM PT
    3091 - Deep Learning and GAN-Synthesis for Auto-Segmentation of Pancreatic Cancer by Non-Enhanced CT for Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Shuai Sun, MD, PhD – Zhongnan Hospital of Wuhan University

  • 4:00 PM – 5:00 PM PT
    3092 - Feasibility of Using Zero-Shot Learning in Transformer-Based Natural Language Processing Algorithm for Key Information Extraction from Head and Neck Tumor Board Notes
    Location: Hall B2

    Presenter: Simeng Zhu, MD – Ohio State University James Cancer Hospital

  • 4:00 PM – 5:00 PM PT
    3093 - Development and Validation of Clinical-Metabolic-Radiomics Model Based on Nomogram-Revised Risk Index for Prognosis Prediction in Patients with Extranodal Natural Kill/T Cell Lymphoma
    Location: Hall B2

    Presenter: Yingming Zhu, MD, PhD – Shandong Anti-Cancer Association

  • 4:00 PM – 5:00 PM PT
    3094 - Prognostic and treatment values of baseline metabolic tumor volume in extranodal nasal-type natural killer/T-cell lymphoma in the modern treatment era
    Location: Hall B2

    Presenter: Yingming Zhu, MD, PhD – Shandong Anti-Cancer Association

  • 5:15 PM – 6:15 PM PT
    3095 - Investigating the Relationship between the Dose to the Recto-Vaginal Reference Point and Vaginal Stenosis among Cervical Cancer Patients Treated at a North American Academic Institution
    Location: Hall B2

    Presenter: Bethel Adefres, MD, BS – Yale New Haven Hospital

  • 5:15 PM – 6:15 PM PT
    3096 - A Novel Method for Intracavitary Cervical HDR Brachytherapy: Express Finger-Guided Implant Insertion at Simulation Table without Speculum, Cervical Dilatation, Sleeve, Anesthesia, or Sedation
    Location: Hall B2

    Presenter: Nasser Al-Dhaibani, MD, FRCPC. – King Abdullah Medical City

  • 5:15 PM – 6:15 PM PT
    3097 - The Use of Problem-Based Learning Curriculum to Increase Medical Student Exposure to Radiation Oncology
    Location: Hall B2

    Presenter: Naba Ali, MD, BS – Emory University

  • 5:15 PM – 6:15 PM PT
    3098 - Predictors of Poor Treatment Experience in Cervical Cancer Patients Receiving Definitive Chemoradiation and Brachytherapy Boost: A Prospective Study
    Location: Hall B2

    Presenter: Lauren Andring, MD – MD Anderson Cancer Center

  • 5:15 PM – 6:15 PM PT
    3099 - Real-Time Precision Needle Tracking for Gynecological Interstitial Brachytherapy: A Phantom Feasibility Study
    Location: Hall B2

    Presenter: Diandra Ayala-Peacock, MD – Duke University Health System

  • 5:15 PM – 6:15 PM PT
    3100 - Characterizing Wellness Leadership in Academic Radiation Oncology Departments in the United States
    Location: Hall B2

    Presenter: Sara Beltran Ponce, MD – Medical College of Wisconsin

  • 5:15 PM – 6:15 PM PT
    3101 - Patterns of failure in pediatric and young adult rhabdomyosarcoma
    Location: Hall B2

    Presenter: Rohini Bhatia, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:15 PM – 6:15 PM PT
    3102 - Radiation Treatment Plan Evaluation Education in Residency: A Needs Assessment
    Location: Hall B2

    Presenter: Graham Boyd, MD – Harvard Radiation Oncology Program

  • 5:15 PM – 6:15 PM PT
    3103 - Outcomes Following Proton Therapy for Non-Metastatic Central Nervous System Germinoma in Children and Adolescents
    Location: Hall B2

    Presenter: Ryan Brisson, MD – University of Florida

  • 5:15 PM – 6:15 PM PT
    3104 - Green Tea Derivative (-)-Epigallocatechin-3-Gallate (EGCG) Prevents against Acute Radiation-Induced Intestinal Injury: A Prospective Phase II Clinical Study in Pelvic Cancer Patients
    Location: Hall B2

    Presenter: Shang Cai, MD, PhD – soochow university

  • 5:15 PM – 6:15 PM PT
    3105 - Using Longitudinal MRI to Manage Proton Range Uncertainty for Pediatric Proton Craniospinal Irradiation
    Location: Hall B2

    Presenter: Chih-Wei Chang, PhD – Emory University

  • 5:15 PM – 6:15 PM PT
    3106 - Clinical Significance of Arginine Signaling in Patients with Cervical Cancer Receiving Cisplatin Chemoradiation Therapy
    Location: Hall B2

    Presenter: Helen Chen, MD, PhD – Taiwan National Cheng Kung University Hospital

  • 5:15 PM – 6:15 PM PT
    3107 - Automation of Dosimetric Data Collection Using C# ESAPI for Intracavitary and Hybrid Intracavitary/Interstitial Brachytherapy Plans
    Location: Hall B2

    Presenter: Karen Cheng, MD – USC Norris Comprehensive Cancer Center

  • 5:15 PM – 6:15 PM PT
    3108 - Toward Burnout Prevention: Can One Short Virtual Reality Relaxation and Mindfulness Training Session for Staff and Patients Decrease Stress and Improve Subjective Sense of Wellbeing?
    Location: Hall B2

    Presenter: Sylvia Choo, BA – University of South Florida College of Medicine

  • 5:15 PM – 6:15 PM PT
    3109 - Cesium-131 Low-Dose Rate Interstitial Brachytherapy as a Salvage Re-Irradiation Technique in Treating Cervical and Uterine Cancer Pelvic Recurrence with Prior History of Pelvic Radiation
    Location: Hall B2

    Presenter: Zeta Chow, MD, MS – University of Kentucky

  • 5:15 PM – 6:15 PM PT
    3110 - Recursive Partitioning Analysis Predicts Survival in Uterine Cancer and Defines Oligometastatic State with Improved Survival: A National Cancer Database Analysis
    Location: Hall B2

    Presenter: Cheryl Claunch, MD, PhD – Baylor College of Medicine

  • 5:15 PM – 6:15 PM PT
    3111 - Single Institute Experience with MRI-Guided Adaptive Brachytherapy for Locally Advanced Cervix Cancer: Long Term Outcomes and Toxicity Analysis
    Location: Hall B2

    Presenter: Sian Cooper, MBBS – Guy's and St. Thomas' NHS Foundation Trust

  • 5:15 PM – 6:15 PM PT
    3111 - Single Institute Experience with MRI-Guided Adaptive Brachytherapy for Locally Advanced Cervix Cancer: Long Term Outcomes and Toxicity Analysis
    Location: Hall B2

    Presenter: Ingrid White, MD, PhD – Guy's and St. Thomas' NHS Foundation Trust

  • 5:15 PM – 6:15 PM PT
    3112 - Role of Brachytherapy in Adjuvant Radiation Practices for FIGO Stage II Endometrial Cancer
    Location: Hall B2

    Presenter: Jessica Cruttenden, MD – Huntsman Cancer Institute at the University of Utah

  • 5:15 PM – 6:15 PM PT
    3113 - Dosimetric Advantages of Online Adaptative Radiotherapy for Cervical Cancer on 1.5T MR-Linac
    Location: Hall B2

    Presenter: Shouliang Ding, MS – Sun Yat-Sen University Cancer Center

  • 5:15 PM – 6:15 PM PT
    3114 - Pediatric Esthesioneuroblastoma Treated with Proton Radiotherapy
    Location: Hall B2

    Presenter: Nicolette Drescher, MD – University of Florida Shands Cancer Center

  • 5:15 PM – 6:15 PM PT
    3115 - Effect of Concurrent Chemoradiotherapy on Regulatory T Cells?CD8/Treg Ratio?PD1 and CTLA-4 in Patients with Cervical Cancer
    Location: Hall B2

    Presenter: Yanjun Du

  • 5:15 PM – 6:15 PM PT
    3116 - Prospective Feasibility Trial of Vertebral Body Sparing Pencil Beam Scanning Proton Craniospinal Irradiation in Growing Children
    Location: Hall B2

    Presenter: Bree Eaton, MD – Emory University

  • 5:15 PM – 6:15 PM PT
    3117 - Is Programmed Death Ligand 1(PD-L1) Expression in Vulvar Cancer Prognostic for Locoregional Control?
    Location: Hall B2

    Presenter: Baher Elgohari, MD, MS, MBBS – UPMC Hillman Cancer Center

  • 5:15 PM – 6:15 PM PT
    3118 - Three Decade Single-Institution Experience of Safety and Efficacy of Radiotherapy and Adjuvant Chemotherapy for Young Adult Patients with Medulloblastoma
    Location: Hall B2

    Presenter: Hesham Elhalawani, MD, MS – Brigham and Women's Hospital/Dana Farber Cancer Institute

  • 5:15 PM – 6:15 PM PT
    3119 - Social Media as a Tool to Directly Address Misinformation in Health Care and Promote Patient Education
    Location: Hall B2

    Presenter: Sarah Emma, BS – Medical College of Wisconsin

  • 5:15 PM – 6:15 PM PT
    3120 - Efficacy and Safety of Local Radiotherapy Combined with Chemotherapy ± Bevacizumab in the Treatment of Patients with Advanced and Recurrent Metastatic Cervical Cancer
    Location: Hall B2

    Presenter: LI Fenghu, PhD, MS

  • 5:15 PM – 6:15 PM PT
    3121 - Impact of Immune, Inflammatory, and Nutritional Indices on Outcome in Patients with Cervical Cancer Treated with Definitive (Chemo)radiotherapy
    Location: Hall B2

    Presenter: Corinne Doll, MD, BS – University of Calgary

  • 5:15 PM – 6:15 PM PT
    3122 - Hypomagnesemia and Survival in Patients with Cervical Cancer Treated with Definitive Chemoradiotherapy
    Location: Hall B2

    Presenter: Corinne Doll, MD, BS – University of Calgary

  • 5:15 PM – 6:15 PM PT
    3123 - A 3D Deep Convolutional Neural Network for Dose Distribution Prediction of Intracavitary HDR Brachytherapy of Cervical Cancer
    Location: Hall B2

    Presenter: Suman Gautam, MS – Virginia Commonwealth University

  • 5:15 PM – 6:15 PM PT
    3124 - Impact of Lymphopenia on Definitive Treatment of Locally Advanced Cervical Cancer
    Location: Hall B2

    Presenter: Emilee Hall – University of Virginia

  • 5:15 PM – 6:15 PM PT
    3125 - Intraoral Gavage of Second Generation Probiotic Lactobacillus Reuteri Releasing IFN-ß (LR-IFN-ß) Mitigates Intestinal Irradiation Toxicity and Improves Survival During Whole Abdomen Irradiati
    Location: Hall B2

    Presenter: Diala Hamade, MD – University of Pittsburgh Medical Center

  • 5:15 PM – 6:15 PM PT
    3126 - A Multi-Institutional Analysis of MRI-Based Brachytherapy for Medically Inoperable Endometrial Cancer
    Location: Hall B2

    Presenter: Matthew Harkenrider, MD – Loyola University Medical Center

  • 5:15 PM – 6:15 PM PT
    3126 - A Multi-Institutional Analysis of MRI-Based Brachytherapy for Medically Inoperable Endometrial Cancer
    Location: Hall B2

    Presenter: Junzo Chino, MD – Duke University Medical Center

  • 5:15 PM – 6:15 PM PT
    3127 - Patient-Reported Distress and Acute Care Utilization for Cervical Cancer Patients Undergoing Concurrent Chemoradiation
    Location: Hall B1

    Presenter: Areeb Hassan

  • 5:15 PM – 6:15 PM PT
    3127 - Patient-Reported Distress and Acute Care Utilization for Cervical Cancer Patients Undergoing Concurrent Chemoradiation
    Location: Hall B2

    Presenter: Jennifer Croke, MD, BS, MHPE – Princess Margaret Cancer Centre

  • 5:15 PM – 6:15 PM PT
    3128 - Comparison of Two Different Adjuvant High Dose Rate Vaginal Brachytherapy Fractionation Regimens in Early-Stage Endometrial Cancer
    Location: Hall B2

    Presenter: Allison Hazy, MD – Beaumont Health

  • 5:15 PM – 6:15 PM PT
    3129 - Survival and Local Recurrence Risk in Patients with High-Risk Neuroblastoma Treated with Proton Therapy over a 10 Year Interval
    Location: Hall B2

    Presenter: Christine Hill-Kayser, MD – University of Pennsylvania

  • 5:15 PM – 6:15 PM PT
    3130 - Medical Student Survey of ASCO Sponsored Oncology Interest Groups in the United States Demonstrates Lack of Education in Radiation Oncology and Negative Perceptions of Future Employment Prospects
    Location: Hall B2

    Presenter: Andrew Hoover, MD – University of Kansas Medical Center

  • 5:15 PM – 6:15 PM PT
    3131 - Correlation of Post-Treatment Biopsy and Fluorodeoxyglucose PET/CT Findings Following Definitive Chemotherapy and Radiation for Cervical Cancer
    Location: Hall B2

    Presenter: Andrew Hoover, MD – University of Kansas Medical Center

  • 5:15 PM – 6:15 PM PT
    3132 - Risk Stratification of Postoperative Adjuvant Therapy for Endometrial Cancera (POAT-ENDORISK) Based on Bayesian Network Model: A Development and Validation Study
    Location: Hall B2

    Presenter: Xiaorong Hou, MD – Pecking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3133 - Academic U.S. Radiation Oncology Department Chairs: Who are They?
    Location: Hall B2

    Presenter: Kristin Hsieh, MD – Icahn School of Medicine at Mount Sinai

  • 5:15 PM – 6:15 PM PT
    3134 - Clinical Outcomes of Sidewall/Parametrial Simultaneous Integrated Boost for Patients with Cervical Cancer
    Location: Hall B2

    Presenter: Christina Huang, MD, MS – Duke University School of Medicine

  • 5:15 PM – 6:15 PM PT
    3135 - Uterine Body Invasion is a Significant Factor of Para-Aortic Lymph Node Recurrence in Patients with Cervical Carcinoma after Pelvic Radiotherapy
    Location: Hall B2

    Presenter: Kuan-Ching Huang, MD – Kaohsiung Chang Gung Memorial Hospital

  • 5:15 PM – 6:15 PM PT
    3136 - Multi-Institutional Phase I Feasibility Trial of Vertebral Body Sparing CSI for Pediatric Brain Tumors
    Location: Hall B2

    Presenter: Myrsini Ioakeim-Ioannidou, MD – Massachusets General Hospital

  • 5:15 PM – 6:15 PM PT
    3137 - Investigating the Potential Role of IKZF3 in HPV-Associated Carcinogenesis
    Location: Hall B2

    Presenter: Amira Ishag-Osman, MS, BS – Tufts University School of Medicine

  • 5:15 PM – 6:15 PM PT
    3138 - Treatment of Recurrent Orbital Rhabdomyosarcoma with Exenteration and HDR Brachytherapy in a Custom Mold
    Location: Hall B2

    Presenter: Christopher Jackson, MD, MS – Memorial Sloan Kettering Cancer Center

  • 5:15 PM – 6:15 PM PT
    3139 - Response-Adapted Omission of Radiotherapy in Pediatric Patients with Intermediate- and High-Risk Hodgkin Lymphoma Treated per EuroNet-PHL-C1: A Single Institution Analysis of Outcomes and Patterns of
    Location: Hall B2

    Presenter: Meredith Jackson, BS – UT Southwestern Medical Center

  • 5:15 PM – 6:15 PM PT
    3140 - Evaluation of National Conference-Associated Medical Student Research and Mentorship Award for Medical Students, Resident Mentors, and Radiation Oncologist Supervisors
    Location: Hall B2

    Presenter: Ruijia Jin, MS4 – University of British Columbia

  • 5:15 PM – 6:15 PM PT
    3141 - Outcomes of Children Diagnosed with Unilateral Retinoblastoma: Retrospective Audit
    Location: Hall B2

    Presenter: Nehal Khanna, MD, MBBS – S L Raheja Hospital

  • 5:15 PM – 6:15 PM PT
    3142 - Identification and Management of Radiation-Induced Premature Ovarian Failure
    Location: Hall B2

    Presenter: Anna Kikut – Virginia Commonwealth University

  • 5:15 PM – 6:15 PM PT
    3143 - Quantifying Radiation Induced Vaginal Stenosis for the Development of a Novel Dilator Device: A Prospective Cohort Study of Patients with Cervical Cancer Treated with Definitive Chemoradiation Therapy
    Location: Hall B2

    Presenter: Sangwoo Kim, MD – University of California, San Diego

  • 5:15 PM – 6:15 PM PT
    3144 - ChatGPT is an Unreliable Tool for Reviewing Radiation Oncology Literature
    Location: Hall B2

    Presenter: Troy Kleber, MD, MS – MD Anderson Cancer Center

  • 5:15 PM – 6:15 PM PT
    3145 - Focused Ultrasound for Blood-Brain Barrier Opening Enhances Delivery of Anti-PD1 in Diffuse Midline Gliomas
    Location: Hall B2

    Presenter: Danae Kokossis, MD – Columbia University Irving Medical Center

  • 5:15 PM – 6:15 PM PT
    3146 - The Changing Profile of Academic Radiation Oncology Leaders: Updates over the Past Decade
    Location: Hall B2

    Presenter: Young Suk Kwon, MD – University of Texas Southwestern Medical Center at Dallas

  • 5:15 PM – 6:15 PM PT
    3147 - Sociotechnical Factors Contributing to Burnout among Radiation Oncology Medical Physicists: Survey and Focus Group Results from a Systems-Analysis Approach
    Location: Hall B2

    Presenter: Elizabeth Kwong, BS – University of North Carolina at Chapel Hill

  • 5:15 PM – 6:15 PM PT
    3148 - Clinical Outcomes for Chest Wall Ewing Sarcoma: A Multi-Center Single Institution Experience
    Location: Hall B2

    Presenter: Brady Laughlin, MD – Mayo Clinic Arizona

  • 5:15 PM – 6:15 PM PT
    3149 - Improving the Efficacy and Safety of Concurrent Chemoradiotherapy by Neoadjuvant Chemotherapy: A Randomized Controlled Study of Locally Advanced Cervical Cancer with a Large Tumor
    Location: Hall B2

    Presenter: Fenghu Li, PhD – Affiliated Hospital of Guizhou Medical University

  • 5:15 PM – 6:15 PM PT
    3150 - Silva Classification System for HPV-Related EAC of Stage I ~ IIIc1p Cervical Adenocarcinoma and Its Effect on Prognosis and Survival
    Location: Hall B2

    Presenter: jiehui Li, PhD

  • 5:15 PM – 6:15 PM PT
    3151 - Image-Guided High-Dose-Rate Brachytherapy for Definitive Management of Primary Vaginal Cancer: A Single Institutional Experience
    Location: Hall B2

    Presenter: Katie Lichter, MD, MD MPH – University of California San Francisco

  • 5:15 PM – 6:15 PM PT
    3152 - Prognostic Value of Tumor Volume Reduction during Radiotherapy in Patients with Locally Advanced Cervical Cancer in Different Risk Groups
    Location: Hall B2

    Presenter: Canyang Lin, MD

  • 5:15 PM – 6:15 PM PT
    3154 - Newly Diagnosed Mental Health Disorders in Patients with Breast Cancer Receiving Radiation Therapy
    Location: Hall B2

    Presenter: Bailey Loving, MD – Beaumont Health - Royal Oak

  • 5:15 PM – 6:15 PM PT
    3155 - VMAT TBI Technique Using Autoplanning Scripts
    Location: Hall B2

    Presenter: Yuliia Lozko, MD – Stanford Cancer Institute Palo Alto

  • 5:15 PM – 6:15 PM PT
    3156 - A Survey of Submission and Review Standards across Clinical Radiation Oncology and Medical Physics Journals: Devising the Optimal Criteria for Reproducibility and Sustained Impact
    Location: Hall B2

    Presenter: John Lucas, MD, MS – St. Jude Children's Research Hospital

  • 5:15 PM – 6:15 PM PT
    3158 - A Machine Learning Framework Integrating Electronic Health Records for Survival Prognostication in Cervix Cancer
    Location: Hall B2

    Presenter: Nauman Malik, MD, MS – University of California San Francisco

  • 5:15 PM – 6:15 PM PT
    3159 - Direction Modulated Brachytherapy Tandem Model Applicators for Treatment Planning of Multi-Institutional Cervical Cancer Cases: Removing Needles in Intracavitary-Interstitial Techniques
    Location: Hall B2

    Presenter: William Song, PhD – Virginia Commonwealth University

  • 5:15 PM – 6:15 PM PT
    3160 - Re-Irradiation for Diffuse Intrinsic Pontine Glioma with 3 Gy per Fraction
    Location: Hall B2

    Presenter: Nikhil Mankuzhy, MD – Memorial Sloan Kettering Cancer Center

  • 5:15 PM – 6:15 PM PT
    3161 - Prophylactic Para-Aortic Extended Field Irradiation with Concurrent Chemotherapy for FIGO Stage IIIC1 Cervical Cancer Using Intensity Modulated Radiotherapy Technique: Acute Toxicity and Dosimetric As
    Location: Hall B2

    Presenter: Akanksha Manral, MBBS – Dr Ram Manohar Lohia Institute of Medical Sciences

  • 5:15 PM – 6:15 PM PT
    3162 - Defining the Transcriptional Landscapes of the Tumor Microenvironment of Cervical and Vaginal Cancers at Single-Cell Resolution
    Location: Hall B2

    Presenter: Serena Mao, MD, PhD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 5:15 PM – 6:15 PM PT
    3163 - Brazilian Pediatric Patients with Gliomas: Treatment Characteristics and Survival Outcomes
    Location: Hall B2

    Presenter: Gustavo Marta, MD, PhD – Hospital Sirio-Libanes

  • 5:15 PM – 6:15 PM PT
    3164 - Prognostic Factors for Pediatric, Adolescent, and Young Adult Patients with Non-DIPG Grade 4 Gliomas: A Contemporary Pooled Institutional Experience
    Location: Hall B2

    Presenter: Jennifer Matsui, PhD – The Ohio State

  • 5:15 PM – 6:15 PM PT
    3165 - Pilot Study Assessing Student Interest in Combined Residency Training Pathways with Radiation Oncology
    Location: Hall B2

    Presenter: Malcolm Mattes, MD – Rutgers Cancer Institute of New Jersey

  • 5:15 PM – 6:15 PM PT
    3166 - ARTIA-Cervix: A Prospective Clinical Trial to Assess Patient Reported Intestinal Toxicity with Adaptive External Beam Radiation Therapy in the Treatment of Cervical Cancer
    Location: Hall B2

    Presenter: Jyoti Mayadev, MD – UCSD

  • 5:15 PM – 6:15 PM PT
    3167 - Burnout Rates in Clinical Radiation Oncology and Variations across Professional Subgroups
    Location: Hall B2

    Presenter: Sean McCauley, BS – University of Arizona College of Medicine - Phoenix

  • 5:15 PM – 6:15 PM PT
    3168 - A Novel Multi-Channel Tandem Applicator for Direction Modulated Brachytherapy
    Location: Hall B2

    Presenter: Moeen Meftahi, PhD – Emory University

  • 5:15 PM – 6:15 PM PT
    3169 - Pre-Brachytherapy Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response as Predictor of Local Control in the Definitive Treatment of Cervical Cancer
    Location: Hall B2

    Presenter: Assaf Moore, MD – Rabin Medical Center - Beilinson Hospital

  • 5:15 PM – 6:15 PM PT
    3170 - Impact of Race and Socioeconomic Factors on Clinical Outcomes in Cervical and Endometrial Cancer Patients Treated with Brachytherapy
    Location: Hall B2

    Presenter: Ria Mulherkar, MD – UPMC Cancer Center

  • 5:15 PM – 6:15 PM PT
    3171 - Radiation Induced Lumbar Plexopathy (RILP) in Patients of Cancer Cervix Treated by IMRT Technique: A Study of Dosimetry and Clinical Correlation
    Location: Hall B2

    Presenter: Sankalp Naidu, MD, MBBS – Bibi Cancer Hospitals

  • 5:15 PM – 6:15 PM PT
    3172 - The Inpatient Consultation Experience in Radiation Oncology: A Contemporary Evaluation of a Single Academic Institution
    Location: Hall B2

    Presenter: Beth Neilsen, MD, PhD – University of California Los Angeles

  • 5:15 PM – 6:15 PM PT
    3173 - Pharmacological Targeting of Interferon-Related DNA Damage Resistant Signature (IRDS) and XRCC4-Mediated DNA Repair Pathways as a Novel Therapeutic Approach to DIPG Radio-Sensitization
    Location: Hall B2

    Presenter: Anatoly Nikolaev, MD, PhD – Cleveland Clinic Florida

  • 5:15 PM – 6:15 PM PT
    3174 - Results From a Multi-Institutional Pilot Study of iContour, an Interactive Online Platform with Real-Time Feedback to Improve Contouring Education for Radiation Oncology Residents
    Location: Hall B2

    Presenter: Megan Orr, MD – UC San Diego Health

  • 5:15 PM – 6:15 PM PT
    3175 - Feasibility and Workflow Efficiency in MRI-Based HDR Brachytherapy for Cervical Cancer at a Community-Based Practice
    Location: Hall B2

    Presenter: Ranjani Padmanabhan, MD – NYP BMH Radiation Oncology

  • 5:15 PM – 6:15 PM PT
    3176 - Maintenance Therapy for Recurrent or Metastatic Cervical Cancer: A Multicenter, Cohort Study
    Location: Hall B2

    Presenter: Chen Peng

  • 5:15 PM – 6:15 PM PT
    3177 - Fixed-Field IMRT for Cervix Carcinoma Patients on an MR-LINAC Platform: Dosimetric Feasibility and Challenges
    Location: Hall B2

    Presenter: Daniel Pham, PhD, CMD, RT – Stanford Health Care

  • 5:15 PM – 6:15 PM PT
    3178 - Enhancing Specialist Training in Radiation Oncology through the Implementation of Structured Radiotherapy Contouring Workshops
    Location: Hall B2

    Presenter: Guhan Rangaswamy, MD, MBBS – St.Lukes Radiation Oncology Network

  • 5:15 PM – 6:15 PM PT
    3179 - A Comparative Analysis of Effect of HIV Infection on Outcomes of Cervical Cancer Treated with Radiotherapy
    Location: Hall B2

    Presenter: Krishna Ratanchandani, MD, MBBS – Gujarat Cancer and Research Institute Ahmedabad

  • 5:15 PM – 6:15 PM PT
    3180 - Comparison of Molecular and Clinicopathologic-Based Classifications and the Transition of Adjuvant Treatment Mode for Early-Stage Endometrial Cancer
    Location: Hall B2

    Presenter: Kang Ren, PhD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3181 - Direction Modulated Brachytherapy Tandem Model Applicators for Treatment Planning of Multi-Institutional Cervical Cancer Cases
    Location: Hall B2

    Presenter: Dylan Richeson, MS – Virginia Commonwealth University

  • 5:15 PM – 6:15 PM PT
    3182 - Prospective Application of an Artificial Intelligence Decision Support Tool for Applicator and Needle Selection in High-Dose-Rate Brachytherapy for Cervical Cancer Patients
    Location: Hall B2

    Presenter: Michael Roumeliotis, PhD – Johns Hopkins University

  • 5:15 PM – 6:15 PM PT
    3183 - Impact of Changing ACGME Case Requirements on Radiation Oncology Resident Rotation Structure
    Location: Hall B2

    Presenter: John Roveda, MD – UAB Hazelrig Salter Radiation Oncology Center

  • 5:15 PM – 6:15 PM PT
    3184 - Prognostic Impact of a Negative Central Pelvic Biopsy after Definitive Chemoradiotherapy (CRT) for Locally Advanced Cervical Cancer (LACC)
    Location: Hall B2

    Presenter: Lucas Sapienza, MD, PhD – Baylor College of Medicine

  • 5:15 PM – 6:15 PM PT
    3185 - TEAMRO: TEAching Mentorship in Radiation Oncology, a Multicenter Prospective Phase 2 Intervention Study on Teaching Mentorship Skills to Residents Working with Medical Students
    Location: Hall B2

    Presenter: Anurag Saraf, MD – Brigham and Women's Hospital/Dana-Farber

  • 5:15 PM – 6:15 PM PT
    3186 - Prevalence of Trauma History and Symptoms in Patients Who Have Received Vaginal Brachytherapy as Part of their Endometrial Cancer Treatment
    Location: Hall B2

    Presenter: Anjali Saripalli, MD, MSE – Loyola University Medical Center

  • 5:15 PM – 6:15 PM PT
    3187 - Concurrent Chemoradiotherapy plus Programmed Death-1 (PD-1) Blockade for Locally Advanced Cervical Cancer: Preliminary Results of a Single-Arm, Open-Label, Phase II Trial
    Location: Hall B2

    Presenter: Runjun Shi, PhD – Suzhou Municipal Hospital

  • 5:15 PM – 6:15 PM PT
    3188 - Favorable Toxicity and Local Control with Ultrahypofractionated Radiation Therapy (UH-RT) for Melanoma of the Lower Genital Tract (LGT)
    Location: Hall B2

    Presenter: Benjamin Silver, MD – Rochester Regional Health System

  • 5:15 PM – 6:15 PM PT
    3189 - Single Institute Experience Treating Uterine Carcinosarcoma: Outcome Analysis
    Location: Hall B2

    Presenter: Van-Ren Sim

  • 5:15 PM – 6:15 PM PT
    3190 - Can Volume-Based MRI-Guided Planning for Interstitial Gynecologic Brachytherapy Overcome Clinicopathologic Risk Factors for Fistula Formation?
    Location: Hall B2

    Presenter: Aranee Sivananthan, MD, MS, BS – University of Chicago

  • 5:15 PM – 6:15 PM PT
    3191 - Understanding Burnout Among US Radiation Oncology Residents
    Location: Hall B2

    Presenter: Christina Small, MD – Medical College of Wisconsin

  • 5:15 PM – 6:15 PM PT
    3192 - Combining Novel Direction Modulated Brachytherapy Tandem-and-Ovoids Applicators for Treatment Planning of Multi-Institutional Cervical Cancer Cases: Removing Needles in Intracavitary-Interstitial Tech
    Location: Hall B2

    Presenter: William Song, PhD – Virginia Commonwealth University

  • 5:15 PM – 6:15 PM PT
    3193 - An On-the-Go Platform for Continuing Medical Education in Radiation Oncology in Brazil
    Location: Hall B2

    Presenter: Maria Thereza Starling, MD – Hospital Sirio Libanes

  • 5:15 PM – 6:15 PM PT
    3194 - Social Media as a Strategy for Continuing Education in Brazil
    Location: Hall B2

    Presenter: Maria Thereza Starling, MD – Hospital Sirio Libanes

  • 5:15 PM – 6:15 PM PT
    3195 - Assessing Equity of Family Members Roles in Supporting Pediatric Patients Receiving Proton Radiation Therapy: A Retrospective Study of Parent/Guardian Attendance at Clinic Visits
    Location: Hall B2

    Presenter: Emily Stiles, BA – University of Washington

  • 5:15 PM – 6:15 PM PT
    3196 - Genomic Characterization of Low and High Grade Cervical Intraepithelial Neoplasia in Comparison to Cervical Cancer
    Location: Hall B2

    Presenter: Shivani Sud, MD – The University of North Carolina at Chapel Hill

  • 5:15 PM – 6:15 PM PT
    3197 - Pseudo CT Images Synthesized from CBCT Based on Unsupervised DDPM in Cervical Cancer Radiotherapy
    Location: Hall B2

    Presenter: Hongfei Sun

  • 5:15 PM – 6:15 PM PT
    3198 - Risk Factors and Clinical Features of Fistula after Concurrent Chemoradiation and Brachytherapy for Locally Advanced Cervical Cancer
    Location: Hall B2

    Presenter: Katherine Sykes Martin, MD, MS – Winship Cancer Institute of Emory University

  • 5:15 PM – 6:15 PM PT
    3199 - Impact of the COVID-19 Pandemic on Academic Productivity in Oncology: A Journal-, Conference- and Author-level Analysis
    Location: Hall B2

    Presenter: Vivian Tan, MD – London Health Sciences Centre

  • 5:15 PM – 6:15 PM PT
    3200 - Radiotherapy Can Influence the Expression of PD-L1 and Circulating Exosomal PD-L1 May Better Predict the Immunotherapy Efficiency in Cervical Cancer Patients
    Location: Hall B2

    Presenter: Wenjie Tang, PhD

  • 5:15 PM – 6:15 PM PT
    3201 - Single Institution Experience of the Effect of Adjuvant Radiation on Outcomes for Patients with Uterine Carcinosarcoma
    Location: Hall B2

    Presenter: Rachel Tobillo, MD – Emory University

  • 5:15 PM – 6:15 PM PT
    3202 - Advantage of Adding Non-Coplanar Arcs for Scalp-Avoidance Whole-Brain Irradiation with Volumetric-Modulated Arc Radiotherapy to Reduce Scalp Dose in Pediatric Patients with Medulloblastomas
    Location: Hall B2

    Presenter: Daichi Torizuka, MD – Kyoto University

  • 5:15 PM – 6:15 PM PT
    3203 - The Impact of Updated ACGME Program Requirements for Radiation Oncology Residencies
    Location: Hall B2

    Presenter: Olivia Trumble, BS – University of Florida College of Medicine

  • 5:15 PM – 6:15 PM PT
    3204 - Can an In-Person Hands-On Applicator-Based Teaching Session Improve Trainee Knowledge and Comfort with Complex Gynecologic Brachytherapy?
    Location: Hall B2

    Presenter: John Austin Vargo, MD, MBA – University of Pittsburgh Medical Center

  • 5:15 PM – 6:15 PM PT
    3205 - Evaluation of Sexual Side Effects in Patients after Chemoradiation and Brachytherapy for Gynecologic Cancers Involving the Lower Vagina and Bulboclitoris
    Location: Hall B2

    Presenter: Pooja Venkatesh – NYU Grossman School of Medicine

  • 5:15 PM – 6:15 PM PT
    3205 - Evaluation of Sexual Side Effects in Patients after Chemoradiation and Brachytherapy for Gynecologic Cancers Involving the Lower Vagina and Bulboclitoris
    Location: Hall B2

    Presenter: Juhi Purswani, MD – New York University School of Medicine

  • 5:15 PM – 6:15 PM PT
    3206 - Multi-Institutional Experience of Proton Therapy for Rhabdomyosarcoma and Ewing Sarcoma in the Proton Collaborative Group (PCG) Prospective Registry
    Location: Hall B2

    Presenter: Katherine Von Werne, MSN – Miami Cancer Institute: Baptist Health South Florida

  • 5:15 PM – 6:15 PM PT
    3207 - Reducing CTV to PTV Margins with Daily Adaptive Radiotherapy in the Postoperative Treatment of Endometrial and Cervical Cancer
    Location: Hall B2

    Presenter: Guangyu Wang, MD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3208 - Clinical Implementation of Optical Surface Imaging Systems in Vulvar Cancer to Reduce Setup Error
    Location: Hall B2

    Presenter: Guangyu Wang, MD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3209 - Weekly Image Guidance in Patients with Cervical Cancer Treated with Intensity Modulated Radiation Therapy: Results of a Large Cohort Study
    Location: Hall B2

    Presenter: Weiping Wang, PhD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3210 - Poor Survival Outcomes in Patients with Stage IIIC2 Cervical Cancer Receiving Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Weiping Wang, PhD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3211 - Mismatch Repair Status is an Effective Prognostic Factor for Early-Stage Endometrial Carcinoma
    Location: Hall B2

    Presenter: Wenhui Wang, MD, PhD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3212 - The Clinical Practice and Dosimetric Outcome of the Manual Adaptive Planning during Definitive Radiotherapy Treatment for Cervical Cancer
    Location: Hall B2

    Presenter: Yiwei Wang, MD, PhD

  • 5:15 PM – 6:15 PM PT
    3213 - Effect of External Beam Radiation Therapy (EBRT) and Brachytherapy (BT) on Circulating MDSC Populations in Patients Treated Definitively for Cervical Cancer
    Location: Hall B2

    Presenter: Matt Berkseth, PhD – University of Minnesota

  • 5:15 PM – 6:15 PM PT
    3214 - The Role of Radiation Therapy for Metastatic Cervical Cancer
    Location: Hall B2

    Presenter: Fang Wu, MD, PhD

  • 5:15 PM – 6:15 PM PT
    3215 - Performance Metric Analysis of a Radiation Oncology Educational Podcast
    Location: Hall B2

    Presenter: Trudy Wu, MD, BS – University of California Los Angeles

  • 5:15 PM – 6:15 PM PT
    3216 - Timing of Postoperative Radiation Therapy for Early Stage Endometrial Carcinoma: A 20-Year Single-Center Retrospective Cohort Experience in China
    Location: Hall B2

    Presenter: Zihan Yan, MB

  • 5:15 PM – 6:15 PM PT
    3217 - Pseudo CT Synthesis Using Cone-Beam CT of Cervical Cancer with GAN-Based Neural Network Model
    Location: Hall B2

    Presenter: Hua Yang, MD – The First Affiliated Hospital of Air Force Medical University

  • 5:15 PM – 6:15 PM PT
    3218 - The Value of Progression-Free Survival at Three Years as a Primary Endpoint for Studies on Radiotherapy in Patients with Locally Advanced Cervical Cancer: Individual Patient Data and Validation From 2
    Location: Hall B2

    Presenter: Xi Yang, MD, PhD – Cancer Institute and Hospital Chinese Acedemy of Medical Sciences

  • 5:15 PM – 6:15 PM PT
    3219 - Total Reference Air Kerma (TRAK) is Associated with Dosimetric Parameters in Template-Based High Dose-Rate (HDR) Interstitial Brachytherapy in Advanced Gynecologic Cancers
    Location: Hall B2

    Presenter: Ravindra Yaparpalvi, MS – Montefiore Medical Center

  • 5:15 PM – 6:15 PM PT
    3220 - Protocol in a Day: An Educational Institutional Workshop for Protocol Development
    Location: Hall B2

    Presenter: Adriana Cavazos, BS – University of Texas MD Anderson Cancer Center

  • 5:15 PM – 6:15 PM PT
    3221 - Continuing Professional Development for Radiation Oncologists: Where are the Gaps and Barriers?
    Location: Hall B2

    Presenter: Sympascho Young, MD, BS – London Regional Cancer Program

  • 5:15 PM – 6:15 PM PT
    3222 - Development and Validation of CT-Based Clinical-Radiomics Nomogram for Early Stage Extranodal Nasal-Type NK/T Cell Lymphoma: A Multicenter Study
    Location: Hall B2

    Presenter: Jian Zang, MD – Xijing Hospital

  • 5:15 PM – 6:15 PM PT
    3223 - Quantifying the Impact of Research Productivity on Salary in Academic Radiation Oncology
    Location: Hall B2

    Presenter: Nicholas Zaorsky, MD, MS – University Hospitals Case Medical Center

  • 5:15 PM – 6:15 PM PT
    3224 - Optimal Cisplatin Cycles in Locally Advanced Cervical Carcinoma Patients Treated with Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Zheng Zeng, MD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3225 - Radiotherapy for Postoperative Vaginal Recurrences of Cervical Cancer Patients: Analysis of Recurrent Causes and Prognosis
    Location: Hall B2

    Presenter: Ziye Zheng, MD – Peking Union Medical College Hospital

  • 5:15 PM – 6:15 PM PT
    3226 - Adjuvant Concurrent Chemoradiotherapy vs. Radiotherapy Alone in Cervical Cancer Patients with Intermediate-Risk Factors after Radical Surgery
    Location: Hall B2

    Presenter: Yuncan Zhou, RT – Peking Union Medical College Hospital

  • Wednesday, October 4, 2023
  • 10:30 AM – 11:45 AM PT
    2573 - Impact of Family Caregiver and Patient Related Factors on Quality of Life in Head Neck Cancer Patients
    Location: Hall B2

    Presenter: Chaitali Waghmare, MD – DVVPPRH and DBVPRMC PIMS-DU LONI

  • 10:30 AM – 11:45 AM PT
    3227 - Which Criteria Should We use to Determine an Adequate Number of Linear Accelerators in Emerging Economy Countries
    Location: Hall B2

    Presenter: Zahid Al Mandhari, MD

  • 10:30 AM – 11:45 AM PT
    3228 - An Update of Stereotactic Body Radiotherapy (SBRT) for the Palliation of Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC)
    Location: Hall B2

    Presenter: Mohammed AlDohan, MBBS – McGill University Health Center

  • 10:30 AM – 11:45 AM PT
    3229 - Positive Predictive Value of PET CT in HPV Associated Oropharyngeal Cancers Treated with Definitive Proton Therapy
    Location: Hall B2

    Presenter: Gregory Alexander, MD – Thomas Jefferson University

  • 10:30 AM – 11:45 AM PT
    3230 - Intensity-Modulated Neutron Therapy (IMNT) for Head and Neck Cancer: Early Toxicity Outcomes
    Location: Hall B2

    Presenter: August Anderson, MD – University of Washington

  • 10:30 AM – 11:45 AM PT
    3231 - Photon vs. Proton Radiotherapy in the Definitive Treatment of Nasopharyngeal Cancer: Single Institution Experience
    Location: Hall B2

    Presenter: Joshua Anderson, MD, BS – Emory University School of Medicine

  • 10:30 AM – 11:45 AM PT
    3232 - Radiomics Based Assessment of Tumor Infiltrating CD8 T-Cells Predicts Induction Systemic Therapy Response in HPV+ Oropharyngeal Cancer: Exploratory Analysis of Prospective Trials
    Location: Hall B2

    Presenter: Muzamil Arshad, MD, PhD – University of Chicago

  • 10:30 AM – 11:45 AM PT
    3233 - Radiation Therapy in the Management of Cutaneous Squamous Cell Carcinoma Metastatic to the Parotid: A 50-Year Single Institution Experience
    Location: Hall B2

    Presenter: Frederick Ashby, PhD, MPH – University of Florida College of Medicine

  • 10:30 AM – 11:45 AM PT
    3234 - Challenging the Role of Subtotal Resection Following Proton Radiotherapy for Adenoid Cystic Carcinoma of the Head and Neck
    Location: Hall B2

    Presenter: Etzer Augustin, MD, MS – UF Health Radiation Oncology – Davis Cancer Pavilion

  • 10:30 AM – 11:45 AM PT
    3235 - VMAT-IGRT Hypofractionated Radiotherapy for Locally Advanced Thyroid Cancer in Resource-Limited Settings: A Retrospective Report from Bolivia
    Location: Hall B2

    Presenter: Lijia Aviles, MD – Lijia Aviles

  • 10:30 AM – 11:45 AM PT
    3236 - Evaluation of Sentinel Lymph Node Drainage Patterns in Early Stage Oral Cavity Cancer
    Location: Hall B2

    Presenter: Omar Azem, MD – Rush University Medical Center

  • 10:30 AM – 11:45 AM PT
    3237 - Stereotactic Boost and Short-Course Radiotherapy for p16-Associated Oropharynx Cancer (SHORT-OPC): First Planned Interim Safety Analysis from a Randomized Phase II Trial
    Location: Hall B2

    Presenter: Houda Bahig, MD, PhD – Centre Hospitalier de l'Universite de Montreal (CHUM)

  • 10:30 AM – 11:45 AM PT
    3238 - Outcomes after Contemporary Definitive Radiotherapy Alone in Patients with TNM-7 Stage III/IV Head and Neck Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Marc Vincent Barcelona, MD – Princess Margaret Cancer Centre

  • 10:30 AM – 11:45 AM PT
    3239 - Toxicity and Outcomes of Definitive Local Therapy in Elderly Patients with HPV-Associated Oropharyngeal Cancer
    Location: Hall B2

    Presenter: Rahul Barve, MD – Ohio State University James Cancer Hospital

  • 10:30 AM – 11:45 AM PT
    3240 - Correlation of Dose Volume Parameters with Dysphagia and Pharyngeal Constrictor Muscle Thickness in Dysphagia Optimized IMRT
    Location: Hall B2

    Presenter: Nikhil Bathija, MD, MBBS – Gujarat Cancer and Research Institute Ahmedabad

  • 10:30 AM – 11:45 AM PT
    3241 - Differences in Radiotherapy-Treated Members with Cancer during COVID-19 Pandemic Using Nationwide Claim Data
    Location: Hall B2

    Presenter: Abigail Berman, MD, MS, MSCE – CVS Health

  • 10:30 AM – 11:45 AM PT
    3242 - Hypo-Fractionated Palliative QUADSHOT Radiotherapy and Concurrent CDDP in Patients with LAHNSCC: Toxicities and Clinical Outcomes
    Location: Hall B2

    Presenter: Suman Bhasker, MD – All India Institute of Medical Sciences

  • 10:30 AM – 11:45 AM PT
    3243 - Trends in the Use of Hypofractionation in Treatment of Breast Cancer in Botswana
    Location: Hall B2

    Presenter: Rohini Bhatia, MD – Johns Hopkins Radiation Oncology Kimmel Cancer Center

  • 10:30 AM – 11:45 AM PT
    3244 - Definitive Radiotherapy is Effective Treatment for Gross Disease in Unresected Differentiated Thyroid Cancer
    Location: Hall B2

    Presenter: David Buchberger, MD, MSc – Cleveland Clinic Foundation

  • 10:30 AM – 11:45 AM PT
    3246 - Partial Tongue Sparing without Marginal Failures: The Dosimetric Advantages for Oral Tongue Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Shauna Campbell, MD, DO – Cleveland Clinic Taussig Cancer Center

  • 10:30 AM – 11:45 AM PT
    3247 - Outcomes of Patients with Oral Cavity Squamous Cell Carcinomas Treated with Adjuvant IMRT with Perineural Invasion
    Location: Hall B2

    Presenter: Kasey Cargill, PhD – University of Pittsburgh School of Medicine

  • 10:30 AM – 11:45 AM PT
    3248 - Voxel Based Analysis of Local Dose Patterns on Radiation Induced Xerostomia in Head and Neck Cancer with Machine Learning Methods
    Location: Hall B2

    Presenter: Ming Chao, PhD

  • 10:30 AM – 11:45 AM PT
    3249 - Demographics, Medical Comorbidities, and Functional Factors Associated with Radiation Therapy Regimen Length in Older Patients
    Location: Hall B2

    Presenter: Daniel Cherry, MD, MAS – Mount Sinai Hospital

  • 10:30 AM – 11:45 AM PT
    3251 - Insurance Request and Approval Process for Proton Beam Therapy in Patients With Esophageal Cancer
    Location: Hall B2

    Presenter: Jennifer Chiang, MD, MS – Stanford Health Care

  • 10:30 AM – 11:45 AM PT
    3252 - Transoral Laser Microsurgery and Radiotherapy for Early Glottic Cancer: An Old Story with a New Ending
    Location: Hall B2

    Presenter: Ju-chun Chien, MD – Kaohsiung Veterans General Hospital

  • 10:30 AM – 11:45 AM PT
    3253 - Impact of Dosimetric Parameters on Local Control and Toxicity of Head and Neck SBRT
    Location: Hall B2

    Presenter: Bhargava Chitti, MD – Northwell Health Center for Advanced Medicine

  • 10:30 AM – 11:45 AM PT
    3254 - External Validation of 8 Normal Tissue Complication Probability Models for Radiation-Associated Primary Hypothyroidism Using Long-Term Thyroid Function Outcomes
    Location: Hall B2

    Presenter: James Chow, MBChB – Queen Elizabeth Hospital

  • 10:30 AM – 11:45 AM PT
    3255 - Oral Cavity Squamous Cell Carcinomas in Patients with a History of Oral Lichen Planus: Frequency and Outcomes
    Location: Hall B2

    Presenter: Samantha Cook, BS

  • 10:30 AM – 11:45 AM PT
    3256 - Characteristics of Premature Radiotherapy Terminations in Patients with Oral Cavity and Laryngeal Carcinomas
    Location: Hall B2

    Presenter: Dylan Cooper, BA – Zucker School of Medicine at Hofstra/Northwell

  • 10:30 AM – 11:45 AM PT
    3257 - Assessing the Compliance and Accuracy of a National Australian Head and Neck Cancer (HNC) Database
    Location: Hall B2

    Presenter: June Corry, MD – GenesisCare

  • 10:30 AM – 11:45 AM PT
    3258 - Racial Disparities in Survival of Patients with High-Risk LA SCCHN in the U.S.
    Location: Hall B2

    Presenter: David Fox, MS, PharmD – Genentech

  • 10:30 AM – 11:45 AM PT
    3259 - Use of Postoperative PET/CT in Altering Management in Adjuvant Head and Neck Radiation Therapy
    Location: Hall B2

    Presenter: Patrick Courtney, MD, MAS – UCLA David Geffen School of Medicine/UCLA Medical Center

  • 10:30 AM – 11:45 AM PT
    3260 - Financial Implications of Evolving Breast Cancer Radiotherapy Treatment Protocols
    Location: Hall B2

    Presenter: Daniel Coyle, MB, ChB, BAO – Beaumont Hospital Dublin

  • 10:30 AM – 11:45 AM PT
    3261 - Evolution of the MOMENTUM Study for Evidence-Based Implementation of MR-Guided Radiotherapy Using the 1.5 Tesla MR-Linac
    Location: Hall B2

    Presenter: Lois Daamen, MD, PhD – UMC Utrecht

  • 10:30 AM – 11:45 AM PT
    3262 - Definitive Chemoradiation with Concurrent Carboplatin and Paclitaxel for HPV-Mediated Oropharyngeal Cancer (p16+ OPSCC): Survival and Local Control
    Location: Hall B2

    Presenter: Kaleb Darrow, MD – Vanderbilt University Medical Center

  • 10:30 AM – 11:45 AM PT
    3263 - Stereotactic Body Radiotherapy in Latin America: Real-World Evidence of Health Outcomes
    Location: Hall B2

    Presenter: M. Dolores De La Mata Moya, MD, PhD, MBA – Centro Medico ABC

  • 10:30 AM – 11:45 AM PT
    3264 - Is 80 the New 70? Octogenarians with Oropharyngeal Squamous Cell Carcinoma
    Location: Hall B2

    Presenter: Daniel Dickstein, MD – Icahn School of Medicine at Mount Sinai

  • 10:30 AM – 11:45 AM PT
    3265 - Cost-Effectiveness of Prophylactic Radiation in Patients with Asymptomatic Bone Metastases
    Location: Hall B2

    Presenter: Anna Dornisch, MD – UC San Diego

  • 10:30 AM – 11:45 AM PT
    3266 - Radiotherapy Quality Indicators in the Pilot Program of the NON in Poland in 2019-2021
    Location: Hall B2

    Presenter: Arkadiusz Drapiewski, MD – Lower Silesian Oncology Center

  • 10:30 AM – 11:45 AM PT
    3267 - Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer
    Location: Hall B2

    Presenter: Stephanie Dudzinski, MD, PhD – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3268 - Carbon Footprint of Photon Therapy
    Location: Hall B2

    Presenter: Tomas Dvorak, MD – Orlando Health

  • 10:30 AM – 11:45 AM PT
    3269 - Unique T-cell Sub-Population Shifts after SBPT and Nivolumab in Platinum Refractory HNC: Biomarker Correlates from ROR1771
    Location: Hall B2

    Presenter: Daniel Ebner, MD, MPH – Mayo Clinic

  • 10:30 AM – 11:45 AM PT
    3270 - Low-Dose Fractionated Radiotherapy Combined with Neoadjuvant Chemotherapy for T3-4 Nasopharyngeal Carcinoma Patients: The Preliminary Results of a Phase II Randomized Controlled Trial
    Location: Hall B2

    Presenter: Mei Feng, MD, PhD – Si Chuan Cancer Hospital

  • 10:30 AM – 11:45 AM PT
    3271 - Long-Term Survival Outcome for Metastatic Nasopharyngeal Carcinoma Patients Receiving Radiation to Primary and Metastatic Sites with Palliative Chemotherapy
    Location: Hall B2

    Presenter: Mei Feng, MD, PhD – Si Chuan Cancer Hospital

  • 10:30 AM – 11:45 AM PT
    3272 - Cervical Cancer Progression in Patients Waiting for Radiotherapy Treatment at A Referral Center in Ethiopia: A Longitudinal Study
    Location: Hall B2

    Presenter: Jilcha Feyisa, MD, MPH – Dartmouth-Hitchcock Medical Center

  • 10:30 AM – 11:45 AM PT
    3273 - Evaluation of Radiotherapy Dose and Survival Outcomes for Teenagers, and Young Adults with Nasopharyngeal Carcinoma in UK and Ireland
    Location: Hall B2

    Presenter: John Gaffney, MD – The Christie NHS Foundation Trust

  • 10:30 AM – 11:45 AM PT
    3274 - Temporal Incidence and Patterns of Distant Failure for Human Papillomavirus (HPV) Related Oropharyngeal Cancer
    Location: Hall B2

    Presenter: John Gaffney, MD – The Christie NHS Foundation Trust

  • 10:30 AM – 11:45 AM PT
    3275 - Definitive and Salvage Radiotherapy Compared to Other Modalities for Laryngeal Carcinoma in Situ
    Location: Hall B2

    Presenter: Ahmed Ghanem, MD, PhD – Henry Ford Cancer Institute/Alexandria University

  • 10:30 AM – 11:45 AM PT
    3276 - Disease Characteristics, Treatment and Survival for Oropharyngeal Squamous Cell Carcinoma of Elderly
    Location: Hall B2

    Presenter: Ahmed Ghanem, MD, PhD – Henry Ford Cancer Institute/Alexandria University

  • 10:30 AM – 11:45 AM PT
    3277 - Treatment Tolerance and Toxicity in Elderly Oropharyngeal Cancer Patients and Implication on Outcomes
    Location: Hall B2

    Presenter: Ahmed Ghanem, MD, PhD – Henry Ford Cancer Institute/Alexandria University

  • 10:30 AM – 11:45 AM PT
    3278 - Quantifying the Travel Undertaken by Cancer Patients Receiving Radiotherapy in Victoria, Australia
    Location: Hall B2

    Presenter: Richard Khor, MBBS – Austin Health

  • 10:30 AM – 11:45 AM PT
    3278 - Quantifying the Travel Undertaken By Cancer Patients Receiving Radiotherapy in Victoria, Australia
    Location: Hall B2

    Presenter: Piers Gillett – University of Melbourne

  • 10:30 AM – 11:45 AM PT
    3279 - Radiation Toxicity Profile Difference in p16+ vs. p16- Oropharyngeal Cancer Patients
    Location: Hall B2

    Presenter: Ronald Goldsberry, BS – Baylor College of Medicine

  • 10:30 AM – 11:45 AM PT
    3280 - Fractionated Stereotactic Radiotherapy in the Management of Dural Recurrence of Olfactory Neuroblastoma
    Location: Hall B2

    Presenter: Christopher Goodman, MD – University of Western Ontario

  • 10:30 AM – 11:45 AM PT
    3281 - Delay in Time to Oncologic Therapies for Patients with Positive COVID-19 Test
    Location: Hall B2

    Presenter: Nicholas Gravbrot, MD – University of Utah Huntsman Cancer Institute

  • 10:30 AM – 11:45 AM PT
    3282 - Hippocampal-Sparing Radiotherapy in Primary Sinonasal and Cutaneous Head and Neck Malignancies: A Feasibility Study
    Location: Hall B2

    Presenter: Jacob Hall, MD – UNC Health

  • 10:30 AM – 11:45 AM PT
    3283 - The Lyman Normal Tissue Complication Probability Model and Risk Prediction for Temporal Lobe Injury after Re-Irradiation in Patients with Recurrent Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Fei Han

  • 10:30 AM – 11:45 AM PT
    3284 - Long-Term Outcomes of Stereotactic Body Radiation Therapy with or without PD-1 Inhibitors in Metastatic Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Jinlan He, MD, MS – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3285 - Impact of Head and Neck Cancer Treatment on CD4 T Cell Decline and Recovery in People with HIV
    Location: Hall B2

    Presenter: Daniel Hicks, MD – Yale New Haven Hospital

  • 10:30 AM – 11:45 AM PT
    3286 - Adjuvant External Beam Radiotherapy and Histopathologic Prognostic Factors in Tall Cell Papillary Thyroid Carcinoma
    Location: Hall B2

    Presenter: Daniel Hong, MD – Washington University in St. Louis

  • 10:30 AM – 11:45 AM PT
    3287 - Prognostic Significance of the Novel Nutrition-Inflammation Marker of Lymphocyte-C-Reactive Protein Ratio in Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Xin Hua, MD

  • 10:30 AM – 11:45 AM PT
    3288 - Standard Therapy vs. Individualized Therapy in Elderly Locally Advanced Nasopharyngeal Carcinoma: A Real-World Study
    Location: Hall B2

    Presenter: Jing Huang, MD

  • 10:30 AM – 11:45 AM PT
    3289 - Radiation-Induced Nasopharyngeal Necrosis in Locally-Recurrent Nasopharyngeal Carcinoma Patients after Re-Radiotherapy
    Location: Hall B2

    Presenter: Runda Huang, PhD, MS, Master of Medicine – Koo Foundation Sun Yat-Sen Cancer Center

  • 10:30 AM – 11:45 AM PT
    3290 - Feasibility of a Keratin-Based Topical Cream for Radiation Dermatitis in Patients with Head and Neck Cancer: Results of a Randomized Pilot Study
    Location: Hall B2

    Presenter: Ryan Hughes, MD – Wake Forest University Baptist Medical Center

  • 10:30 AM – 11:45 AM PT
    3291 - Surgeon, Pathologist and Pathology Technician Effects on Nodal Yield after a Neck Dissection
    Location: Hall B2

    Presenter: Zain Husain, MD – Southern California Permanente Medical Group

  • 10:30 AM – 11:45 AM PT
    3292 - Bridging the Gap of Radiotherapy Treatment Planning Quality between High-Income, and Low- and Middle-Income Countries Using Knowledge-Based Planning
    Location: Hall B2

    Presenter: Milton Ixquiac, MS – Liga Nacional Contra el Cancer

  • 10:30 AM – 11:45 AM PT
    3293 - The Prognostic and Predictive Value of Pre-Treatment Total Lymphocyte Count in HPV+ Oropharyngeal Carcinoma Receiving Definitive (Chemo-) Radiation
    Location: Hall B2

    Presenter: Carlton Johnny, MD – Princess Margaret Cancer Center, University Health Network

  • 10:30 AM – 11:45 AM PT
    3294 - Identifying Key Barriers for Radiation Oncology Financial Advocacy Programs
    Location: Hall B2

    Presenter: Elana Plotkin, BS – Association of Community Cancer Centers

  • 10:30 AM – 11:45 AM PT
    3295 - Disease Control and Toxicity Outcomes after Intraoperative HDR Brachytherapy for Neck Recurrences in Patients Previously Irradiated Head and Neck Cancer
    Location: Hall B2

    Presenter: Julia Khriguian, MD – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3296 - Characterization of Antibody Repertoires in Patients with HPV-Related HNSCC Undergoing Definitive Radiation with Immunotherapy
    Location: Hall B2

    Presenter: Sangwoo Kim, MD – University of California, San Diego

  • 10:30 AM – 11:45 AM PT
    3297 - Stereotactic Body Radiation Therapy (SBRT) for Head and Neck Cancer Re-Irradiation: Should >180° Carotid Encasement or Dermal Involvement Remain an Exclusion Criteria?
    Location: Hall B2

    Presenter: Jenna Kocsis, MD – Cleveland Clinic Taussig Cancer Center

  • 10:30 AM – 11:45 AM PT
    3298 - Radiotherapy Alone vs. Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA Post-Induction Chemotherapy
    Location: Hall B2

    Presenter: Fang Kong, MD – Fudan University Shanghai Cancer Center

  • 10:30 AM – 11:45 AM PT
    3299 - Prognostic Value of Lymph Node-to-Primary Tumor Ratio of PET Standardized Uptake Value for Nasopharyngeal Carcinoma: A Recursive Partitioning Risk Stratification Analysis
    Location: Hall B2

    Presenter: Fang Kong, MD – Fudan University Shanghai Cancer Center

  • 10:30 AM – 11:45 AM PT
    3300 - Outcomes of Patients Treated with Re-Irradiation for Recurrent Head and Neck Cancer Using Pencil Beam Scanning Proton Therapy
    Location: Hall B2

    Presenter: Rebecca Krc, DO – University of Maryland Radiation Oncology

  • 10:30 AM – 11:45 AM PT
    3301 - Using Life Cycle Assessment as a Tool to Evaluate the Environmental Impact of Radiation Oncology and Inform Treatment Decision-Making in Early-Stage Breast Cancer
    Location: Hall B2

    Presenter: Dalia Larios, MD – Harvard Radiation Oncology Program

  • 10:30 AM – 11:45 AM PT
    3302 - Prophylactic vs. Reactive Gastrostomy Tube Placement in Patients Treated with Radiotherapy for Head and Neck Cancer
    Location: Hall B2

    Presenter: Ji Hyae Lee, MD

  • 10:30 AM – 11:45 AM PT
    3303 - Eosinophil Dynamics during Chemo-Radiation Correlate to Clinical Outcome in Stage II-IVA Nasopharyngeal Carcinoma Patients: Results from a Large Cohort Study
    Location: Hall B2

    Presenter: Dan Li, DSc

  • 10:30 AM – 11:45 AM PT
    3304 - Exploring the Clinical Characteristics and Survival of Early-Onset and Late-Onset Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Pian Li, MD

  • 10:30 AM – 11:45 AM PT
    3305 - Study on Lattice Radiotherapy Treatments (LRT) for Head and Neck Bulky Tumors
    Location: Hall B2

    Presenter: Xiongfei Liao, PhD, MS – Sichuan Cancer Hospital

  • 10:30 AM – 11:45 AM PT
    3306 - Impacts of Wildfire Events on California Radiation Oncology Clinics and Patients
    Location: Hall B2

    Presenter: Katie Lichter, MD, MD MPH – University of California San Francisco

  • 10:30 AM – 11:45 AM PT
    3307 - The Environmental Impact of Radiation Oncology: The "Footprint" of External Beam Radiation Therapy
    Location: Hall B2

    Presenter: Katie Lichter, MD, MD MPH – University of California San Francisco

  • 10:30 AM – 11:45 AM PT
    3308 - Automated Contouring of Cervical Lymph Nodes and Clinical Target Volumes for Nasopharyngeal Carcinoma Based on Deep Learning and Experience Constraints
    Location: Hall B2

    Presenter: Li Lin, MD, PhD – Sun Yat-Sen University Cancer Center

  • 10:30 AM – 11:45 AM PT
    3309 - Identification and Automated Delineation of Radioresistant Biological Tumor Volume in Nasopharyngeal Carcinoma Based on Magnetic Resonance Imaging Radiomics
    Location: Hall B2

    Presenter: Li Lin, MD, PhD – Sun Yat-Sen University Cancer Center

  • 10:30 AM – 11:45 AM PT
    3310 - Selectively Irradiation of the Supraclavicular Area in Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
    Location: Hall B2

    Presenter: Shaojun Lin, MD, PhD – Fujian Provincial Cancer Hospital

  • 10:30 AM – 11:45 AM PT
    3311 - Radiopharmaceutical Therapy Practice Patterns Across Medicare Providers: An Opportunity for Growth in Radiation Oncology
    Location: Hall B2

    Presenter: Eulanca Liu, MD, PhD – UCLA Radiation Oncology

  • 10:30 AM – 11:45 AM PT
    3312 - Feasibility of Omitting Contralateral Neck Irradiation in Patients with Node-Negative Sinonasal Squamous Cell Carcinoma Crossing the Midline
    Location: Hall B2

    Presenter: Qian Liu, MD – National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy

  • 10:30 AM – 11:45 AM PT
    3313 - A Phase 2 Trial of Efficacy and Safety of Intraoperative Radiation Therapy for Locally Advanced Laryngocarcinoma
    Location: Hall B2

    Presenter: qingfeng liu, MD – National Cancer Center CAMS & PUMC

  • 10:30 AM – 11:45 AM PT
    3314 - Proposals for the Delineation of Neck Clinical Target Volume Specific to Oral Squamous Cell Cancer Based on Lymph Node Distribution
    Location: Hall B2

    Presenter: Yun-Chang Liu, MD

  • 10:30 AM – 11:45 AM PT
    3315 - Irradiation Dose to the Swallowing Muscles Impacts Nutritional Status in Head and Neck Cancer Patients: The Prospective Randomized HEADNUT Trial
    Location: Hall B2

    Presenter: Anastassia Loeser, MD – University Medical-Center Schleswig-Holstein

  • 10:30 AM – 11:45 AM PT
    3316 - Long Term Clinical Outcomes of a Cohort of Lung-Only Oligometastatic HNSCC Patients Treated with SBRT
    Location: Hall B2

    Presenter: Mauro Loi, MD – Azienda Ospedaliera Universitaria Careggi

  • 10:30 AM – 11:45 AM PT
    3317 - All that Glitters is Not Gold: Examining Cost Effectiveness Analyses in Radiation Oncology
    Location: Hall B2

    Presenter: Alexander Louie, MD, PhD, MSc, FRCPC – Sunnybrook Health Sciences Centre

  • 10:30 AM – 11:45 AM PT
    3318 - Palliative Care as a Component of High Value and Cost-Saving Care During Hospitalization for Metastatic Cancer
    Location: Hall B2

    Presenter: Sifan Lu, BA – SUNY Downstate Health Sciences University

  • 10:30 AM – 11:45 AM PT
    3319 - Refining the TNM M1 Subcategory for De Novo Metastatic Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Tianzhu Lu, MD

  • 10:30 AM – 11:45 AM PT
    3320 - Patient-Family Caregiver Concordance in Assessment of Psychological Distress of Chinese Patients with Head and Neck Cancer during Chemoradiotherapy
    Location: Hall B2

    Presenter: Jianxia Lyu, MS

  • 10:30 AM – 11:45 AM PT
    3321 - Combining Radiotherapy with Chemotherapy and Immunotherapy as First-Line Treatment for De Novo Metastatic Nasopharyngeal Carcinoma: A Dual-Center Retrospective Analysis
    Location: Hall B2

    Presenter: Li Ma, MD

  • 10:30 AM – 11:45 AM PT
    3322 - Optimum Radiation Dose for Palliation in Head and Neck SCC: A Phase III Randomized Controlled Trial (OPRAH)
    Location: Hall B2

    Presenter: Supriya Mallick, MD, MB – All India Institute of Medical Sciences

  • 10:30 AM – 11:45 AM PT
    3323 - Can Advanced Radiotherapy Clinical Trials be Conducted in Resources Limited Countries?
    Location: Hall B2

    Presenter: Wilfred Ngwa, PhD, MS

  • 10:30 AM – 11:45 AM PT
    3324 - Stereotactic Radiotherapy Deserts are Under-Represented among Radiation Oncology Alternative Payment Model Sites
    Location: Hall B2

    Presenter: Erin McCammack, MD, MBA – University of Minnesota

  • 10:30 AM – 11:45 AM PT
    3325 - Tailoring Radiation to the Contralateral Neck for Midline HPV-Mediated Oropharyngeal Squamous Cell Carcinoma (p16+ OPSCC)
    Location: Hall B2

    Presenter: Kyra McComas, MD – Vanderbilt University Medical Center

  • 10:30 AM – 11:45 AM PT
    3326 - Are Different Modes of Weight Loss Associated with Survival in Oropharyngeal Cancer?
    Location: Hall B2

    Presenter: Donal McSweeney, PhD, MS – The University of Manchester

  • 10:30 AM – 11:45 AM PT
    3327 - The Feasibility of Level Ib Sparing Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma Patients with High-Risk Factors: Based on International Guideline
    Location: Hall B2

    Presenter: Zhen Meng

  • 10:30 AM – 11:45 AM PT
    3328 - Prospective Evaluation of Locoregional Control In Oral Cavity Squamous Cell Carcinoma With Infratemporal Fossa Involvement Treated With Surgery And Adjuvant Concurrent Chemoradiotherapy
    Location: Hall B2

    Presenter: Prasoon Mishra, MBBS – Dr Ram Manohar Lohia Institute of Medical Sciences

  • 10:30 AM – 11:45 AM PT
    3329 - Radiotherapy (RT) for Cutaneous Adnexal Carcinoma (CAC): 49 Patients Treated at a Single Institution Over 2 Decades
    Location: Hall B2

    Presenter: Nader Mohamed – SUNY Downstate College of Medicine

  • 10:30 AM – 11:45 AM PT
    3330 - Comparison of Standard vs. Relative Risk Models to Define Candidates for Deintensification in Locoregionally Advanced P16+ Oropharyngeal Cancer
    Location: Hall B2

    Presenter: Ryan Morse, MD – University of North Carolina at Chapel Hill

  • 10:30 AM – 11:45 AM PT
    3331 - Effects of Comprehensive Geriatric Assessment (CGA) Guided Care vs. Usual Care on Overall Survival (OS) and Health-Related Quality of Life (HRQL) for Older Adults with Cancer: A Systematic Review of R
    Location: Hall B2

    Presenter: Zhi Xuan Ng, MBBS – National University Cancer Institute Singapore

  • 10:30 AM – 11:45 AM PT
    3332 - Impact of Outside Referral and Dental Extractions on Package Time With Postoperative Radiation Therapy for Head and Neck Cancer
    Location: Hall B2

    Presenter: Joseph Nguyen, BS – University of Virginia School of Medicine

  • 10:30 AM – 11:45 AM PT
    3333 - Acute and Late Toxicities in Patients with Collagen Vascular Disease Receiving Curative-Intent Intensity-Modulated Radiotherapy to the Head and Neck Region
    Location: Hall B2

    Presenter: Lisa Ni, MD – University of California San Francisco

  • 10:30 AM – 11:45 AM PT
    3334 - Treatment Outcomes of Concurrent Nimotuzumab with Intensity Modulated Radiotherapy in Advanced Nasopharyngeal Carcinoma Patients Unfit for Concurrent Chemoradiotherapy: A Single Institute Experience
    Location: Hall B2

    Presenter: Weiqiong Ni, MD, MS

  • 10:30 AM – 11:45 AM PT
    3335 - An Analysis of Delays in Treatment Time for Prostate Cancer Patients in Sub-Saharan Africa
    Location: Hall B2

    Presenter: Elizabeth Olatunji, BS, MPhil – Johns Hopkins Medicine

  • 10:30 AM – 11:45 AM PT
    3336 - A Novel Multi-Objective Based Feature Selection Method for Response Prediction
    Location: Hall B2

    Presenter: Xiaoying Pan, PhD

  • 10:30 AM – 11:45 AM PT
    3337 - An Adaptive Multi-Feature Fusion Network for Predicting Overall Survival of Patients with Head and Neck Cancer
    Location: Hall B2

    Presenter: Xiaoying Pan, PhD

  • 10:30 AM – 11:45 AM PT
    3338 - Impact of the COVID-19 Pandemic on Brachytherapy and Cancer Patient Outcomes: A Systematic Review
    Location: Hall B2

    Presenter: Shreel Parikh, DO, MS – CINJ/RWJ

  • 10:30 AM – 11:45 AM PT
    3339 - Health Equity Achievement in Radiation Therapy (HEART) Score: A Social Prognosis
    Location: Hall B2

    Presenter: Akshat Patel, MD, BA – Memorial Sloan Kettering Cancer Center

  • 10:30 AM – 11:45 AM PT
    3340 - Expanding Radiotherapy Access in Sub-Saharan Africa: An Analysis of Travel Burdens and Patient-Related Benefits of Hypofractionation
    Location: Hall B2

    Presenter: Saloni Patel, BS – Johns Hopkins Medicine

  • 10:30 AM – 11:45 AM PT
    3341 - Trends in Utilization and Medicare Spending on Shorter vs. Longer Radiotherapy Courses for Breast and Prostate Cancer
    Location: Hall B2

    Presenter: Tej Patel, BS – University of Pennsylvania

  • 10:30 AM – 11:45 AM PT
    3342 - Evaluating Childcare Support in NCI Designated Cancer Centers for Patients with Young Children Undergoing Treatment
    Location: Hall B2

    Presenter: Sonile Peck, BS – University of Florida Proton Therapy Institute

  • 10:30 AM – 11:45 AM PT
    3343 - Mitigation of Dosimetric Uncertainty in MRI-Based Proton Planning Using Spot-Scanning Proton Arc (SPArc) Technique
    Location: Hall B2

    Presenter: Yinglin Peng, PhD – Sun Yat-Sen University Cancer Center

  • 10:30 AM – 11:45 AM PT
    3344 - Predicting Acute Radio-Induced Toxicity for Head and Neck Cancer Patients: Combining Dosimetry with Biomarker Data, Disclosing a Synergistic Effect
    Location: Hall B2

    Presenter: Tiziana Rancati, MS – Fondazione IRCCS - Istituto Nazionale dei Tumori

  • 10:30 AM – 11:45 AM PT
    3345 - The Effect of Package Time on Locally Advanced Oral Cavity Cancer Outcomes
    Location: Hall B2

    Presenter: Taylor Petery, BS, BA – University of Cincinnati College of Medicine

  • 10:30 AM – 11:45 AM PT
    3346 - Toxicity and Dosimetric Analysis of Reirradiation of Head and Neck Cancers with High Dose Rate Brachytherapy
    Location: Hall B2

    Presenter: Christina Phuong, MD – UCSF Dept Radiation Oncology

  • 10:30 AM – 11:45 AM PT
    3347 - Beneficial Role of Multi-Disciplinary Treatment for Anaplastic Thyroid Cancer with Initial Distant Metastasis
    Location: Hall B2

    Presenter: Ji Hoon Pyo, MD – Yonsei Cancer Center Yonsei College of Medicine

  • 10:30 AM – 11:45 AM PT
    3348 - Nomogram to Predict Risk of Early Mortality Following Definitive or Adjuvant Radiation and Systemic Therapy for Head and Neck Cancer
    Location: Hall B2

    Presenter: Gabriel Raab, MD – Weill Cornell Medicine/New York Presbyterian

  • 10:30 AM – 11:45 AM PT
    3348 - Nomogram to Predict Risk of Early Mortality Following Definitive or Adjuvant Radiation and Systemic Therapy for Head and Neck Cancer
    Location: Hall B2

    Presenter: Kaveh Zakeri, MD, MAS – Memorial Sloan Kettering Cancer Center

  • 10:30 AM – 11:45 AM PT
    3349 - Definitive Chemoradiotherapy for Salivary Gland Cancers
    Location: Hall B2

    Presenter: Greeshma Rajeev-Kumar, MD – University of Chicago Medicine

  • 10:30 AM – 11:45 AM PT
    3350 - A Systematic Review and Meta-Analysis of Toxicity in Oropharyngeal Cancer Patients Treated with Proton Therapy
    Location: Hall B2

    Presenter: Niema Razavian, MD – Wake Forest School of Medicine

  • 10:30 AM – 11:45 AM PT
    3351 - Secondary Analysis of RRx-001 on the Incidence of Related Toxicities in Patients Treated with Concomitant Chemoradiation for Locally Advanced Head and Neck Cancer
    Location: Hall B2

    Presenter: Tony Reid

  • 10:30 AM – 11:45 AM PT
    3352 - A Multicenter Study of Clinician and Patient Reported Acute and Late Toxicity after Radical (Chemo)Radiotherapy for Non-Endemic Nasopharyngeal Cancer
    Location: Hall B2

    Presenter: Romelie Rieu, FRCR MSc – The Royal Marsden Hospital

  • 10:30 AM – 11:45 AM PT
    3353 - MRI, FDG-PET/CT and Image-Guidance for Re-Irradiation of Locoregionally Recurrent or Second Primary Head-and-Neck Squamous Cell Carcinoma Patients - Results of a Multicenter Cohort Study
    Location: Hall B2

    Presenter: Alexander Ruhle, MD – University of Leipzig, Medical Center

  • 10:30 AM – 11:45 AM PT
    3354 - Combined Pulsed Radiotherapy ("QUAD SHOT" regimen) with Immune Checkpoint Inhibition (ICI) to Enhance Immune Response for LAHNSCC in Patients Considered Ineligible for Curative Intent Therapy
    Location: Hall B2

    Presenter: Olga Russial, DO, MBA – Thomas Jefferson University

  • 10:30 AM – 11:45 AM PT
    3355 - Outcomes of Head and Neck Cutaneous Angiosarcoma Treated in the IMRT Era
    Location: Hall B2

    Presenter: Saheli Saha, MD – Tata Medical Center

  • 10:30 AM – 11:45 AM PT
    3356 - Multi-Specialty Physician Performance in Predicting Radiographic Extranodal Extension in Nodal Metastases of Oropharyngeal Squamous Carcinoma
    Location: Hall B2

    Presenter: Onur Sahin, PhD, MS – McGovern Medical School

  • 10:30 AM – 11:45 AM PT
    3357 - Comparison of the Direct Power Consumption for Different Linac Treatment Parameters in External Beam Radiation Therapy
    Location: Hall B2

    Presenter: Jessica Salazar, PhD, MBA – Orlando Health Cancer Institute

  • 10:30 AM – 11:45 AM PT
    3357 - Comparison of the Direct Power Consumption for Different Linac Treatment Parameters in External Beam Radiation Therapy
    Location: Hall B2

    Presenter: Tomas Dvorak, MD – Orlando Health

  • 10:30 AM – 11:45 AM PT
    3358 - Initial Clinical Experience Using Daily Artificial Intelligence-Assisted Adaptive Radiotherapy on Cone-Beam CT for Cancer of the Head and Neck
    Location: Hall B2

    Presenter: Ayman Salhab, MD – Hadassah Medical Center

  • 10:30 AM – 11:45 AM PT
    3359 - Analysis of the Cancer Imaging Archive for Patterns of Locoregional Failure in Relation to the Mucous Membranes among Patients with Head and Neck Squamous Cell Carcinoma: Potential Organ at Risk that
    Location: Hall B2

    Presenter: Santanu Samanta, MD – University of Arkansas for Medical Sciences (UAMS)

  • 10:30 AM – 11:45 AM PT
    3360 - Automated Sarcopenia Assessment and Outcomes in Head and Neck Cancer with Deep Learning Analysis of Cervical Neck Skeletal Muscle
    Location: Hall B2

    Presenter: Anurag Saraf, MD – Brigham and Women's Hospital/Dana-Farber

  • 10:30 AM – 11:45 AM PT
    3361 - A Pilot Study of Head and Neck Cancer Patients Treated Daily with an Intraoral Photobiomodulation (PBM) Device while Undergoing IMRT Demonstrates Tolerability, Safety, and Preliminary Efficacy for Red
    Location: Hall B2

    Presenter: Catherine Holtzapfel, MSN – St. Elizabeth Medical Center

  • 10:30 AM – 11:45 AM PT
    3362 - Impact of Surveillance Imaging in Patients with HPV-Associated Oropharyngeal Carcinomas Treated with Definitive Radiation and Chemotherapy
    Location: Hall B2

    Presenter: Trisha Shang, BA – Memorial Sloan Kettering Cancer Center

  • 10:30 AM – 11:45 AM PT
    3363 - Potential Predictive Value of Intravoxel Incoherent Motion Magnetic Resonance for Xerostomia of Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Mingjun Shen, MS

  • 10:30 AM – 11:45 AM PT
    3364 - Environmental Toxicity of Driving Distance to External Beam Radiotherapy (EBRT) for Head and Neck Cancer Patients
    Location: Hall B2

    Presenter: Rachel Shenker, MD – Duke University Hospital

  • 10:30 AM – 11:45 AM PT
    3365 - Distance Traveled by Patients Globally to Access Radiotherapy: A Systematic Review
    Location: Hall B2

    Presenter: Sierra Silverwood, BS – Michigan State University College of Human Medicine

  • 10:30 AM – 11:45 AM PT
    3366 - The Role of Stereotactic Radiotherapy in Deferring the Need for Systemic Therapies in Patients with Progressive Oligometastatic Iodine-Refractory Thyroid Cancer
    Location: Hall B2

    Presenter: Gabriele Simontacchi, MD – Aou Careggi

  • 10:30 AM – 11:45 AM PT
    3367 - Prognostic Value of Depth of Invasion in Squamous Cell Carcinoma of the Oral Cavity of Size 4 cm or Less
    Location: Hall B2

    Presenter: Jun Yeong Song, BS – Seoul National University Hospital

  • 10:30 AM – 11:45 AM PT
    3368 - Rising Gas Prices & Financial Toxicity Related to Radiation Treatment
    Location: Hall B2

    Presenter: Rui Song, MD – SUNY Upstate

  • 10:30 AM – 11:45 AM PT
    3369 - Trends in the Utilization and Outcomes of Brachytherapy vs. Proton Therapy in Localized Uveal Melanoma in the United States
    Location: Hall B2

    Presenter: Tamer Soror, MD – University of Luebeck

  • 10:30 AM – 11:45 AM PT
    3370 - Plasma EBV DNA in Nasopharyngeal Cancer (NPC) Treated with Definitive Radiotherapy (RT)
    Location: Hall B2

    Presenter: Eric Stutheit-Zhao, MD, PhD – Princess Margaret Cancer Centre

  • 10:30 AM – 11:45 AM PT
    3371 - Use of Explainable AI Algorithm Revealing Longitudinal Changes in Practice Patterns and Toxicity Models
    Location: Hall B2

    Presenter: Shiqin Su, PhD – University of Michigan

  • 10:30 AM – 11:45 AM PT
    3372 - Patient Impressions of Telemedicine in Radiation Oncology
    Location: Hall B2

    Presenter: Wasif Talpur, MD – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3373 - Determining the Optimal Sequence of Immunotherapy and Lymph Node Irradiation among Patients with Cancer: A Propensity Score Matched Analysis
    Location: Hall B2

    Presenter: Kekoa Taparra, MD, PhD – Stanford Health Care

  • 10:30 AM – 11:45 AM PT
    3374 - The Role of Radiomics Model to Predict Early Xerostomia in Head and Neck Cancer after Radiotherapy
    Location: Hall B2

    Presenter: Meysam Tavakoli, PhD – UPMC Hillman Cancer Center

  • 10:30 AM – 11:45 AM PT
    3375 - Investigation of Ensemble Learning Method in Predicting Early Xerostomia Using Radiomics Features from CT and MRI
    Location: Hall B2

    Presenter: Meysam Tavakoli, PhD – UPMC Hillman Cancer Center

  • 10:30 AM – 11:45 AM PT
    3376 - Prevalence and Risk Factors for Retropharyngeal and Retro-Styloid Lymph Node Metastasis in Hypopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Ryo Toya, MD, PhD – Nagasaki University

  • 10:30 AM – 11:45 AM PT
    3377 - Reducing the Risk of Post-RT Aspiration by Sparing Specific Aspiration Related Organs at Risk
    Location: Hall B2

    Presenter: Hans Paul van der Laan, PhD – University of Groningen Medical Center

  • 10:30 AM – 11:45 AM PT
    3378 - Deep Learning Based Prognostic Prediction in Oropharyngeal Cancer Patients Using Multiparametric MRI Inputs
    Location: Hall B2

    Presenter: Mohamed Naser, PhD – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3378 - Deep Learning Based Prognostic Prediction in Oropharyngeal Cancer Patients Using Multiparametric MRI Inputs
    Location: Hall B2

    Presenter: Kareem Wahid, PhD, BS – MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3379 - Paging Dr. Google: Characterizing Direct to Consumer Internet Advertisements from Oncology Treatment Centers
    Location: Hall B2

    Presenter: Gary Walker, MD, MS, MPH – Banner MD Anderson Cancer Center

  • 10:30 AM – 11:45 AM PT
    3380 - Comparison and Breakdown of Cost in Head and Neck Cancer Radiation Therapy and Adaptive Replanning
    Location: Hall B2

    Presenter: Robert Walls, BSE – University of Virginia School of Medicine

  • 10:30 AM – 11:45 AM PT
    3381 - Distribution Pattern of Metastatic Lymph Nodes in 870 Cases of Nasopharyngeal Carcinoma: A Clue for Individualized Elective Prophylactic Neck Irradiation
    Location: Hall B2

    Presenter: Lei Wang, MD

  • 10:30 AM – 11:45 AM PT
    3382 - Weekly vs. Bolus Cisplatin Concurrent with Definitive Radiotherapy for Squamous Carcinoma of the Head and Neck: A Systematic Review and Network Meta-Analysis
    Location: Hall B2

    Presenter: Matthew Ward, MD – Levine Cancer Institute

  • 10:30 AM – 11:45 AM PT
    3383 - The Profile of the Oncological Refugee Patient from Ukraine ? Single Institution Experience
    Location: Hall B2

    Presenter: Natalia Wisniewska, MD – Lower Silesian Oncology Center

  • 10:30 AM – 11:45 AM PT
    3384 - Cross-Sectional Muscle Area Change in Head and Neck Magnetic Resonance Imaging Defined Sarcopenic State and Survival in Nasopharyngeal Cancer Patients
    Location: Hall B2

    Presenter: Jeng-You Wu, MD, MBA – Taipei Municipal WanFang Hospital

  • 10:30 AM – 11:45 AM PT
    3385 - Insurance Plan Coverage Modeling of the Marginal Costs from One Week vs. Three Week Radiation Therapy in Standard-Of-Care Treatment of Post-Lumpectomy Early-Stage Breast Cancer Across Medicaid and Med
    Location: Hall B2

    Presenter: Victoria Wu, BA – Case Western Reserve School of Medicine

  • 10:30 AM – 11:45 AM PT
    3386 - Occult Lymph Node Metastasis in cN0 Tongue Squamous Cell Carcinoma: A Prospective Observational Study
    Location: Hall B2

    Presenter: Zheng Wu, MD

  • 10:30 AM – 11:45 AM PT
    3387 - The Short-Term Efficacy and Safety of Induction Chemotherapy Combined with PD-1 Inhibitor or Anti-EGFR in Locoregionally Advanced Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Xiaoyong Xiang, MD

  • 10:30 AM – 11:45 AM PT
    3388 - Cost Analysis of MR-Guided vs. CT-Guided Radiation Therapy for Locally Advanced Pancreatic Cancer
    Location: Hall B2

    Presenter: Amulya Yalamanchili, MD – McGaw Medical Center of Northwestern University

  • 10:30 AM – 11:45 AM PT
    3389 - Dosimetric Benefits of Online Adaptive Radiotherapy in Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Yu-Xian Yang, MD – Sun Yat-Sen University Cancer Center

  • 10:30 AM – 11:45 AM PT
    3390 - Projected Lifetime Earnings of a Radiation Oncologist
    Location: Hall B2

    Presenter: Nicholas Zaorsky, MD, MS – University Hospitals Case Medical Center

  • 10:30 AM – 11:45 AM PT
    3391 - All-in-One Online Radiotherapy for Nasopharyngeal Carcinoma: Preliminary Results of Treatment Time, Contouring Accuracy, Treatment Plan Quality and Patient Compliance
    Location: Hall B2

    Presenter: Guan-Qun Zhou, PhD – Sun Yat-Sen University Cancer Center

  • 10:30 AM – 11:45 AM PT
    3392 - Real-World Treatment Patterns of Older Adults with Locally Advanced SCCHN Using SEER-Medicare
    Location: Hall B2

    Presenter: David Fox, MS, PharmD – Genentech

  • 12:30 PM – 1:45 PM PT
    3393 - Feasibility and Clinical Implementation of Electron FLASH Radiation Therapy in the Yorkshire Swine Model
    Location: Hall B2

    Presenter: Chike Abana, MD, PhD – The University of Texas M.D. Anderson Cancer Center

  • 12:30 PM – 1:45 PM PT
    3394 - Multimodality Dosimetric Evaluation for the Treatment of Recurrent Brain Tumors
    Location: Hall B2

    Presenter: Ala Amini, MS – University Hospitals

  • 12:30 PM – 1:45 PM PT
    3395 - Patient-Specific Deep Learning Auto-Segmentation for MR-Guided Adaptive Radiotherapy of Prostate Cancer
    Location: Hall B2

    Presenter: Asma Amjad, PhD – Medical College of Wisconsin

  • 12:30 PM – 1:45 PM PT
    3396 - Radiosensitizer-Releasing Fiducial Nanofiducial: A New Concept in Radiotherapy
    Location: Hall B2

    Presenter: Ipek Pınar Aral, MD – Ankara Ataturk Chest Diseases, Chest Surgery Training and Research Hospital

  • 12:30 PM – 1:45 PM PT
    3397 - Technical Infrastructure for Clinical Translation of Electron FLASH
    Location: Hall B2

    Presenter: Muhammad Ramish Ashraf, PhD – Stanford Radiation Oncology

  • 12:30 PM – 1:45 PM PT
    3398 - Target Re-Delineation in Daily Online Adaptive Radiotherapy of Bladder Cancer: AI vs. Adapters
    Location: Hall B2

    Presenter: Lina Åström, MS

  • 12:30 PM – 1:45 PM PT
    3399 - The Effect of Deep Inspiration Breath-Hold Technique on Right Coronary Artery, Heart, and Liver Doses in Right Breast Cancer Radiotherapy
    Location: Hall B2

    Presenter: Barbaros Aydin, MD

  • 12:30 PM – 1:45 PM PT
    3400 - Knowledge Based Planning Evolution: Multi-Criteria Optimization of Prostates. Is There Always a Better Model?
    Location: Hall B2

    Presenter: Laura Baker, CMD, RT – Northern Sydney Cancer Centre - Royal North Shore Hospital

  • 12:30 PM – 1:45 PM PT
    3401 - Evaluation of Daily Patient Position Accuracy and Calculation of Setup Errors with Skin Markers and Surface-Guided Radiotherapy (SGRT) in Breast Cancer
    Location: Hall B2

    Presenter: Gizem Bakıcıerler

  • 12:30 PM – 1:45 PM PT
    3402 - Evaluation of Plan Quality and Complexity for Automated Intracranial SBRT VMAT Treatment Plans
    Location: Hall B2

    Presenter: Garrett Baltz, MS – Scripps MD Anderson Cancer Center, John J. Hopkins

  • 12:30 PM – 1:45 PM PT
    3403 - Assessing Displacement of Plastic Interstitial Catheters in Image-Guided Gynecological HDR Brachytherapy
    Location: Hall B2

    Presenter: Michael Campbell, MS – Long Beach Memorial Medical Center

  • 12:30 PM – 1:45 PM PT
    3404 - Equivalent Uniform Dose (EUD) and the Evaluation of Cell Survival in Spatially Fractionated Radiotherapy (SFRT)
    Location: Hall B2

    Presenter: Stefan Bartzsch, PhD

  • 12:30 PM – 1:45 PM PT
    3405 - Dosimetric Analysis of Patients Treated with Stereotactic Body Radiation Therapy for Malignant Portal Vein Tumor Thrombosis Using MRI-Guided vs. CT-Guided Linear Accelerator
    Location: Hall B2

    Presenter: Hanna Batchelor, BS – University of Virginia

  • 12:30 PM – 1:45 PM PT
    3406 - Clinical Feasibility of Daily Online Adaptive Bladder Cancer Radiotherapy with Cone Beam CT, Using Fiducial Makers
    Location: Hall B2

    Presenter: Arjan Bel, PhD – Amsterdam University Medical Center (AUMC)

  • 12:30 PM – 1:45 PM PT
    3407 - Dosimetry Validation of MR-Only Treatment Planning Based upon the Synthetic MRCAT Pelvis with Continuous Hounsfield Units in Prostate Cancer
    Location: Hall B2

    Presenter: Maoz Benayun, PhD – Sheba Medical Center

  • 12:30 PM – 1:45 PM PT
    3408 - Comparison of Dynamic Trajectory Radiotherapy and Volumetric Modulated Arc Therapy for Loco-Regionally Advanced Oropharyngeal Cancer
    Location: Hall B2

    Presenter: Jenny Bertholet, PhD – Inselspital Bern University Hospital

  • 12:30 PM – 1:45 PM PT
    3409 - Intra Fraction Organs at Risk Movements in Adaptive Radiotherapy of Upper-Abdominal Stereotactic Body Radiotherapy on 0.35 T MR-Linac
    Location: Hall B1

    Presenter: Igor Bessieres, PhD – Centre Georges-Francois Leclerc

  • 12:30 PM – 1:45 PM PT
    3409 - Intra Fraction Organs at Risk Movements in Adaptive Radiotherapy of Upper-Abdominal Stereotactic Body Radiotherapy on 0.35 T MR-Linac
    Location: Hall B2

    Presenter: Alexandre Beige, MD РCentre Georges Fran̤ois LECLERC

  • 12:30 PM – 1:45 PM PT
    3410 - Computed Tomography-Based Delta-Radiomics for Early Prediction of Short-Term Response to Concurrent Chemoradiotherapy in Patients with NSCLC
    Location: Hall B2

    Presenter: Jianping Bi, MD, PhD – Hubei Cancer Hospital

  • 12:30 PM – 1:45 PM PT
    3411 - EPIDEEP: Using a Deep Learning Model to Predict In Vivo Electronic Portal Imaging Device (EPID) Transit Images
    Location: Hall B2

    Presenter: Casey Bojechko, PhD – University of California San Diego

  • 12:30 PM – 1:45 PM PT
    3412 - Robustness Analysis of Reference Surfaces for Surface Guided Radiation Therapy of the Breast
    Location: Hall B2

    Presenter: Victoria Bry, PhD – University of Washington

  • 12:30 PM – 1:45 PM PT
    3413 - A Free, Open-Source Toolkit to Produce 3D Bolus in the Clinic
    Location: Hall B2

    Presenter: Courtney Buckey, PhD – Mayo Clinic Arizona

  • 12:30 PM – 1:45 PM PT
    3414 - Defining the Role of Intensity Modulation in Electron Conformal Therapy for the Treatment of Head and Neck Cancer
    Location: Hall B2

    Presenter: Jonathan Cabrera, MS – Montefiore Einstein Cancer Center

  • 12:30 PM – 1:45 PM PT
    3415 - Towards Biology-Guided Radiotherapy Planning and Delivery on a Novel O-Ring PET-Linac Platform: Extended Beyond Bone and Lung Lesions
    Location: Hall B2

    Presenter: Bin Cai, PhD – University of Texas Southwestern Medical Center

  • 12:30 PM – 1:45 PM PT
    3416 - Evaluation of Patient-Specific Quality Control (QC) for Markerless Dynamic Tumor Tracking (MDTT) Deliveries
    Location: Hall B2

    Presenter: Marie-Laure Camborde, MSc – BC Cancer - Vancouver Centre

  • 12:30 PM – 1:45 PM PT
    3418 - Parametric Response Mapping of Co-Registered Ivim MRI and PET to Identify Radioresistant Sub-Volumes in Locally Advanced Cervical Carcinoma Undergoing CCRT
    Location: Hall B2

    Presenter: Dante Capaldi, PhD – UCSF

  • 12:30 PM – 1:45 PM PT
    3419 - New Advantage in Stereotactic Treatment of Lung and Pancreatic Cancer. Performance of Ultra-High Energy Electron (VHEE) Therapy Adjuvanted to the FLASH Effect: Clinical Implications and Treatment Plan
    Location: Hall B2

    Presenter: Daniele Carlotti, MD, PhD – Universita di Roma Sapienza

  • 12:30 PM – 1:45 PM PT
    3420 - Estimating Potential Benefits of Online Adaptive Proton Therapy for Head-and-Neck Cancer: A Retrospective Study
    Location: Hall B2

    Presenter: Chih-Wei Chang, PhD – Emory University

  • 12:30 PM – 1:45 PM PT
    3421 - Development of the Independent Dose Verification Method for the Ring Gantry PET/CT Linac
    Location: Hall B2

    Presenter: Jina Chang, PhD – University of Pittsburgh Medical Center

  • 12:30 PM – 1:45 PM PT
    3422 - Daily Head and Neck Treatment Assessment for Optimal Proton Planning Robustness
    Location: Hall B2

    Presenter: Leslie Chang, MD – Johns Hopkins University

  • 12:30 PM – 1:45 PM PT
    3423 - Use of Radiomics to Predict Treatment Response in CNS, Head, Neck and Lung Tumors
    Location: Hall B2

    Presenter: Yhana Chavis, DO – University of Virginia Health Systems

  • 12:30 PM – 1:45 PM PT
    3424 - Dosimetric Analysis of Proton Beam Therapy vs. Photon Radiotherapy for Cardiac Tumors with or without Deep Inspiratory Breath Holding: A Case Report
    Location: Hall B2

    Presenter: DongJie Chen, MM

  • 12:30 PM – 1:45 PM PT
    3426 - Improving Interfraction Robustness for IMPT Treatment Planning for Lung Cancer Using Multiple-CT Incorporated Robust Optimization
    Location: Hall B2

    Presenter: Mei Chen, MS – Shanghai Jiao Tong University

  • 12:30 PM – 1:45 PM PT
    3427 - Artificial Intelligence-Assisted Automated Applicator Digitization for Fully-Automated Gynecological High-Dose Rate Brachytherapy Treatment Planning
    Location: Hall B2

    Presenter: Samuel Chen, MD – University of Cincinnati Medical Center/College of Medicine

  • 12:30 PM – 1:45 PM PT
    3428 - Deep Learning-Based Dose Prediction Model for Automated Spot-Scanning Proton Arc Planning
    Location: Hall B2

    Presenter: Shupeng Chen, PhD – Corewell Health William Beaumont University Hospital

  • 12:30 PM – 1:45 PM PT
    3429 - Tumor Treatment Response Assessed During the Concurrent Chemoradiotherapy for Nasopharyngeal Patients
    Location: Hall B2

    Presenter: Xiao Qiang Chen, PhD – West China Hospital of Sichuan University

  • 12:30 PM – 1:45 PM PT
    3430 - A Comparison of Two Plan Optimization Methods in Three-Dimensional Brachytherapy for Cervical Cancer
    Location: Hall B2

    Presenter: Yazheng Chen, PhD – West China Second University Hospital

  • 12:30 PM – 1:45 PM PT
    3432 - The Robotic System for the Treatment of Locally Advanced Cervical Cancer with Stereotactic Body Radiotherapy Boost: Results of a Phantom-Based and Preliminary Study
    Location: Hall B2

    Presenter: Yuangui Chen, MD, PhD

  • 12:30 PM – 1:45 PM PT
    3433 - Relationship Between Spatial Distribution Tumor Location and Dosimetric Outcomes in Patients Receiving Definitive Proton Therapy for Locally Advanced Lung Cancer
    Location: Hall B2

    Presenter: Hua-Ren Cherng, MD – University of Maryland Medical Center

  • 12:30 PM – 1:45 PM PT
    3434 - Radio-Immune Response of Spatially Fractionated Radiotherapy for VMAT Lattice Plans
    Location: Hall B2

    Presenter: Young-Bin Cho, PhD – Cleveland Clinic

  • 12:30 PM – 1:45 PM PT
    3435 - Radio-Immune Response Model for Radiotherapy Plans with Heterogeneous Dose Distribution
    Location: Hall B2

    Presenter: Young-Bin Cho, PhD – Cleveland Clinic

  • 12:30 PM – 1:45 PM PT
    3436 - Development of Novel Focal Irradiation Tool for High-Precision Irradiation Using Clinical Brachytherapy System
    Location: Hall B2

    Presenter: Chang Heon Choi, PhD – Seoul National University Hospital

  • 12:30 PM – 1:45 PM PT
    3437 - Clinical Feasibility of Deep Learning-Based CT during Treatment CBCT Tumor Registration-Segmentation in Thoracic Radiotherapy (RT)
    Location: Hall B2

    Presenter: Chloe Choi, MS – Memorial Sloan Kettering Cancer Center

  • 12:30 PM – 1:45 PM PT
    3438 - Determining the Dosimetric Accuracy of Deep Learning-Based Fully Automated Registration-Segmentation Approach for Thoracic Cancer Organs-at-Risk Contouring
    Location: Hall B2

    Presenter: Chloe Choi, MS – Memorial Sloan Kettering Cancer Center

  • 12:30 PM – 1:45 PM PT
    3439 - Assessment of Bladder Filling Type on Radiation Dose to Organs at Risk in MR-Guided Intracavity Brachytherapy for Cervical Cancer
    Location: Hall B2

    Presenter: Euncheol Choi, MD, MS – Keimyung University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3440 - The Effect of Filament Density on the Build-Up Region Responsiveness of 3D Printed Boluses in High-Energy Photon Radiotherapy
    Location: Hall B2

    Presenter: Andreea Ciobanu, PhD – Ovidius Clinical Hospital

  • 12:30 PM – 1:45 PM PT
    3441 - Application of a Novel Methodology for Efficient Optimization of Hippocampal Avoidance Whole-Brain Radiotherapy
    Location: Hall B2

    Presenter: Ruth Dadush Azuz, MSc – Davidoff Cancer Center, Rabin Medical Center – Beilinson Hospital, Petach Tikva, Israel

  • 12:30 PM – 1:45 PM PT
    3442 - Reinforcement Learning Powered Station Parameter Optimized Radiation Therapy (SPORT): A Novel Treatment Planning and Beam Delivery Technique
    Location: Hall B2

    Presenter: Xianjin Dai, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3443 - An Investigation of High-Z Material for Bolus in Electron Beam Therapy
    Location: Hall B2

    Presenter: Indra Das, PhD, FASTRO – Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine

  • 12:30 PM – 1:45 PM PT
    3444 - Can a 10 MV-FFF Photon Beam be Used in Stereotactic Thalamotomy to Reduce Beam Delivery Times: A Dosimetric Evaluation
    Location: Hall B2

    Presenter: George Ding, PhD – Vanderbilt University Medical Center

  • 12:30 PM – 1:45 PM PT
    3445 - Adaptive Auto-Segmentation for MRI-Guided Online Adaptive Radiotherapy of Cervical Carcinoma
    Location: Hall B2

    Presenter: Shouliang Ding, MS – Sun Yat-Sen University Cancer Center

  • 12:30 PM – 1:45 PM PT
    3446 - Patient-Specific 3D CT Images Reconstruction from 2D KV Images Via Vision Transformer-Based Deep-Learning
    Location: Hall B2

    Presenter: Yuzhen Ding, PhD

  • 12:30 PM – 1:45 PM PT
    3447 - Potential Dosimetric Predictors of Patient-Reported Quality of Life for Head and Neck Cancer Following Chemoradiation IMRT
    Location: Hall B2

    Presenter: Lyna Dinh, BS – UCLA

  • 12:30 PM – 1:45 PM PT
    3448 - Performance of Adaptive Deep Learning Models for Dose Predictions on High-Quality Cone-Beam Computed Tomography Images
    Location: Hall B2

    Presenter: Zehao Dong, PhD – Washington University in St. Louis

  • 12:30 PM – 1:45 PM PT
    3449 - Closing the Loop: Toward Sustainable 3D Print Recycling in the Clinic
    Location: Hall B2

    Presenter: Piotr Dubrowski, MS, MCCPM – Stanford University

  • 12:30 PM – 1:45 PM PT
    3450 - Novel Dose Criteria for Lung Cancer SBRT to Improve Local Control in Patients Treated to 50 Gy/5 Fractions Using Deep Learning Methods and Explainability Techniques
    Location: Hall B2

    Presenter: Denis Dudas, PhD – Moffitt Cancer Center

  • 12:30 PM – 1:45 PM PT
    3451 - Multi-Criteria Optimization and RapidPlan for Improved Organs at Risk Sparing in Treatment Planning of Malignant Pleural Mesothelioma
    Location: Hall B2

    Presenter: Vishruta Dumane, PhD – Mount Sinai School of Medicine

  • 12:30 PM – 1:45 PM PT
    3452 - Single Institution Preliminary Evaluation of a National Study for the Development of Daily Online Magnetic Resonance Image Guided Radiotherapy
    Location: Hall B2

    Presenter: Cynthia Eccles, PhD, RT, BS – The Christie NHS Foundation Trust

  • 12:30 PM – 1:45 PM PT
    3453 - Longitudinal Monitoring of Quantitative Imaging Kinetics of Primary Tumor and Nodal Volumes Using the MR-Linac Device in Head and Neck Cancer Patients
    Location: Hall B2

    Presenter: Dina El-Habashy, MD – MD Anderson Cancer Center

  • 12:30 PM – 1:45 PM PT
    3454 - Adaptation of a Clinical Proton Pencil Beam Scanning System for FLASH Experiments
    Location: Hall B2

    Presenter: Danielle Erickson, PhD – University of Washington

  • 12:30 PM – 1:45 PM PT
    3455 - Automated Lattice Treatment Planning for Bulky Tumors
    Location: Hall B2

    Presenter: Andrew Frankart, MD – University of Cincinnati

  • 12:30 PM – 1:45 PM PT
    3456 - Imaging Performance of the PET Scan on a Novel Ring Gantry-Based PET/CT Linear Accelerator System in the First-in-Human Study of Biology-Guided Radiotherapy
    Location: Hall B2

    Presenter: Aurelie Garant, MD – UT Southwestern Medical Center

  • 12:30 PM – 1:45 PM PT
    3457 - Investigation of the Relationship between Aperture Use for Treating Small and Shallow Brain Lesions in Proton Therapy with Different Spot Size Variations in Three Proton Therapy Systems
    Location: Hall B2

    Presenter: Tara Gray, PhD, MS – Cleveland Clinic

  • 12:30 PM – 1:45 PM PT
    3458 - Decay Series Dose Delivery Validation of a Biology-Guided Radiotherapy (BgRT) Methodology
    Location: Hall B2

    Presenter: Andrew Groll, PhD

  • 12:30 PM – 1:45 PM PT
    3460 - Statistical Analysis to Determine the Predictors of Liver Segmental Hypertrophy Observed Post-Radiotherapy
    Location: Hall B2

    Presenter: Kristy Brock, PhD, FASTRO – MD Anderson Cancer Center

  • 12:30 PM – 1:45 PM PT
    3461 - Motion Effects on Spatially Fractionated Lattice Therapy
    Location: Hall B2

    Presenter: Jonathan Ha, PhD – Salinas Radiation Oncology Center

  • 12:30 PM – 1:45 PM PT
    3462 - Impact of Stomach Deformability on PTV Coverage in Patients with Gastric MALTs Treated with Deep Inspiration Breath Hold (DIBH) and Daily CT-based Image-guided Radiation Therapy (IGRT)
    Location: Hall B2

    Presenter: Gideon Haber, MD, MS – Washington University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3463 - Patient-Adaptive Automated Segmentation in Daily kVCT Images for Radiotherapy of Head and Neck and Prostate Cancer
    Location: Hall B2

    Presenter: Bin Han, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3464 - Characterization of Biology-Guided Radiotherapy Accuracy as a Function of PET Tracer Uptake
    Location: Hall B2

    Presenter: Jeffrey Schmall, PhD

  • 12:30 PM – 1:45 PM PT
    3464 - Characterization of Biology-Guided Radiotherapy Accuracy as a Function of PET Tracer Uptake
    Location: Hall B2

    Presenter: Bin Han, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3465 - Dosimetric Study of Total Marrow and Lymphoid Irradiation on a Ring Gantry-Based Medical Linac with a Two-Layer Multi-Leaf Collimator
    Location: Hall B2

    Presenter: Chunhui Han, PhD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3466 - Reproducibility and Repeatability of Pelvic Radiomics Features with Daily Imaging on a Novel Biology-Guided Radiotherapy Machine Compared to Daily Imaging on Other Radiotherapy Delivery Systems
    Location: Hall B2

    Presenter: Chunhui Han, PhD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3467 - Comparison of AI-Based Auto-Segmentation Quality with Different Daily IGRT Imaging Modalities for Adaptive Radiotherapy Treatment Planning
    Location: Hall B2

    Presenter: Chunhui Han, PhD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3468 - Real-Time Spinal Cord Motion Tracking for MR-guided Spine SBRT (A Pilot Study)
    Location: Hall B2

    Presenter: Eun Young Han, PhD – MD Anderson Cancer Center

  • 12:30 PM – 1:45 PM PT
    3469 - Proton Online Adaptation Using Novel Cone-Beam Computed Tomography System
    Location: Hall B2

    Presenter: Yao Hao, PhD – Washington University in St. Louis

  • 12:30 PM – 1:45 PM PT
    3470 - Radiobiological Insights of Staged Brachytherapy Using Eye Plaque for Large Uveal Melanoma
    Location: Hall B2

    Presenter: Rui He, PhD – University of Mississippi Medical Center

  • 12:30 PM – 1:45 PM PT
    3471 - The Feasibility of Fast, Four-Dimensional Computed Tomography-Based O-Ring Linac Plans for Stereotactic Body Radiotherapy in Patients with Poor Performance Status
    Location: Hall B2

    Presenter: Eun Jeong Heo, MS – Korea University

  • 12:30 PM – 1:45 PM PT
    3472 - Improving Ultrasound Visualization of Catheters During Interstitial Brachytherapy
    Location: Hall B2

    Presenter: Jordan Holmes, MD, MPH – Indiana University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3473 - A Comparative Study of Measuring Bladder Volume in Patients with Pelvic Tumor Receiving Radiotherapy Using a Portable Bladder Scanner Made in China and CT Analog Positioning Machine
    Location: Hall B2

    Presenter: Qiu Hu, MS

  • 12:30 PM – 1:45 PM PT
    3474 - Dose Coverage Variation Caused by Setup Uncertainties in VMAT-TBI Treatment
    Location: Hall B2

    Presenter: Ke (Colin) Huang, PhD, MS – Indiana University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3475 - Low Tesla MR Imaging for Spine with Hardware
    Location: Hall B2

    Presenter: Soon Huh, PhD – University of Florida Proton Therapy Institute

  • 12:30 PM – 1:45 PM PT
    3476 - Assessment of Daily Target Motion to Optimize ITV Margins in Online Adaptive Plan for Liver and Pancreatic SBRT on MR-LINAC
    Location: Hall B2

    Presenter: Min-Sig Hwang, PhD – Allegheny Health Network

  • 12:30 PM – 1:45 PM PT
    3477 - Dosimetric Comparison of Automated Non-Coplanar Volumetric-Modulated Arc Therapy and Intensity-Modulated Proton Therapy in Angiosarcoma of the Scalp
    Location: Hall B2

    Presenter: Shoki Inui, PhD – Osaka International Cancer Institute

  • 12:30 PM – 1:45 PM PT
    3478 - Standardizing LT Chest Wall Radiotherapy Treatment Planning in a Low- or Middle- Income Country Radiotherapy Clinic Using Knowledge Based Planning
    Location: Hall B2

    Presenter: Milton Ixquiac, MS – Liga Nacional Contra el Cancer

  • 12:30 PM – 1:45 PM PT
    3479 - An Online AI-Powered Interactive Histological Image Annotation Platform for Analyzing Intestinal Regenerating Crypts in Post-Irradiated Mice
    Location: Hall B2

    Presenter: Hao Jiang

  • 12:30 PM – 1:45 PM PT
    3480 - Scatter Corrected Cone-Beam CT for Radiomics in SBRT: A Feasibility Study
    Location: Hall B2

    Presenter: Yangkang Jiang

  • 12:30 PM – 1:45 PM PT
    3481 - Feasibility and Safety of Single-Isocenter/Multi-Lesion (SIML) HyperArc Brain SRT: Clinical Implementation and Early Outcomes
    Location: Hall B2

    Presenter: Jeremiah Johnson, MD, MS – University of Kentucky

  • 12:30 PM – 1:45 PM PT
    3482 - Clinical Outcomes of Synchronous Lung Stereotactic Body Radiation Therapy Lesions via Single-Isocenter/Multi-Lesion Treatments
    Location: Hall B2

    Presenter: Mark Kenamond, MD – University of Kentucky

  • 12:30 PM – 1:45 PM PT
    3483 - Dynamic Contrast Enhanced MRI as a Biomarker of Tumor Response and Oncologic Outcomes in Head and Neck Cancer: Results of a Single Institution Prospective Imaging Study
    Location: Hall B2

    Presenter: Yomna Khamis, MD – Beaumont Health

  • 12:30 PM – 1:45 PM PT
    3484 - Comprehensive Beam Modeling, Secondary Dose Computations and Treatment Planning for a 1.5 T MRgRT System
    Location: Hall B2

    Presenter: Roel G.J. Kierkels, PhD, MSc – Radiotherapiegroep

  • 12:30 PM – 1:45 PM PT
    3485 - Superiority of BNCT Treatment Planning Metrics Achieved Using Novel vs. Reference (BPA-F) Pharmaceuticals in Head and Neck Locations
    Location: Hall B2

    Presenter: Chad Lee, PhD – TAE Life Sciences

  • 12:30 PM – 1:45 PM PT
    3486 - Knowledge Based Planning for Lung SBRT: Model Transferability between Treatment Systems and Calculation Algorithms
    Location: Hall B2

    Presenter: Hayeon Kim, PhD – Magee Womens Hospital of University of Pittsburgh Medical Center and Hillman Cancer Center

  • 12:30 PM – 1:45 PM PT
    3487 - Hippocampal Sparing Whole Brain Radiation Therapy: 2 Arc Coplanar and 4 Arc Noncoplanar Planning Comparison
    Location: Hall B2

    Presenter: Ji Kim, MD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3488 - Developing a 4-D Dynamic Model for GammaTile Dose Distribution
    Location: Hall B2

    Presenter: Sean King, BS

  • 12:30 PM – 1:45 PM PT
    3489 - Accuracy of Electron Density Mapping of a Novel kVCBCT System Designed for Planning
    Location: Hall B2

    Presenter: Brandon Koger, PhD

  • 12:30 PM – 1:45 PM PT
    3490 - Intrafraction Dosimetric Evaluation of Biology-Guided Radiotherapy to a Target Under Respiratory Motion
    Location: Hall B2

    Presenter: Nataliya Kovalchuk, PhD – Stanford Cancer Institute Palo Alto

  • 12:30 PM – 1:45 PM PT
    3491 - Robustness Settings for a Plan-of-the-Day IMPT Strategy for Locally Advanced Cervical Cancer
    Location: Hall B2

    Presenter: Sander Kuipers, MS – Erasmus MC Cancer Institute

  • 12:30 PM – 1:45 PM PT
    3492 - Enhancing Clinical Accuracy in DIBH Pattern Detection with a Combined Ultrasonic and IR Sensor System
    Location: Hall B2

    Presenter: Jae Kwag, PhD, CMD – North Mississippi Medical Center

  • 12:30 PM – 1:45 PM PT
    3493 - Assessment of Cardiac Radiation Dose in the Co-60 Prone Based Stereotactic Partial Breast Irradiation (CP-sPBI) Using the Distance from the Heart to the Planning Treatment Volume as a Surrogate Marker
    Location: Hall B2

    Presenter: Young Suk Kwon, MD – University of Texas Southwestern Medical Center at Dallas

  • 12:30 PM – 1:45 PM PT
    3494 - Hybrid-Supervised Deep Learning for Proton-Acoustic Reconstruction for 3D In Vivo Proton Dose Verification
    Location: Hall B2

    Presenter: Yankun Lang

  • 12:30 PM – 1:45 PM PT
    3495 - Validation of a Fast-Helical Free-Breathing CT-Based Ventilation Technique Using Ventilation/Perfusion SPECT Imaging
    Location: Hall B2

    Presenter: Ricky Savjani, MD, PhD – UCLA Radiation Oncology

  • 12:30 PM – 1:45 PM PT
    3496 - Beam Delivery and Patient Alignment: Perspective of the Innovative Cycloton 400MEV/u Multi-Ion System
    Location: Hall B2

    Presenter: Virgile Letellier, PhD – Normandy Hadrontherapy

  • 12:30 PM – 1:45 PM PT
    3497 - Noninvasive Radiation Markers Based on Lung Cancer CT Images and Dosimetry Features to Predict the Immune Response to Radiotherapy in Tumor Microenvironment
    Location: Hall B2

    Presenter: Guang Li, PhD

  • 12:30 PM – 1:45 PM PT
    3498 - Challenges of Treating Lung Cancer Patients at MR-Linac Using MR-Based Synthetic CT Calculation in the Adaptive Workflow
    Location: Hall B2

    Presenter: Jie Li, PhD, MS, Prof – Sichuan Cancer Hospital and Institute

  • 12:30 PM – 1:45 PM PT
    3499 - Deep-Learning Based Auto-Segmentation for Liver Yttrium-90 Selective Internal Radiation Therapy
    Location: Hall B2

    Presenter: Jun Li, PhD – Thomas Jefferson University

  • 12:30 PM – 1:45 PM PT
    3500 - Stakeholder Model for Standard Operating Procedure of Radiation Safety Practice in Radiopharmaceutical Therapy
    Location: Hall B2

    Presenter: Kaile Li, PhD, MS, DABR MHA – Varian Medical Systems, A Siemens Healthineers Company

  • 12:30 PM – 1:45 PM PT
    3501 - Exploring the Benefits of 3D-Printed Bolus in Cone Beam CT for Modified Radical Mastectomy Breast Cancer
    Location: Hall B2

    Presenter: Shao-Ti Li, MS – Chung Shan Medical University Hospital

  • 12:30 PM – 1:45 PM PT
    3502 - Small Samples and Low-Cost Auto-Segmentation Method for Pelvic Organ-at-Risk Segmentation in Magnetic Resonance Images Using Deep-Learning
    Location: Hall B2

    Presenter: Xianan Li, MD – Peking University People's Hospital

  • 12:30 PM – 1:45 PM PT
    3503 - Preserving Structural Consistency in the Generation of Synthetic CT in Pelvic MR-Only Radiation Treatment Planning
    Location: Hall B2

    Presenter: Xianan Li, MD – Peking University People's Hospital

  • 12:30 PM – 1:45 PM PT
    3504 - Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy (SBRT): A Robust Single Institution Experience
    Location: Hall B2

    Presenter: Dong Han, PhD – New York Proton Center

  • 12:30 PM – 1:45 PM PT
    3505 - First Implementation of Full-Workflow Automation for Online Adaptive Radiotherapy of Nasopharyngeal Carcinoma
    Location: Hall B2

    Presenter: Li Lin, MD, PhD – Sun Yat-Sen University Cancer Center

  • 12:30 PM – 1:45 PM PT
    3506 - Simulation-Omitted Replan with Cone Beam Computed Tomography based Adaptive Online Radiotherapy System ? Transferring Adapted Plan to Non-Adaptive Ring Gantry Linear Accelerator for Image Guided Radio
    Location: Hall B2

    Presenter: Mu-Han Lin, PhD – UT Southwestern Medical Center

  • 12:30 PM – 1:45 PM PT
    3507 - Dosimetric Plan Evaluation of Biology Guided Radiotherapy Using [18F]-DCFPyL PSMA Radiotracer in Patients with Prostate Cancer
    Location: Hall B2

    Presenter: Bo Liu, PhD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3508 - Cardiopulmonary Protection for Bilateral Breast Irradiation: A Dosimetric Comparison between Proton and Photon Plans
    Location: Hall B2

    Presenter: Cheng Sheng Liu, MD – Taipei Medical University Hospital

  • 12:30 PM – 1:45 PM PT
    3509 - The Interplay Effect and Mitigations with Cyclotron and Linac Proton Beam Scanning for Lung SBRT
    Location: Hall B2

    Presenter: Chieh-Wen Liu, PhD – Cleveland Clinic

  • 12:30 PM – 1:45 PM PT
    3510 - End-to-End Verification and Dosimetric Comparative Study of Brainlab Monte Carlo and Eclipse Acuros XB Photon Dose Calculation Algorithm for VMAT SRS Planning
    Location: Hall B2

    Presenter: Han Liu, MS – Mayo Clinic

  • 12:30 PM – 1:45 PM PT
    3511 - The Impact of Intra-Fraction Bowel Motion on Luminal Gastrointestinal Organ at Risk Dosimetry When Using Stereotactic Adaptive Radiotherapy for Abdominal Malignancies
    Location: Hall B2

    Presenter: Weiren Liu, MD, MS – Washington University School of Medicine in St. Louis

  • 12:30 PM – 1:45 PM PT
    3513 - A Feasibility Study of Dose Band Prediction in Radiotherapy: Predicting a Dose Spectrum
    Location: Hall B2

    Presenter: Yaoying Liu, PhD – School of Physics, Beihang University

  • 12:30 PM – 1:45 PM PT
    3514 - Deep Learning-Based Esophageal Tumor Identification on CT Slice
    Location: Hall B2

    Presenter: Saiquan Lu

  • 12:30 PM – 1:45 PM PT
    3515 - Prediction Analysis of Dose Verification Based on Plan Complexity Metrics during Radiotherapy
    Location: Hall B2

    Presenter: Huanli Luo, PhD – Chongqing University Cancer Hospital

  • 12:30 PM – 1:45 PM PT
    3516 - Dose Rate Assessment of Spot-Scanning Very High Energy Electrons FLASH Radiotherapy Driven by Laser Plasma Acceleration
    Location: Hall B2

    Presenter: Jianfeng Lv, PhD

  • 12:30 PM – 1:45 PM PT
    3517 - Treatment Delivery Gating of MRI-Guided Stereotactic Radiotherapy for Prostate Cancer: An Exploratory Analysis of a Phase III Randomized Trial of CT-Vs. MR-Guided Radiotherapy (MIRAGE)
    Location: Hall B2

    Presenter: John Neylon, PhD – UCLA Health

  • 12:30 PM – 1:45 PM PT
    3518 - The Feasibility of Adaptive CT Simulation-Free Radiation Therapy
    Location: Hall B2

    Presenter: R. Lee MacDonald, PhD, MS, BS, MCCPM – Nova Scotia Health Authority

  • 12:30 PM – 1:45 PM PT
    3519 - Offline Verification of Daily Adaptive Therapy for Locally Advanced Lung Cancer
    Location: Hall B2

    Presenter: Spencer MacLeod, BS – University of Alabama at Birmingham

  • 12:30 PM – 1:45 PM PT
    3520 - GTV Based Automatic Delineation of Clinical Target Volume for Cervical Cancer
    Location: Hall B2

    Presenter: Shufan Mao, MS – Perception Vision Medical Technology Co Ltd

  • 12:30 PM – 1:45 PM PT
    3523 - A Dosimetric Assessment of Sexual Organ Sparing Proton Radiotherapy in Female Pelvic Cancer Patients
    Location: Hall B2

    Presenter: Deborah Marshall, MD, MAS – Icahn School of Medicine at Mount Sinai

  • 12:30 PM – 1:45 PM PT
    3524 - Identifying and Re-Planning Challenging Retrospective SRS Patients to Evaluate the Potential for a White Matter Tract Sparing Knowledge-Based Planning Model
    Location: Hall B2

    Presenter: Danilo Maziero, PhD – Sylvester Comprehensive Cancer Center, University of Miami

  • 12:30 PM – 1:45 PM PT
    3525 - Planning Target Volume Margin Quantification of Retroperitoneal Tumors Using Robotic Stereotactic Body Radiotherapy with Spine Tracking
    Location: Hall B2

    Presenter: Grant McKenzie, MD – University of Louisville

  • 12:30 PM – 1:45 PM PT
    3526 - Quantifying Cardiac Chamber Motion for Noninvasive Stereotactic Cardiac Radiosurgery Using Deformable Image Registration
    Location: Hall B2

    Presenter: Trevor McKeown, MS, BS – Duke University

  • 12:30 PM – 1:45 PM PT
    3527 - Anatomically Realistic 3D Printed Mouse Phantom for Multi-Institutional Benchmarking of FLASH and CONV Irradiation
    Location: Hall B2

    Presenter: Stavros Melemenidis, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3528 - Treatment Plan Creation and Delivery with and without BgRT for Static and Motion Trajectories
    Location: Hall B2

    Presenter: Ayan Mitra, PhD

  • 12:30 PM – 1:45 PM PT
    3529 - Changes in Target Coverage and Dose to the Normal Brain during Fractionated Stereotactic Radiotherapy for Metastatic Brain Tumors
    Location: Hall B2

    Presenter: Hideharu Miura, PhD – Hiroshima High-Precision Radiotherapy Cancer Center

  • 12:30 PM – 1:45 PM PT
    3530 - The Development and Evaluation of an All-Purpose Bolus for Radiotherapy
    Location: Hall B2

    Presenter: Hajime Monzen, PhD – Kindai University

  • 12:30 PM – 1:45 PM PT
    3531 - Pelvis Treatment Plan Dose Comparison for Proton Therapy Using Single Energy and Dual Energy Computed Tomography Simulation Methods
    Location: Hall B2

    Presenter: Sina Mossahebi, PhD – University of Maryland School of Medicine, Baltimore

  • 12:30 PM – 1:45 PM PT
    3532 - Feasibility Study of Robust Treatment Planning in VMAT for Head and Neck Cancer
    Location: Hall B2

    Presenter: Kana Motegi, PhD – National Cancer Center Hospital East

  • 12:30 PM – 1:45 PM PT
    3533 - Alternating Tumor Treating Fields (TTFields) Layouts for Reduced Risk of Skin Irritation during Treatment of Solid Tumors in the Epigastric Region
    Location: Hall B2

    Presenter: Avishai Nahshoni, MD – Novocure (Israel) Ltd

  • 12:30 PM – 1:45 PM PT
    3533 - Alternating Tumor Treating Fields (TTFields) Layouts for Reduced Risk of Skin Irritation during Treatment of Solid Tumors in the Epigastric Region
    Location: Hall B2

    Presenter: Nadav Shapira

  • 12:30 PM – 1:45 PM PT
    3534 - Prospective Dosimetric Comparison Study Between Volumetric Modulated Arc Therapy and Intracavitary Brachytherapy for Cervical Cancer
    Location: Hall B2

    Presenter: Yujiro Nakajima, PhD – Komazawa University

  • 12:30 PM – 1:45 PM PT
    3535 - Data Driven Approach to Exactrac Setup Parameters after CBCT for Cranial Radiotherapy
    Location: Hall B2

    Presenter: Sreeram Narayanan, MD, PhD – Virginia Mason Medical Center

  • 12:30 PM – 1:45 PM PT
    3536 - Integrating a Tool to Automatically Determine Necessity of Online Adaptive Replanning
    Location: Hall B2

    Presenter: Haidy Nasief, PhD, MS – Froedtert and Medical College of Wisconsin

  • 12:30 PM – 1:45 PM PT
    3537 - Clinical Implementation of Weak Magnetic Field Generator in Radiation Therapy
    Location: Hall B2

    Presenter: Louise Naumann, BS – University of California, Los Angeles

  • 12:30 PM – 1:45 PM PT
    3538 - Acute Gastrointestinal and Genitourinary Toxicity Results from a Prospective Randomized Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometri
    Location: Hall B2

    Presenter: Killian Nugent, MD – St Luke’s Radiation Oncology Network

  • 12:30 PM – 1:45 PM PT
    3539 - Commissioning and Initial Validation of Commercial Treatment Planning System for the Electron FLASH Research Extension
    Location: Hall B2

    Presenter: Kyuhak Oh, PhD – University of Nebraska

  • 12:30 PM – 1:45 PM PT
    3540 - Plan Comparison of Left Breast Postmastectomy Radiotherapy: Halcyon IMRT and VMAT Plan vs. Truebeam Fixed-Jaws Plan
    Location: Hall B2

    Presenter: Hailun Pan, MS

  • 12:30 PM – 1:45 PM PT
    3541 - Dosimetric Impact of Intrafraction Prostate Motion and Interfraction Anatomical Changes in Dose-Escalated Linac-Based SBRT
    Location: Hall B2

    Presenter: Denis Panizza, MS – ASST Monza

  • 12:30 PM – 1:45 PM PT
    3542 - Evaluation of Usefulness of Yeast-Based Biological Phantom and Preliminary Study for Verification of Hypoxic Effect of Flash Radiotherapy
    Location: Hall B2

    Presenter: Chan Beom Park, MS – The Catholic University of Korea

  • 12:30 PM – 1:45 PM PT
    3543 - CT-on-Rails Utilization for Image Guidance and Plan Adaptation at a Single-Room Proton Therapy Center
    Location: Hall B2

    Presenter: Adam Paxton, PhD – University of Utah

  • 12:30 PM – 1:45 PM PT
    3544 - What MRI Sequences are Necessary for Automated Neural Network-Based Metastasis Segmentation ? An Ablation Study
    Location: Hall B2

    Presenter: Jan Peeken, MD – Technical University Munich

  • 12:30 PM – 1:45 PM PT
    3545 - Optimal Fractionation and Timing of Weekly Cone-Beam CT in Daily Surface-Guided Radiotherapy for Breast Cancer
    Location: Hall B2

    Presenter: Haiyan Peng, MS – Chongqing University Cancer Hospital

  • 12:30 PM – 1:45 PM PT
    3546 - Comparison of Plan Quality Metrics after Left Anterior Descending Coronary Artery Sparing in VMAT Esophageal Radiotherapy
    Location: Hall B2

    Presenter: Daniel Pham, PhD, CMD, RT – Stanford Health Care

  • 12:30 PM – 1:45 PM PT
    3547 - Cherenkov and Plan Integration for Real-Time Delivery Verification: The Opportunity for Automated Visualization and Guidance of All Treatments in EBRT
    Location: Hall B2

    Presenter: Brian Pogue, PhD – University of Wisonsin School of Medicine and Public Health

  • 12:30 PM – 1:45 PM PT
    3548 - kV-CBCT-Guided Daily Adaptation Improves Target Coverage and Spares Normal Tissue for Accelerated Partial Breast Irradiation
    Location: Hall B2

    Presenter: Dennis Stanley, PhD – University of Alabama at Birmingham

  • 12:30 PM – 1:45 PM PT
    3548 - kV-CBCT-Guided Daily Adaptation Improves Target Coverage and Spares Normal Tissue for Accelerated Partial Breast Irradiation
    Location: Hall B2

    Presenter: Joel Pogue, PhD – University of Alabama at Birmingham

  • 12:30 PM – 1:45 PM PT
    3549 - Commissioning and Assessment of Radiation Field and Dose Inhomogeneity for a Dual X-Ray Tube Cabinet Irradiator: To Ensure Accurate Dosimetry in Radiation Biology Experiments
    Location: Hall B2

    Presenter: Mitchell Polizzi, MS – Virginia Commonwealth University Health System

  • 12:30 PM – 1:45 PM PT
    3550 - Clinical Evaluation of an Automated Iterative Optimization System for Radiation Oncology
    Location: Hall B2

    Presenter: Matthew Price, MS, BS – GenesisCare

  • 12:30 PM – 1:45 PM PT
    3551 - Radiomics Model for Predicting Pulmonary Metastasis in Sarcoma Patients
    Location: Hall B2

    Presenter: Phillip Prior, PhD – Medical College of Wisconsin

  • 12:30 PM – 1:45 PM PT
    3552 - Feature Selection Based on Unsupervised Clustering Mechanism on Multiple-Sequence MRIs for Predicting Neoadjuvant Chemoradiation Response in Locally Advanced Rectal Cancer
    Location: Hall B2

    Presenter: Xiangrong Qi, PhD – UCLA Radiation Oncology

  • 12:30 PM – 1:45 PM PT
    3553 - Adaptive Dose-Staged Stereotactic Ablative Body Radiotherapy is Beneficial for Treatment of Large Central NSCLC Lung Tumors: A Dosimetric Simulation Study
    Location: Hall B2

    Presenter: Javad Rahimian, PhD – Kaiser Permanente Los Angeles Medical Center

  • 12:30 PM – 1:45 PM PT
    3554 - Hypoxia Informed RBE-Weighted Beam Orientation Optimization for Intensity Modulated Proton Therapy Using [18F]-FMISO-PET Estimation of pO2
    Location: Hall B2

    Presenter: Pavitra Ramesh, MS – University of California Los Angeles

  • 12:30 PM – 1:45 PM PT
    3555 - Comparison of a Pre-Trained AI Contouring Model to Unseen Institutional Data
    Location: Hall B2

    Presenter: Satyapal Rathee, PhD – University of Alberta

  • 12:30 PM – 1:45 PM PT
    3556 - How Linear Elastic Material Properties Affect Lung Tumor Motion and Deformation: A Finite Element Analysis
    Location: Hall B2

    Presenter: Noelle Ray, MS, BS – University of Maryland, Baltimore County

  • 12:30 PM – 1:45 PM PT
    3557 - Pelvic Nodal Auto-Segmentation Using a Deep Image to Image Network (DI2IN) Auto-Segmentation Algorithm: Comparing Male vs. Female Pelvis
    Location: Hall B2

    Presenter: Kareem Rayn, MD – Columbia University Irving Medical Center

  • 12:30 PM – 1:45 PM PT
    3558 - Evaluation of a Deep Image to Image Network (DI2IN) Auto-Segmentation Algorithm across a Network of Cancer Centers
    Location: Hall B2

    Presenter: Kareem Rayn, MD – Columbia University Irving Medical Center

  • 12:30 PM – 1:45 PM PT
    3559 - Using Scorecards to Tune Ethos Directive Templates: An ARTIA Cervix Dosimetric Planning Study
    Location: Hall B2

    Presenter: Kareem Rayn, MD – Columbia University Irving Medical Center

  • 12:30 PM – 1:45 PM PT
    3560 - Feasibility of EPID Based In Vivo Dosimetry for On-Couch Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Gary Razinskas, PhD – University Hospital Wuerzburg

  • 12:30 PM – 1:45 PM PT
    3561 - 1.5T MR-Guided Daily Adaptive Radiotherapy: Preliminary Clinical Report of the First 5000 Fractions
    Location: Hall B2

    Presenter: Michele Rigo, MD

  • 12:30 PM – 1:45 PM PT
    3562 - Feasibility of Acquiring Radiotherapy Linac Commissioning Data with a Three-Dimensional Cubic Electronic Detector Array
    Location: Hall B2

    Presenter: Dante Roa, PhD – Mission Viejo Radiation Oncology

  • 12:30 PM – 1:45 PM PT
    3563 - Dosimetric Implications of Weekly On-Line MR-Guided Adaptive Radiotherapy (RT) for Glioblastomas (GBM) Growing during RT
    Location: Hall B2

    Presenter: Mark Ruschin, PhD – Sunnybrook Health Sciences Centre

  • 12:30 PM – 1:45 PM PT
    3564 - A Novel Approach to Support Quality Assurance (QA) of Intensity Modulated Neutron Therapy (IMNT)
    Location: Hall B2

    Presenter: George Sandison, PhD, PhD, FCCPM, FAAPM – Univeristy of Washington

  • 12:30 PM – 1:45 PM PT
    3565 - Is Robust Optimization Essential When Planning Pencil Beam Scanned Proton Therapy for Intracranial Lesions?
    Location: Hall B2

    Presenter: Vikren Sarkar, PhD, MBA – University of Utah Huntsman Cancer Institute

  • 12:30 PM – 1:45 PM PT
    3566 - Image-Guided IORT after Surgical Resection of Brain Malignancies: A Feasibility Study
    Location: Hall B2

    Presenter: Gustavo Sarria, MD – University Hospital Bonn

  • 12:30 PM – 1:45 PM PT
    3567 - A Novel Analytic Method of Automatically Assessing Beamline Geometric Range Variations for CBCT-Guided Intensity-Modulated Proton Therapy (IMPT) for Localized Prostate Cancer
    Location: Hall B2

    Presenter: Grant Evans, MS – SFPTI

  • 12:30 PM – 1:45 PM PT
    3568 - Prostate Tumor Regression during Radiation Therapy in Relation to Image Derived Estimates of Fibrosis Using Ultrashort Echo Time MRI
    Location: Hall B2

    Presenter: Khadija Sheikh, PhD, MS – Johns Hopkins University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3569 - A New Treatment Planning Method for Efficient Proton ARC Therapy with Direct Minimization of Number of Energy Jumps
    Location: Hall B2

    Presenter: Hao Gao, PhD – University of Kansas Medical Center

  • 12:30 PM – 1:45 PM PT
    3570 - Automatic Treatment Planning for Multi-focal Dynamic Conformal Arc GRID Therapy for Late Stage Lung Cancer: A Feasibility Study
    Location: Hall B2

    Presenter: Yang Sheng, PhD – Duke University Medical Center

  • 12:30 PM – 1:45 PM PT
    3571 - First-Year Experience of IMRT/SBRT Treatments Using a Novel Biology-Guided Radiation Therapy System
    Location: Hall B2

    Presenter: Mengying Shi, PhD – University of California, Irvine

  • 12:30 PM – 1:45 PM PT
    3572 - Left Anterior Descending Coronary Artery-Optimized Knowledge-Based Radiotherapy Planning in Patients with Locally Advanced Non-Small Cell Lung Cancer
    Location: Hall B2

    Presenter: Alex Shin, BS – Cedars-Sinai Medical Center

  • 12:30 PM – 1:45 PM PT
    3573 - Temporospatial Feathering of Hot Spots for Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Ultra-Central Thorax
    Location: Hall B2

    Presenter: Emily Sigmund, BS – Washington University School of Medicine in St. Louis

  • 12:30 PM – 1:45 PM PT
    3574 - Clinical Review on Head and Neck CBCT Images
    Location: Hall B2

    Presenter: Sze Yarn Sin, MS – National Cancer Centre Singapore

  • 12:30 PM – 1:45 PM PT
    3575 - Quantifying the Dosimetric Impact of Tissue Hounsfield Unit Assignment in Deep Learning-based Synthetic CT Images For MRI-Only Radiation Therapy Of The Head And Neck
    Location: Hall B1

    Presenter: Kamal Singhrao, PhD – UCSF

  • 12:30 PM – 1:45 PM PT
    3575 - Quantifying the Dosimetric Impact of Tissue Hounsfield Unit Assignment in Deep Learning-based Synthetic CT Images For MRI-Only Radiation Therapy Of The Head And Neck
    Location: Hall B2

    Presenter: Catherine Dugan, BA – University of California San Francisco

  • 12:30 PM – 1:45 PM PT
    3576 - Tumor Treatment Response Assessed During the Chemo-Radiotherapy for Locally Advanced NSCLC
    Location: Hall B2

    Presenter: YINGPENG SONG, PhD

  • 12:30 PM – 1:45 PM PT
    3577 - Implementation of a Patient Specific QA Protocol for a Novel Dedicated Stereotactic Radiosurgery Linear Accelerator
    Location: Hall B2

    Presenter: Carlos Rodrigues

  • 12:30 PM – 1:45 PM PT
    3578 - A Working Framework for TTFields Treatment Planning and Dosimetry
    Location: Hall B1

    Presenter: Kirill Stepovoy, MS – Novocure (Israel) Ltd

  • 12:30 PM – 1:45 PM PT
    3578 - A Working TTFields Therapy Framework for Patient-Specific Segmentation-Based Treatment Planning and Dosimetry
    Location: Hall B2

    Presenter: Brian Berger, MD – Novocure - Williamsburg

  • 12:30 PM – 1:45 PM PT
    3579 - Evaluating the Use of SGRT and Abdominal Compression Device for Improved Patient Positioning in Liver Cancer Radiotherapy
    Location: Hall B2

    Presenter: Lin Su, MS

  • 12:30 PM – 1:45 PM PT
    3580 - An Efficient Transformer Model for Synthesizing Dual Energy CT from Single Energy Scanner
    Location: Hall B2

    Presenter: Liyan Sun, PhD – Stanford University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3581 - Dosimetric Accuracy of Multi-Target Biology-Guided Radiotherapy Treatments in a Single Session
    Location: Hall B2

    Presenter: Murat Surucu, PhD – Stanford University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3581 - Dosimetric Accuracy of Multi-Target Biology-Guided Radiotherapy Treatments in a Single Session
    Location: Hall B2

    Presenter: Jeffrey Schmall, PhD

  • 12:30 PM – 1:45 PM PT
    3582 - Evaluation of Treatment Interruptions and Recovery during Biology-Guided Radiotherapy Delivery
    Location: Hall B2

    Presenter: Murat Surucu, PhD – Stanford University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3583 - Validation of Hypoxia Detection Sequences on the MR Linac
    Location: Hall B2

    Presenter: Martin Swinton, MBBChir – The Christie NHS Foundation Trust

  • 12:30 PM – 1:45 PM PT
    3583 - Validation of Hypoxia Detection Sequences on the MR Linac
    Location: Hall B2

    Presenter: Ananya Choudhury, PhD, MA MRCP FRCR – The Christie NHS Foundation Trust

  • 12:30 PM – 1:45 PM PT
    3584 - Dosimetric Evaluation of Targets and Organs at Risk in Dose Escalation Study for Total Marrow and Lymphoid Irradiation
    Location: Hall B2

    Presenter: Takuto Takizawa, MS – Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

  • 12:30 PM – 1:45 PM PT
    3585 - Evaluation of a Deep-Learning Auto-Segmentation Model of Cardiac Substructures
    Location: Hall B2

    Presenter: Andrew Tam, MD – City of Hope National Medical Center

  • 12:30 PM – 1:45 PM PT
    3586 - A Multicenter Study of Clinical to Planning Target Volume Margins for Adjuvant Partial Breast Irradiation Delivered on the 1.5T MR-Linear Accelerator
    Location: Hall B1

    Presenter: Ian Zing Tan, MBBS

  • 12:30 PM – 1:45 PM PT
    3586 - A Multicenter Study of Clinical to Planning Target Volume Margins for Adjuvant Partial Breast Irradiation Delivered on the 1.5T MR-Linear Accelerator
    Location: Hall B2

    Presenter: Anna Kirby, MD – Royal Marsden NHS Foundation Trust

  • 12:30 PM – 1:45 PM PT
    3587 - Effectiveness of Bladder Filling Control during Online MR-Guided Adaptive Radiotherapy for Rectum Cancer
    Location: Hall B2

    Presenter: Bin Tang, PhD, MS – Sichuan Cancer Hospital and Institute

  • 12:30 PM – 1:45 PM PT
    3588 - Clinical Utility of Dual Phase FDG PET for Distinguishing Tumor Progression from Radionecrosis in the Modern Era
    Location: Hall B1

    Presenter: Trenton Taros, MD – Mass General Brigham

  • 12:30 PM – 1:45 PM PT
    3588 - Clinical Utility of Dual Phase FDG PET for Distinguishing Tumor Progression from Radionecrosis in the Modern Era
    Location: Hall B2

    Presenter: Luke Peng, MD, MS – Brigham and Women's/Dana Farber Cancer Institute

  • 12:30 PM – 1:45 PM PT
    3590 - A Hybrid Intelligence (HI) System for Segmenting Rectoprostatic Spacer Gel and Key OARs on CT Images for Prostate Cancer Radiation Therapy Planning
    Location: Hall B2

    Presenter: Michelle Svatos, PhD – Palette Life Sciences

  • 12:30 PM – 1:45 PM PT
    3590 - A Hybrid Intelligence (HI) System for Segmenting Rectoprostatic Spacer Gel and Key OARs on CT Images for Prostate Cancer Radiation Therapy Planning
    Location: Hall B2

    Presenter: Joe Camaratta, MS, BS – Quantaras

  • 12:30 PM – 1:45 PM PT
    3591 - Agreement among Radiation Oncologists and Radiologist in Contouring GTV on Planning and Mid-Treatment MRI for Locally Advanced Oropharynx Cancer
    Location: Hall B2

    Presenter: Marion Tonneau, MD

  • 12:30 PM – 1:45 PM PT
    3591 - Agreement among Radiation Oncologists and Radiologist in Contouring GTV on Planning and Mid-Treatment MRI for Locally Advanced Oropharynx Cancer
    Location: Hall B2

    Presenter: Houda Bahig, MD, PhD – Centre Hospitalier de l'Universite de Montreal (CHUM)

  • 12:30 PM – 1:45 PM PT
    3592 - Feasibility of Using a Single Planning MRI for Two-Insertion Intracavitary Brachytherapy for Cervical Cancer
    Location: Hall B2

    Presenter: Michael Trager, MS – Memorial Sloan Kettering Cancer Center

  • 12:30 PM – 1:45 PM PT
    3594 - Difference in Radiotherapeutic Plan of HyperArc-Based and Cyberkinfe-Based Stereotactic Radiotherapy (SRT) Techniques for Multiple Brain Metastases
    Location: Hall B2

    Presenter: Chia-Jen Tsai, MD – Chi-Mei Medical Center

  • 12:30 PM – 1:45 PM PT
    3595 - Combined Radiotherapy Using a Method for Biologically Informed IMRT Planning
    Location: Hall B2

    Presenter: Adam Turner, PhD

  • 12:30 PM – 1:45 PM PT
    3596 - Online Adaptive Radiotherapy for Pharyngeal Cancer: Dose-Volume Histogram Analysis between Adapted and Scheduled Plan
    Location: Hall B2

    Presenter: Takuya Uehara, MD – Kindai University Faculty of Medicine

  • 12:30 PM – 1:45 PM PT
    3597 - Decision Tool to Select Prostate Patients for Fully Adaptive Prostate Treatment vs. Intra-Fractional Monitoring and Intervention
    Location: Hall B2

    Presenter: Frank Van Den Heuvel, PhD, FAAPM – Zuidwest Radiotherapeutisch Instituut

  • 12:30 PM – 1:45 PM PT
    3598 - Prioritizing Toxicities in Automated Outcome-Directed Treatment Plan Optimization
    Location: Hall B2

    Presenter: Hans Paul van der Laan, PhD – University of Groningen Medical Center

  • 12:30 PM – 1:45 PM PT
    3599 - Cross-Platform Assessment of CBCT-Based Dose Evaluations for Head and Neck Cancer Proton Therapy
    Location: Hall B2

    Presenter: Nadine Vatterodt, MS – Danish Center for Particle Therapy

  • 12:30 PM – 1:45 PM PT
    3600 - Rapid Mechanical Ventilation Superior to Rapid Jet Ventilation for Diaphragm Motion Reduction in Radiotherapy
    Location: Hall B2

    Presenter: Johannes Veldman, MS – Amsterdam University Medical Center (AUMC)

  • 12:30 PM – 1:45 PM PT
    3601 - Comparison of Four Software Packages for Automated Contouring
    Location: Hall B2

    Presenter: Neil Wallace, MB BCh BaO – Peter MacCallum Cancer Centre

  • 12:30 PM – 1:45 PM PT
    3602 - Sub-Grouping Strategy for Improving Atlas-Based Segmentation Performance
    Location: Hall B2

    Presenter: Binbing Wang, MS – Zhejiang Cancer Hospital

  • 12:30 PM – 1:45 PM PT
    3603 - Predicting Dosimetry of Stereotactic Ablative Radiotherapy for the Treatment of Multiple Lung Lesions
    Location: Hall B2

    Presenter: Edward Wang – Western University

  • 12:30 PM – 1:45 PM PT
    3604 - Application of the Integrated Deep Reinforcement Learning Solution in Automatic IMRT Planning for Gastric Cancer
    Location: Hall B2

    Presenter: Hanlin Wang

  • 12:30 PM – 1:45 PM PT
    3605 - Proton Therapy for Ocular Melanoma: A Dosimetric Comparison of Three Different Delivery Systems
    Location: Hall B2

    Presenter: Hazel Wang, MS – Northwestern Medicine

  • 12:30 PM – 1:45 PM PT
    3606 - Proton Based Stereotactic Radiotherapy for Skull Base Patients: Dosimetric Comparison to 4 Modern Radiation Treatment Modalities
    Location: Hall B2

    Presenter: He Wang, PhD – MD Anderson Cancer Center

  • 12:30 PM – 1:45 PM PT
    3607 - Application of the Ion Chamber Array in Magnetic Resonance Accelerator QA
    Location: Hall B2

    Presenter: Jiaxin Wang, PhD

  • 12:30 PM – 1:45 PM PT
    3608 - Balancing Quality and Efficiency of Head and Neck Contour Revision for Online Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Siqiu Wang, PhD – University of Texas Southwestern Medical Center

  • 12:30 PM – 1:45 PM PT
    3609 - CBCT Guided Interfraction Absolute Displacement and Setup Error Assessment during Breast Prone Radiotherapy
    Location: Hall B2

    Presenter: Wei Wang, MD, PhD – Shandong Anti-Cancer Association

  • 12:30 PM – 1:45 PM PT
    3610 - Study on Dosimetric Benefits of Adaptive Brachytherapy in the Treatment of Postoperative Cervical Cancer Patients
    Location: Hall B2

    Presenter: Xianliang Wang, PhD – Sichuan Cancer Hospital and Institute

  • 12:30 PM – 1:45 PM PT
    3611 - Creation and Implementation of an Interdisciplinary Workflow for CBCT-Based Online Adaptive Radiotherapy
    Location: Hall B2

    Presenter: Yi-Fang Wang, PhD, MS – Columbia University College of Physicians and Surgeons

  • 12:30 PM – 1:45 PM PT
    3612 - Performance Evaluation in Automatic Plan Generation for Ethos Intelligent Optimization Engine
    Location: Hall B2

    Presenter: Qun Wang, MS

  • 12:30 PM – 1:45 PM PT
    3613 - First Demonstration of the Commissioning of a New Multi-Modality Radiotherapy Platform
    Location: Hall B2

    Presenter: Zhongfei Wang, MD

  • 12:30 PM – 1:45 PM PT
    3614 - Develop and Evaluate a Dose Calculation Strategy Using Electron Density Maps from Spectral CT
    Location: Hall B2

    Presenter: Ning Wen, PhD, MBA – Ruijin Hospital, Shanghai Jiaotong University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3615 - Retrospective Assessment of Surface Imaging Set up Accuracy for Intensity Modulated Proton Therapy of Comprehensive Breast Irradiation
    Location: Hall B2

    Presenter: Andrew Wroe, PhD – Miami Cancer Institute

  • 12:30 PM – 1:45 PM PT
    3616 - Evaluation of Flattening-Filter-Free and Flattening Filter Dosimetric and Radiobiological Criteria for Lung SBRT: A Volume-Based Analysis
    Location: Hall B2

    Presenter: Junxiang Wu, MS

  • 12:30 PM – 1:45 PM PT
    3617 - From Protons to Picasso: Recreating Famous Paintings Using Proton Beams as a "Paintbrush"
    Location: Hall B2

    Presenter: Jin Sup(Andy) Shim, CMD, BS – New York Proton Center

  • 12:30 PM – 1:45 PM PT
    3619 - Adaptive Radiotherapy with Dose Fractionation Painting
    Location: Hall B2

    Presenter: Di Yan, DSc – William Beaumont Hospital

  • 12:30 PM – 1:45 PM PT
    3620 - A Feasible Study for Auto Planning and Auto Re-Planning for Nasopharyngeal Carcinoma (NPC) Adaptive Radiation Therapy (ART)
    Location: Hall B2

    Presenter: Xin Yang, PhD

  • 12:30 PM – 1:45 PM PT
    3621 - Clinical Implementation of an Automated IMRT/VMAT Treatment Planning Tool
    Location: Hall B2

    Presenter: Yong Yang, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3622 - Optimizing the Imaging Scheme of Small-Dose Contrast Agent in 4D-CT Localization Enhancement Scan for Radiotherapy of Liver Cancer
    Location: Hall B2

    Presenter: Wei Yao, RT – radiotherapy department

  • 12:30 PM – 1:45 PM PT
    3623 - Study on the Clinical Use of a Respiratory Navigator Combined with Breath-Hold for MRI- Guided Liver SBRT
    Location: Hall B2

    Presenter: Xinghong Yao, PhD

  • 12:30 PM – 1:45 PM PT
    3624 - Clinical Experience with Commissioning a GRID Collimator for Spatially Fractionated Radiation Therapy
    Location: Hall B2

    Presenter: Ravindra Yaparpalvi, MS – Montefiore Medical Center

  • 12:30 PM – 1:45 PM PT
    3625 - Evaluation of a Novel Metal Artifact Reduction Algorithm for Reconstruction of Cone Beam CT (CBCT) Images Acquired on a New Imaging System
    Location: Hall B2

    Presenter: Abby Yashayaeva, MS, BS – Dalhousie University

  • 12:30 PM – 1:45 PM PT
    3626 - Accelerating Volumetric CT and MRI Imaging by Reference-Free Deep Learning Transformation from Low-Resolution to High-Resolution
    Location: Hall B2

    Presenter: Siqi Ye, PhD – Stanford University

  • 12:30 PM – 1:45 PM PT
    3627 - Enough and Some to Spare: Improved OAR Sparing with Daily Online Cone Beam Adaptive Radiation Therapy (OnC-ART) of the Cervix
    Location: Hall B2

    Presenter: Allen Yen, MD, BS – UT Southwestern Medical Center

  • 12:30 PM – 1:45 PM PT
    3628 - Liver Regeneration Following Radiation Therapy in Hepatocellular Carcinoma Patients: Insights from Functional Liver Imaging
    Location: Hall B2

    Presenter: Peter Zaki, MD – University of Washington

  • 12:30 PM – 1:45 PM PT
    3630 - Biological Effective Dose (BED) in Evaluation of Rectal Dose in Prostate Cancer Patients with Hydrogel Spacer Who Underwent an EBRT with Different Fractionation Schemes
    Location: Hall B2

    Presenter: Honglai Zhang, PhD, CMD – Northwell Health

  • 12:30 PM – 1:45 PM PT
    3631 - Respiratory Motion Compensation Using Xsight Diaphragm Tracking for Liver Tumor in CK Synchrony Treatment: A Feasibility Study
    Location: Hall B2

    Presenter: Jianping Zhang, MD

  • 12:30 PM – 1:45 PM PT
    3632 - Implementation of L4 Automation for Patient-Specific Quality Assurance Using the AUTOFRAME Platform and a Robotic Mechanism
    Location: Hall B2

    Presenter: Jenghwa Chang, PhD – Northwell Health

  • 12:30 PM – 1:45 PM PT
    3633 - Auto Assistant VMAT Planning with HID Automation
    Location: Hall B2

    Presenter: Jenghwa Chang, PhD – Northwell Health

  • 12:30 PM – 1:45 PM PT
    3634 - Variation in Left Anterior Descending Coronary Artery Accumulated Dose Estimates during Breast Cancer Radiotherapy
    Location: Hall B2

    Presenter: Samuel Zhang, MD – Cedars-Sinai Medical Center

  • 12:30 PM – 1:45 PM PT
    3635 - Dosimetric Validation of 3D-Printed Bolus at Different Printing Infill Percentage in VMAT Plan
    Location: Hall B2

    Presenter: Te Zhang, MD

  • 12:30 PM – 1:45 PM PT
    3636 - Virtual-Collimator Based Spatial Dose Modulation for Proton GRID Therapy
    Location: Hall B2

    Presenter: Hao Gao, PhD – University of Kansas Medical Center

  • 12:30 PM – 1:45 PM PT
    3637 - Vertex Position Optimization for LATTICE Therapy
    Location: Hall B2

    Presenter: Yuting Lin, PhD – University of Kansas Medical Center

  • 12:30 PM – 1:45 PM PT
    3638 - 2V-CBCT: Two-Orthogonal-Projection Based CBCT Reconstruction and Dose Calculation from Real CBCT Projection Data
    Location: Hall B2

    Presenter: Wangyao Li, PhD – University of Kansas Medical Center

  • 12:30 PM – 1:45 PM PT
    3639 - Introducing an Experimental Approach to Predict Spot Scanning Time Parameters for a Superconducting Cyclotron Proton Therapy Machine
    Location: Hall B2

    Presenter: Peilin Liu, MD, MS – Peking University First Hospital

  • 12:30 PM – 1:45 PM PT
    3640 - An In Silico study of a One-Day One-Machine Workflow for Definitive Radiotherapy Cases on a Novel Simulation and Treatment Platform
    Location: Hall B2

    Presenter: Tianyu Zhao, PhD – Washington University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3641 - Accuracy of Electron Density and Planning Dosimetry in a Novel High-Quality CBCT Imaging System
    Location: Hall B2

    Presenter: Tianyu Zhao, PhD – Washington University School of Medicine

  • 12:30 PM – 1:45 PM PT
    3642 - Preheating Thermoplastic Membrane Reduce Setup Error in Patients with Thoracic Cancer Undergoing Radiation Therapy: A Prospective Randomized Controlled Study
    Location: Hall B2

    Presenter: Liu Zixuan, BS, MBBS